
@article{10November2021,
  title = {10 {{November}} 2021 {{Risk}} Assessment for {{SARS-CoV-2}} Variant: {{VUI-21OCT-01 AY}}.4.2},
  pages = {1},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X8NESZAH\\10 November 2021 Risk assessment for SARS-CoV-2 va.pdf}
}

@misc{2019CoronavirusKorean,
  title = {2019 Coronavirus: {{The Korean}} Clusters},
  shorttitle = {2019 Coronavirus},
  journal = {Reuters},
  abstract = {How coronavirus cases exploded in South Korean churches and hospitals},
  howpublished = {https://graphics.reuters.com/CHINA-HEALTH-SOUTHKOREA-CLUSTERS/0100B5G33SB/index.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3SP79ZIQ\\index.html}
}

@misc{23LatestMicrosoftUpdates,
  title = {Latest {{Microsoft}} Updates Erase {{Word}} Customizations, Can Break {{Edge}}, {{Outlook}}, {{File Explorer}}},
  author = {23, Joel Hruska on December and Pm, 2015 at 1:02},
  journal = {ExtremeTech},
  abstract = {Microsoft's latest cumulative update for Windows 10 was supposed to improve wireless connectivity, but it introduced some substantial bugs as well.},
  howpublished = {http://www.extremetech.com/computing/219908-latest-windows-10-update-erases-word-customizations-can-break-edge-outlook-file-explorer},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GC2EISGV\\23 and Pm - Latest Microsoft updates erase Word customizations.html}
}

@misc{23LatestMicrosoftUpdatesa,
  title = {Latest {{Microsoft}} Updates Erase {{Word}} Customizations, Can Break {{Edge}}, {{Outlook}}, {{File Explorer}}},
  author = {23, Joel Hruska on December and Pm, 2015 at 1:02},
  journal = {ExtremeTech},
  abstract = {Microsoft's latest cumulative update for Windows 10 was supposed to improve wireless connectivity, but it introduced some substantial bugs as well.},
  howpublished = {http://www.extremetech.com/computing/219908-latest-windows-10-update-erases-word-customizations-can-break-edge-outlook-file-explorer},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Z8U3V6CQ\\23 and Pm - Latest Microsoft updates erase Word customizations.html}
}

@article{abbasiPromisePerilAntibody2020,
  title = {The {{Promise}} and {{Peril}} of {{Antibody Testing}} for {{COVID-19}}},
  author = {Abbasi, Jennifer},
  year = {2020},
  month = apr,
  journal = {JAMA},
  doi = {10.1001/jama.2020.6170},
  abstract = {This Medical News article discusses how antibody tests should\textemdash and should not\textemdash be used during the SARS-CoV-2 pandemic.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DSLLYUSK\\Abbasi - 2020 - The Promise and Peril of Antibody Testing for COVI.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\H9NX9I4M\\2764954.html}
}

@article{abbottEstimatingTimevaryingReproduction2020,
  title = {Estimating the Time-Varying Reproduction Number of {{SARS-CoV-2}} Using National and Subnational Case Counts},
  author = {Abbott, Sam and Hellewell, Joel and Thompson, Robin N. and Sherratt, Katharine and Gibbs, Hamish P. and Bosse, Nikos I. and Munday, James D. and Meakin, Sophie and Doughty, Emma L. and Chun, June Young and Chan, Yung-Wai Desmond and Finger, Flavio and Campbell, Paul and Endo, Akira and Pearson, Carl A. B. and Gimma, Amy and Russell, Tim and {CMMID COVID modelling group} and Flasche, Stefan and Kucharski, Adam J. and Eggo, Rosalind M. and Funk, Sebastian},
  year = {2020},
  month = jun,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {112},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.16006.1},
  abstract = {Background:               Interventions are now in place worldwide to reduce transmission of the novel coronavirus. Assessing temporal variations in transmission in different countries is essential for evaluating the effectiveness of public health interventions and the impact of changes in policy.                                         Methods:               We use case notification data to generate daily estimates of the time-dependent reproduction number in different regions and countries. Our modelling framework, based on open source tooling, accounts for reporting delays, so that temporal variations in reproduction number estimates can be compared directly with the times at which interventions are implemented.                                         Results:               We provide three example uses of our framework. First, we demonstrate how the toolset displays temporal changes in the reproduction number. Second, we show how the framework can be used to reconstruct case counts by date of infection from case counts by date of notification, as well as to estimate the reproduction number. Third, we show how maps can be generated to clearly show if case numbers are likely to decrease or increase in different regions. Results are shown for regions and countries worldwide on our website (               https://epiforecasts.io/covid/               ) and are updated daily. Our tooling is provided as an open-source R package to allow replication by others.                                         Conclusions:               This decision-support tool can be used to assess changes in virus transmission in different regions and countries worldwide. This allows policymakers to assess the effectiveness of current interventions, and will be useful for inferring whether or not transmission will increase when interventions are lifted. As well as providing daily updates on our website, we also provide adaptable computing code so that our approach can be used directly by researchers and policymakers on confidential datasets. We hope that our tool will be used to support decisions in countries worldwide throughout the ongoing COVID-19 pandemic.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6NVRL2CB\\Abbott et al. - 2020 - Estimating the time-varying reproduction number of.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\953X5CFJ\\v1.html}
}

@incollection{AbbreviationsAcronyms2017,
  title = {Abbreviations and {{Acronyms}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {405--406},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.abbrev},
  abstract = {No Abstract.},
  isbn = {978-1-118-63198-0},
  langid = {english},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.abbrev},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZUS3T52M\\2017 - Abbreviations and Acronyms.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\9GW7BF6Z\\9781118631980.html}
}

@article{abu-raddadCharacterizingSymmetricEquilibrium2005,
  title = {Characterizing the Symmetric Equilibrium of Multi-Strain Host-Pathogen Systems in the Presence of Cross Immunity},
  author = {{Abu-Raddad}, L.J. and Ferguson, N.M.},
  year = {2005},
  month = apr,
  journal = {Journal of Mathematical Biology},
  volume = {50},
  number = {5},
  pages = {531--558},
  issn = {1432-1416},
  doi = {10.1007/s00285-004-0292-4},
  abstract = {We investigate the population dynamics of host-pathogen systems in which the pathogen has a potentially arbitrary number of antigenically distinct strains interacting via cross-immunity. The interior equilibrium configuration of the symmetric multiple strain SIR model with cross-immunity is characterized. We develop an efficient iterative method for numerically solving the equilibrium equation together with a number of informative analytical approximations to the full solution. Equilibrium properties are studied as a function of the number of strains, reproduction number, infectious period, and cross immunity profile. We establish that the prevalence in the system increases monotonically with the number of strains and the reduction in cross immunity. Moreover, we demonstrate the existence of a phase transition separating high prevalence and low prevalence parameter regions, with the critical point being defined by {$\sigma$}R0{$\cong$}1, where {$\sigma$} is the level of cross-immunity and R0 is the reproduction number. Above the threshold, prevalence saturates with increasing numbers of strains as a result of the inclusion of prohibition of co-infection in the model. Below the threshold, prevalence saturates much more rapidly as the number of strains increases - indicating that when cross-protection is sufficiently intense, the selective advantage for a pathogen to increase its diversity is substantially less than in the threshold region. Similarly, there is limited benefit to increased transmissibility (or decreased cross-immunity) both for the high and low diversity pathogen systems compared with systems at the threshold {$\sigma$}R0{$\cong$}1 where small increase in transmissibility can result in significant increase in prevalence.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YRHQHMMX\\Abu-Raddad and Ferguson - 2005 - Characterizing the symmetric equilibrium of multi-.pdf}
}

@article{abu-raddadEffectivenessBNT162b2Covid192021,
  title = {Effectiveness of the {{BNT162b2 Covid-19 Vaccine}} against the {{B}}.1.1.7 and {{B}}.1.351 {{Variants}}},
  author = {{Abu-Raddad}, Laith J. and Chemaitelly, Hiam and Butt, Adeel A.},
  year = {2021},
  month = may,
  journal = {New England Journal of Medicine},
  volume = {0},
  number = {0},
  pages = {null},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMc2104974},
  annotation = {\_eprint: https://www.nejm.org/doi/pdf/10.1056/NEJMc2104974},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZVUYNEFG\\Abu-Raddad et al. - 2021 - Effectiveness of the BNT162b2 Covid-19 Vaccine aga.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UQXGSXHU\\NEJMc2104974.html}
}

@article{accorsiHowDetectReduce2021,
  title = {How to Detect and Reduce Potential Sources of Biases in Studies of {{SARS-CoV-2}} and {{COVID-19}}},
  author = {Accorsi, Emma K. and Qiu, Xueting and Rumpler, Eva and {Kennedy-Shaffer}, Lee and Kahn, Rebecca and Joshi, Keya and Goldstein, Edward and Stensrud, Mats J. and Niehus, Rene and Cevik, Muge and Lipsitch, Marc},
  year = {2021},
  month = feb,
  journal = {European Journal of Epidemiology},
  issn = {1573-7284},
  doi = {10.1007/s10654-021-00727-7},
  abstract = {In response to the coronavirus disease (COVID-19) pandemic, public health scientists have produced a large and rapidly expanding body of literature that aims to answer critical questions, such as the proportion of the population in a geographic area that has been infected; the transmissibility of the virus and factors associated with high infectiousness or susceptibility to infection; which groups are the most at risk of infection, morbidity and mortality; and the degree to which antibodies confer protection to re-infection. Observational studies are subject to a number of different biases, including confounding, selection bias, and measurement error, that may threaten their validity or influence the interpretation of their results. To assist in the critical evaluation of a vast body of literature and contribute to future study design, we outline and propose solutions to biases that can occur across different categories of observational studies of COVID-19. We consider potential biases that could occur in five categories of studies: (1) cross-sectional seroprevalence, (2) longitudinal seroprotection, (3) risk factor studies to inform interventions, (4) studies to estimate the secondary attack rate, and (5) studies that use secondary attack rates to make inferences about infectiousness and susceptibility.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2ZSSD9WJ\\Accorsi et al. - 2021 - How to detect and reduce potential sources of bias.pdf}
}

@article{ahmadLeadingCausesDeath2021,
  title = {The {{Leading Causes}} of {{Death}} in the {{US}} for 2020},
  author = {Ahmad, Farida B. and Anderson, Robert N.},
  year = {2021},
  month = mar,
  journal = {JAMA},
  issn = {0098-7484},
  doi = {10.1001/jama.2021.5469},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LARBLGMV\\Ahmad and Anderson - 2021 - The Leading Causes of Death in the US for 2020.pdf}
}

@article{ainslieEvidenceInitialSuccess2020,
  title = {Evidence of Initial Success for {{China}} Exiting {{COVID-19}} Social Distancing Policy after Achieving Containment},
  author = {Ainslie, Kylie E C and Walters, Caroline E. and Fu, Han and Bhatia, Sangeeta and Wang, Haowei and Xi, Xiaoyue and Baguelin, Marc and Bhatt, Samir and Boonyasiri, Adhiratha and Boyd, Olivia and Cattarino, Lorenzo and Ciavarella, Constanze and Cucunuba, Zulma and {Cuomo-Dannenburg}, Gina and Dighe, Amy and Dorigatti, Ilaria and {van Elsland}, Sabine L and FitzJohn, Rich and Gaythorpe, Katy and Ghani, Azra C and Green, Will and Hamlet, Arran and Hinsley, Wes and Imai, Natsuko and Jorgensen, David and Knock, Edward and Laydon, Daniel and {Nedjati-Gilani}, Gemma and Okell, Lucy C and Siveroni, Igor and Thompson, Hayley A and Unwin, H Juliette T and Verity, Robert and Vollmer, Michaela and Walker, Patrick G T and Wang, Yuanrong and Watson, Oliver J and Whittaker, Charles and Winskill, Peter and Donnelly, Christl A and Ferguson, Neil M and Riley, Steven},
  year = {2020},
  month = apr,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {81},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.15843.1},
  abstract = {Background               : The COVID-19 epidemic was declared a Global Pandemic by WHO on 11 March 2020. By 24 March 2020, over 440,000 cases and almost 20,000 deaths had been reported worldwide. In response to the fast-growing epidemic, which began in the Chinese city of Wuhan, Hubei, China imposed strict social distancing in Wuhan on 23 January 2020 followed closely by similar measures in other provinces. These interventions have impacted economic productivity in China, and the ability of the Chinese economy to resume without restarting the epidemic was not clear.                                         Methods               : Using daily reported cases from mainland China and Hong Kong SAR, we estimated transmissibility over time and compared it to daily within-city movement, as a proxy for economic activity.                                         Results               : Initially, within-city movement and transmission were very strongly correlated in the five mainland provinces most affected by the epidemic and Beijing. However, that correlation decreased rapidly after the initial sharp fall in transmissibility. In general, towards the end of the study period, the correlation was no longer apparent, despite substantial increases in within-city movement. A similar analysis for Hong Kong shows that intermediate levels of local activity were maintained while avoiding a large outbreak. At the very end of the study period, when China began to experience the re-introduction of a small number of cases from Europe and the United States, there is an apparent up-tick in transmission.                                         Conclusions:               Although these results do not preclude future substantial increases in incidence, they suggest that after very intense social distancing (which resulted in containment), China successfully exited its lockdown to some degree. Elsewhere, movement data are being used as proxies for economic activity to assess the impact of interventions. The results presented here illustrate how the eventual decorrelation between transmission and movement is likely a key feature of successful COVID-19 exit strategies.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GQDE7MNX\\5-81.html}
}

@article{al-alyHighdimensionalCharacterizationPostacute2021,
  title = {High-Dimensional Characterization of Post-Acute Sequalae of {{COVID-19}}},
  author = {{Al-Aly}, Ziyad and Xie, Yan and Bowe, Benjamin},
  year = {2021},
  month = apr,
  journal = {Nature},
  pages = {1--8},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-021-03553-9},
  abstract = {The acute clinical manifestations of COVID-19 are well characterized1,2; however, its post-acute sequalae have not been comprehensively described. Here, we use the national healthcare databases of the US Department of Veterans Affairs to systematically and comprehensively identify 6-month incident sequalae including diagnoses, medication use, and laboratory abnormalities in 30-day survivors of COVID-19. We show that beyond the first 30 days of illness, people with COVID-19 exhibit higher risk of death and health resource utilization. Our high dimensional approach identifies incident sequalae in the respiratory system and several others including nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain, and anemia. We show increased incident use of several therapeutics including pain medications (opioids and non-opioids), antidepressants, anxiolytics, antihypertensives, and oral hypoglycemics and evidence of laboratory abnormalities in multiple organ systems. Analysis of an array of pre-specified outcomes reveals a risk gradient that increased across severity of the acute COVID-19 infection (non-hospitalized, hospitalized, admitted to intensive care). The findings show that beyond the acute illness, substantial burden of health loss \textemdash{} spanning pulmonary and several extrapulmonary organ systems \textemdash{} is experienced by COVID-19 survivors. The results provide a roadmap to inform health system planning and development of multidisciplinary care strategies to reduce chronic health loss among COVID-19 survivors.},
  copyright = {2021 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q726H2TC\\s41586-021-03553-9.html}
}

@article{aliSerialIntervalSARSCoV22020,
  title = {Serial Interval of {{SARS-CoV-2}} Was Shortened over Time by Nonpharmaceutical Interventions},
  author = {Ali, Sheikh Taslim and Wang, Lin and Lau, Eric H. Y. and Xu, Xiao-Ke and Du, Zhanwei and Wu, Ye and Leung, Gabriel M. and Cowling, Benjamin J.},
  year = {2020},
  month = aug,
  journal = {Science},
  volume = {369},
  number = {6507},
  pages = {1106--1109},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc9004},
  abstract = {From cough to splutter In epidemiology, serial intervals are measured from when one infected person starts to show symptoms to when the next person infected becomes symptomatic. For any specific infection, the serial interval is assumed to be a fixed characteristic. Using valuable transmission pair data for coronavirus disease (COVID-19) in mainland China, Ali et al. noticed that the average serial interval changed as nonpharmaceutical interventions were introduced. In mid-January 2020, serial intervals were on average 7.8 days, whereas in early February 2020, they decreased to an average of 2.2 days. The more quickly infected persons were identified and isolated, the shorter the serial interval became and the fewer the opportunities for virus transmission. The change in serial interval may not only measure the effectiveness of infection control interventions but may also indicate rising population immunity. Science, this issue p. 1106 Studies of novel coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have reported varying estimates of epidemiological parameters, including serial interval distributions\textemdash i.e., the time between illness onset in successive cases in a transmission chain\textemdash and reproduction numbers. By compiling a line-list database of transmission pairs in mainland China, we show that mean serial intervals of COVID-19 shortened substantially from 7.8 to 2.6 days within a month (9 January to 13 February 2020). This change was driven by enhanced nonpharmaceutical interventions, particularly case isolation. We also show that using real-time estimation of serial intervals allowing for variation over time provides more accurate estimates of reproduction numbers than using conventionally fixed serial interval distributions. These findings could improve our ability to assess transmission dynamics, forecast future incidence, and estimate the impact of control measures. The serial interval distribution of COVID-19 changes in response to interventions and offers a measure for effectiveness of control. The serial interval distribution of COVID-19 changes in response to interventions and offers a measure for effectiveness of control.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32694200},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5WWYNPCJ\\Ali et al. - 2020 - Serial interval of SARS-CoV-2 was shortened over t.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\SUEZM43J\\1106.html}
}

@article{althouseStochasticityHeterogeneityTransmission,
  title = {Stochasticity and Heterogeneity in the Transmission Dynamics of {{SARS-CoV-2}}},
  author = {Althouse, Benjamin M and Wenger, Edward A and Miller, Joel C and Allard, Antoine},
  pages = {10},
  abstract = {SARS-CoV-2 causing COVID-19 disease has moved rapidly around the globe, infecting millions and killing hundreds of thousands. The basic reproduction number, which has been widely used and misused to characterize the transmissibility of the virus, hides the fact that transmission is stochastic, is dominated by a small number of individuals, and is driven by super-spreading events (SSEs). The distinct transmission features, such as high stochasticity under low prevalence, and the central role played by SSEs on transmission dynamics, should not be overlooked. Many explosive SSEs have occurred in indoor settings stoking the pandemic and shaping its spread, such as long-term care facilities, prisons, meat-packing plants, fish factories, cruise ships, family gatherings, parties and night clubs. These SSEs demonstrate the urgent need to understand routes of transmission, while posing an opportunity that outbreak can be effectively contained with targeted interventions to eliminate SSEs. Here, we describe the potential types of SSEs, how they influence transmission, and give recommendations for control of SARS-CoV-2.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\STFST598\\Althouse et al. - Stochasticity and heterogeneity in the transmissio.pdf}
}

@misc{AnalysisSevereOutcomes,
  title = {Analysis of Severe Outcomes Associated with the {{SARS-CoV-2 Variant}} of {{Concern}} 202012/01 in {{England}} Using {{ICNARC Case Mix Programme}} and {{QResearch}} Databases | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2021.03.11.21253364v1}
}

@article{andreasenEpidemicsCompetitionPartial2018,
  title = {Epidemics in {{Competition}}: {{Partial Cross-Immunity}}},
  shorttitle = {Epidemics in {{Competition}}},
  author = {Andreasen, Viggo},
  year = {2018},
  month = nov,
  journal = {Bulletin of Mathematical Biology},
  volume = {80},
  number = {11},
  pages = {2957--2977},
  issn = {1522-9602},
  doi = {10.1007/s11538-018-0495-2},
  abstract = {The competition between two pathogen strains during the course of an epidemic represents a fundamental step in the early evolution of emerging diseases as well as in the antigenic drift process of influenza. The outcome of the competition, however, depends not only on the epidemic properties of the two strains but also on the timing and size of the introduction, characteristics that are poorly captured by deterministic mean-field epidemic models. We describe those aspects of the competition that can be determined from the mean-field models giving the range of possible final sizes of susceptible hosts and cumulated attack rates that could be observed after an epidemic with two cross-reacting strains. In the limit where the size of the initial infection goes to zero, the possible outcomes lie on a (one dimensional) curve in the outcome space.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6KMTNRFK\\Andreasen - 2018 - Epidemics in Competition Partial Cross-Immunity.pdf}
}

@techreport{andrewsEffectivenessBNT162b2Comirnaty2021,
  type = {Preprint},
  title = {Effectiveness of {{BNT162b2}} ({{Comirnaty}}, {{Pfizer-BioNTech}}) {{COVID-19}} Booster Vaccine against Covid-19 Related Symptoms in {{England}}: Test Negative Case-Control Study},
  shorttitle = {Effectiveness of {{BNT162b2}} ({{Comirnaty}}, {{Pfizer-BioNTech}}) {{COVID-19}} Booster Vaccine against Covid-19 Related Symptoms in {{England}}},
  author = {Andrews, Nick and Stowe, Julia and Kirsebom, Freja and Gower, Charlotte and Ramsay, Mary and Lopez Bernal, Jamie},
  year = {2021},
  month = nov,
  institution = {{Epidemiology}},
  doi = {10.1101/2021.11.15.21266341},
  abstract = {Background In September 2021, the UK Government introduced a booster programme targeting individuals over 50 and those in a clinical risk group. Individuals were offered either a full dose of the BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine or a half dose of the mRNA-1273 (Spikevax, Moderna) vaccine, irrespective of the vaccine received as the primary course. Methods We used a test-negative case-control design to estimate the vaccine effectiveness (VE) of the booster dose BNT162b2 (Comirnaty, Pfizer-BioNTech) in those aged over 50 against symptomatic disease in post booster time intervals compared to individuals at least 140 days post a second dose with no booster dose recorded. In a secondary analysis, we also compared to unvaccinated individuals and to the 2 to 6 day period after a booster dose was received. Analyses were stratified by which primary doses had been received and any mixed primary courses were excluded. Results The relative VE estimate in the 14 days after the BNT162b2 (Comirnaty, Pfizer-BioNTech) booster dose, compared to individuals that received a 2-dose primary course, was 87.4 (95\% confidence interval 84.9-89.4) in those individuals who received 2 doses ChAdOx1-S (Vaxzevria, AstraZeneca) as a primary course and 84.4 (95\% confidence interval 82.8-85.8) in those individuals who received 2 doses of BNT162b2 (Comirnaty, Pfizer-BioNTech) as a primary course. Using the 2 to 6 day period post the booster dose as the baseline gave similar results. The absolute VE from 14 days after the booster, using the unvaccinated baseline, was 93.1(95\% confidence interval 91.7-94.3) in those with ChAdOx1-S (Vaxzevria, AstraZeneca) as their primary course and 94.0 (93.4-94.6) for BNT162b2 (Comirnaty, Pfizer-BioNTech) as their primary course. Conclusions Our study provides real world evidence of significant increased protection from the booster vaccine dose against symptomatic disease in those aged over 50 year of age irrespective of which primary course was received.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AIBVZI89\\Andrews et al. - 2021 - Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNT.pdf}
}

@incollection{Appendix2017,
  title = {Appendix},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {377--404},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.app},
  abstract = {No Abstract.},
  isbn = {978-1-118-63198-0},
  langid = {english},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.app},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KPDYEGW8\\2017 - Appendix.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q8Y56USK\\9781118631980.html}
}

@article{bakerSusceptibleSupplyLimits2020,
  title = {Susceptible Supply Limits the Role of Climate in the Early {{SARS-CoV-2}} Pandemic},
  author = {Baker, Rachel E. and Yang, Wenchang and Vecchi, Gabriel A. and Metcalf, C. Jessica E. and Grenfell, Bryan T.},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc2535},
  abstract = {Preliminary evidence suggests that climate may modulate the transmission of SARS-CoV-2. Yet it remains unclear whether seasonal and geographic variations in climate can substantially alter the pandemic trajectory, given high susceptibility is a core driver. Here, we use a climate-dependent epidemic model to simulate the SARS-CoV-2 pandemic probing different scenarios based on known coronavirus biology. We find that while variations in weather may be important for endemic infections, during the pandemic stage of an emerging pathogen the climate drives only modest changes to pandemic size. A preliminary analysis of non-pharmaceutical control measures indicates that they may moderate the pandemic-climate interaction via susceptible depletion. Our findings suggest, without effective control measures, strong outbreaks are likely in more humid climates and summer weather will not substantially limit pandemic growth.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32423996},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZWCVVAZH\\Baker et al. - 2020 - Susceptible supply limits the role of climate in t.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\4IK4ET4P\\science.html}
}

@article{banerjeeEstimatingExcess1year2020,
  title = {Estimating Excess 1-Year Mortality Associated with the {{COVID-19}} Pandemic According to Underlying Conditions and Age: A Population-Based Cohort Study},
  shorttitle = {Estimating Excess 1-Year Mortality Associated with the {{COVID-19}} Pandemic According to Underlying Conditions and Age},
  author = {Banerjee, Amitava and Pasea, Laura and Harris, Steve and {Gonzalez-Izquierdo}, Arturo and Torralbo, Ana and Shallcross, Laura and Noursadeghi, Mahdad and Pillay, Deenan and Sebire, Neil and Holmes, Chris and Pagel, Christina and Wong, Wai Keong and Langenberg, Claudia and Williams, Bryan and Denaxas, Spiros and Hemingway, Harry},
  year = {2020},
  month = may,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)30854-0},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated information on high-risk conditions or their longer-term baseline (pre-COVID-19) mortality. We estimated the excess number of deaths over 1 year under different COVID-19 incidence scenarios based on varying levels of transmission suppression and differing mortality impacts based on different relative risks for the disease.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}In this population-based cohort study, we used linked primary and secondary care electronic health records from England (Health Data Research UK\textendash CALIBER). We report prevalence of underlying conditions defined by Public Health England guidelines (from March 16, 2020) in individuals aged 30 years or older registered with a practice between 1997 and 2017, using validated, openly available phenotypes for each condition. We estimated 1-year mortality in each condition, developing simple models (and a tool for calculation) of excess COVID-19-related deaths, assuming relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared with background mortality) of 1{$\cdot$}5, 2{$\cdot$}0, and 3{$\cdot$}0 at differing infection rate scenarios, including full suppression (0{$\cdot$}001\%), partial suppression (1\%), mitigation (10\%), and do nothing (80\%). We also developed an online, public, prototype risk calculator for excess death estimation.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}We included 3 862 012 individuals (1 957 935 [50{$\cdot$}7\%] women and 1 904 077 [49{$\cdot$}3\%] men). We estimated that more than 20\% of the study population are in the high-risk category, of whom 13{$\cdot$}7\% were older than 70 years and 6{$\cdot$}3\% were aged 70 years or younger with at least one underlying condition. 1-year mortality in the high-risk population was estimated to be 4{$\cdot$}46\% (95\% CI 4{$\cdot$}41\textendash 4{$\cdot$}51). Age and underlying conditions combined to influence background risk, varying markedly across conditions. In a full suppression scenario in the UK population, we estimated that there would be two excess deaths (\emph{vs} baseline deaths) with an RR of 1{$\cdot$}5, four with an RR of 2{$\cdot$}0, and seven with an RR of 3{$\cdot$}0. In a mitigation scenario, we estimated 18 374 excess deaths with an RR of 1{$\cdot$}5, 36 749 with an RR of 2{$\cdot$}0, and 73 498 with an RR of 3{$\cdot$}0. In a do nothing scenario, we estimated 146 996 excess deaths with an RR of 1{$\cdot$}5, 293 991 with an RR of 2{$\cdot$}0, and 587 982 with an RR of 3{$\cdot$}0.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}We provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Institute for Health Research University College London Hospitals Biomedical Research Centre, Health Data Research UK.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MCTMU2LZ\\Banerjee et al. - 2020 - Estimating excess 1-year mortality associated with.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\RDNUMYKD\\fulltext.html}
}

@article{bar-onQuantitativeCompendiumCOVID19,
  title = {A Quantitative Compendium of {{COVID-19}} Epidemiology},
  author = {{Bar-On}, Yinon M and Sender, Ron and Flamholz, Avi I and Phillips, Rob and Milo, Ron},
  pages = {54},
  abstract = {Accurate numbers are needed to understand and predict viral dynamics. Curation of high-quality literature values for the infectious period duration or household secondary attack rate, for example, is especially pressing currently because these numbers inform decisions about how and when to lockdown or reopen societies. We aim to provide a curated source for the key numbers that help us understand the virus driving our current global crisis. This compendium focuses solely on COVID-19 epidemiology. The numbers reported in summary format are substantiated by annotated references. For each property, we provide a concise definition, description of measurement and inference methods, and associated caveats. We hope this compendium will make essential numbers more accessible and avoid common sources of confusion for the many newcomers to the field such as using the incubation period to denote and quantify the latent period or using the hospitalization duration for the infectiousness period duration. This document will be repeatedly updated and the community is invited to participate in improving it.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NLQAYWIQ\\Bar-On et al. - A quantitative compendium of COVID-19 epidemiology.pdf}
}

@article{barnardModellingPotentialConsequences,
  title = {Modelling the Potential Consequences of the {{Omicron SARS-CoV-2}} Variant in {{England}}},
  author = {Barnard, Rosanna C and Davies, Nicholas G and Pearson, Carl A B and Jit, Mark and John, W},
  pages = {21},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9MWCBQMX\\Barnard et al. - Modelling the potential consequences of the Omicro.pdf}
}

@article{barros-martinsImmuneResponsesSARSCoV22021,
  title = {Immune Responses against {{SARS-CoV-2}} Variants after Heterologous and Homologous {{ChAdOx1 nCoV-19}}/{{BNT162b2}} Vaccination},
  author = {{Barros-Martins}, Joana and Hammerschmidt, Swantje I. and Cossmann, Anne and Odak, Ivan and Stankov, Metodi V. and Morillas Ramos, Gema and {Dopfer-Jablonka}, Alexandra and Heidemann, Annika and Ritter, Christiane and Friedrichsen, Michaela and {Schultze-Florey}, Christian and Ravens, Inga and Willenzon, Stefanie and Bubke, Anja and Ristenpart, Jasmin and Janssen, Anika and Ssebyatika, George and Bernhardt, G{\"u}nter and M{\"u}nch, Jan and Hoffmann, Markus and P{\"o}hlmann, Stefan and Krey, Thomas and Bo{\v s}njak, Berislav and F{\"o}rster, Reinhold and Behrens, Georg M. N.},
  year = {2021},
  month = jul,
  journal = {Nature Medicine},
  pages = {1--5},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-021-01449-9},
  abstract = {Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n\,=\,32) or BioNTech/Pfizer's BNT162b2 (n\,=\,55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.},
  copyright = {2021 The Author(s)},
  langid = {english},
  annotation = {Bandiera\_abtest: a Cc\_license\_type: cc\_by Cg\_type: Nature Research Journals Primary\_atype: Research Subject\_term: B cells;Medical research;SARS-CoV-2;T cells;Vaccines Subject\_term\_id: b-cells;medical-research;sars-cov-2;t-cells;vaccines},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VIV3C2X4\\Barros-Martins et al. - 2021 - Immune responses against SARS-CoV-2 variants after.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\VC4Y2LXP\\s41591-021-01449-9.html}
}

@article{basuEstimatingInfectionFatality2020,
  title = {Estimating {{The Infection Fatality Rate Among Symptomatic COVID-19 Cases~In The United States}}},
  author = {Basu, Anirban},
  year = {2020},
  month = may,
  journal = {Health Affairs},
  pages = {10.1377/hlthaff.2020.00455},
  publisher = {{Health Affairs}},
  issn = {0278-2715},
  doi = {10.1377/hlthaff.2020.00455},
  abstract = {Knowing the infection fatality rate (IFR) of SARS-CoV and SARS-CoV-2 infections is essential for the fight against the COVID-19 pandemic. Using data through April 20, 2020, we fit a statistical model to COVID-19 case fatality rates over time at the US county level to estimate the COVID-19 IFR among symptomatic cases (IFR-S) as time goes to infinity. The IFR-S in the US was estimated to be 1.3\% (95\% central credible interval: 0.6\% to 2.1\%). County-specific rates varied from 0.5\% to 3.6\%. The overall IFR for COVID-19 should be lower when we account for cases that remain and recover without symptoms. When used with other estimating approaches, our model and our estimates can help disease and policy modelers to obtain more accurate predictions for the epidemiology of the disease and the impact of alternative policy levers to contain this pandemic. The model could also be used with future epidemics to get an early sense of the magnitude of symptomatic infection at the population-level before more direct estimates are available. Substantial variation across patient demographics likely exists and should be the focus of future studies. [Editor's Note: This Fast Track Ahead Of Print article is the accepted version of the peer-reviewed manuscript. The final edited version will appear in an upcoming issue of Health Affairs.]},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CYYLCNKU\\Basu - 2020 - Estimating The Infection Fatality Rate Among Sympt.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\S75H8NB4\\hlthaff.2020.html}
}

@techreport{basuPerformanceAbbottID2020,
  type = {Preprint},
  title = {Performance of {{Abbott ID NOW COVID-19}} Rapid Nucleic Acid Amplification Test in Nasopharyngeal Swabs Transported in Viral Media and Dry Nasal Swabs, in a {{New York City}} Academic Institution},
  author = {Basu, Atreyee and Zinger, Tatyana and Inglima, Kenneth and Woo, Kar-mun and Atie, Onome and Yurasits, Lauren and See, Benjamin and {Aguero-Rosenfeld}, Maria E.},
  year = {2020},
  month = may,
  institution = {{Microbiology}},
  doi = {10.1101/2020.05.11.089896},
  abstract = {Abstract           The recent emergence of the SARS-CoV-2 pandemic has posed formidable challenges for clinical laboratories seeking reliable laboratory diagnostic confirmation. The swift advance of the crisis in the United States has led to Emergency Use Authorization (EUA) facilitating the availability of molecular diagnostic assays without the more rigorous examination to which tests are normally subjected prior to FDA approval. Our laboratory currently uses two real time RT-PCR platforms, the Roche Cobas SARS-CoV2 and the Cepheid Xpert Xpress SARS-CoV-2. Both platforms demonstrate comparable performance; however, the run times for each assay are 3.5 hours and 45 minutes, respectively. In search for a platform with shorter turnaround time, we sought to evaluate the recently released Abbott ID NOW COVID-19 assay which is capable of producing positive results in as little as 5 minutes. We present here the results of comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media and comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media for Cepheid and dry nasal swabs for Abbott ID NOW. Regardless of method of collection and sample type, Abbott ID NOW COVID-19 had negative results in a third of the samples that tested positive by Cepheid Xpert Xpress when using nasopharyngeal swabs in viral transport media and 45\% when using dry nasal swabs.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QGY3957M\\Basu et al. - 2020 - Performance of Abbott ID NOW COVID-19 rapid nuclei.pdf}
}

@misc{BayesianDiagnosticTest,
  title = {Bayesian {{Diagnostic Test Accuracy Meta-Analysis}}},
  howpublished = {https://bayesdta.shinyapps.io/meta-analysis/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HJSLEC7C\\meta-analysis.html}
}

@article{belongiaCOVID19FluPerfect2020,
  title = {{{COVID-19}} and Flu, a Perfect Storm},
  author = {Belongia, Edward A. and Osterholm, Michael T.},
  year = {2020},
  month = jun,
  journal = {Science},
  volume = {368},
  number = {6496},
  pages = {1163--1163},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abd2220},
  abstract = {The world is in uncharted waters for the 2020 respiratory virus season. For the first time in modern history, the Northern Hemisphere faces the prospect of the coronavirus disease 2019 (COVID-19) pandemic and a simultaneous epidemic of seasonal influenza. Each causes life-threatening illness and death, especially in older adults, people with chronic diseases, and other vulnerable populations. How can we prepare for this convergence? The timing and severity of a COVID-19 wave in the fall and winter are uncertain, but past experiences with the 1918 and 1957 influenza pandemics point to the possibility of a resurgence. Almost nothing is known about the interaction of influenza virus and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, the cause of COVID-19) within individuals. Does coinfection increase the risk of severe illness or amplify virus shedding? Few coinfections have been reported from China during the early phase of the pandemic. The Southern Hemisphere influenza season is just beginning, and it may provide some clues as to what can be expected in the Northern Hemisphere later this year. Much of the population remains susceptible to SARS-CoV-2, and the stress on hospitals will be greatest if the COVID-19 and influenza epidemics overlap and peak around the same time. It is possible that the number of individuals infected with each virus will peak at different times, reducing the peak demand for hospital beds. If a surge in COVID-19 cases occurs this fall, tightening mitigation strategies will be necessary. Social distancing and stay-at-home orders are socially and economically disruptive, but can reduce demand on hospitals and protect vulnerable populations. They will also reduce transmission of other respiratory viruses, including influenza and respiratory syncytial virus. Supplies of personal protective equipment must sufficiently meet the projected demand of a severe influenza season along with COVID-19. There are important differences in the epidemiology of COVID-19 and seasonal influenza, but symptoms overlap. Molecular diagnostic testing for SARS-CoV-2 is critical for all patients with acute respiratory illness, especially during periods of co-circulation. Rapid-turn-around testing is necessary to distinguish between influenza and COVID-19, guide patient care, and support a comprehensive COVID-19 control program (including isolation of cases and rapid identification and quarantine of contacts). Every effort should be made to ensure that resources will be available for combined testing for COVID-19 and influenza. These tests should be without charge to patients because they serve a dual purpose for public health and patient care. We do not yet have a COVID-19 vaccine, but safe and moderately effective influenza vaccines are available. Their widespread use is more important now than ever, and we encourage health care providers, employers, and community leaders to promote vaccination. Vaccine effectiveness varies by season and subtype, but vaccination offers similar protection against laboratory-confirmed influenza hospitalization and outpatient illness. Widespread misinformation on social media includes the false claim that influenza vaccination increases the risk of SARS-CoV-2 infection. Scientists, health care providers, and public health leaders must counter these claims with clear, evidence-based information on the importance of influenza vaccination during the COVID-19 pandemic. The prospect of a second COVID-19 wave requires planning to ensure optimal delivery of influenza vaccines starting in the early fall. Community vaccination sites are often set up for maximum volume and efficiency, and alternative approaches will be needed to maintain physical distancing and minimize the risk of SARS-CoV-2 transmission, particularly because many influenza vaccine recipients are at high risk for both influenza and COVID-19 complications. Randomized trials have shown that some enhanced influenza vaccines (e.g., high-dose inactivated vaccine and recombinant vaccines) generate greater protection in older adults compared to standard-dose inactivated vaccine. The optimal timing of influenza vaccination in patients with confirmed COVID-19 is uncertain. There are no clinical studies on the effects of influenza vaccination in patients with COVID-19, but it may be prudent to delay vaccine administration until after the acute illness has resolved. Over 400,000 COVID-19 deaths were reported worldwide by 6 June, including over 109,000 in the United States. The actual death count is almost certainly higher, and we are still in the early phase of the pandemic. The U.S. Centers for Disease Control and Prevention estimates that influenza has killed 12,000 to 61,000 each season over the past decade. Will there be a perfect storm of COVID-19 and influenza during the 2020\textendash 2021 season? We do not yet know, but we must start preparing in the coming months.},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. http://www-sciencemag-org.uaccess.univie.ac.at/about/science-licenses-journal-article-reuseThis is an article distributed under the terms of the Science Journals Default License.},
  langid = {english},
  pmid = {32527804},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QBL5YAFI\\Belongia and Osterholm - 2020 - COVID-19 and flu, a perfect storm.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\2GZ4P9VW\\1163.html}
}

@article{benatiaEstimatingCOVID19Prevalence,
  title = {Estimating {{COVID-19 Prevalence}} in the {{United States}}: {{A Sample Selection Model Approach}}},
  author = {Benatia, David and Godefroy, Raphael and Lewis, Joshua},
  pages = {24},
  abstract = {Background Public health efforts to determine population infection rates from coronavirus disease 2019 (COVID-19) have been hampered by limitations in testing capabilities and the large shares of mild and asymptomatic cases. We developed a methodology that corrects observed positive test rates for non-random sampling to estimate population infection rates across U.S. states from March 31 to April 7.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YW9Z4IJW\\Benatia et al. - Estimating COVID-19 Prevalence in the United State.pdf}
}

@article{berlinSevereCovid192020,
  title = {Severe {{Covid-19}}},
  author = {Berlin, David A. and Gulick, Roy M. and Martinez, Fernando J.},
  year = {2020},
  month = may,
  journal = {New England Journal of Medicine},
  volume = {0},
  number = {0},
  pages = {null},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMcp2009575},
  abstract = {Key Clinical Points Evaluation and Management of Severe Covid-19 Patients with severe coronavirus disease 2019 (Covid-19) may become critically ill with acute respiratory distress syndrome that typically begins approximately 1 week after the onset of symptoms. Deciding when a patient with severe Covid-19 should receive endotracheal intubation is an essential component of care. After intubation, patients should receive lung-protective ventilation with plateau pressure less than or equal to 30 cm of water and with tidal volumes based on the patient's height. Prone positioning is a potential treatment strategy for refractory hypoxemia. Thrombosis and renal failure are well-recognized complications of severe Covid-19. Data are needed from randomized trials to inform the benefits and risks of antiviral or immunomodulatory therapies for severe Covid-19; as of mid-May 2020, no agents had been approved by the Food and Drug Administration for treatment of these patients. Preliminary data from a randomized, placebo-controlled trial involving patients with severe Covid-19 suggest that the investigational antiviral remdesivir shortens time to recovery.},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMcp2009575},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ESGR9D37\\Berlin et al. - 2020 - Severe Covid-19.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\P3EFELDQ\\NEJMcp2009575.html}
}

@article{bettencourtRealTimeBayesian2008,
  title = {Real {{Time Bayesian Estimation}} of the {{Epidemic Potential}} of {{Emerging Infectious Diseases}}},
  author = {Bettencourt, Lu{\'i}s M. A. and Ribeiro, Ruy M.},
  editor = {Lusseau, David},
  year = {2008},
  month = may,
  journal = {PLoS ONE},
  volume = {3},
  number = {5},
  pages = {e2185},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0002185},
  abstract = {Background: Fast changes in human demographics worldwide, coupled with increased mobility, and modified land uses make the threat of emerging infectious diseases increasingly important. Currently there is worldwide alert for H5N1 avian influenza becoming as transmissible in humans as seasonal influenza, and potentially causing a pandemic of unprecedented proportions. Here we show how epidemiological surveillance data for emerging infectious diseases can be interpreted in real time to assess changes in transmissibility with quantified uncertainty, and to perform running time predictions of new cases and guide logistics allocations. Methodology/Principal Findings: We develop an extension of standard epidemiological models, appropriate for emerging infectious diseases, that describes the probabilistic progression of case numbers due to the concurrent effects of (incipient) human transmission and multiple introductions from a reservoir. The model is cast in terms of surveillance observables and immediately suggests a simple graphical estimation procedure for the effective reproductive number R (mean number of cases generated by an infectious individual) of standard epidemics. For emerging infectious diseases, which typically show large relative case number fluctuations over time, we develop a Bayesian scheme for real time estimation of the probability distribution of the effective reproduction number and show how to use such inferences to formulate significance tests on future epidemiological observations. Conclusions/Significance: Violations of these significance tests define statistical anomalies that may signal changes in the epidemiology of emerging diseases and should trigger further field investigation. We apply the methodology to case data from World Health Organization reports to place bounds on the current transmissibility of H5N1 influenza in humans and establish a statistical basis for monitoring its evolution in real time.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\E7KT43AZ\\Bettencourt and Ribeiro - 2008 - Real Time Bayesian Estimation of the Epidemic Pote.pdf}
}

@misc{BevolkerungNachAlter,
  title = {Bev\"olkerung Nach {{Alter}} Und {{Geschlecht}}},
  howpublished = {https://www.statistik.at/web\_de/statistiken/menschen\_und\_gesellschaft/bevoelkerung/bevoelkerungsstruktur/bevoelkerung\_nach\_alter\_geschlecht/index.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\59UZG5X2\\index.html}
}

@techreport{bicherSupportingAustriaCOVID192020,
  type = {Preprint},
  title = {Supporting {{Austria}} through the {{COVID-19 Epidemics}} with a {{Forecast-Based Early Warning System}}},
  author = {Bicher, Martin and Zuba, Martin and Rainer, Lukas and Bachner, Florian and Rippinger, Claire and Ostermann, Herwig and Popper, Nikolas and Thurner, Stefan and Klimek, Peter},
  year = {2020},
  month = oct,
  institution = {{Health Policy}},
  doi = {10.1101/2020.10.18.20214767},
  abstract = {Background             The corona crisis hit Austria at the end of February 2020 with one of the first European superspreading events. In response, the governmental crisis unit commissioned a forecast consortium with regularly projections of case numbers and demand for hospital beds.                                   Methods             We consolidated the output of three independent epidemiological models (ranging from agent-based micro simulation to parsimonious compartmental models) and published weekly short-term forecasts for the number of confirmed cases as well as estimates and upper bounds for the required hospital beds.                                   Findings             Here, we report om four key contributions by which our forecasting and reporting system has helped shaping Austria's policy to navigate the crisis and re-open the country step-wise, namely (i) when and where case numbers are expected to peak during the first wave, (ii) how to safely re-open the country after passing this peak, (iii) how to evaluate the effects of non-pharmaceutical interventions and (iv) provide hospital managers guidance to plan health-care capacities.                                   Interpretation             Complex mathematical epidemiological models play an important role in guiding governmental responses during pandemic crises, provided they are used as a monitoring system to detect epidemiological change points. For policy-makers, the media and the public, it might be problematic to distinguish short-term forecasts from worst-case scenarios with undefined levels of certainty, creating distrust in the legitimacy and accuracy of such models. However, when used as a short-term forecast-based monitoring system, the models can inform decisions to ease or strengthen governmental responses.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\P7T2HDKD\\Bicher et al. - 2020 - Supporting Austria through the COVID-19 Epidemics .pdf}
}

@techreport{bicherSupportingAustriaCOVID192020a,
  type = {Preprint},
  title = {Supporting {{Austria}} through the {{COVID-19 Epidemics}} with a {{Forecast-Based Early Warning System}}},
  author = {Bicher, Martin and Zuba, Martin and Rainer, Lukas and Bachner, Florian and Rippinger, Claire and Ostermann, Herwig and Popper, Nikolas and Thurner, Stefan and Klimek, Peter},
  year = {2020},
  month = oct,
  institution = {{Health Policy}},
  doi = {10.1101/2020.10.18.20214767},
  abstract = {Background             The corona crisis hit Austria at the end of February 2020 with one of the first European superspreading events. In response, the governmental crisis unit commissioned a forecast consortium with regularly projections of case numbers and demand for hospital beds.                                   Methods             We consolidated the output of three independent epidemiological models (ranging from agent-based micro simulation to parsimonious compartmental models) and published weekly short-term forecasts for the number of confirmed cases as well as estimates and upper bounds for the required hospital beds.                                   Findings             Here, we report om four key contributions by which our forecasting and reporting system has helped shaping Austria's policy to navigate the crisis and re-open the country step-wise, namely (i) when and where case numbers are expected to peak during the first wave, (ii) how to safely re-open the country after passing this peak, (iii) how to evaluate the effects of non-pharmaceutical interventions and (iv) provide hospital managers guidance to plan health-care capacities.                                   Interpretation             Complex mathematical epidemiological models play an important role in guiding governmental responses during pandemic crises, provided they are used as a monitoring system to detect epidemiological change points. For policy-makers, the media and the public, it might be problematic to distinguish short-term forecasts from worst-case scenarios with undefined levels of certainty, creating distrust in the legitimacy and accuracy of such models. However, when used as a short-term forecast-based monitoring system, the models can inform decisions to ease or strengthen governmental responses.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X3AWMFLU\\Bicher et al. - 2020 - Supporting Austria through the COVID-19 Epidemics .pdf}
}

@article{biEpidemiologyTransmissionCOVID192020,
  title = {Epidemiology and Transmission of {{COVID-19}} in 391 Cases and 1286 of Their Close Contacts in {{Shenzhen}}, {{China}}: A Retrospective Cohort Study},
  shorttitle = {Epidemiology and Transmission of {{COVID-19}} in 391 Cases and 1286 of Their Close Contacts in {{Shenzhen}}, {{China}}},
  author = {Bi, Qifang and Wu, Yongsheng and Mei, Shujiang and Ye, Chenfei and Zou, Xuan and Zhang, Zhen and Liu, Xiaojian and Wei, Lan and Truelove, Shaun A. and Zhang, Tong and Gao, Wei and Cheng, Cong and Tang, Xiujuan and Wu, Xiaoliang and Wu, Yu and Sun, Binbin and Huang, Suli and Sun, Yu and Zhang, Juncen and Ma, Ting and Lessler, Justin and Feng, Tiejian},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30287-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, prompted heightened surveillance in Shenzhen, China. The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control measures.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}From Jan 14 to Feb 12, 2020, the Shenzhen Center for Disease Control and Prevention identified 391 SARS-CoV-2 cases and 1286 close contacts. We compared cases identified through symptomatic surveillance and contact tracing, and estimated the time from symptom onset to confirmation, isolation, and admission to hospital. We estimated metrics of disease transmission and analysed factors influencing transmission risk.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Cases were older than the general population (mean age 45 years) and balanced between males (n=187) and females (n=204). 356 (91\%) of 391 cases had mild or moderate clinical severity at initial assessment. As of Feb 22, 2020, three cases had died and 225 had recovered (median time to recovery 21 days; 95\% CI 20\textendash 22). Cases were isolated on average 4{$\cdot$}6 days (95\% CI 4{$\cdot$}1\textendash 5{$\cdot$}0) after developing symptoms; contact tracing reduced this by 1{$\cdot$}9 days (95\% CI 1{$\cdot$}1\textendash 2{$\cdot$}7). Household contacts and those travelling with a case were at higher risk of infection (odds ratio 6{$\cdot$}27 [95\% CI 1{$\cdot$}49\textendash 26{$\cdot$}33] for household contacts and 7{$\cdot$}06 [1{$\cdot$}43\textendash 34{$\cdot$}91] for those travelling with a case) than other close contacts. The household secondary attack rate was 11{$\cdot$}2\% (95\% CI 9{$\cdot$}1\textendash 13{$\cdot$}8), and children were as likely to be infected as adults (infection rate 7{$\cdot$}4\% in children {$<$}10 years \emph{vs} population average of 6{$\cdot$}6\%). The observed reproductive number (\emph{R}) was 0{$\cdot$}4 (95\% CI 0{$\cdot$}3\textendash 0{$\cdot$}5), with a mean serial interval of 6{$\cdot$}3 days (95\% CI 5{$\cdot$}2\textendash 7{$\cdot$}6).{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Our data on cases as well as their infected and uninfected close contacts provide key insights into the epidemiology of SARS-CoV-2. This analysis shows that isolation and contact tracing reduce the time during which cases are infectious in the community, thereby reducing the \emph{R}. The overall impact of isolation and contact tracing, however, is uncertain and highly dependent on the number of asymptomatic cases. Moreover, children are at a similar risk of infection to the general population, although less likely to have severe symptoms; hence they should be considered in analyses of transmission and control.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Emergency Response Program of Harbin Institute of Technology, Emergency Response Program of Peng Cheng Laboratory, US Centers for Disease Control and Prevention.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32353347},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7NGQEITF\\Bi et al. - 2020 - Epidemiology and transmission of COVID-19 in 391 c.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\X25FLRY4\\fulltext.html}
}

@article{biEpidemiologyTransmissionCOVID192020a,
  title = {Epidemiology and Transmission of {{COVID-19}} in 391 Cases and 1286 of Their Close Contacts in {{Shenzhen}}, {{China}}: A Retrospective Cohort Study},
  shorttitle = {Epidemiology and Transmission of {{COVID-19}} in 391 Cases and 1286 of Their Close Contacts in {{Shenzhen}}, {{China}}},
  author = {Bi, Qifang and Wu, Yongsheng and Mei, Shujiang and Ye, Chenfei and Zou, Xuan and Zhang, Zhen and Liu, Xiaojian and Wei, Lan and Truelove, Shaun A. and Zhang, Tong and Gao, Wei and Cheng, Cong and Tang, Xiujuan and Wu, Xiaoliang and Wu, Yu and Sun, Binbin and Huang, Suli and Sun, Yu and Zhang, Juncen and Ma, Ting and Lessler, Justin and Feng, Tiejian},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30287-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, prompted heightened surveillance in Shenzhen, China. The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control measures.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}From Jan 14 to Feb 12, 2020, the Shenzhen Center for Disease Control and Prevention identified 391 SARS-CoV-2 cases and 1286 close contacts. We compared cases identified through symptomatic surveillance and contact tracing, and estimated the time from symptom onset to confirmation, isolation, and admission to hospital. We estimated metrics of disease transmission and analysed factors influencing transmission risk.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Cases were older than the general population (mean age 45 years) and balanced between males (n=187) and females (n=204). 356 (91\%) of 391 cases had mild or moderate clinical severity at initial assessment. As of Feb 22, 2020, three cases had died and 225 had recovered (median time to recovery 21 days; 95\% CI 20\textendash 22). Cases were isolated on average 4{$\cdot$}6 days (95\% CI 4{$\cdot$}1\textendash 5{$\cdot$}0) after developing symptoms; contact tracing reduced this by 1{$\cdot$}9 days (95\% CI 1{$\cdot$}1\textendash 2{$\cdot$}7). Household contacts and those travelling with a case were at higher risk of infection (odds ratio 6{$\cdot$}27 [95\% CI 1{$\cdot$}49\textendash 26{$\cdot$}33] for household contacts and 7{$\cdot$}06 [1{$\cdot$}43\textendash 34{$\cdot$}91] for those travelling with a case) than other close contacts. The household secondary attack rate was 11{$\cdot$}2\% (95\% CI 9{$\cdot$}1\textendash 13{$\cdot$}8), and children were as likely to be infected as adults (infection rate 7{$\cdot$}4\% in children {$<$}10 years \emph{vs} population average of 6{$\cdot$}6\%). The observed reproductive number (\emph{R}) was 0{$\cdot$}4 (95\% CI 0{$\cdot$}3\textendash 0{$\cdot$}5), with a mean serial interval of 6{$\cdot$}3 days (95\% CI 5{$\cdot$}2\textendash 7{$\cdot$}6).{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Our data on cases as well as their infected and uninfected close contacts provide key insights into the epidemiology of SARS-CoV-2. This analysis shows that isolation and contact tracing reduce the time during which cases are infectious in the community, thereby reducing the \emph{R}. The overall impact of isolation and contact tracing, however, is uncertain and highly dependent on the number of asymptomatic cases. Moreover, children are at a similar risk of infection to the general population, although less likely to have severe symptoms; hence they should be considered in analyses of transmission and control.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Emergency Response Program of Harbin Institute of Technology, Emergency Response Program of Peng Cheng Laboratory, US Centers for Disease Control and Prevention.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32353347},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NEFI8INQ\\Bi et al. - 2020 - Epidemiology and transmission of COVID-19 in 391 c.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ED73JYZ7\\fulltext.html}
}

@article{biggerstaffEstimatesReproductionNumber2014,
  title = {Estimates of the Reproduction Number for Seasonal, Pandemic, and Zoonotic Influenza: A Systematic Review of the Literature},
  shorttitle = {Estimates of the Reproduction Number for Seasonal, Pandemic, and Zoonotic Influenza},
  author = {Biggerstaff, Matthew and Cauchemez, Simon and Reed, Carrie and Gambhir, Manoj and Finelli, Lyn},
  year = {2014},
  month = sep,
  journal = {BMC Infectious Diseases},
  volume = {14},
  number = {1},
  pages = {480},
  issn = {1471-2334},
  doi = {10.1186/1471-2334-14-480},
  abstract = {The potential impact of an influenza pandemic can be assessed by calculating a set of transmissibility parameters, the most important being the reproduction number (R), which is defined as the average number of secondary cases generated per typical infectious case.},
  keywords = {Influenza,Pandemics,Reproductive number,Zoonotic influenza},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6EX4F432\\Biggerstaff et al. - 2014 - Estimates of the reproduction number for seasonal,.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\T7ZZ3X7Q\\1471-2334-14-480.html}
}

@article{bin-rezaUseMasksRespirators2012,
  title = {The Use of Masks and Respirators to Prevent Transmission of Influenza: A Systematic Review of the Scientific Evidence},
  shorttitle = {The Use of Masks and Respirators to Prevent Transmission of Influenza},
  author = {{bin-Reza}, Faisal and Lopez Chavarrias, Vicente and Nicoll, Angus and Chamberland, Mary E.},
  year = {2012},
  month = jul,
  journal = {Influenza and Other Respiratory Viruses},
  volume = {6},
  number = {4},
  pages = {257--267},
  issn = {1750-2640},
  doi = {10.1111/j.1750-2659.2011.00307.x},
  abstract = {Please cite this paper as: bin-Reza et~al. (2012) The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. Influenza and Other Respiratory Viruses 6(4), 257\textendash 267., There are limited data on the use of masks and respirators to reduce transmission of influenza. A systematic review was undertaken to help inform pandemic influenza guidance in the United Kingdom. The initial review was performed in November 2009 and updated in June 2010 and January 2011. Inclusion criteria included randomised controlled trials and quasi-experimental and observational studies of humans published in English with an outcome of laboratory-confirmed or clinically-diagnosed influenza and other viral respiratory infections. There were 17 eligible studies. Six of eight randomised controlled trials found no significant differences between control and intervention groups (masks with or without hand hygiene; N95/P2 respirators). One household trial found that mask wearing coupled with hand sanitiser use reduced secondary transmission of upper respiratory infection/influenza-like illness/laboratory-confirmed influenza compared with education; hand sanitiser alone resulted in no reduction. One hospital-based trial found a lower rate of clinical respiratory illness associated with non-fit-tested N95 respirator use compared with medical masks. Eight of nine retrospective observational studies found that mask and/or respirator use was independently associated with a reduced risk of severe acute respiratory syndrome (SARS). Findings, however, may not be applicable to influenza and many studies were suboptimal. None of the studies established a conclusive relationship between mask/respirator use and protection against influenza infection. Some evidence suggests that mask use is best undertaken as part of a package of personal protection especially hand hygiene. The effectiveness of masks and respirators is likely linked to early, consistent and correct usage.},
  pmcid = {PMC5779801},
  pmid = {22188875},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PWQ79LWU\\binReza et al. - 2012 - The use of masks and respirators to prevent transm.pdf}
}

@article{BiologicalDelaySystems1990,
  title = {Biological Delay Systems: {{Linear}} Stability Theory},
  shorttitle = {Biological Delay Systems},
  year = {1990},
  month = mar,
  journal = {Acta Applicandae Mathematica},
  volume = {18},
  number = {3},
  pages = {297--300},
  issn = {1572-9036},
  doi = {10.1007/BF00049132},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\742PRY8Y\\1990 - Biological delay systems Linear stability theory.pdf}
}

@article{blackwoodIntroductionCompartmentalModeling2018,
  title = {An Introduction to Compartmental Modeling for the Budding Infectious Disease Modeler},
  author = {Blackwood, Julie C. and Childs, Lauren M.},
  year = {2018},
  month = dec,
  journal = {Letters in Biomathematics},
  volume = {5},
  number = {1},
  pages = {195--221},
  issn = {2373-7867},
  doi = {10.1080/23737867.2018.1509026},
  abstract = {Mathematical models are ubiquitous in the study of the transmission dynamics of infectious diseases, In particular, the classic `susceptibleinfectious-recovered' (SIR) paradigm provides a modeling framework that can be adapted to describe the core transmission dynamics of a range of human and wildlife diseases. These models provide an important tool for uncovering the mechanisms generating observed disease dynamics, evaluating potential control strategies, and predicting future outbreaks. With ongoing advances in computational tools as well as access to disease incidence data, the use of such models continues to increase. Here, we provide a basic introduction to disease modeling that is primarily intended for individuals who are new to developing SIR-type models. In particular, we highlight several common issues encountered when structuring and analyzing these models.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LE2NKZDE\\Blackwood and Childs - 2018 - An introduction to compartmental modeling for the .pdf}
}

@misc{BlinkistServingCurious,
  title = {Blinkist: {{Serving}} Curious Minds.},
  shorttitle = {Blinkist},
  journal = {Blinkist Webpage},
  abstract = {Blinkist offers summaries of great nonfiction books' key insights in a made for mobile format. Learn something new every day - on your smartphone, tablet or PC.},
  howpublished = {https://app.blinkist.com/en/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XTA6DKZU\\Blinkist Serving curious minds..html}
}

@misc{bmsgpkCOVID19ZeitreiheVerabreichten,
  title = {{COVID-19: Zeitreihe der verabreichten Impfdosen der Corona-Schutzimpfung - data.gv.at}},
  shorttitle = {{COVID-19}},
  author = {{BMSGPK}},
  abstract = {Die Zeitreihe der verabreichten Impfdosen der Corona-Schutzimpfung, aufgeteilt nach Hersteller, Dosisnummer und Bundesl\"andern. Wird einmal t\"aglich aus dem System des e-Impfpass aktualisiert.},
  howpublished = {https://www.data.gv.at/katalog/dataset/276ffd1e-efdd-42e2-b6c9-04fb5fa2b7ea},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IGBDILCX\\276ffd1e-efdd-42e2-b6c9-04fb5fa2b7ea.html}
}

@article{boelleTrajectoriesHospitalizationCOVID192020,
  title = {Trajectories of {{Hospitalization}} in {{COVID-19 Patients}}: {{An Observational Study}} in {{France}}},
  shorttitle = {Trajectories of {{Hospitalization}} in {{COVID-19 Patients}}},
  author = {Bo{\"e}lle, Pierre-Yves and Delory, Tristan and Maynadier, Xavier and Janssen, C{\'e}cile and Piarroux, Renaud and Pichenot, Marie and Lemaire, Xavier and Baclet, Nicolas and Weyrich, Pierre and Melliez, Hugues and Meybeck, Agn{\`e}s and Lanoix, Jean-Philippe and Robineau, Olivier},
  year = {2020},
  month = sep,
  journal = {Journal of Clinical Medicine},
  volume = {9},
  number = {10},
  pages = {3148},
  issn = {2077-0383},
  doi = {10.3390/jcm9103148},
  abstract = {Describing the characteristics of COVID-19 patients in the hospital is of importance to assist in the management of hospital capacity in the future. Here, we analyze the trajectories of 1321 patients admitted to hospitals in northern and eastern France. We found that the time from onset to hospitalization decreased with age, from 7.3 days in the 20\textendash 65 year-olds to 4.5 in the {$>$}80 year-olds (p {$<$} 0.0001). Overall, the length of stay in the hospital was 15.9 days, and the death rate was 20\%. One patient out of four was admitted to the intensive care unit (ICU) for approximately one month. The characteristics of trajectories changed with age: fewer older patients were admitted to the ICU and the death rate was larger in the elderly. Admission shortly after onset was associated with increased mortality (odds-ratio (OR) = 1.8, Confidence Interval (CI) 95\% [1.3, 2.6]) as well as male sex (OR = 2.1, CI 95\% [1.5, 2.9]). Time from admission within the hospital to the transfer to ICU was short. The age- and sex-adjusted mortality rate decreased over the course of the epidemic, suggesting improvement in care over time. In the SARS-CoV-2 epidemic, the urgent need for ICU at admission and the prolonged length of stay in ICU are a challenge for bed management and organization of care.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PMCVIJ8V\\Bolle et al. - 2020 - Trajectories of Hospitalization in COVID-19 Patien.pdf}
}

@article{bohmerInvestigationCOVID19Outbreak2020,
  title = {Investigation of a {{COVID-19}} Outbreak in {{Germany}} Resulting from a Single Travel-Associated Primary Case: A Case Series},
  shorttitle = {Investigation of a {{COVID-19}} Outbreak in {{Germany}} Resulting from a Single Travel-Associated Primary Case},
  author = {B{\"o}hmer, Merle M. and Buchholz, Udo and Corman, Victor M. and Hoch, Martin and Katz, Katharina and Marosevic, Durdica V. and B{\"o}hm, Stefanie and Woudenberg, Tom and Ackermann, Nikolaus and Konrad, Regina and Eberle, Ute and Treis, Bianca and Dangel, Alexandra and Bengs, Katja and Fingerle, Volker and Berger, Anja and H{\"o}rmansdorfer, Stefan and Ippisch, Siegfried and Wicklein, Bernd and Grahl, Andreas and P{\"o}rtner, Kirsten and Muller, Nadine and Zeitlmann, Nadine and Boender, T. Sonia and Cai, Wei and Reich, Andreas and an der Heiden, Maria and Rexroth, Ute and Hamouda, Osamah and Schneider, Julia and Veith, Talitha and M{\"u}hlemann, Barbara and W{\"o}lfel, Roman and Antwerpen, Markus and Walter, Mathias and Protzer, Ulrike and Liebl, Bernhard and Haas, Walter and Sing, Andreas and Drosten, Christian and Zapf, Andreas},
  year = {2020},
  month = may,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30314-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}In December, 2019, the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, causing COVID-19, a respiratory disease presenting with fever, cough, and often pneumonia. WHO has set the strategic objective to interrupt spread of SARS-CoV-2 worldwide. An outbreak in Bavaria, Germany, starting at the end of January, 2020, provided the opportunity to study transmission events, incubation period, and secondary attack rates.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}A case was defined as a person with SARS-CoV-2 infection confirmed by RT-PCR. Case interviews were done to describe timing of onset and nature of symptoms and to identify and classify contacts as high risk (had cumulative face-to-face contact with a confirmed case for {$\geq$}15 min, direct contact with secretions or body fluids of a patient with confirmed COVID-19, or, in the case of health-care workers, had worked within 2 m of a patient with confirmed COVID-19 without personal protective equipment) or low risk (all other contacts). High-risk contacts were ordered to stay at home in quarantine for 14 days and were actively followed up and monitored for symptoms, and low-risk contacts were tested upon self-reporting of symptoms. We defined fever and cough as specific symptoms, and defined a prodromal phase as the presence of non-specific symptoms for at least 1 day before the onset of specific symptoms. Whole genome sequencing was used to confirm epidemiological links and clarify transmission events where contact histories were ambiguous; integration with epidemiological data enabled precise reconstruction of exposure events and incubation periods. Secondary attack rates were calculated as the number of cases divided by the number of contacts, using Fisher's exact test for the 95\% CIs.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Patient 0 was a Chinese resident who visited Germany for professional reasons. 16 subsequent cases, often with mild and non-specific symptoms, emerged in four transmission generations. Signature mutations in the viral genome occurred upon foundation of generation 2, as well as in one case pertaining to generation 4. The median incubation period was 4{$\cdot$}0 days (IQR 2{$\cdot$}3\textendash 4{$\cdot$}3) and the median serial interval was 4{$\cdot$}0 days (3{$\cdot$}0\textendash 5{$\cdot$}0). Transmission events were likely to have occurred presymptomatically for one case (possibly five more), at the day of symptom onset for four cases (possibly five more), and the remainder after the day of symptom onset or unknown. One or two cases resulted from contact with a case during the prodromal phase. Secondary attack rates were 75{$\cdot$}0\% (95\% CI 19{$\cdot$}0\textendash 99{$\cdot$}0; three of four people) among members of a household cluster in common isolation, 10{$\cdot$}0\% (1{$\cdot$}2\textendash 32{$\cdot$}0; two of 20) among household contacts only together until isolation of the patient, and 5{$\cdot$}1\% (2{$\cdot$}6\textendash 8{$\cdot$}9; 11 of 217) among non-household, high-risk contacts.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Although patients in our study presented with predominately mild, non-specific symptoms, infectiousness before or on the day of symptom onset was substantial. Additionally, the incubation period was often very short and false-negative tests occurred. These results suggest that although the outbreak was controlled, successful long-term and global containment of COVID-19 could be difficult to achieve.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\43WI9MVZ\\Bhmer et al. - 2020 - Investigation of a COVID-19 outbreak in Germany re.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\9UD5RQLZ\\fulltext.html}
}

@techreport{borremansQuantifyingAntibodyKinetics2020,
  type = {Preprint},
  title = {Quantifying Antibody Kinetics and {{RNA}} Shedding during Early-Phase {{SARS-CoV-2}} Infection},
  author = {Borremans, Benny and Gamble, Amandine and Prager, Kc and Helman, Sarah K and McClain, Abby M and Cox, Caitlin and Savage, Van and {Lloyd-Smith}, James O.},
  year = {2020},
  month = may,
  institution = {{Open Science Framework}},
  doi = {10.31219/osf.io/evy4q},
  abstract = {Our ability to understand and mitigate the spread of SARS-CoV-2 depends largely on antibody and viral RNA data that provide information about past exposure and shedding. Five months into the outbreak there is an impressive number of studies reporting antibody kinetics and RNA shedding dynamics, but extensive variation in detection assays, study group demographics, and laboratory protocols has presented a challenge for inferring the true biological patterns. Here, we combine existing data on SARS-CoV-2 IgG, IgM and RNA kinetics using a formal quantitative approach that enables integration of 3,214 data points from 516 individuals, published in 22 studies. This allows us to determine the mean values and distributions of IgG and IgM seroconversion times and titer kinetics, and to characterize how antibody and RNA detection probabilities change during the early phase of infection. We observe extensive variation in antibody response patterns and RNA detection  patterns, explained by both individual heterogeneity and protocol differences such as targeted antigen and sample type. These results provide a robust reference for clinical management of individual patients, and a foundation for the mathematical models and serological surveys that underpin public health policies.}
}

@misc{bostonSeasonalitySARSCoV2Will2020,
  title = {Seasonality of {{SARS-CoV-2}}: {{Will COVID-19}} Go Away on Its Own in Warmer Weather?},
  shorttitle = {Seasonality of {{SARS-CoV-2}}},
  author = {Boston, 677 Huntington Avenue and Ma 02115 +1495-1000},
  year = {2020},
  month = feb,
  journal = {Center for Communicable Disease Dynamics},
  abstract = {Marc Lipsitch, DPhil Professor of Epidemiology and Director, Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health (tl;dr) Probably not. Several people, including the \ldots},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\42C5CDMJ\\will-covid-19-go-away-on-its-own-in-warmer-weather.html}
}

@article{boulwareRandomizedTrialHydroxychloroquine2020,
  title = {A {{Randomized Trial}} of {{Hydroxychloroquine}} as {{Postexposure Prophylaxis}} for {{Covid-19}}},
  author = {Boulware, David R. and Pullen, Matthew F. and Bangdiwala, Ananta S. and Pastick, Katelyn A. and Lofgren, Sarah M. and Okafor, Elizabeth C. and Skipper, Caleb P. and Nascene, Alanna A. and Nicol, Melanie R. and Abassi, Mahsa and Engen, Nicole W. and Cheng, Matthew P. and LaBar, Derek and Lother, Sylvain A. and MacKenzie, Lauren J. and Drobot, Glen and Marten, Nicole and Zarychanski, Ryan and Kelly, Lauren E. and Schwartz, Ilan S. and McDonald, Emily G. and Rajasingham, Radha and Lee, Todd C. and Hullsiek, Kathy H.},
  year = {2020},
  month = jun,
  journal = {New England Journal of Medicine},
  publisher = {{Massachusetts Medical Society}},
  doi = {10.1056/NEJMoa2016638},
  abstract = {Original Article from The New England Journal of Medicine \textemdash{} A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19},
  copyright = {Copyright \textcopyright{} 2020 Massachusetts Medical Society. All rights reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WQBXF5KY\\NEJMoa2016638.html}
}

@techreport{braunPresenceSARSCoV2Reactive2020,
  type = {Preprint},
  title = {Presence of {{SARS-CoV-2}} Reactive {{T}} Cells in {{COVID-19}} Patients and Healthy Donors},
  author = {Braun, Julian and Loyal, Lucie and Frentsch, Marco and Wendisch, Daniel and Georg, Philipp and Kurth, Florian and Hippenstiel, Stefan and Dingeldey, Manuela and Kruse, Beate and Fauchere, Florent and Baysal, Emre and Mangold, Maike and Henze, Larissa and Lauster, Roland and Mall, Marcus and Beyer, Kirsten and Roehmel, Jobst and Schmitz, Juergen and Miltenyi, Stefan and Mueller, Marcel A and Witzenrath, Martin and Suttorp, Norbert and Kern, Florian and Reimer, Ulf and Wenschuh, Holger and Drosten, Christian and Corman, Victor M and {Giesecke-Thiel}, Claudia and Sander, Leif-Erik and Thiel, Andreas},
  year = {2020},
  month = apr,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2020.04.17.20061440},
  abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly unfolding pandemic, overwhelming health care systems worldwide1. Clinical manifestations of Corona-virus-disease 2019 (COVID-19) vary broadly, ranging from asymptomatic infection to acute respiratory failure and death2, yet the underlying physiological conditions and mechanisms for this high variability are still unknown. Also, the role of host immune responses in viral clearance and its involvement in pathogenesis remains unresolved. For SARS-CoV (2002/03), however, CD4+ T cell responses are generally associated with positive outcomes3,4, while cellular immune responses to SARS-CoV-2 have not yet been investigated. Here we describe an assay that allows direct detection and characterization of SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cells in peripheral blood. We demonstrate the presence of S-reactive CD4+ T cells in 83\% of COVID-19 patients, as well as in 34\% of SARS-CoV-2 seronegative healthy donors, albeit at lower frequencies. Strikingly, in COVID-19 patients S-reactive CD4+ T cells equally targeted both N-terminal and C-terminal parts of S whereas in healthy donors S-reactive CD4+ T cells reacted almost exclusively to the Cterminal part that is a) characterized by higher homology to spike glycoprotein of human endemic "common cold" coronaviruses, and b) contains the S2 subunit of S with the cytoplasmic peptide (CP), the fusion peptide (FP), and the transmembrane domain (TM) but not the receptor-binding domain (RBD). S-reactive CD4+ T cells from COVID-19 patients were further distinct to those from healthy donors as they co-expressed higher levels of CD38 and HLA-DR, indicating their recent in vivo activation. Our study is the first to directly measure SARS-CoV-2-reactive T cell responses providing critical tools for large scale testing, in depth epitope mapping and characterization of potential cross-reactive cellular immunity to SARS-CoV-2. The presence of pre-existing SARS-CoV-2-reactive T cells in healthy donors is of high interest but larger scale prospective cohort studies are needed to assess whether their presence is a correlate of protection or pathology. Results of such studies will be key for a mechanistic understanding of the SARS-CoV-2 pandemic, adaptation of containment methods and to support vaccine development.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UA7F3R3H\\Braun et al. - 2020 - Presence of SARS-CoV-2 reactive T cells in COVID-1.pdf}
}

@techreport{brazeauReport34COVID192020,
  title = {Report 34: {{COVID-19}} Infection Fatality Ratio: Estimates from Seroprevalence},
  shorttitle = {Report 34},
  author = {Brazeau, N and Verity, R and Jenks, S and Fu, H and Whittaker, C and Winskill, P and Dorigatti, I and Walker, P and Riley, S and Schnekenberg, RP and Heltgebaum, H and Mellan, T and Mishra, S and Unwin, H and Watson, O and Cucunuba Perez, Z and Baguelin, M and Whittles, L and Bhatt, S and Ghani, A and Ferguson, N and Okell, L},
  year = {2020},
  month = oct,
  institution = {{Imperial College London}},
  doi = {10.25561/83545},
  abstract = {The infection fatality ratio (IFR) is a key statistic for estimating the burden of coronavirus disease 2019 (COVID-19) and has been continuously debated throughout the current pandemic. Previous estimates have relied on data early in the epidemic, or have not fully accounted for uncertainty in serological test characteristics and delays from onset of infection to seroconversion, death, and antibody waning. After screening 175 studies, we identified 10 representative antibody surveys to obtain updated estimates of the IFR using a modelling framework that addresses the limitations listed above. We inferred serological test specificity from regional variation within serosurveys, which is critical for correctly estimating the cumulative proportion infected when seroprevalence is still low. We find that age-specific IFRs follow an approximately log-linear pattern, with the risk of death doubling approximately every eight years of age. Using these age-specific estimates, we estimate the overall IFR in a typical low-income country, with a population structure skewed towards younger individuals, to be 0.23\% (0.14-0.42 95\% prediction interval range). In contrast, in a typical high income country, with a greater concentration of elderly individuals, we estimate the overall IFR to be 1.15\% (0.78-1.79 95\% prediction interval range). We show that accounting for seroreversion, the waning of antibodies leading to a negative serological result, can slightly reduce the IFR among serosurveys conducted several months after the first wave of the outbreak, such as Italy. In contrast, uncertainty in test false positive rates combined with low seroprevalence in some surveys can reconcile apparently low crude fatality ratios with the IFR in other countries. Unbiased estimates of the IFR continue to be critical to policymakers to inform key response decisions. It will be important to continue to monitor the IFR as new treatments are introduced.},
  collaborator = {Medical Research Council (MRC) and Foundation, Abdul Latif Jameel},
  copyright = {\textcopyright{} 2020. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/)., Creative Commons Attribution Non Commercial No Derivatives 4.0 International, 10000-01-01},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XTN623L9\\Brazeau et al. - 2020 - Report 34 COVID-19 infection fatality ratio esti.pdf}
}

@article{brittonMathematicalModelReveals2020,
  title = {A Mathematical Model Reveals the Influence of Population Heterogeneity on Herd Immunity to {{SARS-CoV-2}}},
  author = {Britton, Tom and Ball, Frank and Trapman, Pieter},
  year = {2020},
  month = jun,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc6810},
  abstract = {Despite various levels of preventive measures, in 2020 many countries have suffered severely from the coronavirus 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. We show that population heterogeneity can significantly impact disease-induced immunity as the proportion infected in groups with the highest contact rates is greater than in groups with low contact rates. We estimate that if R0 = 2.5 in an age-structured community with mixing rates fitted to social activity then the disease-induced herd immunity level can be around 43\%, which is substantially less than the classical herd immunity level of 60\% obtained through homogeneous immunization of the population. Our estimates should be interpreted as an illustration of how population heterogeneity affects herd immunity, rather than an exact value or even a best estimate.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32576668},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9CXJFEQ3\\Britton et al. - 2020 - A mathematical model reveals the influence of popu.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\YFEEW8QY\\science.html}
}

@article{bubarModelinformedCOVID19Vaccine2021,
  title = {Model-Informed {{COVID-19}} Vaccine Prioritization Strategies by Age and Serostatus},
  author = {Bubar, Kate M. and Reinholt, Kyle and Kissler, Stephen M. and Lipsitch, Marc and Cobey, Sarah and Grad, Yonatan H. and Larremore, Daniel B.},
  year = {2021},
  month = feb,
  journal = {Science},
  volume = {371},
  number = {6532},
  pages = {916--921},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abe6959},
  abstract = {Vaccine prioritization There is likely to be high demand for the limited supplies of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), so how should vaccine distribution be prioritized? Bubar et al. modeled across countries how uncertainty about a vaccine's characteristics affects prioritization strategies for reducing deaths and transmission (see the Perspective by Fitzpatrick and Galvani). In the model, vaccine efficacy and its ability to reduce disease and/or block transmission was accounted for in relation to age-related variations in susceptibility, fatality rates, and immune decline. In almost all circumstances, reducing fatalities required distributing the vaccine to those who are most at risk of death, usually persons over 60 years of age and those with comorbidities. If a vaccine is leaky or poorly efficacious in older adults, then priority could be given to younger age groups. To increase the available doses, further priority should be given to seronegative individuals. Science, this issue p. 916; see also p. 890 Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts. To minimize mortality, vaccinate seronegative persons most at risk of death: those with comorbidities and those 60+ years of age. To minimize mortality, vaccinate seronegative persons most at risk of death: those with comorbidities and those 60+ years of age.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {33479118},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MRFSTLL7\\Bubar et al. - 2021 - Model-informed COVID-19 vaccine prioritization str.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MIB9YGTE\\916.html}
}

@article{buiCoronavirusModelsAre2020,
  title = {Coronavirus {{Models Are Nearing Consensus}}, but {{Reopening Could Throw Them Off Again}}},
  author = {Bui, Quoctrung and Katz, Josh and Parlapiano, Alicia and {Sanger-Katz}, Margot},
  year = {2020},
  month = may,
  journal = {The New York Times},
  issn = {0362-4331},
  abstract = {The convergence coincides with growing uncertainty about the effects of changing public policy.},
  chapter = {The Upshot},
  langid = {american},
  keywords = {Coronavirus (2019-nCoV),Statistics}
}

@misc{bundesministeriumbildungwissenschaftundforschungEckpunkteAktivierungSchulsystems2020,
  title = {Eckpunkte Der {{Aktivierung}} Des {{Schulsystems}}},
  author = {{Bundesministerium Bildung, Wissenschaft und Forschung}},
  year = {2020},
  month = apr,
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SIVHGD2I\\corona_etappenplan_2020424.pdf}
}

@misc{bundesministeriumbildungwissenschaftundforschungUmsetzungEtappenplansFur2020,
  title = {Umsetzung Des {{Etappenplans}} F\"ur {{Schulen}}},
  author = {{Bundesministerium Bildung, Wissenschaft und Forschung}},
  year = {2020},
  month = may,
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\K2FPH7H9\\corona_etappenplan_info_20200507.pdf}
}

@article{buonannoEstimationAirborneViral2020,
  title = {Estimation of Airborne Viral Emission: {{Quanta}} Emission Rate of {{SARS-CoV-2}} for Infection Risk Assessment},
  shorttitle = {Estimation of Airborne Viral Emission},
  author = {Buonanno, G. and Stabile, L. and Morawska, L.},
  year = {2020},
  month = aug,
  journal = {Environment International},
  volume = {141},
  pages = {105794},
  issn = {0160-4120},
  doi = {10.1016/j.envint.2020.105794},
  abstract = {Airborne transmission is a pathway of contagion that is still not sufficiently investigated despite the evidence in the scientific literature of the role it can play in the context of an epidemic. While the medical research area dedicates efforts to find cures and remedies to counteract the effects of a virus, the engineering area is involved in providing risk assessments in indoor environments by simulating the airborne transmission of the virus during an epidemic. To this end, virus air emission data are needed. Unfortunately, this information is usually available only after the outbreak, based on specific reverse engineering cases. In this work, a novel approach to estimate the viral load emitted by a contagious subject on the basis of the viral load in the mouth, the type of respiratory activity (e.g. breathing, speaking, whispering), respiratory physiological parameters (e.g. inhalation rate), and activity level (e.g. resting, standing, light exercise) is proposed. The results showed that high quanta emission rates ({$>$}100~quanta~h-1) can be reached by an asymptomatic infectious SARS-CoV-2 subject performing vocalization during light activities (i.e. walking slowly) whereas a symptomatic SARS-CoV-2 subject in resting conditions mostly has a low quanta emission rate ({$<$}1~quantum~h-1). The findings in terms of quanta emission rates were then adopted in infection risk models to demonstrate its application by evaluating the number of people infected by an asymptomatic SARS-CoV-2 subject in Italian indoor microenvironments before and after the introduction of virus containment measures. The results obtained from the simulations clearly highlight that a key role is played by proper ventilation in containment of the virus in indoor environments.},
  langid = {english},
  keywords = {Coronavirus,Indoor,SARS-CoV-2 (CoVID19),Ventilation,Viral load,Virus airborne transmission},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\56JPSQD3\\Buonanno et al. - 2020 - Estimation of airborne viral emission Quanta emis.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WG9R8YKW\\S0160412020312800.html}
}

@article{buranyiScathingCOVID19Book2020,
  title = {Scathing {{COVID-19}} Book from {{Lancet}} Editor \textemdash{} Rushed but Useful},
  author = {Buranyi, Stephen},
  year = {2020},
  month = jun,
  journal = {Nature},
  volume = {582},
  number = {7813},
  pages = {478--479},
  publisher = {{Nature Publishing Group}},
  doi = {10.1038/d41586-020-01839-y},
  abstract = {Richard Horton skewers leaders in two of the richest, most powerful and scientifically advanced countries for getting it so wrong.},
  copyright = {2020 Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FFNSSPSQ\\d41586-020-01839-y.html}
}

@article{burtonGenerationMusicalSequences1999,
  title = {Generation of {{Musical Sequences}} with {{Genetic Techniques}}},
  author = {Burton, Anthony R. and Vladimirova, Tanya},
  year = {1999},
  journal = {Computer Music Journal},
  volume = {23},
  number = {4},
  pages = {59--73},
  issn = {0148-9267},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RWX27PK4\\Burton and Vladimirova - 1999 - Generation of Musical Sequences with Genetic Techn.pdf}
}

@book{bushbergEssentialPhysicsMedical2012,
  title = {The Essential Physics of Medical Imaging},
  author = {Bushberg, Jerrold T},
  year = {2012},
  publisher = {{Wolters Kluwer Health/Lippincott Williams \& Wilkins}},
  address = {{Philadelphia}},
  abstract = {The basic science important to nuclear imaging, including the nature and production of radioactivity, internal dosimetry and radiation detection and measurement, are presented clearly and concisely. Current concepts in the fields of radiation biology and radiation protection relevant to medical imaging, and a number of helpful appendices complete this comprehensive textbook. The text is enhanced by numerous full color charts, tables, images and superb illustrations that reinforce central concepts. The book is ideal for medical imaging professionals, and teachers and students in medical physics and biomedical engineering. Radiology residents will find this text especially useful in bolstering their understanding of imaging physics and related topics prior to board exams."--pub. desc.},
  isbn = {978-0-7817-8057-5 0-7817-8057-8},
  langid = {english}
}

@article{butler-laporteComparisonSalivaNasopharyngeal2021,
  title = {Comparison of {{Saliva}} and {{Nasopharyngeal Swab Nucleic Acid Amplification Testing}} for {{Detection}} of {{SARS-CoV-2}}: {{A Systematic Review}} and {{Meta-analysis}}},
  author = {{Butler-Laporte}, Guillaume and Lawandi, Alexander and Schiller, Ian and Yao, Mandy C. and Dendukuri, Nandini and McDonald, Emily G. and Lee, Todd C.},
  year = {2021},
  month = jan,
  journal = {JAMA Internal Medicine},
  issn = {2168-6106},
  doi = {10.1001/jamainternmed.2020.8876},
  abstract = {Nasopharyngeal swab nucleic acid amplification testing (NAAT) is the noninvasive criterion standard for diagnosis of coronavirus disease 2019 (COVID-19). However, it requires trained personnel, limiting its availability. Saliva NAAT represents an attractive alternative, but its diagnostic performance is unclear.To assess the diagnostic accuracy of saliva NAAT for COVID-19.In this systematic review, a search of the MEDLINE and medRxiv databases was conducted on August 29, 2020, to find studies of diagnostic test accuracy. The final meta-analysis was performed on November 17, 2020.Studies needed to provide enough data to measure salivary NAAT sensitivity and specificity compared with imperfect nasopharyngeal swab NAAT as a reference test. An imperfect reference test does not perfectly reflect the truth (ie, it can give false results). Studies were excluded if the sample contained fewer than 20 participants or was neither random nor consecutive. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to assess the risk of bias.Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed for the systematic review, with multiple authors involved at each stage of the review. To account for the imperfect reference test sensitivity, we used a bayesian latent class bivariate model for the meta-analysis.The primary outcome was pooled sensitivity and specificity. Two secondary analyses were performed: one restricted to peer-reviewed studies, and a post hoc analysis limited to ambulatory settings.The search strategy yielded 385 references, and 16 unique studies were identified for quantitative synthesis. Eight peer-reviewed studies and 8 preprints were included in the meta-analyses (5922 unique patients). There was significant variability in patient selection, study design, and stage of illness at which patients were enrolled. Fifteen studies included ambulatory patients, and 9 exclusively enrolled from an outpatient population with mild or no symptoms. In the primary analysis, the saliva NAAT pooled sensitivity was 83.2\% (95\% credible interval [CrI], 74.7\%-91.4\%) and the pooled specificity was 99.2\% (95\% CrI, 98.2\%-99.8\%). The nasopharyngeal swab NAAT had a sensitivity of 84.8\% (95\% CrI, 76.8\%-92.4\%) and a specificity of 98.9\% (95\% CrI, 97.4\%-99.8\%). Results were similar in secondary analyses.These results suggest that saliva NAAT diagnostic accuracy is similar to that of nasopharyngeal swab NAAT, especially in the ambulatory setting. These findings support larger-scale research on the use of saliva NAAT as an alternative to nasopharyngeal swabs.}
}

@misc{CampingDiningOut,
  title = {From {{Camping To Dining Out}}: {{Here}}'s {{How Experts Rate The Risks Of}} 14 {{Summer Activities}}},
  shorttitle = {From {{Camping To Dining Out}}},
  journal = {NPR.org},
  abstract = {The weather is warming up and public spaces are starting to reopen. How do you decide what's safe to do? We have guidance to help you compare and evaluate the risks.},
  howpublished = {https://www.npr.org/sections/health-shots/2020/05/23/861325631/from-camping-to-dining-out-heres-how-experts-rate-the-risks-of-14-summer-activit},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HVN25KGG\\from-camping-to-dining-out-heres-how-experts-rate-the-risks-of-14-summer-activit.html}
}

@article{canigliaDifferenceinDifferenceTimeCholera2020,
  title = {Difference-in-{{Difference}} in the {{Time}} of {{Cholera}}: A {{Gentle Introduction}} for {{Epidemiologists}}},
  shorttitle = {Difference-in-{{Difference}} in the {{Time}} of {{Cholera}}},
  author = {Caniglia, Ellen C. and Murray, Eleanor J.},
  year = {2020},
  journal = {Current Epidemiology Reports},
  doi = {10.1007/s40471-020-00245-2},
  abstract = {The goal of this article is to provide an introduction to the intuition behind the difference-in-difference method for epidemiologists. We focus on the theoretical aspects of this tool, including the types of questions for which difference-in-difference is appropriate, and what assumptions must hold for the results to be causally interpretable. While currently under-utilized in epidemiologic research, the difference-in-difference method is a useful tool to examine effects of population level exposures, but relies on strong assumptions. We use the famous example of John Snow's investigation of the cause of cholera mortality in London to illustrate the difference-in-difference approach and corresponding assumptions. We conclude by arguing that this method deserves a second look from epidemiologists interested in asking causal questions about the impact of a population level exposure change on a population level outcome for the group that experienced the change.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LK7DPU72\\10.html}
}

@techreport{caoCitywideNucleicAcid2020,
  type = {Preprint},
  title = {Citywide {{Nucleic Acid Screening}} of {{SARS-CoV-2 Infections}} in {{Post-lockdown Wuhan}}, {{China}}: {{Results}} and {{Implications}}},
  shorttitle = {Citywide {{Nucleic Acid Screening}} of {{SARS-CoV-2 Infections}} in {{Post-lockdown Wuhan}}, {{China}}},
  author = {Cao, Shiyi and Gan, Yong and Wang, Chao and Bachmann, Max and Huang, Yuchai and Wang, Tiantian and Li, Liqing and Lu, Kai and Jiang, Heng and Gong, Yanhong and Xv, Hongbin and Shen, Xin and Tian, Qingfeng and Lv, Chuanzhu and Song, Fujian and Yin, Xiaoxv and Lu, Zuxun},
  year = {2020},
  month = jun,
  institution = {{Public and Global Health}},
  doi = {10.1101/2020.06.29.20142554},
  abstract = {Background: After the outbreak of Coronavirus disease in 2019 (COVID-19), stringent lockdown measures were imposed in Wuhan between January 23, 2020 and April 8, 2020. To provide evidence on the post-lockdown risk of COVID-19 epidemic in Wuhan, the city government conducted a citywide nucleic acid screening of SARS-CoV-2 infection between May 14 and June 1, 2020. Methods: All city residents aged {$\geq$}6 years were potentially eligible to participate the screening programme. The rate of detection of asymptomatic infected cases was calculated, and their demographic and geographic distributions were investigated. ArcGIS 10.0 was used to draw a geographic distribution of asymptomatic infected persons. Results: The screening programme recruited a total of 9,899,828 persons (response rate, 92.9\%). The screening found no newly confirmed patients with COVID-19, and identified 300 asymptomatic infected cases (detection rate 0.303/10,000). In addition, 107 of 34,424 previously recovered patients with a history of COVID-19 diagnosis were tested positive (relapse rate, 0.31\%). Virus culture of SARS-CoV-2 was negative for all 300 asymptomatic cases and all 107 recovered COVID-19 patients. A total of 1,174 close contacts of asymptomatic cases were traced and all of them had a negative nucleic acid testing result. Conclusions: Prevalence of COVID-19 nucleic acid test positivity was very low in the Wuhan general population, in recovered cases and in contacts of asymptomatic cases, five to eight weeks after the end of lockdown. These findings help resolve concerns about the post-lockdown risk of COVID-19 epidemic, and promote the recovery of economy and normal social life in Wuhan.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6Y6Y6X3U\\Cao et al. - 2020 - Citywide Nucleic Acid Screening of SARS-CoV-2 Infe.pdf}
}

@misc{caoCitywideNucleicAcid2020a,
  title = {Citywide {{Nucleic Acid Screening}} of {{SARS-CoV-2 Infections}} in {{Post-lockdown Wuhan}}, {{China}}: {{Results}} and {{Implications}}},
  shorttitle = {Citywide {{Nucleic Acid Screening}} of {{SARS-CoV-2 Infections}} in {{Post-lockdown Wuhan}}, {{China}}},
  author = {Cao, Shiyi and Gan, Yong and Wang, Chao and Bachmann, Max and Huang, Yuchai and Wang, Tiantian and Li, Liqing and Lu, Kai and Jiang, Heng and Gong, Yanhong and Xv, Hongbin and Shen, Xin and Tian, Qingfeng and Lv, Chuanzhu and Song, Fujian and Yin, Xiaoxv and Lu, Zuxun},
  year = {2020},
  month = jun,
  pages = {2020.06.29.20142554},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.06.29.20142554},
  abstract = {Background After the outbreak of Coronavirus disease in 2019 (COVID-19), stringent lockdown measures were imposed in Wuhan between January 23, 2020 and April 8, 2020. To provide evidence on the post-lockdown risk of COVID-19 epidemic in Wuhan, the city government conducted a citywide nucleic acid screening of SARS-CoV-2 infection between May 14 and June 1, 2020. Methods All city residents aged {$\geq$}6 years were potentially eligible to participate the screening programme. The rate of detection of asymptomatic infected cases was calculated, and their demographic and geographic distributions were investigated. ArcGIS 10.0 was used to draw a geographic distribution of asymptomatic infected persons. Results The screening programme recruited a total of 9,899,828 persons (response rate, 92.9\%). The screening found no newly confirmed patients with COVID-19, and identified 300 asymptomatic infected cases (detection rate 0.303/10,000). In addition, 107 of 34,424 previously recovered patients with a history of COVID-19 diagnosis were tested positive (relapse rate, 0.31\%). Virus culture of SARS-CoV-2 was negative for all 300 asymptomatic cases and all 107 recovered COVID-19 patients. A total of 1,174 close contacts of asymptomatic cases were traced and all of them had a negative nucleic acid testing result. Conclusions Prevalence of COVID-19 nucleic acid test positivity was very low in the Wuhan general population, in recovered cases and in contacts of asymptomatic cases, five to eight weeks after the end of lockdown. These findings help resolve concerns about the post-lockdown risk of COVID-19 epidemic, and promote the recovery of economy and normal social life in Wuhan.},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4F9JLNC8\\Cao et al. - 2020 - Citywide Nucleic Acid Screening of SARS-CoV-2 Infe.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MVIT6LIM\\2020.06.29.html}
}

@misc{CaseFatalityRisk,
  title = {Case Fatality Risk of the {{SARS-CoV-2}} Variant of Concern {{B}}.1.1.7 in {{England}} | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2021.03.04.21252528v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y2RPQLCX\\2021.03.04.html}
}

@misc{cdcCoronavirusDisease20192020,
  title = {Coronavirus {{Disease}} 2019 ({{COVID-19}})},
  author = {CDC},
  year = {2020},
  month = feb,
  journal = {Centers for Disease Control and Prevention},
  abstract = {Coronavirus disease 2019 (COVID-19) is a virus (more specifically, a coronavirus) identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.},
  howpublished = {https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\INJNDWA8\\forecasting-us.html}
}

@misc{cdcCoronavirusDisease20192020a,
  title = {Coronavirus {{Disease}} 2019 ({{COVID-19}})},
  author = {CDC},
  year = {2020},
  month = feb,
  journal = {Centers for Disease Control and Prevention},
  abstract = {CDC provides credible COVID-19 health information to the U.S.},
  howpublished = {https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\34K8EQRX\\fully-vaccinated-people.html}
}

@misc{cdcCoronavirusDisease20192020b,
  title = {Coronavirus {{Disease}} 2019 ({{COVID-19}})},
  author = {CDC},
  year = {2020},
  month = feb,
  journal = {Centers for Disease Control and Prevention},
  abstract = {CDC provides credible COVID-19 health information to the U.S.},
  howpublished = {https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WWASDMYZ\\fully-vaccinated-people.html}
}

@misc{centerforhistoryandnewmediaSchnelleinstieg,
  title = {Schnelleinstieg},
  author = {{Center for History and New Media}},
  howpublished = {http://zotero.org/support/quick\_start\_guide}
}

@techreport{chadeau-hyamREACT1Study142021,
  type = {Preprint},
  title = {{{REACT-1}} Study Round 14: {{High}} and Increasing Prevalence of {{SARS-CoV-2}} Infection among School-Aged Children during {{September}} 2021 and Vaccine Effectiveness against Infection in {{England}}},
  shorttitle = {{{REACT-1}} Study Round 14},
  author = {{Chadeau-Hyam}, Marc and Wang, Haowei and Eales, Oliver and Haw, David and Bodinier, Barbara and Whitaker, Matthew and Walters, Caroline E. and Ainslie, Kylie E. C. and Atchison, Christina and Fronterre, Claudio and Diggle, Peter J. and Page, Andrew J. and Trotter, Alexander J. and {The COVID-19 Genomics UK (COG-UK) Consortium} and Ashby, Deborah and Barclay, Wendy and Taylor, Graham and Cooke, Graham and Ward, Helen and Darzi, Ara and Riley, Steven and Donnelly, Christl A. and Elliott, Paul},
  year = {2021},
  month = oct,
  institution = {{Epidemiology}},
  doi = {10.1101/2021.10.14.21264965},
  abstract = {Abstract                        Background             England experienced a third wave of the COVID-19 epidemic from end May 2021 coinciding with the rapid spread of Delta variant. Since then, the population eligible for vaccination against COVID-19 has been extended to include all 12-15-year-olds, and a booster programme has been initiated among adults aged 50 years and over, health care and care home workers, and immunocompromised people. Meanwhile, schoolchildren have returned to school often with few COVID-19-related precautions in place.                                   Methods             In the REal-time Assessment of Community Transmission-1 (REACT-1) study, throat and nose swabs were sent to non-overlapping random samples of the population aged 5 years and over in England. We analysed prevalence of SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR) swab-positivity data from REACT-1 round 14 (between 9 and 27 September 2021). We combined results for round 14 with round 13 (between 24 June and 12 July 2021) and estimated vaccine effectiveness and prevalence of swab-positivity among double-vaccinated individuals. Unlike all previous rounds, in round 14, we switched from dry swabs transported by courier on a cold chain to wet swabs using saline. Also, at random, 50\% of swabs (not chilled until they reached the depot) were transported by courier and 50\% were sent through the priority COVID-19 postal service.                                   Results             We observed stable or rising prevalence (with an R of 1.03 (0.94, 1.14) overall) during round 14 with a weighted prevalence of 0.83\% (0.76\%, 0.89\%). The highest weighted prevalence was found in children aged 5 to 12 years at 2.32\% (1.96\%, 2.73\%) and 13 to 17 years at 2.55\% (2.11\%, 3.08\%). All positive virus samples analysed correspond to the Delta variant or sub-lineages of Delta with one instance of the E484K escape mutation detected. The epidemic was growing in those aged 17 years and under with an R of 1.18 (1.03, 1.34), but decreasing in those aged 18 to 54 years with an R of 0.81 (0.68, 0.97). For all participants and all vaccines combined, at ages 18 to 64 years, vaccine effectiveness against infection (rounds 13 and 14 combined) was estimated to be 62.8\% (49.3\%, 72.7\%) after two doses compared to unvaccinated people when adjusted for round, age, sex, index of multiple deprivation, region and ethnicity; the adjusted estimate was 44.8\% (22.5\%, 60.7\%) for AstraZeneca and 71.3\% (56.6\%, 81.0\%) for Pfizer-BioNTech, and for all vaccines combined it was 66.4\% (49.6\%, 77.6\%) against symptomatic infection (one or more of 26 surveyed symptoms in month prior). Across rounds 13 and 14, at ages 18 years and over, weighted prevalence of swab-positivity was 0.55\% (0.50\%, 0.61\%) for those who received their second dose 3-6 months before their swab compared to 0.35\% (0.31\%, 0.40\%) for those whose second dose was within 3 months of their swab, while weighted prevalence among unvaccinated individuals was1.76\% (1.60\%, 1.95\%). In round 14, age group, region, key worker status, and household size jointly contributed to the risk of higher prevalence of swab-positivity.                                   Discussion             In September 2021 infections were increasing exponentially in the 5-to-17-year age group coinciding with the start of the autumn school term in England. Relatively few schoolchildren aged 5 to 17 years have been vaccinated in the UK though single doses are now being offered to those aged 12 years and over. In adults, the higher prevalence of swab-positivity following two doses of vaccine from 3 to 6 months compared to within 3 months of second dose supports the use of a booster vaccine. It is important that the vaccination programme maintains high coverage and reaches children and unvaccinated or partially vaccinated adults to reduce transmission and associated disruptions to work and education.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F5L3VZEC\\Chadeau-Hyam et al. - 2021 - REACT-1 study round 14 High and increasing preval.pdf}
}

@article{chauNaturalHistoryTransmission,
  title = {The Natural History and Transmission Potential of Asymptomatic {{SARS-CoV-2}} Infection},
  author = {Chau, Nguyen Van Vinh and Lam, Vo Thanh and Dung, Nguyen Thanh and Yen, Lam Minh and Ngoc, Ngo and Minh, Quang and Hung, Le Manh and Ngoc, Nghiem My and Dung, Nguyen Tri and Huy, Dinh Nguyen and Nguyet, Lam Anh and Nhat, Le Thanh Hoang and Nhu, Le Nguyen Truc and Han, Nguyen Thi and Hong, Nguyen Thi Thu and Kestelyn, Evelyne and Dung, Nguyen Thi Phuong and Chanh, Tran and Hien, Tran Tinh and Phong, Nguyen Thanh and Tu, Tran Nguyen Hoang},
  pages = {26},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\85PAHU3V\\Chau et al. - The natural history and transmission potential of .pdf}
}

@article{chenPotentialTransmissionSARSCoV22020,
  title = {Potential Transmission of {{SARS-CoV-2}} on a Flight from {{Singapore}} to {{Hanghzou}}, {{China}}: {{An}} Epidemiological Investigation},
  shorttitle = {Potential Transmission of {{SARS-CoV-2}} on a Flight from {{Singapore}} to {{Hanghzou}}, {{China}}},
  author = {Chen, Junfang and He, Hanqing and Cheng, Wei and Liu, Yan and Sun, Zhou and Chai, Chengliang and Kong, Qingxin and Sun, Wanwan and Zhang, Jiaqi and Guo, Song and Shi, Xuguang and Wang, Jinna and Chen, Enfu and Chen, Zhiping},
  year = {2020},
  month = jul,
  journal = {Travel Medicine and Infectious Disease},
  pages = {101816},
  issn = {1477-8939},
  doi = {10.1016/j.tmaid.2020.101816},
  abstract = {Background Between January 24, 2020 and February 15, 2020, an outbreak of COVID-19 occurred among 335 passengers on a flight from Singapore to Hangzhou in China. This study aimed to investigate the source of the outbreak and assess the risk of transmission of COVID-19 during the flight. Method Using a standardized questionnaire, we collected information on the travelers' demographic characteristics and illness before, during, and after the flight. We also collected data on factors potentially associated with COVID-19 transmission during the flight. Results A total of 16 COVID-19 patients were diagnosed among all passengers; the overall attack rate was 4.8\%. The attack rate among passengers who had departed from Wuhan was significantly higher than that among those who had departed from other places. One passenger without an epidemiological history of exposure before boarding developed COVID-19. During the flight, he was seated near four infected passengers from Wuhan for approximately an hour and did not wear his facemask correctly during the flight. Conclusions COVID-19 transmission may have occurred during the flight. However, the majority of the cases in the flight-associated outbreak could not be attributed to transmission on the flight but were associated with exposure to the virus in Wuhan or to infected members in a single tour group.},
  langid = {english},
  keywords = {Air travel,COVID-19,Outbreak investigation,Travel-associated infections},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NGJQBIQH\\Chen et al. - 2020 - Potential transmission of SARS-CoV-2 on a flight f.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3J3CJ6H2\\S1477893920303124.html}
}

@article{choisyFirst100Days,
  title = {The First 100 Days of {{SARS-CoV-2}} Control in {{Vietnam}}},
  author = {Choisy, Marc},
  pages = {28},
  abstract = {Background: One hundred days after SARS-CoV-2 was first reported in Vietnam on January 23rd, 270 cases have been confirmed, with no deaths. We describe the control measures used and their relationship with imported and domestically-acquired case numbers. Methods: Data on the first 270 SARS-CoV-2 infected cases and the timing and nature of control measures were captured by Vietnam's National Steering Committee for COVID-19 response. Apple and Google mobility data provided population movement proxies. Serial intervals were calculated from 33 infector-infectee pairs and used to estimate the proportion of pre-symptomatic transmission events and time-varying reproduction numbers. Results: After the first confirmed case on January 23rd, the Vietnamese Government initiated mass communications measures, contact tracing, mandatory 14-day quarantine, school and university closures, and progressive flight restrictions. A national lockdown was implemented between April 1st and 22nd. Around 200,000 people were quarantined and 266,122 RT-PCR tests conducted. Population mobility decreased progressively before lockdown. 60\% (163/270) of cases were imported; 43\% (89/208) of resolved infections were asymptomatic. 21 developed severe disease, with no deaths. The serial interval was 3.24 days, and 27.5\% (95\% confidence interval, 15.7\%-40.0\%) of transmissions occurred pre-symptomatically. Limited transmission amounted to a maximum reproduction number of 1.15 (95\% confidence interval, 0.37-2.36). No community transmission has been detected since April 15th. Conclusions:},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\R7CWTFU5\\Choisy - The first 100 days of SARS-CoV-2 control in Vietna.pdf}
}

@misc{christensenQuantifyingChangesVaccine2021,
  title = {Quantifying Changes in Vaccine Coverage in Mainstream Media as a Result of {{COVID-19}} Outbreak},
  author = {Christensen, Bente and Laydon, Daniel J. and Chelkowski, Tadeusz and Jemielniak, Dariusz and Vollmer, Michaela and Bhatt, Samir and Krawczyk, Konrad},
  year = {2021},
  month = nov,
  pages = {2021.11.07.21266018},
  abstract = {Background Achieving vaccine-derived herd immunity depends on public acceptance of vaccination, which in turn relies on people's understanding of its risks and benefits. The fundamental objective of public health messaging on vaccines is therefore the clear and concise communication of often complex information, and increasingly the countering of misinformation. The primary outlet shaping societal understanding is the mainstream online news media. There was widespread media coverage of the multiple vaccines that were rapidly developed in response to COVID-19. We studied vaccine coverage on the front pages of mainstream online news, using text-mining analysis to quantify the amount of information and sentiment polarization of vaccine coverage delivered to readers. Methods We analyzed 28 million articles from 172 major news sources, across 11 countries between July 2015 and April 2021. We employed keyword-based frequency analysis to estimate the proportion of coverage given to vaccines in our dataset. We performed topic detection using BERTopic and Named Entity Recognition to identify the leading subjects and actors mentioned in the context of vaccines. We used the Vader Python module to perform sentiment polarization quantification of all our English-language articles. Results We find that the proportion of headlines mentioning vaccines on the front pages of international major news sites increased from 0.1\% to 3.8\% with the outbreak of COVID-19. The absolute number of negatively polarized articles increased from a total of 6,698 before the COVID-19 outbreak 2015-2019 compared to 28,552 in 2020-2021. Overall, however, before the COVID-19 pandemic, vaccine coverage was slightly negatively polarized (57\% negative) whereas with the outbreak, the coverage was primarily positively polarized (38\% negative). Conclusions Because of COVID-19, vaccines have risen from a marginal topic to a widely discussed topic on the front pages of major news outlets. Despite a perceived rise in hesitancy, the mainstream online media, i.e. the primary information source to most individuals, has been strongly positive compared to pre-pandemic vaccine news, which was mainly negative. However, the pandemic was accompanied with an order of magnitude increase in vaccine news volume that due to pre-pandemic low frequency sampling bias may contribute to a perceived negative sentiment. These results highlight the important interactions between the volume of news and overall polarisation. To the best of our knowledge, our work is the first systematic text mining study of vaccines in the context of COVID-19.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english}
}

@article{chuPhysicalDistancingFace2020,
  title = {Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of {{SARS-CoV-2}} and {{COVID-19}}: A Systematic Review and Meta-Analysis},
  shorttitle = {Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of {{SARS-CoV-2}} and {{COVID-19}}},
  author = {Chu, Derek K. and Akl, Elie A. and Duda, Stephanie and Solo, Karla and Yaacoub, Sally and Sch{\"u}nemann, Holger J. and Chu, Derek K. and Akl, Elie A. and {El-harakeh}, Amena and Bognanni, Antonio and Lotfi, Tamara and Loeb, Mark and Hajizadeh, Anisa and Bak, Anna and Izcovich, Ariel and {Cuello-Garcia}, Carlos A. and Chen, Chen and Harris, David J. and Borowiack, Ewa and Chamseddine, Fatimah and Sch{\"u}nemann, Finn and Morgano, Gian Paolo and Sch{\"u}nemann, Giovanna E. U. Muti and Chen, Guang and Zhao, Hong and Neumann, Ignacio and Chan, Jeffrey and Khabsa, Joanne and Hneiny, Layal and Harrison, Leila and Smith, Maureen and Rizk, Nesrine and Rossi, Paolo Giorgi and AbiHanna, Pierre and {El-khoury}, Rayane and Stalteri, Rosa and Baldeh, Tejan and Piggott, Thomas and Zhang, Yuan and Saad, Zahra and Khamis, Assem and Reinap, Marge and Duda, Stephanie and Solo, Karla and Yaacoub, Sally and Sch{\"u}nemann, Holger J.},
  year = {2020},
  month = jun,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)31142-9},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 and is spread person-to-person through close contact. We aimed to investigate the effects of physical distance, face masks, and eye protection on virus transmission in health-care and non-health-care (eg, community) settings.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did a systematic review and meta-analysis to investigate the optimum distance for avoiding person-to-person virus transmission and to assess the use of face masks and eye protection to prevent transmission of viruses. We obtained data for SARS-CoV-2 and the betacoronaviruses that cause severe acute respiratory syndrome, and Middle East respiratory syndrome from 21 standard WHO-specific and COVID-19-specific sources. We searched these data sources from database inception to May 3, 2020, with no restriction by language, for comparative studies and for contextual factors of acceptability, feasibility, resource use, and equity. We screened records, extracted data, and assessed risk of bias in duplicate. We did frequentist and Bayesian meta-analyses and random-effects meta-regressions. We rated the certainty of evidence according to Cochrane methods and the GRADE approach. This study is registered with PROSPERO, CRD42020177047.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Our search identified 172 observational studies across 16 countries and six continents, with no randomised controlled trials and 44 relevant comparative studies in health-care and non-health-care settings (n=25 697 patients). Transmission of viruses was lower with physical distancing of 1 m or more, compared with a distance of less than 1 m (n=10 736, pooled adjusted odds ratio [aOR] 0{$\cdot$}18, 95\% CI 0{$\cdot$}09 to 0{$\cdot$}38; risk difference [RD] -10{$\cdot$}2\%, 95\% CI -11{$\cdot$}5 to -7{$\cdot$}5; moderate certainty); protection was increased as distance was lengthened (change in relative risk [RR] 2{$\cdot$}02 per m; \emph{p}\textsubscript{interaction}=0{$\cdot$}041; moderate certainty). Face mask use could result in a large reduction in risk of infection (n=2647; aOR 0{$\cdot$}15, 95\% CI 0{$\cdot$}07 to 0{$\cdot$}34, RD -14{$\cdot$}3\%, -15{$\cdot$}9 to -10{$\cdot$}7; low certainty), with stronger associations with N95 or similar respirators compared with disposable surgical masks or similar (eg, reusable 12\textendash 16-layer cotton masks; \emph{p}\textsubscript{interaction}=0{$\cdot$}090; posterior probability {$>$}95\%, low certainty). Eye protection also was associated with less infection (n=3713; aOR 0{$\cdot$}22, 95\% CI 0{$\cdot$}12 to 0{$\cdot$}39, RD -10{$\cdot$}6\%, 95\% CI -12{$\cdot$}5 to -7{$\cdot$}7; low certainty). Unadjusted studies and subgroup and sensitivity analyses showed similar findings.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}The findings of this systematic review and meta-analysis support physical distancing of 1 m or more and provide quantitative estimates for models and contact tracing to inform policy. Optimum use of face masks, respirators, and eye protection in public and health-care settings should be informed by these findings and contextual factors. Robust randomised trials are needed to better inform the evidence for these interventions, but this systematic appraisal of currently best available evidence might inform interim guidance.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}World Health Organization.{$<$}/p{$>$}},
  langid = {english}
}

@article{citronComparingMetapopulationDynamics2021,
  title = {Comparing Metapopulation Dynamics of Infectious Diseases under Different Models of Human Movement},
  author = {Citron, Daniel T. and Guerra, Carlos A. and Dolgert, Andrew J. and Wu, Sean L. and Henry, John M. and C, H{\'e}ctor M. S{\'a}nchez and Smith, David L.},
  year = {2021},
  month = may,
  journal = {Proceedings of the National Academy of Sciences},
  volume = {118},
  number = {18},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.2007488118},
  abstract = {Newly available datasets present exciting opportunities to investigate how human population movement contributes to the spread of infectious diseases across large geographical distances. It is now possible to construct realistic models of infectious disease dynamics for the purposes of understanding global-scale epidemics. Nevertheless, a remaining unanswered question is how best to leverage the new data to parameterize models of movement, and whether one's choice of movement model impacts modeled disease outcomes. We adapt three well-studied models of infectious disease dynamics, the susceptible\textendash infected\textendash recovered model, the susceptible\textendash infected\textendash susceptible model, and the Ross\textendash Macdonald model, to incorporate either of two candidate movement models. We describe the effect that the choice of movement model has on each disease model's results, finding that in all cases, there are parameter regimes where choosing one movement model instead of another has a profound impact on epidemiological outcomes. We further demonstrate the importance of choosing an appropriate movement model using the applied case of malaria transmission and importation on Bioko Island, Equatorial Guinea, finding that one model produces intelligible predictions of R0, whereas the other produces nonsensical results.},
  chapter = {Physical Sciences},
  copyright = {Copyright \textcopyright{} 2021 the Author(s). Published by PNAS.. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).},
  langid = {english},
  keywords = {human population movement,infectious disease modeling,malaria,mathematical epidemiology},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3VQYL4RS\\Citron et al. - 2021 - Comparing metapopulation dynamics of infectious di.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QCY7KBAU\\e2007488118.html}
}

@article{clarkGlobalRegionalNational2020,
  title = {Global, Regional, and National Estimates of the Population at Increased Risk of Severe {{COVID-19}} Due to Underlying Health Conditions in 2020: A Modelling Study},
  shorttitle = {Global, Regional, and National Estimates of the Population at Increased Risk of Severe {{COVID-19}} Due to Underlying Health Conditions in 2020},
  author = {Clark, Andrew and Jit, Mark and {Warren-Gash}, Charlotte and Guthrie, Bruce and Wang, Harry H X and Mercer, Stewart W and Sanderson, Colin and McKee, Martin and Troeger, Christopher and Ong, Kanyin L and Checchi, Francesco and Perel, Pablo and Joseph, Sarah and Gibbs, Hamish P and Banerjee, Amitava and Eggo, Rosalind M and Nightingale, Emily S and O'Reilly, Kathleen and Jombart, Thibaut and Edmunds, W John and Rosello, Alicia and Sun, Fiona Yueqian and Atkins, Katherine E and Bosse, Nikos I and Clifford, Samuel and Russell, Timothy W and Deol, Arminder K and Liu, Yang and Procter, Simon R and Leclerc, Quentin J and Medley, Graham and Knight, Gwen and Munday, James D and Kucharski, Adam J and Pearson, Carl A B and Klepac, Petra and Prem, Kiesha and Houben, Rein M G J and Endo, Akira and Flasche, Stefan and Davies, Nicholas G and Diamond, Charlie and {van Zandvoort}, Kevin and Funk, Sebastian and Auzenbergs, Megan and Rees, Eleanor M and Tully, Damien C and Emery, Jon C and Quilty, Billy J and Abbott, Sam and {Villabona-Arenas}, Ch Julian and Hu{\'e}, St{\'e}phane and Hellewell, Joel and Gimma, Amy and Jarvis, Christopher I},
  year = {2020},
  month = jun,
  journal = {The Lancet Global Health},
  issn = {2214-109X},
  doi = {10.1016/S2214-109X(20)30264-3},
  abstract = {Background The risk of severe COVID-19 if an individual becomes infected is known to be higher in older individuals and those with underlying health conditions. Understanding the number of individuals at increased risk of severe COVID-19 and how this varies between countries should inform the design of possible strategies to shield or vaccinate those at highest risk. Methods We estimated the number of individuals at increased risk of severe disease (defined as those with at least one condition listed as ``at increased risk of severe COVID-19'' in current guidelines) by age (5-year age groups), sex, and country for 188 countries using prevalence data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 and UN population estimates for 2020. The list of underlying conditions relevant to COVID-19 was determined by mapping the conditions listed in GBD 2017 to those listed in guidelines published by WHO and public health agencies in the UK and the USA. We analysed data from two large multimorbidity studies to determine appropriate adjustment factors for clustering and multimorbidity. To help interpretation of the degree of risk among those at increased risk, we also estimated the number of individuals at high risk (defined as those that would require hospital admission if infected) using age-specific infection\textendash hospitalisation ratios for COVID-19 estimated for mainland China and making adjustments to reflect country-specific differences in the prevalence of underlying conditions and frailty. We assumed males were twice at likely as females to be at high risk. We also calculated the number of individuals without an underlying condition that could be considered at increased risk because of their age, using minimum ages from 50 to 70 years. We generated uncertainty intervals (UIs) for our estimates by running low and high scenarios using the lower and upper 95\% confidence limits for country population size, disease prevalences, multimorbidity fractions, and infection\textendash hospitalisation ratios, and plausible low and high estimates for the degree of clustering, informed by multimorbidity studies. Findings We estimated that 1{$\cdot$}7 billion (UI 1{$\cdot$}0\textendash 2{$\cdot$}4) people, comprising 22\% (UI 15\textendash 28) of the global population, have at least one underlying condition that puts them at increased risk of severe COVID-19 if infected (ranging from {$<$}5\% of those younger than 20 years to {$>$}66\% of those aged 70 years or older). We estimated that 349 million (186\textendash 787) people (4\% [3\textendash 9] of the global population) are at high risk of severe COVID-19 and would require hospital admission if infected (ranging from {$<$}1\% of those younger than 20 years to approximately 20\% of those aged 70 years or older). We estimated 6\% (3\textendash 12) of males to be at high risk compared with 3\% (2\textendash 7) of females. The share of the population at increased risk was highest in countries with older populations, African countries with high HIV/AIDS prevalence, and small island nations with high diabetes prevalence. Estimates of the number of individuals at increased risk were most sensitive to the prevalence of chronic kidney disease, diabetes, cardiovascular disease, and chronic respiratory disease. Interpretation About one in five individuals worldwide could be at increased risk of severe COVID-19, should they become infected, due to underlying health conditions, but this risk varies considerably by age. Our estimates are uncertain, and focus on underlying conditions rather than other risk factors such as ethnicity, socioeconomic deprivation, and obesity, but provide a starting point for considering the number of individuals that might need to be shielded or vaccinated as the global pandemic unfolds. Funding UK Department for International Development, Wellcome Trust, Health Data Research UK, Medical Research Council, and National Institute for Health Research.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FWJG6HXL\\Clark et al. - 2020 - Global, regional, and national estimates of the po.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IXAAAZ32\\S2214109X20302643.html}
}

@misc{ClusterCOVID19Northern,
  title = {Cluster of {{COVID-19}} in Northern {{France}}: {{A}} Retrospective Closed Cohort Study | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.04.18.20071134v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3QFFQGSK\\2020.04.18.html}
}

@article{cobeyConcernsSARSCoV2Evolution2021,
  title = {Concerns about {{SARS-CoV-2}} Evolution Should Not Hold Back Efforts to Expand Vaccination},
  author = {Cobey, Sarah and Larremore, Daniel B. and Grad, Yonatan H. and Lipsitch, Marc},
  year = {2021},
  month = apr,
  journal = {Nature Reviews Immunology},
  pages = {1--6},
  publisher = {{Nature Publishing Group}},
  issn = {1474-1741},
  doi = {10.1038/s41577-021-00544-9},
  abstract = {When vaccines are in limited supply, expanding the number of people who receive some vaccine, such as by halving doses or increasing the interval between doses, can reduce disease and mortality compared with concentrating available vaccine doses in a subset of the population. A corollary of such dose-sparing strategies is that the vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine-escape variants, ultimately undermining vaccine effectiveness. We argue that, although this is possible, preliminary evidence instead suggests such strategies should slow the rate of viral escape from vaccine or naturally induced immunity. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence of efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution.},
  copyright = {2021 Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IFQKXSFD\\Cobey et al. - 2021 - Concerns about SARS-CoV-2 evolution should not hol.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\RXQW7ADD\\s41577-021-00544-9.html}
}

@article{coleMeasuringInterpretingPoint2011,
  title = {Measuring and Interpreting Point Spread Functions to Determine Confocal Microscope Resolution and Ensure Quality Control},
  author = {Cole, Richard W. and Jinadasa, Tushare and Brown, Claire M.},
  year = {2011},
  month = dec,
  journal = {Nature Protocols},
  volume = {6},
  number = {12},
  pages = {1929--1941},
  issn = {1754-2189},
  doi = {10.1038/nprot.2011.407},
  abstract = {This protocol outlines a procedure for collecting and analyzing point spread functions (PSFs). It describes how to prepare fluorescent microsphere samples, set up a confocal microscope to properly collect 3D confocal image data of the microspheres and perform PSF measurements. The analysis of the PSF is used to determine the resolution of the microscope and to identify any problems with the quality of the microscope's images. The PSF geometry is used as an indicator to identify problems with the objective lens, confocal laser scanning components and other relay optics. Identification of possible causes of PSF abnormalities and solutions to improve microscope performance are provided. The microsphere sample preparation requires 2\textendash 3 h plus an overnight drying period. The microscope setup requires 2 h (1 h for laser warm up), whereas collecting and analyzing the PSF images require an additional 2\textendash 3 h.},
  copyright = {\textcopyright{} 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9X57GVQV\\Cole et al. - 2011 - Measuring and interpreting point spread functions .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\FC757TMV\\Cole et al. - 2011 - Measuring and interpreting point spread functions .html}
}

@article{coleMeasuringInterpretingPoint2011a,
  title = {Measuring and Interpreting Point Spread Functions to Determine Confocal Microscope Resolution and Ensure Quality Control},
  author = {Cole, Richard W and Jinadasa, Tushare and Brown, Claire M},
  year = {2011},
  month = dec,
  journal = {Nature protocols},
  volume = {6},
  number = {12},
  pages = {1929--1941},
  issn = {1750-2799},
  doi = {10.1038/nprot.2011.407},
  abstract = {This protocol outlines a procedure for collecting and analyzing point spread functions (PSFs). It describes how to prepare fluorescent microsphere samples, set up a confocal microscope to properly collect 3D confocal image data of the microspheres and perform PSF measurements. The analysis of the PSF is used to determine the resolution of the microscope and to identify any problems with the quality of the microscope's images. The PSF geometry is used as an indicator to identify problems with the objective lens, confocal laser scanning components and other relay optics. Identification of possible causes of PSF abnormalities and solutions to improve microscope performance are provided. The microsphere sample preparation requires 2-3 h plus an overnight drying period. The microscope setup requires 2 h (1 h for laser warm up), whereas collecting and analyzing the PSF images require an additional 2-3 h.},
  langid = {english},
  pmid = {22082987},
  keywords = {Imaging; Three-Dimensional,Microscopy; Confocal,Microspheres,Quality Control,Weights and Measures}
}

@misc{CoMixStudySocial2020,
  title = {{{CoMix}} Study - {{Social}} Contact Survey in the {{UK}}.},
  year = {2020},
  month = oct,
  journal = {CMMID Repository},
  abstract = {Reports from CoMix social contact survey},
  howpublished = {https://cmmid.github.io/topics/covid19/comix-reports.html},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PVB7FI7S\\comix-reports.html}
}

@misc{CommonStatisticalTests,
  title = {Common Statistical Tests Are Linear Models (or: How to Teach Stats)},
  howpublished = {https://lindeloev.github.io/tests-as-linear/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YV8K5U57\\tests-as-linear.html}
}

@misc{ComparisonSevenCommercial,
  title = {Comparison of Seven Commercial {{SARS-CoV-2}} Rapid {{Point-of-Care Antigen}} Tests | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.11.12.20230292v1}
}

@misc{ComputationalAnalysisEffect,
  title = {Computational Analysis of the Effect of {{SARS-CoV-2}} Variant {{Omicron Spike}} Protein Mutations on Dynamics, {{ACE2}} Binding and Propensity for Immune Escape - {{SARS-CoV-2}} Coronavirus},
  journal = {Virological},
  abstract = {A discussion forum for analysis and interpretation of virus molecular evolution and epidemiology.},
  howpublished = {https://virological.org/t/computational-analysis-of-the-effect-of-sars-cov-2-variant-omicron-spike-protein-mutations-on-dynamics-ace2-binding-and-propensity-for-immune-escape/776},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9UWY5QUT\\776.html}
}

@incollection{ControllingVariance2017,
  title = {Controlling the {{Variance}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {133--186},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch5},
  abstract = {This chapter examines basic theoretical and practical aspects of variance reduction techniques. The control variables method is a widely used variance reduction technique. Permutation Monte Carlo is a conditional Monte Carlo technique for network reliability estimation. The second method used to estimate unreliability effectively employs the concept of a minimal cut. A minimal cut set is a minimal set of components whose failure ensures the failure of the system. The multilevel Monte Carlo method of Giles reduces the computational effort required to obtain both small bias and estimation error, by simulating the process at multiple grids. An alternative approach for choosing an ``optimal'' reference parameter vector is based on the Kullback\textendash Leibler cross-entropy, or simply cross-entropy (CE). Sequential importance sampling (SIS), also called dynamic importance sampling, is simply importance sampling carried out in a sequential manner. The self-avoiding random walk, or simply self-avoiding walk, is a basic mathematical model for polymer chains.},
  chapter = {5},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {KullbackLeibler cross-entropy,permutation Monte Carlo,polymer chains,Sequential importance sampling (SIS),variance reduction techniques},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch5},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZDAXYB9S\\2017 - Controlling the Variance.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\YXQ2DZWG\\9781118631980.html}
}

@article{coriNewFrameworkSoftware2013,
  title = {A {{New Framework}} and {{Software}} to {{Estimate Time-Varying Reproduction Numbers During Epidemics}}},
  author = {Cori, Anne and Ferguson, Neil M. and Fraser, Christophe and Cauchemez, Simon},
  year = {2013},
  month = nov,
  journal = {American Journal of Epidemiology},
  volume = {178},
  number = {9},
  pages = {1505--1512},
  issn = {1476-6256, 0002-9262},
  doi = {10.1093/aje/kwt133},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D4PPJFL2\\Cori et al. - 2013 - A New Framework and Software to Estimate Time-Vary.pdf}
}

@misc{CoronavirusAustriaNew2020,
  title = {Coronavirus in {{Austria}} | {{New Website Provides Case Forecasts}} up to 3 {{Weeks}} in {{Advance}}},
  year = {2020},
  month = dec,
  journal = {Metropole},
  abstract = {The coronavirus is shaping our lives. Here's everything you need to know about COVID-19 in Austria on December 10, 2020 \textendash{} updated regularly.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UUB24264\\coronavirus-in-austria-december-10.html}
}

@misc{CoronavirusAustriaNew2020a,
  title = {Coronavirus in {{Austria}} | {{New Website Provides Case Forecasts}} up to 3 {{Weeks}} in {{Advance}} | {{Page}} 2 of 2},
  year = {2020},
  month = dec,
  journal = {Metropole},
  abstract = {The coronavirus is shaping our lives. Here's everything you need to know about COVID-19 in Austria on December 10, 2020 \textendash{} updated regularly.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HQKNA7LG\\2.html}
}

@article{CoronavirusResearchUpdates2020,
  title = {Coronavirus Research Updates: {{Lifting}} Lockdown Could Spell Surge of Infections for {{France}}},
  shorttitle = {Coronavirus Research Updates},
  year = {2020},
  month = may,
  journal = {Nature},
  publisher = {{Nature Publishing Group}},
  doi = {10.1038/d41586-020-00502-w},
  abstract = {A selection of the latest research on the new coronavirus.},
  copyright = {2020 Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MW8DWC6S\\d41586-020-00502-w.html}
}

@article{CoronavirusResearchUpdates2020a,
  title = {Coronavirus Research Updates: {{Virus}} Conscripts a Pair of Human Proteins to Invade Cells},
  shorttitle = {Coronavirus Research Updates},
  year = {2020},
  month = jun,
  journal = {Nature},
  publisher = {{Nature Publishing Group}},
  doi = {10.1038/d41586-020-00502-w},
  abstract = {A selection of the latest research on the new coronavirus.},
  copyright = {2020 Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\477PW3HY\\d41586-020-00502-w.html}
}

@article{CoronavirusTestingBasics2020,
  title = {Coronavirus {{Testing Basics}}},
  year = {2020},
  pages = {3},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8KYY8UQD\\2020 - Coronavirus Testing Basics.pdf}
}

@article{correa-martinezPandemicTimesGlobal2020,
  title = {A {{Pandemic}} in {{Times}} of {{Global Tourism}}: {{Superspreading}} and {{Exportation}} of {{COVID-19 Cases}} from a {{Ski Area}} in {{Austria}}},
  shorttitle = {A {{Pandemic}} in {{Times}} of {{Global Tourism}}},
  author = {{Correa-Mart{\'i}nez}, Carlos L. and Kampmeier, Stefanie and K{\"u}mpers, Philipp and Schwierzeck, Vera and Hennies, Marc and Hafezi, Wali and K{\"u}hn, Joachim and Pavenst{\"a}dt, Hermann and Ludwig, Stephan and Mellmann, Alexander},
  year = {2020},
  month = may,
  journal = {Journal of Clinical Microbiology},
  volume = {58},
  number = {6},
  publisher = {{American Society for Microbiology Journals}},
  issn = {0095-1137, 1098-660X},
  doi = {10.1128/JCM.00588-20},
  abstract = {On 7 January 2020, the World Health Organization (WHO) announced a novel coronavirus to be the cause of pneumonia cases whose cause was unclear in China. The infection came to be known as a coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After},
  chapter = {Letter to the Editor},
  copyright = {Copyright \textcopyright{} 2020 Correa-Mart\'inez et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.},
  langid = {english},
  pmid = {32245833},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IYKZM5FI\\Correa-Martnez et al. - 2020 - A Pandemic in Times of Global Tourism Superspread.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\T8JV4ZRZ\\e00588-20.html}
}

@article{coutinhojonathanm.IncidenceCerebralVenous2012,
  title = {The {{Incidence}} of {{Cerebral Venous Thrombosis}}},
  author = {{Coutinho Jonathan M.} and {Zuurbier Susanna M.} and {Aramideh Majid} and {Stam Jan}},
  year = {2012},
  month = dec,
  journal = {Stroke},
  volume = {43},
  number = {12},
  pages = {3375--3377},
  publisher = {{American Heart Association}},
  doi = {10.1161/STROKEAHA.112.671453},
  abstract = {Background and Purpose\textemdash The purpose of this study was to determine the incidence of adult cerebral venous thrombosis.Methods\textemdash A retrospective cross-sectional study was conducted among all 19 hospitals located in 2 Dutch provinces serving 3.1 million people. Adult cerebral venous thrombosis cases diagnosed between January 1, 2008, and December 31, 2010, were identified using the Dutch financial coding system for hospital care and the International Classification of Diseases, 9th Revision. Medical records of potential patients were hand searched to identify cerebral venous thrombosis cases. The Dutch National Bureau for Statistics provided population figures of the 2 provinces during 2008 to 2010.Results\textemdash Among 9270 potential cases, we identified 147 patients diagnosed with cerebral venous thrombosis. Of these, 53 patients did not meet the inclusion criteria; therefore, 94 patients were included in the analysis. The overall incidence was 1.32 per 100 000 person-years (95\% CI, 1.06\textendash 1.61). Among women between the ages of 31 and 50 years, the incidence was 2.78 (95\% CI, 1.98\textendash 3.82).Conclusions\textemdash The incidence of cerebral venous thrombosis among adults is probably higher than previously believed.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KQYCBNSK\\Coutinho Jonathan M. et al. - 2012 - The Incidence of Cerebral Venous Thrombosis.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\GQI66UCC\\strokeaha.112.html}
}

@misc{COVID19AustriaMapped,
  title = {{{COVID-19}} in {{Austria}} Mapped: {{New}} Tool Projects Trajectory of Virus in {{Austria}} | {{Imperial News}} | {{Imperial College London}}},
  shorttitle = {{{COVID-19}} in {{Austria}} Mapped},
  journal = {Imperial News},
  abstract = {A new COVID-19 analysis tool that estimates which districts in Austria could become coronavirus hotspots has been launched by Imperial.},
  chapter = {health},
  howpublished = {https://www.imperial.ac.uk/news/210493/covid19-austria-mapped-new-tool-projects/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7NJH7IJA\\covid19-austria-mapped-new-tool-projects.html}
}

@misc{Covid19HasForced2020,
  title = {Covid-19 Has Forced a Reckoning\textemdash the {{UK}} Has Much to Learn from Low Income Settings},
  year = {2020},
  month = may,
  journal = {The BMJ},
  abstract = {The UK should draw from some of the low cost, high impact strategies used in countries that have recently experienced epidemics, say Samuel Boland, Gillian McKay, Benjamin Black, and Susannah [...]More...},
  howpublished = {https://blogs.bmj.com/bmj/2020/05/14/covid-19-has-forced-a-reckoning-the-uk-has-much-to-learn-from-low-income-settings/},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UVGENVT7\\covid-19-has-forced-a-reckoning-the-uk-has-much-to-learn-from-low-income-settings.html}
}

@misc{COVID19HospitalizationsICU,
  title = {{{COVID-19 Hospitalizations}}, {{ICU Admissions}} and {{Deaths Associated}} with the {{New Variants}} of {{Concern}}},
  journal = {Ontario COVID-19 Science Advisory Table},
  doi = {10.47326/ocsat.2021.02.18.1.0},
  abstract = {New variants of concern (VOCs) now account for 67\% of all Ontario SARS-CoV-2 infections. Compared with early variants of SARS-CoV-2, VOCs are associated with a 63\% increased risk of hospitalization, a 103\% increased risk of intensive care unit (ICU) admission and a 56\% increased risk of death due to COVID-19. VOCs are having a substantial impact on Ontario's healthcare system. On March 28, 2021, the daily number of new SARS-CoV-2 infections in Ontario reached the daily number of cases observed near the height of the second wave, at the start of the province-wide lockdown, on December 26, 2020. The number of people hospitalized with COVID-19 is now 21\% higher than at the start of the province-wide lockdown, while ICU occupancy is 28\% higher (Figure 1). The percentage of COVID-19 patients in ICUs who are younger than 60 years is about 50\% higher now than it was prior to the start of the province-wide lockdown. Because the increased risk of COVID-19 hospitalization, ICU admission and death with VOCs is most pronounced 14 to 28 days after diagnosis, there will be significant delays until the full burden to the health care system becomes apparent.},
  howpublished = {https://covid19-sciencetable.ca/sciencebrief/covid-19-hospitalizations-icu-admissions-and-deaths-associated-with-the-new-variants-of-concern/},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CVK374Z6\\covid-19-hospitalizations-icu-admissions-and-deaths-associated-with-the-new-variants-of-concern.html}
}

@article{COVID19VaccineSurveillance,
  title = {{{COVID-19}} Vaccine Surveillance Report - Week 28},
  pages = {24},
  abstract = {Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6JT7EI6B\\COVID-19 vaccine surveillance report - week 28.pdf}
}

@misc{COVID19ZeitreiheVerabreichten,
  title = {{COVID-19: Zeitreihe der verabreichten Impfdosen der Corona-Schutzimpfung - data.gv.at}},
  shorttitle = {{COVID-19}},
  abstract = {Die Zeitreihe der verabreichten Impfdosen der Corona-Schutzimpfung, aufgeteilt nach Hersteller, Dosisnummer und Bundesl\"andern. Wird einmal t\"aglich aus dem System des e-Impfpass aktualisiert.},
  howpublished = {https://www.data.gv.at/katalog/dataset/276ffd1e-efdd-42e2-b6c9-04fb5fa2b7ea},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2X8NVPKN\\276ffd1e-efdd-42e2-b6c9-04fb5fa2b7ea.html}
}

@article{covidVaccinesRelatedBiological,
  title = {Vaccines and {{Related Biological Products Advisory Committee Meeting December}} 10, 2020},
  author = {Covid, Pfizer-BioNTech},
  pages = {53},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TZZDQI3H\\Covid - Vaccines and Related Biological Products Advisory .pdf}
}

@article{coxNotJustAntibodies2020,
  title = {Not Just Antibodies: {{B}} Cells and {{T}} Cells Mediate Immunity to {{COVID-19}}},
  shorttitle = {Not Just Antibodies},
  author = {Cox, Rebecca J. and Brokstad, Karl A.},
  year = {2020},
  month = oct,
  journal = {Nature Reviews Immunology},
  volume = {20},
  number = {10},
  pages = {581--582},
  publisher = {{Nature Publishing Group}},
  issn = {1474-1741},
  doi = {10.1038/s41577-020-00436-4},
  abstract = {Recent reports that antibodies to SARS-CoV-2 are not maintained in the serum following recovery from the virus have caused alarm. However, the absence of specific antibodies in the serum does not necessarily mean an absence of immune memory. Here, we discuss our current understanding of the relative contribution of B cells and T cells to immunity to SARS-CoV-2 and the implications for the development of effective treatments and vaccines for COVID-19.},
  copyright = {2020 Springer Nature Limited},
  langid = {english},
  annotation = {Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype: Comments \& Opinion Subject\_term: Antibodies;B cells;Immunological memory;SARS-CoV-2;T cells Subject\_term\_id: antibodies;b-cells;immunological-memory;sars-cov-2;t-cells},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\J5858PIK\\Cox and Brokstad - 2020 - Not just antibodies B cells and T cells mediate i.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\JKPWYWRX\\s41577-020-00436-4.html}
}

@incollection{CrossEntropyMethod2017,
  title = {Cross-{{Entropy Method}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {257--306},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch8},
  abstract = {This chapter presents a general introduction to the cross-entropy (CE) method, explaining how the idea behind the method is to get as close as possible to the optimal importance sampling distribution by using the Kullback\textendash Leibler CE distance as a measure of closeness. The parameter values corresponding to the bottleneck elements should be smaller than those for the non-bottleneck. An optimization problem involving both discrete and continuous variables is called a mixed optimization problem. A discrete optimization problem is called a combinatorial optimization problem. The same CE program can be used to tackle max-cut problems of much higher dimension, comprising hundreds or thousands of nodes. The MinxEnt program, which presents a constrained functional optimization problem, can be solved via Lagrange multipliers. It suggests how to specify a path generation mechanism and the corresponding CE updating rules.},
  chapter = {8},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {cross-entropy (CE) method,discrete optimization problem,KullbackLeibler CE,Lagrange multipliers,MinxEnt program},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch8},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\R3G95R6H\\2017 - Cross-Entropy Method.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\2PBCVZRX\\9781118631980.html}
}

@article{daganBNT162b2MRNACovid192021,
  title = {{{BNT162b2 mRNA Covid-19 Vaccine}} in a {{Nationwide Mass Vaccination Setting}}},
  author = {Dagan, Noa and Barda, Noam and Kepten, Eldad and Miron, Oren and Perchik, Shay and Katz, Mark A. and Hern{\'a}n, Miguel A. and Lipsitch, Marc and Reis, Ben and Balicer, Ran D.},
  year = {2021},
  month = feb,
  journal = {New England Journal of Medicine},
  publisher = {{Massachusetts Medical Society}},
  doi = {10.1056/NEJMoa2101765},
  abstract = {Original Article from The New England Journal of Medicine \textemdash{} BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting},
  copyright = {Copyright \textcopyright{} 2021 Massachusetts Medical Society. All rights reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2K334Q5H\\NEJMoa2101765.html}
}

@misc{DatadistaDatasets,
  title = {Datadista/Datasets},
  journal = {GitHub},
  abstract = {Fuente de datos de los reportajes y proyectos de periodismo de investigaci\'on y datos de DATADISTA - datadista/datasets},
  howpublished = {https://github.com/datadista/datasets},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MFMKZV32\\COVID 19.html}
}

@article{daviesAgedependentEffectsTransmission2020,
  title = {Age-Dependent Effects in the Transmission and Control of {{COVID-19}} Epidemics},
  author = {Davies, Nicholas G. and Klepac, Petra and Liu, Yang and Prem, Kiesha and Jit, Mark and Eggo, Rosalind M.},
  year = {2020},
  month = jun,
  journal = {Nature Medicine},
  pages = {1--7},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0962-9},
  abstract = {The COVID-19 pandemic has shown a markedly low proportion of cases among children1\textendash 4. Age disparities in observed cases could be explained by children having lower susceptibility to infection, lower propensity to show clinical symptoms or both. We evaluate these possibilities by fitting an age-structured mathematical model to epidemic data from China, Italy, Japan, Singapore, Canada and South Korea. We estimate that susceptibility to infection in individuals under 20 years of age is approximately half that of adults aged over 20 years, and that clinical symptoms manifest in 21\% (95\% credible interval: 12\textendash 31\%) of infections in 10- to 19-year-olds, rising to 69\% (57\textendash 82\%) of infections in people aged over 70 years. Accordingly, we find that interventions aimed at children might have a relatively small impact on reducing SARS-CoV-2 transmission, particularly if the transmissibility of subclinical infections is low. Our age-specific clinical fraction and susceptibility estimates have implications for the expected global burden of COVID-19, as a result of demographic differences across settings. In countries with younger population structures\textemdash such as many low-income countries\textemdash the expected per capita incidence of clinical cases would be lower than in countries with older population structures, although it is likely that comorbidities in low-income countries will also influence disease severity. Without effective control measures, regions with relatively older populations could see disproportionally more cases of COVID-19, particularly in the later stages of an unmitigated epidemic.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XC4FQ6L7\\Davies et al. - 2020 - Age-dependent effects in the transmission and cont.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\R5JSNDCN\\s41591-020-0962-9.html}
}

@article{daviesEstimatedTransmissibilityImpact2021,
  title = {Estimated Transmissibility and Impact of {{SARS-CoV-2}} Lineage {{B}}.1.1.7 in {{England}}},
  author = {Davies, Nicholas G. and Abbott, Sam and Barnard, Rosanna C. and Jarvis, Christopher I. and Kucharski, Adam J. and Munday, James D. and Pearson, Carl A. B. and Russell, Timothy W. and Tully, Damien C. and Washburne, Alex D. and Wenseleers, Tom and Gimma, Amy and Waites, William and Wong, Kerry L. M. and {van Zandvoort}, Kevin and Silverman, Justin D. and {CMMID COVID-19 Working Group} and {COVID-19 Genomics UK (COG-UK) Consortium} and {Diaz-Ordaz}, Karla and Keogh, Ruth and Eggo, Rosalind M. and Funk, Sebastian and Jit, Mark and Atkins, Katherine E. and Edmunds, W. John},
  year = {2021},
  month = apr,
  journal = {Science},
  volume = {372},
  number = {6538},
  pages = {eabg3055},
  publisher = {{American Association for the Advancement of Science}},
  doi = {10.1126/science.abg3055},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\M7VVMVZJ\\Davies et al. - 2021 - Estimated transmissibility and impact of SARS-CoV-.pdf}
}

@article{davisCrypticTransmissionSARSCoV22021,
  title = {Cryptic Transmission of {{SARS-CoV-2}} and the First {{COVID-19}} Wave in {{Europe}} and the {{United States}}},
  author = {Davis, Jessica T. and Chinazzi, Matteo and Perra, Nicola and Mu, Kunpeng and y Piontti, Ana Pastore and Ajelli, Marco and Dean, Natalie E. and Gioannini, Corrado and Litvinova, Maria and Merler, Stefano and Rossi, Luca and Sun, Kaiyuan and Xiong, Xinyue and Halloran, M. Elizabeth and Longini, Ira M. and Viboud, C{\'e}cile and Vespignani, Alessandro},
  year = {2021},
  month = mar,
  journal = {medRxiv},
  pages = {2021.03.24.21254199},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.03.24.21254199},
  abstract = {{$<$}p{$>$}Given the narrowness of the initial testing criteria, the SARS-CoV-2 virus spread through cryptic transmission in January and February, setting the stage for the epidemic wave experienced in March and April, 2020. We use a global metapopulation epidemic model to provide a mechanistic understanding of the global dynamic underlying the establishment of the COVID-19 pandemic in Europe and the United States (US). The model is calibrated on international case introductions at the early stage of the pandemic. We find that widespread community transmission of SARS-CoV-2 was likely in several areas of Europe and the US by January 2020, and estimate that by early March, only 1-3 in 100 SARS-CoV-2 infections were detected by surveillance systems. Modeling results indicate international travel as the key driver of the introduction of SARS-CoV-2 with possible importation and transmission events as early as December, 2019. We characterize the resulting heterogeneous spatio-temporal spread of SARS-CoV-2 and the burden of the first COVID-19 wave (February-July 2020). We estimate infection attack rates ranging from 0.78\%-15.2\% in the US and 0.19\%-13.2\% in Europe. The spatial modeling of SARS-CoV-2 introductions and spreading provides insights into the design of innovative, model-driven surveillance systems and preparedness plans that have a broader initial capacity and indication for testing.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DR47F7FW\\Davis et al. - 2021 - Cryptic transmission of SARS-CoV-2 and the first C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\JT4C4FRN\\2021.03.24.html}
}

@article{deanCovid19VaccineEffectiveness2021,
  title = {Covid-19 {{Vaccine Effectiveness}} and the {{Test-Negative Design}}},
  author = {Dean, Natalie E. and Hogan, Joseph W. and Schnitzer, Mireille E.},
  year = {2021},
  month = sep,
  journal = {New England Journal of Medicine},
  doi = {10.1056/NEJMe2113151},
  abstract = {Editorial from The New England Journal of Medicine \textemdash{} Covid-19 Vaccine Effectiveness and the Test-Negative Design},
  copyright = {Copyright \textcopyright{} 2021 Massachusetts Medical Society. All rights reserved.},
  langid = {english}
}

@article{deanCovid19VaccineEffectiveness2021a,
  title = {Covid-19 {{Vaccine Effectiveness}} and the {{Test-Negative Design}}},
  author = {Dean, Natalie E. and Hogan, Joseph W. and Schnitzer, Mireille E.},
  year = {2021},
  month = sep,
  journal = {New England Journal of Medicine},
  publisher = {{Massachusetts Medical Society}},
  doi = {10.1056/NEJMe2113151},
  abstract = {Editorial from The New England Journal of Medicine \textemdash{} Covid-19 Vaccine Effectiveness and the Test-Negative Design},
  copyright = {Copyright \textcopyright{} 2021 Massachusetts Medical Society. All rights reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9CJK55BS\\NEJMe2113151.html}
}

@article{December2021Risk,
  title = {9 {{December}} 2021 {{Risk}} Assessment for {{SARS-CoV-2}} Variant: {{Omicron VOC-21NOV-01}} ({{B}}.1.1.529)},
  pages = {1},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\L67MGZGE\\9 December 2021 Risk assessment for SARS-CoV-2 var.pdf}
}

@article{December2021Riska,
  title = {9 {{December}} 2021 {{Risk}} Assessment for {{SARS-CoV-2}} Variant: {{Omicron VOC-21NOV-01}} ({{B}}.1.1.529)},
  pages = {1},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8KJSB4FZ\\9 December 2021 Risk assessment for SARS-CoV-2 var.pdf}
}

@article{deeksAntibodyTestsIdentification2020,
  title = {Antibody Tests for Identification of Current and Past Infection with {{SARS}}-{{CoV}}-2},
  author = {Deeks, Jonathan J. and Dinnes, Jacqueline and Takwoingi, Yemisi and Davenport, Clare and Spijker, Ren{\'e} and {Taylor-Phillips}, Sian and Adriano, Ada and Beese, Sophie and Dretzke, Janine and di Ruffano, Lavinia Ferrante and Harris, Isobel M. and Price, Malcolm J. and Dittrich, Sabine and Emperador, Devy and Hooft, Lotty and Leeflang, Mariska MG and den Bruel, Ann Van and Group, Cochrane COVID-19 Diagnostic Test Accuracy},
  year = {2020},
  journal = {Cochrane Database of Systematic Reviews},
  number = {6},
  publisher = {{John Wiley \& Sons, Ltd}},
  issn = {1465-1858},
  doi = {10.1002/14651858.CD013652},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MTPLLBCE\\Deeks et al. - 2020 - Antibody tests for identification of current and p.pdf}
}

@article{deeksAntibodyTestsIdentification2020a,
  title = {Antibody Tests for Identification of Current and Past Infection with {{SARS}}-{{CoV}}-2},
  author = {Deeks, Jonathan J. and Dinnes, Jacqueline and Takwoingi, Yemisi and Davenport, Clare and Spijker, Ren{\'e} and {Taylor-Phillips}, Sian and Adriano, Ada and Beese, Sophie and Dretzke, Janine and di Ruffano, Lavinia Ferrante and Harris, Isobel M. and Price, Malcolm J. and Dittrich, Sabine and Emperador, Devy and Hooft, Lotty and Leeflang, Mariska MG and den Bruel, Ann Van and Group, Cochrane COVID-19 Diagnostic Test Accuracy},
  year = {2020},
  journal = {Cochrane Database of Systematic Reviews},
  number = {6},
  publisher = {{John Wiley \& Sons, Ltd}},
  issn = {1465-1858},
  doi = {10.1002/14651858.CD013652},
  langid = {english}
}

@article{dehningInferringChangePoints2020,
  title = {Inferring Change Points in the Spread of {{COVID-19}} Reveals the Effectiveness of Interventions},
  author = {Dehning, Jonas and Zierenberg, Johannes and Spitzner, F. Paul and Wibral, Michael and Neto, Joao Pinheiro and Wilczek, Michael and Priesemann, Viola},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb9789},
  abstract = {As COVID-19 is rapidly spreading across the globe, short-term modeling forecasts provide time-critical information for decisions on containment and mitigation strategies. A major challenge for short-term forecasts is the assessment of key epidemiological parameters and how they change when first interventions show an effect. By combining an established epidemiological model with Bayesian inference, we analyze the time dependence of the effective growth rate of new infections. Focusing on COVID-19 spread in Germany, we detect change points in the effective growth rate that correlate well with the times of publicly announced interventions. Thereby, we can quantify the effect of interventions, and we can incorporate the corresponding change points into forecasts of future scenarios and case numbers. Our code is freely available and can be readily adapted to any country or region.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32414780},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VNHPDXIP\\Dehning et al. - 2020 - Inferring change points in the spread of COVID-19 .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\I4S5TPTK\\science.html}
}

@article{delamaterComplexityBasicReproduction,
  title = {Complexity of the {{Basic Reproduction Number}} ({{R0}}) - {{Volume}} 25, {{Number}} 1\textemdash{{January}} 2019 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Delamater, Paul L. and Street, Erica J. and Leslie, Timothy F. and Yang, Y. Tony and Jacobsen, Kathryn H.},
  doi = {10.3201/eid2501.171901},
  abstract = {Complexity of the Basic Reproduction Number},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2AJ5PUT7\\Delamater et al. - Complexity of the Basic Reproduction Number (R0) -.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\GHSBLIHK\\17-1901_article.html}
}

@misc{DemographicScalingModel,
  title = {A Demographic Scaling Model for Estimating the Total Number of {{COVID-19}} Infections | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.04.23.20077719v2},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\88USZCBB\\2020.04.23.html}
}

@article{dienerWhyPeopleAre2015,
  title = {Why {{People Are}} in a {{Generally Good Mood}}},
  author = {Diener, Ed and Kanazawa, Satoshi and Suh, Eunkook M. and Oishi, Shigehiro},
  year = {2015},
  month = aug,
  journal = {Personality and Social Psychology Review},
  volume = {19},
  number = {3},
  pages = {235--256},
  issn = {1088-8683, 1532-7957},
  doi = {10.1177/1088868314544467},
  abstract = {Evidence shows that people feel mild positive moods when no strong emotional events are occurring, a phenomenon known as positive mood offset. We offer an evolutionary explanation of this characteristic, showing that it improves fertility, fecundity, and health, and abets other characteristics that were critical to reproductive success. We review research showing that positive mood offset is virtually universal in the nations of the world, even among people who live in extremely difficult circumstances. Positive moods increase the likelihood of the types of adaptive behaviors that likely characterized our Paleolithic ancestors, such as creativity, planning, mating, and sociality. Because of the ubiquity and apparent advantages of positive moods, it is a reasonable hypothesis that humans were selected for positivity offset in our evolutionary past. We outline additional evidence that is needed to help confirm that positive mood offset is an evolutionary adaptation in humans and we explore the research questions that the hypothesis generates.},
  langid = {english},
  pmid = {25253069},
  keywords = {emotion,evolutionary psychology,well-being},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TEF9K2ZK\\Diener et al. - 2015 - Why People Are in a Generally Good Mood.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\I6I6EE6X\\Diener et al. - 2015 - Why People Are in a Generally Good Mood.html}
}

@misc{draulansmay.8FinallyVirusGot2020,
  title = {`{{Finally}}, a Virus Got Me.' {{Scientist}} Who Fought {{Ebola}} and {{HIV}} Reflects on Facing Death from {{COVID-19}}},
  author = {DraulansMay. 8, Dirk and {2020} and Pm, 5:00},
  year = {2020},
  month = may,
  journal = {Science | AAAS},
  abstract = {Top virologist Peter Piot spent 1 week at a London hospital in April and has been recovering at home since},
  howpublished = {http://www.sciencemag.org/news/2020/05/finally-virus-got-me-scientist-who-fought-ebola-and-hiv-reflects-facing-death-covid-19},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PWHF2IQM\\finally-virus-got-me-scientist-who-fought-ebola-and-hiv-reflects-facing-death-covid-19.html}
}

@article{drewRapidImplementationMobile2020,
  title = {Rapid Implementation of Mobile Technology for Real-Time Epidemiology of {{COVID-19}}},
  author = {Drew, David A. and Nguyen, Long H. and Steves, Claire J. and Menni, Cristina and Freydin, Maxim and Varsavsky, Thomas and Sudre, Carole H. and Cardoso, M. Jorge and Ourselin, Sebastien and Wolf, Jonathan and Spector, Tim D. and Chan, Andrew T. and Consortium{\textsection}, Cope},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc0473},
  abstract = {The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) presents challenges to the robust collection of population-scale data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE) consortium to bring together scientists with expertise in big data research and epidemiology to develop a COVID-19 Symptom Tracker mobile application that we launched in the UK on March 24, 2020 and the US on March 29, 2020 garnering more than 2.8 million users as of May 2, 2020. This mobile application offers data on risk factors, herald symptoms, clinical outcomes, and geographical hot spots. This initiative offers critical proof-of-concept for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection and analysis which is critical for a data-driven response to this public health challenge.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32371477},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8AWLAKUU\\Drew et al. - 2020 - Rapid implementation of mobile technology for real.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\YX39USKT\\science.html}
}

@article{duyNosocomialCoronavirusDisease,
  title = {Nosocomial {{Coronavirus Disease Outbreak Containment}}, {{Hanoi}}, {{Vietnam}}, {{March}}\textendash{{April}} 2020 - {{Volume}} 27, {{Number}} 1\textemdash{{January}} 2021 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Duy, Cuong and Nong, Vuong Minh and Ngo, An Van and Doan, Tra Thu and Nguyen, Tuan Quang and Truong, Phuong Thai and Olson, Linus and Larsson, Mattias},
  doi = {10.3201/eid2701.202656},
  abstract = {We report on the public health response generated by an outbreak of coronavirus disease (COVID-19) that occurred during March 2020 at Bach Mai Hospit...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QVNQ6MD4\\Duy et al. - Nosocomial Coronavirus Disease Outbreak Containmen.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QQ2RZELH\\20-2656_article.html}
}

@misc{EarlyReleaseContact,
  title = {Early {{Release}} - {{Contact Tracing}} during {{Coronavirus Disease Outbreak}}, {{South Korea}}, 2020 - {{Volume}} 26, {{Number}} 10\textemdash{{October}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  howpublished = {https://wwwnc.cdc.gov/eid/article/26/10/20-1315\_article},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZLQDFQAV\\20-1315_article.html}
}

@misc{EffectivenessBNT162b2Comirnaty,
  title = {Effectiveness of {{BNT162b2}} ({{Comirnaty}}, {{Pfizer-BioNTech}}) {{COVID-19}} Booster Vaccine against Covid-19 Related Symptoms in {{England}}: Test Negative Case-Control Study | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2021.11.15.21266341v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PKT5XXLF\\2021.11.15.html}
}

@article{EmpfehlungCoronaKommission10,
  title = {{Empfehlung der Corona-Kommission\_10.09.2020}},
  pages = {20},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6K4RYDKE\\Empfehlung der Corona-Kommission_10.09.2020.pdf}
}

@article{EmpfehlungCoronaKommission2020,
  title = {{Empfehlung der Corona-Kommission 3.9.2020}},
  pages = {9},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8D4VQR2Z\\Empfehlung der Corona-Kommission 3.9.2020.pdf}
}

@article{EmpfehlungenZurPCR,
  title = {{Empfehlungen zur PCR Testung auf Infektion mit SARS-CoV-2}},
  pages = {14},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XY5325GS\\Empfehlungen zur PCR Testung auf Infektion mit SAR.pdf}
}

@article{endoEstimatingOverdispersionCOVID192020,
  title = {Estimating the Overdispersion in {{COVID-19}} Transmission Using Outbreak Sizes Outside {{China}}},
  author = {Endo, Akira and {Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group} and Abbott, Sam and Kucharski, Adam J. and Funk, Sebastian},
  year = {2020},
  month = apr,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {67},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.15842.1},
  abstract = {Background:               A novel coronavirus disease (COVID-19) outbreak has now spread to a number of countries worldwide. While sustained transmission chains of human-to-human transmission suggest high basic reproduction number               R               0               , variation in the number of secondary transmissions (often characterised by so-called superspreading events) may be large as some countries have observed fewer local transmissions than others.                                         Methods:               We quantified individual-level variation in COVID-19 transmission by applying a mathematical model to observed outbreak sizes in affected countries. We extracted the number of imported and local cases in the affected countries from the~World Health Organization situation report and applied a branching process model where the number of secondary transmissions was assumed to follow a negative-binomial distribution.                                         Results:               Our model suggested a high degree of individual-level variation in the transmission of COVID-19. Within the current consensus range of               R               0               (2-3), the overdispersion parameter               k               of a negative-binomial distribution was estimated to be around 0.1 (median estimate 0.1; 95\% CrI: 0.05-0.2 for R0 = 2.5), suggesting that 80\% of secondary transmissions may have been caused by a small fraction of infectious individuals (\textasciitilde 10\%). A joint estimation yielded likely ranges for               R               0               and               k               (95\% CrIs:               R               0               1.4-12;               k               0.04-0.2); however, the upper bound of               R               0               was not well informed by the model and data, which did not notably differ from that of the prior distribution.                                         Conclusions:               Our finding of a highly-overdispersed offspring distribution highlights a potential benefit to focusing intervention efforts on superspreading. As most infected individuals do not contribute to the expansion of an epidemic, the effective reproduction number could be drastically reduced by preventing relatively rare superspreading events.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DXGBM6XY\\Endo et al. - 2020 - Estimating the overdispersion in COVID-19 transmis.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3IPPIVJV\\5-67.html}
}

@article{endoEstimatingOverdispersionCOVID192020a,
  title = {Estimating the Overdispersion in {{COVID-19}} Transmission Using Outbreak Sizes Outside {{China}}},
  author = {Endo, Akira and {Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group} and Abbott, Sam and Kucharski, Adam J. and Funk, Sebastian},
  year = {2020},
  month = apr,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {67},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.15842.1},
  abstract = {Background:               A novel coronavirus disease (COVID-19) outbreak has now spread to a number of countries worldwide. While sustained transmission chains of human-to-human transmission suggest high basic reproduction number               R               0               , variation in the number of secondary transmissions (often characterised by so-called superspreading events) may be large as some countries have observed fewer local transmissions than others.                                         Methods:               We quantified individual-level variation in COVID-19 transmission by applying a mathematical model to observed outbreak sizes in affected countries. We extracted the number of imported and local cases in the affected countries from the~World Health Organization situation report and applied a branching process model where the number of secondary transmissions was assumed to follow a negative-binomial distribution.                                         Results:               Our model suggested a high degree of individual-level variation in the transmission of COVID-19. Within the current consensus range of               R               0               (2-3), the overdispersion parameter               k               of a negative-binomial distribution was estimated to be around 0.1 (median estimate 0.1; 95\% CrI: 0.05-0.2 for R0 = 2.5), suggesting that 80\% of secondary transmissions may have been caused by a small fraction of infectious individuals (\textasciitilde 10\%). A joint estimation yielded likely ranges for               R               0               and               k               (95\% CrIs:               R               0               1.4-12;               k               0.04-0.2); however, the upper bound of               R               0               was not well informed by the model and data, which did not notably differ from that of the prior distribution.                                         Conclusions:               Our finding of a highly-overdispersed offspring distribution highlights a potential benefit to focusing intervention efforts on superspreading. As most infected individuals do not contribute to the expansion of an epidemic, the effective reproduction number could be drastically reduced by preventing relatively rare superspreading events.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CC6XZAL9\\5-67.html}
}

@misc{epicentroSorveglianzaIntegrataCOVID19,
  title = {{Sorveglianza integrata COVID-19: i principali dati nazionali}},
  shorttitle = {{Sorveglianza integrata COVID-19}},
  author = {EpiCentro},
  howpublished = {https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati?fbclid=IwAR0XcmtCn2soLjVRdZdJqWcH1IN9hjRmOrRRvhwNclSe7wbd0LTCdi9Ufk8},
  langid = {italian},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IJZ6V7SK\\sars-cov-2-sorveglianza-dati.html}
}

@article{EpidemicModelsDifferential2009,
  title = {Epidemic Models with Differential Susceptibility and Staged Progression and Their Dynamics},
  year = {2009},
  journal = {Mathematical Biosciences and Engineering},
  volume = {6},
  number = {2},
  pages = {321},
  publisher = {{AIMS Press}},
  doi = {10.3934/mbe.2009.6.321},
  abstract = {We formulate and study epidemic models with differential susceptibilities and staged-progressions, based on systems of ordinary differential equations, for disease transmission where the susceptibility of susceptible individuals vary and the infective individuals progress the disease gradually through stages with different infectiousness in each stage. We consider the contact rates to be proportional to the total population or constant such that the infection rates have a bilinear or standard form, respectively. We derive explicit formulas for the reproductive number \$R\_0\$, and show that the infection-free equilibrium is globally asymptotically stable if \$R\_0{$<$}1\$ when the infection rate has a bilinear form. We investigate existence of the endemic equilibrium for the two cases and show that there exists a unique endemic equilibrium for the bilinear incidence, and at least one endemic equilibrium for the standard incidence when \$R\_0{$>$}1\$.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5KEQIQLN\\mbe.2009.6.html}
}

@misc{EpidemiologischeAbklaerungAm,
  title = {{Epidemiologische Abkl\"arung am Beispiel COVID-19}},
  journal = {AGES - \"Osterreichische Agentur f\"ur Gesundheit und Ern\"ahrungssicherheit},
  abstract = {Die AGES informiert: Epidemiologische Abkl\"arung am Beispiel COVID-19},
  howpublished = {https://www.ages.at/service/service-presse/pressemeldungen/epidemiologische-abklaerung-am-beispiel-covid-19/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FB2VNP8C\\epidemiologische-abklaerung-am-beispiel-covid-19.html}
}

@misc{EpidemiologischeAbklaerungAma,
  title = {{Epidemiologische Abkl\"arung am Beispiel COVID-19}},
  journal = {AGES - \"Osterreichische Agentur f\"ur Gesundheit und Ern\"ahrungssicherheit},
  abstract = {Die AGES informiert: Epidemiologische Abkl\"arung am Beispiel COVID-19},
  howpublished = {https://www.ages.at/service/service-presse/pressemeldungen/epidemiologische-abklaerung-am-beispiel-covid-19/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SLXWNL6J\\epidemiologische-abklaerung-am-beispiel-covid-19.html}
}

@misc{EpidemiologyRiskFactors,
  title = {Epidemiology, Risk Factors and Clinical Course of {{SARS-CoV-2}} Infected Patients in a {{Swiss}} University Hospital: An Observational Retrospective Study | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.05.11.20097741v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\66S232KI\\2020.05.11.html}
}

@misc{EpiEstmPackageVignette,
  title = {{{EpiEstm R Package Vignette}}},
  abstract = {This vignette provides a short demonstration of the package. We consider a dataset containing information on pandemic influenza. The dataset contains:}
}

@misc{EpirecipesCookbookEpidemiological,
  title = {Epirecipes: {{A}} Cookbook of Epidemiological Models in {{R}}, {{Python}}, {{Julia}} (and More)},
  shorttitle = {Epirecipes},
  journal = {epirecipes},
  howpublished = {https://epirecipes.github.io/epicookbook/},
  langid = {english}
}

@misc{ErlauterungenAmtlichenDashboard2020,
  title = {Erl\"auterungen Zum {{Amtlichen Dashboard COVID19}}},
  year = {2020},
  month = apr,
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\69SNWTXQ\\BasisInformationen.pdf}
}

@misc{errCoronavirusEstoniaAll2020,
  title = {Coronavirus in {{Estonia}}: {{All}} You Need to Know},
  shorttitle = {Coronavirus in {{Estonia}}},
  author = {ERR, ERR News |},
  year = {2020},
  month = mar,
  journal = {ERR},
  abstract = {Following the first cases of coronavirus in Estonia in February 2020, the Health Board (Terviseamet) and government have issued advice, recommendations and restrictions to residents of Estonia. ERR News has rounded up this information and put it all in one place.},
  chapter = {News},
  howpublished = {https://news.err.ee/1061575/coronavirus-in-estonia-all-you-need-to-know},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XLZMVANA\\coronavirus-in-estonia-all-you-need-to-know.html}
}

@misc{errKallasCoronavirusTest2021,
  title = {Kallas: {{Coronavirus}} Test Proof Not Acceptable Certification from {{Monday}}},
  shorttitle = {Kallas},
  author = {ERR, ERR News |, BNS},
  year = {2021},
  month = oct,
  journal = {ERR},
  abstract = {Proof of a negative coronavirus test result will no longer be sufficient to gain access to indoor public events from Monday, the prime minister announced Tuesday afternoon. The rule is part of new coronavirus restrictions being introduced amid soaring rates and hospitalizations.},
  chapter = {Coronavirus},
  howpublished = {https://news.err.ee/1608375035/kallas-coronavirus-test-proof-not-acceptable-certification-from-monday},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9U49Q7SE\\kallas-coronavirus-test-proof-not-acceptable-certification-from-monday.html}
}

@misc{EstimatingEffectivenessFrequent2020,
  title = {Estimating Effectiveness of Frequent {{PCR}} Testing at Different Intervals for Detection of {{SARS-CoV-2}} Infections},
  year = {2020},
  month = nov,
  journal = {CMMID Repository},
  abstract = {Using data on twice weekly PCR testing of front-line healthcare workers, we estimated individual infection times and probability of testing PCR positive through time since infection.},
  howpublished = {https://cmmid.github.io/topics/covid19/pcr-positivity-over-time.html},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\36VCQ45L\\pcr-positivity-over-time.html}
}

@misc{EtappenplanZurAktivierung,
  title = {Etappenplan Zur {{Aktivierung}} Des {{Schulbetriebs}}},
  howpublished = {https://www.bmbwf.gv.at/Themen/schule/beratung/corona/corona\_info/corona\_etappenplan.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\US54BRFW\\corona_etappenplan.html}
}

@misc{EURLex52020DC0245EURLex,
  title = {{{EUR-Lex}} - {{52020DC0245}} - {{EN}} - {{EUR-Lex}}},
  howpublished = {https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327\&uri=CELEX\%3A52020DC0245},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KWYNVJP8\\TXT.html}
}

@misc{fabianvalkaEstimationInteractiveVisualization,
  title = {Estimation and {{Interactive Visualization}} of the {{Time-Varying Reproduction Number Rt}} and the {{Time-Delay}} from {{Infection}} to {{Estimation}} | {{medRxiv}}},
  author = {{Fabian Valka} and {Carla Schuler}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.09.19.20197970v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RHATWINB\\2020.09.19.html}
}

@article{fariaGenomicsEpidemiologyNovel,
  title = {Genomics and Epidemiology of a Novel {{SARS-CoV-2}} Lineage in {{Manaus}}, {{Brazil}}},
  author = {Faria, Nuno R and Mellan, Thomas A and Whittaker, Charles and Claro, Ingra M},
  pages = {44},
  abstract = {Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor. Molecular clock analysis shows that P.1 emergence occurred around early November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4\textendash 2.2 times more transmissible and able to evade 25-61\% of protective immunity elicited by previous infection with non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PN26UKY9\\Faria et al. - Genomics and epidemiology of a novel SARS-CoV-2 li.pdf}
}

@article{faustAllCauseExcessMortality2020,
  title = {All-{{Cause Excess Mortality}} and {{COVID-19}}\textendash{{Related Mortality Among US Adults Aged}} 25-44 {{Years}}, {{March-July}} 2020},
  author = {Faust, Jeremy Samuel and Krumholz, Harlan M. and Du, Chengan and Mayes, Katherine Dickerson and Lin, Zhenqiu and Gilman, Cleavon and Walensky, Rochelle P.},
  year = {2020},
  month = dec,
  journal = {JAMA},
  issn = {0098-7484},
  doi = {10.1001/jama.2020.24243},
  langid = {english}
}

@article{fengInfluenceWindRelative2020,
  title = {Influence of Wind and Relative Humidity on the Social Distancing Effectiveness to Prevent {{COVID-19}} Airborne Transmission: {{A}} Numerical Study},
  shorttitle = {Influence of Wind and Relative Humidity on the Social Distancing Effectiveness to Prevent {{COVID-19}} Airborne Transmission},
  author = {Feng, Yu and Marchal, Thierry and Sperry, Ted and Yi, Hang},
  year = {2020},
  month = sep,
  journal = {Journal of Aerosol Science},
  volume = {147},
  pages = {105585},
  issn = {0021-8502},
  doi = {10.1016/j.jaerosci.2020.105585},
  abstract = {It has been confirmed that the coronavirus disease 2019 (COVID-19) can transmit through droplets created when an infected human coughs or sneezes. Accordingly, 1.83-m (6-feet) social distancing is advised to reduce the spread of the disease among humans. This is based on the assumption that no air circulation exists around people. However, it is not well investigated whether the ambient wind and relative humidity (RH) will cause SARS-CoV-2 laden droplets to transport farther in the air, and make the current social distancing policy insufficient. To provide evidence and insight into the ``social distancing'' guidelines, a validated computational fluid-particle dynamics (CFPD) model was employed to simulate the transient transport, condensation/evaporation, and deposition of SARS-CoV-2 laden droplets emitted by coughs, with different environmental wind velocities and RHs. Initial droplet diameters range from 2 to 2000~{$\mu$}m, and the wind velocities range from 0 to 16~km/h, representing different wind forces from calm air to moderate breeze. The comparison between a steady-state wind and a gust with a constant frequency has also been performed. Ambient RHs are 40\% and 99.5\%. The distances between the two virtual humans are 1.83~m and 3.05~m (6 feet and 10 feet). The facial covering effect on reducing the airborne transmission of the cough droplets has also been evaluated. Numerical results indicate that the ambient wind will enhance the complexity of the secondary flows with recirculation between the two virtual humans. Microdroplets follow the airflow streamlines well and deposit on both human bodies and head regions, even with the 3.05-m (10-feet) separation distance. The rest of the microdroplets can transport in the air farther than 3.05~m (10 feet) due to wind convection, causing a potential health risk to nearby people. High RH will increase the droplet sizes due to the hygroscopic growth effect, which increases the deposition fractions on both humans and the ground. With the complex environmental wind and RH conditions, the 6-feet social distancing policy may not be sufficient to protect the inter-person aerosol transmission, since the suspending micro-droplets were influenced by convection effects and can transport from the human coughs/sneezes to the other human in less than 5~seconds. Due to the complex real-world environmental ventilation conditions, a social distance longer than 1.83 m (6 feet) needs to be considered. Wearing masks should also be recommended for both infected and healthy humans to reduce the airborne cough droplet numbers.},
  langid = {english},
  keywords = {Computational fluid-particle dynamics (CFPD),Mask,Relative humidity,SARS-CoV-2-laden cough droplets,Social distancing,Wind and gust},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CPJFLK6H\\Feng et al. - 2020 - Influence of wind and relative humidity on the soc.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\VCBIQUB8\\S0021850220300744.html}
}

@techreport{fergusonReport49Growth2021,
  title = {Report 49: {{Growth}} and Immune Escape of the {{Omicron SARS-CoV-2}} Variant of Concern in {{England}}},
  shorttitle = {Report 49},
  author = {Ferguson, N},
  year = {2021},
  month = dec,
  institution = {{Imperial College London}},
  doi = {10.25561/93038},
  abstract = {To estimate the growth of the Omicron variant of concern (1) and its immune escape (2\textendash 9) characteristics, we analysed data from all PCR-confirmed SARS-CoV-2 cases in England excluding those with a history of recent international travel. We undertook separate analyses according to two case definitions. For the first definition, we included all cases with a definitive negative S-gene Target Failure (SGTF) result and specimen dates between 29/11/2021 and 11/12/2021 inclusive. For the second definition, we included cases with a positive genotype result and specimen date between 23/11/2021 and 11/12/2021 inclusive. We chose a later start date for the SGTF definition to ensure greater specificity of SGTF for Omicron.},
  collaborator = {Medical Research Council (MRC)},
  copyright = {\textcopyright{} 2021 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License., Creative Commons Attribution Non Commercial No Derivatives 4.0 International, 2021-12-15},
  langid = {english},
  keywords = {Coronavirus,COVID-19},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HP8R57YA\\Ferguson - 2021 - Report 49 Growth and immune escape of the Omicron.pdf}
}

@misc{Ferienkalender20192020,
  title = {Ferienkalender 2019/2020},
  howpublished = {https://www.oesterreich.gv.at/themen/bildung\_und\_neue\_medien/schule/3/2/Seite1.1100102.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\M4ZZHUQ8\\Seite1.1100102.html}
}

@article{ferrettiTimingCOVID19Transmission2020,
  title = {The Timing of {{COVID-19}} Transmission},
  author = {Ferretti, Luca and Ledda, Alice and Wymant, Chris and Zhao, Lele and Ledda, Virginia and Dorner, Lucie Abeler- and Kendall, Michelle and Nurtay, Anel and Cheng, Hao-Yuan and Ng, Ta-Chou and Lin, Hsien-Ho and Hinch, Rob and Masel, Joanna and Kilpatrick, A. Marm and Fraser, Christophe},
  year = {2020},
  month = sep,
  journal = {medRxiv},
  pages = {2020.09.04.20188516},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.09.04.20188516},
  abstract = {{$<$}p{$>$}The timing of SARS-CoV-2 transmission is a critical factor to understand the epidemic trajectory and the impact of isolation, contact tracing and other non- pharmaceutical interventions on the spread of COVID-19 epidemics. We examined the distribution of transmission events with respect to exposure and onset of symptoms. We show that for symptomatic individuals, the timing of transmission of SARS-CoV-2 is more strongly linked to the onset of clinical symptoms of COVID-19 than to the time since infection. We found that it was approximately centered and symmetric around the onset of symptoms, with three quarters of events occurring in the window from 2-3 days before to 2-3 days after. However, we caution against overinterpretation of the right tail of the distribution, due to its dependence on behavioural factors and interventions. We also found that the pre-symptomatic infectious period extended further back in time for individuals with longer incubation periods. This strongly suggests that information about when a case was infected should be collected where possible, in order to assess how far into the past their contacts should be traced. Overall, the fraction of transmission from strictly pre-symptomatic infections was high (41\%; 95\%CI 31-50\%), which limits the efficacy of symptom-based interventions, and the large fraction of transmissions (35\%; 95\%CI 26-45\%) that occur on the same day or the day after onset of symptoms underlines the critical importance of individuals distancing themselves from others as soon as they notice any symptoms, even if they are mild. Rapid or at-home testing and contextual risk information would greatly facilitate efficient early isolation.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5KE6ERS2\\Ferretti et al. - 2020 - The timing of COVID-19 transmission.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q8HZNFJJ\\2020.09.04.html}
}

@misc{FinancialTimesCoronavirusexcessmortalitydata,
  title = {Financial-{{Times}}/Coronavirus-Excess-Mortality-Data},
  journal = {GitHub},
  abstract = {Excess mortality data compiled by the FT Visual \& Data Journalism team - Financial-Times/coronavirus-excess-mortality-data},
  howpublished = {https://github.com/Financial-Times/coronavirus-excess-mortality-data},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BGVIMTM5\\sources.html}
}

@article{fineHerdImmunityRough2011,
  title = {``{{Herd Immunity}}'': {{A Rough Guide}}},
  shorttitle = {``{{Herd Immunity}}''},
  author = {Fine, Paul and Eames, Ken and Heymann, David L.},
  year = {2011},
  month = apr,
  journal = {Clinical Infectious Diseases},
  volume = {52},
  number = {7},
  pages = {911--916},
  publisher = {{Oxford Academic}},
  issn = {1058-4838},
  doi = {10.1093/cid/cir007},
  abstract = {Abstract. The term ``herd immunity'' is widely used but carries a variety of meanings [1\textendash 7]. Some authors use it to describe the proportion immune among individua},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\33DYN6GD\\Fine et al. - 2011 - Herd Immunity A Rough Guide.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\NQTI9SJR\\299077.html}
}

@techreport{fismanProgressiveIncreaseVirulence2021,
  type = {Preprint},
  title = {Progressive {{Increase}} in {{Virulence}} of {{Novel SARS-CoV-2 Variants}} in {{Ontario}}, {{Canada}}},
  author = {Fisman, David N. and Tuite, Ashleigh R.},
  year = {2021},
  month = jul,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2021.07.05.21260050},
  abstract = {Background: The period from February to June 2021 was one during which initial wild-type SARS-CoV-2 strains were supplanted in Ontario, Canada, first by variants of concern (VOC) with the N501Y mutation (Alpha/B1.1.17, Beta/B.1.351 and Gamma/P.1 variants), and then by the Delta/B.1.617 variant. The increased transmissibility of these VOCs has been documented but data for increased virulence is limited. We used Ontario's COVID-19 case data to evaluate the virulence of these VOCs compared to non-VOC SARS-CoV-2 infections, as measured by risk of hospitalization, intensive care unit (ICU) admission, and death. Methods: We created a retrospective cohort of people in Ontario testing positive for SARSCoV-2 and screened for VOCs, with dates of test report between February 7 and June 22, 2021 (n=211,197). We constructed mixed effects logistic regression models with hospitalization, ICU admission, and death as outcome variables. Models were adjusted for age, sex, time, comorbidities, and pregnancy status. Health units were included as random intercepts. Results: Compared to non-VOC SARS-CoV-2 strains, the adjusted elevation in risk associated with N501Y-positive variants was 59\% (49-69\%) for hospitalization; 105\% (82-134\%) for ICU admission; and 61\% (40-87\%) for death. Increases with Delta variant were more pronounced: 120\% (93-153\%) for hospitalization; 287\% (198-399\%) for ICU admission; and 137\% (50230\%) for death. Interpretation: The progressive increase in transmissibility and virulence of SARS-CoV-2 VOCs will result in a significantly larger, and more deadly, pandemic than would have occurred in the absence of VOC emergence.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7WYA992E\\Fisman and Tuite - 2021 - Progressive Increase in Virulence of Novel SARS-Co.pdf}
}

@article{flaxmanEstimatingEffectsNonpharmaceutical2020,
  title = {Estimating the Effects of Non-Pharmaceutical Interventions on {{COVID-19}} in {{Europe}}},
  author = {Flaxman, Seth and Mishra, Swapnil and Gandy, Axel and Unwin, H. Juliette T. and Mellan, Thomas A. and Coupland, Helen and Whittaker, Charles and Zhu, Harrison and Berah, Tresnia and Eaton, Jeffrey W. and Monod, M{\'e}lodie and Ghani, Azra C. and Donnelly, Christl A. and Riley, Steven M. and Vollmer, Michaela A. C. and Ferguson, Neil M. and Okell, Lucy C. and Bhatt, Samir},
  year = {2020},
  month = jun,
  journal = {Nature},
  pages = {1--8},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-020-2405-7},
  abstract = {Following the emergence of a novel coronavirus1 (SARS-CoV-2) and its spread outside of China, Europe has experienced large epidemics. In response, many European countries have implemented unprecedented non-pharmaceutical interventions such as closure of schools and national lockdowns. We study the impact of major interventions across 11 European countries for the period from the start of COVID-19 until the 4th of May 2020 when lockdowns started to be lifted. Our model calculates backwards from observed deaths to estimate transmission that occurred several weeks prior, allowing for the time lag between infection and death. We use partial pooling of information between countries with both individual and shared effects on the reproduction number. Pooling allows more information to be used, helps overcome data idiosyncrasies, and enables more timely estimates. Our model relies on fixed estimates of some epidemiological parameters such as the infection fatality rate, does not include importation or subnational variation and assumes that changes in the reproduction number are an immediate response to interventions rather than gradual changes in behavior. Amidst the ongoing pandemic, we rely on death data that is incomplete, with systematic biases in reporting, and subject to future consolidation. We estimate that, for all the countries we consider, current interventions have been sufficient to drive the reproduction number \$\$\{R\}\_\{t\}\$\$Rt below 1 (probability \$\$\{R\}\_\{t\}\textbackslash,\$\$Rt{$<$} 1.0 is 99.9\%) and achieve epidemic control. We estimate that, across all 11 countries, between 12 and 15 million individuals have been infected with SARS-CoV-2 up to 4th May, representing between 3.2\% and 4.0\% of the population. Our results show that major non-pharmaceutical interventions and lockdown in particular have had a large effect on reducing transmission. Continued intervention should be considered to keep transmission of SARS-CoV-2 under control.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3RFDLUSM\\s41586-020-2405-7.html}
}

@incollection{frankTimeDelays2018,
  title = {Time {{Delays}}},
  booktitle = {Control {{Theory Tutorial}}: {{Basic Concepts Illustrated}} by {{Software Examples}}},
  author = {Frank, Steven A.},
  editor = {Frank, Steven A.},
  year = {2018},
  series = {{{SpringerBriefs}} in {{Applied Sciences}} and {{Technology}}},
  pages = {95--102},
  publisher = {{Springer International Publishing}},
  address = {{Cham}},
  doi = {10.1007/978-3-319-91707-8_13},
  abstract = {Delays often occur between an input into a system and the output from that system. Delays complicate dynamics, create system instabilities, and reduce the information that systems can use to respond to the environment. Adjusting for delays often requires systems to predict future states based on past inputs. Error-correcting feedback can enhance a system's predictions and improve its ability to cope with delays.},
  isbn = {978-3-319-91707-8},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VXXJC9XA\\Frank - 2018 - Time Delays.pdf}
}

@misc{FranzAllerbergerDieses2020,
  title = {{Franz Allerberger: "Dieses Virus ist nicht so ansteckend, wie manche annehmen``}},
  shorttitle = {{Franz Allerberger}},
  year = {2020},
  month = may,
  journal = {profil.at},
  abstract = {Der AGES-Mediziner hadert mit der Maskenpflicht und h\"atte sowohl die Bundesg\"arten als auch die Kinderg\"arten offengehalten.},
  howpublished = {https://www.profil.at/oesterreich/franz-allerberger-corona-interview-11472377},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8R922ZZY\\franz-allerberger-corona-interview-11472377.html}
}

@incollection{FrontMatter2017,
  title = {Front {{Matter}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {i-xvii},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.fmatter},
  abstract = {The prelims comprise: Half Title Wiley Series in Probability and Statistics Title Copyright Dedication Contents Preface Acknowledgments},
  isbn = {978-1-118-63198-0},
  langid = {english},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.fmatter},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5792I6KW\\2017 - Front Matter.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3SCYX26P\\9781118631980.html}
}

@article{furuseEarlyReleaseClusters,
  title = {Early {{Release}} - {{Clusters}} of {{Coronavirus Disease}} in {{Communities}}, {{Japan}}, {{January}}\textendash{{April}} 2020 - {{Volume}} 26, {{Number}} 9\textemdash{{September}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Furuse, Yuki and Sando, Eiichiro and Tsuchiya, Naho and Miyahara, Reiko and Yasuda, Ikkoh and Ko, Yura K. and Saito, Mayuko and Morimoto, Konosuke and Imamura, Takeaki and Shobugawa, Yugo and Nagata, Shohei and Jindai, Kazuaki and Imamura, Tadatsugu and Sunagawa, Tomimasa and Suzuki, Motoi and Nishiura, Hiroshi and Oshitani, Hitoshi},
  doi = {10.3201/eid2609.202272},
  abstract = {We analyzed 3,184 cases of coronavirus disease in Japan and identified 61 case-clusters in healthcare and other care facilities, restaurants and bars,...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\REVXEJ2G\\20-2272_article.html}
}

@article{gattoSpreadDynamicsCOVID192020,
  title = {Spread and Dynamics of the {{COVID-19}} Epidemic in {{Italy}}: {{Effects}} of Emergency Containment Measures},
  shorttitle = {Spread and Dynamics of the {{COVID-19}} Epidemic in {{Italy}}},
  author = {Gatto, Marino and Bertuzzo, Enrico and Mari, Lorenzo and Miccoli, Stefano and Carraro, Luca and Casagrandi, Renato and Rinaldo, Andrea},
  year = {2020},
  month = apr,
  journal = {Proceedings of the National Academy of Sciences},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.2004978117},
  abstract = {The spread of coronavirus disease 2019 (COVID-19) in Italy prompted drastic measures for transmission containment. We examine the effects of these interventions, based on modeling of the unfolding epidemic. We test modeling options of the spatially explicit type, suggested by the wave of infections spreading from the initial foci to the rest of Italy. We estimate parameters of a metacommunity Susceptible\textendash Exposed\textendash Infected\textendash Recovered (SEIR)-like transmission model that includes a network of 107 provinces connected by mobility at high resolution, and the critical contribution of presymptomatic and asymptomatic transmission. We estimate a generalized reproduction number (R0R0{$<$}mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"{$><$}mml:msub{$><$}mml:mrow{$><$}mml:mi{$>$}R{$<$}/mml:mi{$><$}/mml:mrow{$><$}mml:mrow{$><$}mml:mn{$>$}0{$<$}/mml:mn{$><$}/mml:mrow{$><$}/mml:msub{$><$}/mml:math{$>$} = 3.60 [3.49 to 3.84]), the spectral radius of a suitable next-generation matrix that measures the potential spread in the absence of containment interventions. The model includes the implementation of progressive restrictions after the first case confirmed in Italy (February 21, 2020) and runs until March 25, 2020. We account for uncertainty in epidemiological reporting, and time dependence of human mobility matrices and awareness-dependent exposure probabilities. We draw scenarios of different containment measures and their impact. Results suggest that the sequence of restrictions posed to mobility and human-to-human interactions have reduced transmission by 45\% (42 to 49\%). Averted hospitalizations are measured by running scenarios obtained by selectively relaxing the imposed restrictions and total about 200,000 individuals (as of March 25, 2020). Although a number of assumptions need to be reexamined, like age structure in social mixing patterns and in the distribution of mobility, hospitalization, and fatality, we conclude that verifiable evidence exists to support the planning of emergency measures.},
  chapter = {Biological Sciences},
  copyright = {Copyright \textcopyright{} 2020 the Author(s). Published by PNAS.. https://creativecommons.org/licenses/by/4.0/This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).},
  langid = {english},
  pmid = {32327608},
  keywords = {disease outbreak scenarios,SARS-CoV-2,SEIR models,social contact restrictions,spatially explicit epidemiology},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\J75QYEJL\\Gatto et al. - 2020 - Spread and dynamics of the COVID-19 epidemic in It.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\76S63VNW\\2004978117.html}
}

@misc{GemeinsameInteresseGesundheit,
  title = {{Das gemeinsame Interesse von Gesundheit und Wirtschaft: Eine Szenarienrechnung zur Eind\"ammung der Corona- Pandemie}},
  shorttitle = {{Das gemeinsame Interesse von Gesundheit und Wirtschaft}},
  abstract = {In der \"offentlichen Diskussion \"uber den weiteren Kurs in der Bek\"ampfung der Corona-Pandemie werden die Interessen des Gesundheitsschutzes oft als Gegensatz zu den Interessen der Wirtschaft dargestellt. Das wird der Problemlage nicht gerecht. Wenn vorzeitige Lockerungen der Beschr\"ankungen zu einer zweiten Infektionswelle f\"uhrten, w\"urde das Vertrauen von Konsumenten und Investoren besch\"adigt.},
  howpublished = {http://www.ifo.de/publikationen/2020/article-journal/das-gemeinsame-interesse-von-gesundheit-und-wirtschaft},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6QNR4R9S\\das-gemeinsame-interesse-von-gesundheit-und-wirtschaft.html}
}

@misc{GenomicSurveillanceTracks,
  title = {Genomic Surveillance Tracks the First Communitary Outbreak of {{Delta}} ({{B}}.1.17.2) Variant in {{Brazil}} - {{SARS-CoV-2}} Coronavirus / {{nCoV-2019 Genomic Epidemiology}} - {{Virological}}},
  howpublished = {https://virological.org/t/genomic-surveillance-tracks-the-first-communitary-outbreak-of-delta-b-1-17-2-variant-in-brazil/733},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YZI9WIX5\\733.html}
}

@article{geogheganGenomicEpidemiologyReveals2020,
  title = {Genomic Epidemiology Reveals Transmission Patterns and Dynamics of {{SARS-CoV-2}} in {{Aotearoa New Zealand}}},
  author = {Geoghegan, Jemma L. and Ren, Xiaoyun and Storey, Matthew and Hadfield, James and Jelley, Lauren and Jefferies, Sarah and Sherwood, Jill and Paine, Shevaun and Huang, Sue and Douglas, Jordan and Mendes, F{\'a}bio K. and Sporle, Andrew and Baker, Michael G. and Murdoch, David R. and French, Nigel and Simpson, Colin R. and Welch, David and Drummond, Alexei J. and Holmes, Edward C. and Duch{\^e}ne, Sebasti{\'a}n and {de Ligt}, Joep},
  year = {2020},
  month = dec,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {6351},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-20235-8},
  abstract = {New Zealand, a geographically remote Pacific island with easily sealable borders, implemented a nationwide `lockdown' of all non-essential services to curb the spread of COVID-19. Here, we generate 649 SARS-CoV-2 genome sequences from infected patients in New Zealand with samples collected during the `first wave', representing 56\% of all confirmed cases in this time period. Despite its remoteness, the viruses imported into New Zealand represented nearly all of the genomic diversity sequenced from the global virus population. These data helped to quantify the effectiveness of public health interventions. For example, the effective reproductive number, Re of New Zealand's largest cluster decreased from 7 to 0.2 within the first week of lockdown. Similarly, only 19\% of virus introductions into New Zealand resulted in ongoing transmission of more than one additional case. Overall, these results demonstrate the utility of genomic pathogen surveillance to inform public health and disease mitigation.},
  copyright = {2020 The Author(s)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y49IW5LW\\Geoghegan et al. - 2020 - Genomic epidemiology reveals transmission patterns.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\M662E3AC\\s41467-020-20235-8.html}
}

@article{gesFactsheetIntensivpflegeUnd2021,
  title = {{Factsheet Intensivpflege und COVID}},
  author = {Ges, heit {\"O}sterreich GmbH},
  year = {2021},
  pages = {5},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PPMC5QRW\\Ges - 2021 - Factsheet Intensivpflege und COVID.pdf}
}

@article{gilbertImmuneCorrelatesAnalysis,
  title = {Immune Correlates Analysis of the {{mRNA-1273 COVID-19}} Vaccine Efficacy Clinical Trial},
  author = {Gilbert, Peter B. and Montefiori, David C. and McDermott, Adrian B. and Fong, Youyi and Benkeser, David and Deng, Weiping and Zhou, Honghong and Houchens, Christopher R. and Martins, Karen and Jayashankar, Lakshmi and Castellino, Flora and Flach, Britta and Lin, Bob C. and O'Connell, Sarah and McDanal, Charlene and Eaton, Amanda and {Sarzotti-Kelsoe}, Marcella and Lu, Yiwen and Yu, Chenchen and Borate, Bhavesh and {van der Laan}, Lars W. P. and Hejazi, Nima S. and Huynh, Chuong and Miller, Jacqueline and El Sahly, Hana M. and Baden, Lindsey R. and Baron, Mira and De La Cruz, Luis and Gay, Cynthia and Kalams, Spyros and Kelley, Colleen F. and Andrasik, Michele P. and Kublin, James G. and Corey, Lawrence and Neuzil, Kathleen M. and Carpp, Lindsay N. and Pajon, Rolando and Follmann, Dean and Donis, Ruben O. and Koup, Richard A. and {Immune Assays Team} and {Moderna, Inc. Team} and {Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team} and {UNITED STATES GOVERNMENT (USG)/COVPN BIOSTATISTICS TEAM}},
  journal = {Science},
  volume = {0},
  number = {0},
  pages = {eab3435},
  publisher = {{American Association for the Advancement of Science}},
  doi = {10.1126/science.abm3425},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VFD8Q3K8\\Gilbert et al. - Immune correlates analysis of the mRNA-1273 COVID-.pdf}
}

@article{giordanoModellingCOVID19Epidemic2020,
  title = {Modelling the {{COVID-19}} Epidemic and Implementation of Population-Wide Interventions in {{Italy}}},
  author = {Giordano, Giulia and Blanchini, Franco and Bruno, Raffaele and Colaneri, Patrizio and Di Filippo, Alessandro and Di Matteo, Angela and Colaneri, Marta},
  year = {2020},
  month = apr,
  journal = {Nature Medicine},
  pages = {1--6},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0883-7},
  abstract = {A new epidemiological model, termed SIDARTHE, distinguishes between diagnosed and undiagnosed cases of SARS-CoV-2 infection, as well as modeling effects of social distancing and widespread testing, to predict possible outcomes of the COVID-19 epidemic in Italy.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\J6XLHCR8\\Giordano et al. - 2020 - Modelling the COVID-19 epidemic and implementation.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UN9UR9LJ\\s41591-020-0883-7.html}
}

@article{giordanoModellingCOVID19Epidemic2020a,
  title = {Modelling the {{COVID-19}} Epidemic and Implementation of Population-Wide Interventions in {{Italy}}},
  author = {Giordano, Giulia and Blanchini, Franco and Bruno, Raffaele and Colaneri, Patrizio and Di Filippo, Alessandro and Di Matteo, Angela and Colaneri, Marta},
  year = {2020},
  month = apr,
  journal = {Nature Medicine},
  pages = {1--6},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0883-7},
  abstract = {A new epidemiological model, termed SIDARTHE, distinguishes between diagnosed and undiagnosed cases of SARS-CoV-2 infection, as well as modeling effects of social distancing and widespread testing, to predict possible outcomes of the COVID-19 epidemic in Italy.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TYZQWXJ9\\Giordano et al. - 2020 - Modelling the COVID-19 epidemic and implementation.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WDAC59XF\\s41591-020-0883-7.html}
}

@misc{gmtHowControlTheory2020,
  title = {How {{Control Theory Can Help Us Control COVID-19}} - {{IEEE Spectrum}}},
  author = {GMT, Posted 17 Apr 2020 | 11:00},
  year = {2020},
  month = may,
  journal = {IEEE Spectrum: Technology, Engineering, and Science News},
  howpublished = {https://spectrum.ieee.org/biomedical/diagnostics/how-control-theory-can-help-control-covid19},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3F2QCR2R\\how-control-theory-can-help-control-covid19.html}
}

@article{goeyvaertsEstimatingInfectiousDisease2010,
  title = {Estimating {{Infectious Disease Parameters}} from {{Data}} on {{Social Contacts}} and {{Serological Status}}},
  author = {Goeyvaerts, Nele and Hens, Niel and Ogunjimi, Benson and Aerts, Marc and Shkedy, Ziv and Van Damme, Pierre and Beutels, Philippe},
  year = {2010},
  journal = {Journal of the Royal Statistical Society. Series C (Applied Statistics)},
  volume = {59},
  number = {2},
  pages = {255--277},
  publisher = {{[Wiley, Royal Statistical Society]}},
  issn = {0035-9254},
  abstract = {In dynamic models of infectious disease transmission, typically various mixing patterns are imposed on the so-called 'who acquires infection from whom' matrix. These imposed mixing patterns are based on prior knowledge of age-related social mixing behaviour rather than observations. Alternatively, we can assume that transmission rates for infections transmitted predominantly through non-sexual social contacts are proportional to rates of conversational contact which can be estimated from a contact survey. In general, however, contacts reported in social contact surveys are proxies of those events by which transmission may occur and there may be age-specific characteristics that are related to susceptibility and infectiousness which are not captured by the contact rates. Therefore, we model transmission as the product of two age-specific variables: the age-specific contact rate and an age-specific proportionality factor, which entails an improvement of fit for the seroprevalence of the varicella zoster virus in Belgium. Furthermore, we address the effect on the estimation of the basic reproduction number, using non-parametric bootstrapping to account for different sources of variability and using multimodel inference to deal with model selection uncertainty. The method proposed makes it possible to obtain important information on transmission dynamics that cannot be inferred from approaches that have been traditionally applied hitherto.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BQSUHUTH\\Goeyvaerts et al. - 2010 - Estimating Infectious Disease Parameters from Data.pdf}
}

@techreport{gomesdasilvaHealthLiteracyInland2020,
  type = {Preprint},
  title = {Health Literacy of Inland Population in the Mitigation Phase 3.2. of {{COVID-19}}'s Pandemic in {{Portugal}} - a Descriptive Cohort Study},
  author = {{Gomes da Silva}, Joana and Sofia Silva, Carla and Alexandre, Barbara and Morgado, Pedro},
  year = {2020},
  month = may,
  institution = {{Primary Care Research}},
  doi = {10.1101/2020.05.11.20098061},
  abstract = {Background: COVID-19 is a respiratory disease transmitted through respiratory droplets with a high transmission rate. There's still no effective and approved antiretroviral treatment or vaccine, thus, preventive measures are the main key to contain this pandemic. Portugal is now in phase 3.2 of the mitigation of COVID-19, being imperative to understand the health literacy of our country and how to prevent the lack of information, through community empowerment. Material and methods: A cross-sectional study with a cohort from a primary care facility was conducted. We collected demographic and epidemiological data and carried out a questionnaire by phone call. Descriptive statistics and nonparametric tests were used to assess associations between the independent variables and the level of health literacy. The level of significance was set at p{$<$}0.05. Results: Our cohort includes 222 subjects (median age: 62 years old), mostly females (131), undergraduate (193) and with at least one risk factor for COVID-19 (144). Globally, younger individuals, females, graduates and the Non-Risk Group appear to have higher levels of health literacy, with some exceptions to this pattern. Conclusions: We observe a well-informed population. However, being a pandemic situation, we intend to identify and correct outliers/misconceptions. This work allows a perspective of the current state/pattern of health literacy as well as its possible predictors. Furthermore, this study makes aware of how relevant the specific communication approaches are. Further studies to understand the predictors of health literacy are necessary.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CBFWVNYA\\Gomes da Silva et al. - 2020 - Health literacy of inland population in the mitiga.pdf}
}

@techreport{gomez-expositoMonitoringTrackingEvolution2020,
  type = {Preprint},
  title = {Monitoring and {{Tracking}} the {{Evolution}} of a {{Viral Epidemic Through Nonlinear Kalman Filtering}}: {{Application}} to the {{Covid-19 Case}}},
  shorttitle = {Monitoring and {{Tracking}} the {{Evolution}} of a {{Viral Epidemic Through Nonlinear Kalman Filtering}}},
  author = {{Gomez-Exposito}, Antonio and {Rosendo-Macias}, Jose A. and {Gonzalez-Cagigal}, Miguel A.},
  year = {2020},
  month = may,
  institution = {{Epidemiology}},
  doi = {10.1101/2020.05.11.20098087},
  abstract = {This work presents a novel methodology for systematically processing the time series that report the number of positive, recovered and deceased cases from a viral epidemic, such as Covid-19. The main objective is to unveil the evolution of the number of real infected people, and consequently to predict the peak of the epidemic and subsequent evolution. For this purpose, an original nonlinear model relating the raw data with the timevarying geometric ratio of infected people is elaborated, and a Kalman Filter is used to estimate the involved state variables. A hypothetical simulated case is used to show the adequacy and limitations of the proposed method. Then, several countries, including China, South Korea, Italy, Spain, UK and the USA, are tested to illustrate its behavior when real-life data are processed. The results obtained clearly show the beneficial effect of the social distancing measures adopted worldwide, confirming that the Covid-19 epidemic peak is left behind in those countries where the outbreak started earlier, and anticipating when the peak will take place in the remaining countries.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SXNXUZYG\\Gomez-Exposito et al. - 2020 - Monitoring and Tracking the Evolution of a Viral E.pdf}
}

@article{gonzalez-reicheIntroductionsEarlySpread2020,
  title = {Introductions and Early Spread of {{SARS-CoV-2}} in the {{New York City}} Area},
  author = {{Gonzalez-Reiche}, Ana S. and Hernandez, Matthew M. and Sullivan, Mitchell J. and Ciferri, Brianne and Alshammary, Hala and Obla, Ajay and Fabre, Shelcie and Kleiner, Giulio and Polanco, Jose and Khan, Zenab and Alburquerque, Bremy and van de Guchte, Adriana and Dutta, Jayeeta and Francoeur, Nancy and Melo, Betsaida Salom and Oussenko, Irina and Deikus, Gintaras and Soto, Juan and Sridhar, Shwetha Hara and Wang, Ying-Chih and Twyman, Kathryn and Kasarskis, Andrew and Altman, Deena R. and Smith, Melissa and Sebra, Robert and Aberg, Judith and Krammer, Florian and {Garc{\'i}a-Sastre}, Adolfo and Luksza, Marta and Patel, Gopi and {Paniz-Mondolfi}, Alberto and Gitman, Melissa and Sordillo, Emilia Mia and Simon, Viviana and van Bakel, Harm},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc1917},
  abstract = {New York City (NYC) has emerged as one of the epicenters of the current SARS-CoV-2 pandemic. To identify the early transmission events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus causing COVID-19 in patients seeking care at the Mount Sinai Health System. Phylogenetic analysis of 84 distinct SARS-CoV2 genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts of the United States. Moreover, we find evidence for community transmission of SARS-CoV-2 as suggested by clusters of related viruses found in patients living in different neighborhoods of the city.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X9PNFF2R\\Gonzalez-Reiche et al. - 2020 - Introductions and early spread of SARS-CoV-2 in th.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\SWYP4SDR\\science.html}
}

@misc{GoogleScholar,
  title = {Google {{Scholar}}},
  howpublished = {https://scholar-google-com.uaccess.univie.ac.at/scholar?hl=en\&as\_sdt=0\%2C5\&q=generation+time+\&btnG=},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\G8LXH9AJ\\scholar.html}
}

@misc{GoogleScholara,
  title = {Google {{Scholar}}},
  howpublished = {https://scholar-google-com.uaccess.univie.ac.at/scholar?hl=en\&as\_sdt=0\%2C5\&q=generation+time+\&btnG=}
}

@article{gosticPracticalConsiderationsMeasuring,
  title = {Practical Considerations for Measuring the Effective Reproductive Number, {{Rt}}},
  author = {Gostic, Katelyn M and McGough, Lauren and Baskerville, Ed and Abbott, Sam and Joshi, Keya and Tedijanto, Christine and Kahn, Rebecca and Niehus, Rene and Hay, James and {de Salazar}, Pablo and Meakin, Sophie and Munday, James and Bosse, Nikos I and Sherrat, Katharine and White, Laura F and Huisman, Jana S and Scire, Jeremie and Stadler, Tanja and Wallinga, Jacco and Funk, Sebastian and Lipsitch, Marc and Cobey, Sarah},
  pages = {21},
  abstract = {Estimation of the effective reproductive number, Rt, is important for detecting changes in disease transmission over time. During the COVID-19 pandemic, policymakers and public health officials are using Rt to assess the effectiveness of interventions and to inform policy. However, estimation of Rt from available data presents several challenges, with critical implications for the interpretation of the course of the pandemic. The purpose of this document is to summarize these challenges, illustrate them with examples from synthetic data, and, where possible, make methodological recommendations. For near real-time estimation of Rt, we recommend the approach of Cori et al. (2013), which uses data from before time t and empirical estimates of the distribution of time between infections. Methods that require data from after time t, such as Wallinga and Teunis (2004), are conceptually and methodologically less suited for near real-time estimation, but may be appropriate for some retrospective analyses. We advise against using methods derived from Bettencourt and Ribeiro (2008), as the resulting Rt estimates may be biased if the underlying structural assumptions are not met. A challenge common to all approaches is reconstruction of the time series of new infections from observations occurring long after the moment of transmission. Naive approaches for dealing with observation delays, such as subtracting delays sampled from a distribution, can introduce bias. We provide suggestions for how to mitigate this and other technical challenges and highlight open problems in Rt estimation.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X9PMHXP9\\Gostic et al. - Practical considerations for measuring the effecti.pdf}
}

@article{grantImpactSARSCoV2Delta2021,
  title = {Impact of {{SARS-CoV-2 Delta}} Variant on Incubation, Transmission Settings and Vaccine Effectiveness: {{Results}} from a Nationwide Case-Control Study in {{France}}},
  shorttitle = {Impact of {{SARS-CoV-2 Delta}} Variant on Incubation, Transmission Settings and Vaccine Effectiveness},
  author = {Grant, Rebecca and Charmet, Tiffany and Schaeffer, Laura and Galmiche, Simon and Madec, Yoann and Platen, Cassandre Von and Ch{\'e}ny, Olivia and Omar, Fa{\"i}za and David, Christophe and Rogoff, Alexandra and Paireau, Juliette and Cauchemez, Simon and Carrat, Fabrice and Septfons, Alexandra and {Levy-Bruhl}, Daniel and Mailles, Alexandra and Fontanet, Arnaud},
  year = {2021},
  month = nov,
  journal = {The Lancet Regional Health \textendash{} Europe},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2666-7762},
  doi = {10.1016/j.lanepe.2021.100278},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D5HMUP5H\\Grant et al. - 2021 - Impact of SARS-CoV-2 Delta variant on incubation, .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\LXATLFNE\\fulltext.html}
}

@article{greenhalghManagementPostacuteCovid192020,
  title = {Management of Post-Acute Covid-19 in Primary Care},
  author = {Greenhalgh, Trisha and Knight, Matthew and A'Court, Christine and Buxton, Maria and Husain, Laiba},
  year = {2020},
  month = aug,
  journal = {BMJ},
  volume = {370},
  pages = {m3026},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.m3026},
  abstract = {\#\#\# What you need to know Post-acute covid-19 (``long covid'') seems to be a multisystem disease, sometimes occurring after a relatively mild acute illness.1 Clinical management requires a whole-patient perspective.2 This article, intended for primary care clinicians, relates to the patient who has a delayed recovery from an episode of covid-19 that was managed in the community or in a standard hospital ward. Broadly, such patients can be divided into those who may have serious sequelae (such as thromboembolic complications) and those with a non-specific clinical picture, often dominated by fatigue and breathlessness. The specialist rehabilitation needs of a third group, covid-19 patients whose acute illness required intensive care, have been covered elsewhere.3 In the absence of agreed definitions, for the purposes of this article we define post-acute covid-19 as extending beyond three weeks from the onset of first symptoms and chronic covid-19 as extending beyond 12 weeks. Since many people were not tested, and false negative tests are common,4 we suggest that a positive test for covid-19 is not a prerequisite for diagnosis. \#\#\# How common is it? Around 10\% of patients who have tested positive for SARS-CoV-2 virus remain unwell beyond three weeks, and a smaller proportion for months (see box 1).7 This is based on the UK COVID Symptom Study, in which people enter their ongoing symptoms on a smartphone app. This percentage is lower than that cited in many published observational \ldots},
  chapter = {Practice},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group-bmj-com.uaccess.univie.ac.at/group/rights-licensing/permissions. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ.  You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj-com.uaccess.univie.ac.at/coronavirus/usage},
  langid = {english},
  pmid = {32784198},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4U2RZ6CV\\Greenhalgh et al. - 2020 - Management of post-acute covid-19 in primary care.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KWLIW8KD\\bmj.html}
}

@article{greinacherThromboticThrombocytopeniaChAdOx12021,
  title = {Thrombotic {{Thrombocytopenia}} after {{ChAdOx1 nCov-19 Vaccination}}},
  author = {Greinacher, Andreas and Thiele, Thomas and Warkentin, Theodore E. and Weisser, Karin and Kyrle, Paul A. and Eichinger, Sabine},
  year = {2021},
  month = apr,
  journal = {New England Journal of Medicine},
  volume = {0},
  number = {0},
  pages = {null},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2104840},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa2104840},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LVHSESZT\\Greinacher et al. - 2021 - Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7KAK69C5\\NEJMoa2104840.html}
}

@article{griffinRapidReviewAvailable2020,
  title = {Rapid Review of Available Evidence on the Serial Interval and Generation Time of {{COVID-19}}},
  author = {Griffin, John and Casey, Miriam and Collins, {\'A}ine and Hunt, Kevin and McEvoy, David and Byrne, Andrew and McAloon, Conor and Barber, Ann and Lane, Elizabeth Ann and More, SImon},
  year = {2020},
  month = nov,
  journal = {BMJ Open},
  volume = {10},
  number = {11},
  pages = {e040263},
  issn = {2044-6055, 2044-6055},
  doi = {10.1136/bmjopen-2020-040263},
  abstract = {The serial interval is the time between symptom onsets in an infector\textendash infectee pair. The generation time, also known as the generation interval, is the time between infection events in an infector\textendash infectee pair. The serial interval and the generation time are key parameters for assessing the dynamics of a disease. A number of scientific papers reported information pertaining to the serial interval and/or generation time for COVID-19. Objective\hspace{0.6em} Conduct a review of available evidence to advise on appropriate parameter values for serial interval and generation time in national COVID-19 transmission models for Ireland and on methodological issues relating to those parameters. Methods\hspace{0.6em} We conducted a rapid review of the literature covering the period 1 January 2020 and 21 August 2020, following predefined eligibility criteria. Forty scientific papers met our inclusion criteria and were included in the review. Results\hspace{0.6em} The mean of the serial interval ranged from 3.03 to 7.6 days, based on 38 estimates, and the median from 1.0 to 6.0 days (based on 15 estimates). Only three estimates were provided for the mean of the generation time. These ranged from 3.95 to 5.20 days. One estimate of 5.0 days was provided for the median of the generation time. Discussion\hspace{0.6em} Estimates of the serial interval and the generation time are very dependent on the specific factors that apply at the time that the data are collected, including the level of social contact. Consequently, the estimates may not be entirely relevant to other environments. Therefore, local estimates should be obtained as soon as possible. Careful consideration should be given to the methodology that is used. Real-\-time estimations of the serial interval/generation time, allowing for variations over time, may provide more accurate estimates of reproduction numbers than using conventionally fixed serial interval/generation time distributions.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D45GNARS\\Griffin et al. - 2020 - Rapid review of available evidence on the serial i.pdf}
}

@article{gronvallDevelopingNationalStrategy,
  title = {Developing a {{National Strategy}} for {{Serology}} ({{Antibody Testing}}) in the {{United States}}},
  author = {Gronvall, Gigi and Connell, Nancy and Kobokovich, Amanda},
  pages = {38},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5G3SV485\\Gronvall et al. - Contributors from Johns Hopkins University.pdf}
}

@article{guanClinicalCharacteristicsCoronavirus2020,
  title = {Clinical {{Characteristics}} of {{Coronavirus Disease}} 2019 in {{China}}},
  author = {Guan, Wei-jie and Ni, Zheng-yi and Hu, Yu and Liang, Wen-hua and Ou, Chun-quan and He, Jian-xing and Liu, Lei and Shan, Hong and Lei, Chun-liang and Hui, David S.C. and Du, Bin and Li, Lan-juan and Zeng, Guang and Yuen, Kwok-Yung and Chen, Ru-chong and Tang, Chun-li and Wang, Tao and Chen, Ping-yan and Xiang, Jie and Li, Shi-yue and Wang, Jin-lin and Liang, Zi-jing and Peng, Yi-xiang and Wei, Li and Liu, Yong and Hu, Ya-hua and Peng, Peng and Wang, Jian-ming and Liu, Ji-yang and Chen, Zhong and Li, Gang and Zheng, Zhi-jian and Qiu, Shao-qin and Luo, Jie and Ye, Chang-jiang and Zhu, Shao-yong and Zhong, Nan-shan},
  year = {2020},
  month = apr,
  journal = {New England Journal of Medicine},
  volume = {382},
  number = {18},
  pages = {1708--1720},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2002032},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa2002032},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MUPY2WXH\\Guan et al. - 2020 - Clinical Characteristics of Coronavirus Disease 20.pdf}
}

@article{guanClinicalCharacteristicsCoronavirus2020a,
  title = {Clinical {{Characteristics}} of {{Coronavirus Disease}} 2019 in {{China}}},
  author = {Guan, Wei-jie and Ni, Zheng-yi and Hu, Yu and Liang, Wen-hua and Ou, Chun-quan and He, Jian-xing and Liu, Lei and Shan, Hong and Lei, Chun-liang and Hui, David S.C. and Du, Bin and Li, Lan-juan and Zeng, Guang and Yuen, Kwok-Yung and Chen, Ru-chong and Tang, Chun-li and Wang, Tao and Chen, Ping-yan and Xiang, Jie and Li, Shi-yue and Wang, Jin-lin and Liang, Zi-jing and Peng, Yi-xiang and Wei, Li and Liu, Yong and Hu, Ya-hua and Peng, Peng and Wang, Jian-ming and Liu, Ji-yang and Chen, Zhong and Li, Gang and Zheng, Zhi-jian and Qiu, Shao-qin and Luo, Jie and Ye, Chang-jiang and Zhu, Shao-yong and Zhong, Nan-shan},
  year = {2020},
  month = apr,
  journal = {New England Journal of Medicine},
  volume = {382},
  number = {18},
  pages = {1708--1720},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2002032},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa2002032}
}

@techreport{guentherInvestigationSuperspreadingEvent2020,
  type = {{{SSRN Scholarly Paper}}},
  title = {Investigation of a Superspreading Event Preceding the Largest Meat Processing Plant-Related {{SARS-Coronavirus}} 2 Outbreak in {{Germany}}},
  author = {Guenther, Thomas and {Czech-Sioli}, Manja and Indenbirken, Daniela and Robitailles, Alexis and Tenhaken, Peter and Exner, Martin and Ottinger, Matthias and Fischer, Nicole and Grundhoff, Adam and Brinkmann, Melanie},
  year = {2020},
  month = jul,
  number = {ID 3654517},
  address = {{Rochester, NY}},
  institution = {{Social Science Research Network}},
  abstract = {BackgroundHere, we describe a multifactorial investigation of the events of a SARS-CoV-2 outbreak in the largest meat processing complex in Germany. MethodsTiming of infection events, spatial relationship between workers in the meat processing plant, climate and ventilation conditions, sharing of living quarters and transport, and full viral genome sequences recovered from PCR-confirmed SARS-CoV-2 cases were analyzed.FindingsTransmissions occurred in a confined area of a meat processing plant in which air is constantly re-circulated and cooled to 10\textdegree C. Index case B1 transmitted the virus to co-workers in a radius of more than 8 meters during work-shifts on 3 consecutive days. Assessment of viral sequences shows that all cases share a set of eight single nucleotide mutations representing a novel sub-branch in the SARS-CoV-2 C20 clade. We identified the same set of mutations in samples collected in the time period between the initial infection cluster and a subsequent outbreak in the following month, with the largest number of confirmed SARS-CoV-2 positive cases in a meat processing facility reported so far.   InterpretationOur results indicate climate conditions and airflow as factors that can promote efficient spread of SARS-CoV-2 via distances of more than 8 meters and provide insights into possible requirements for pandemic mitigation strategies in industrial workplace settings.FundingNone.},
  langid = {english},
  keywords = {amplicon seqeuncing,meat processing plant,SARS-CoV-2 outbreak,superspreading event,variant sequencing},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\K3GQJIK7\\papers.html}
}

@article{gunster6MonthFollow86792021,
  title = {6-{{Month Follow Up}} of 8679 {{Hospitalized COVID-19 Patients}} in {{Germany}}: {{A Nationwide Cohort Study}}},
  shorttitle = {6-{{Month Follow Up}} of 8679 {{Hospitalized COVID-19 Patients}} in {{Germany}}},
  author = {G{\"u}nster, Christian and Busse, Reinhard and Spoden, Melissa and Rombey, Tanja and Schillinger, Gerhard and Hoffmann, Wolfgang and {Weber-Carstens}, Steffen and Schuppert, Andreas and Karagiannidis, Christian},
  year = {2021},
  month = apr,
  journal = {medRxiv},
  pages = {2021.04.24.21256029},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.04.24.21256029},
  abstract = {{$<$}p{$>$}Background: Data on long-term outcomes of hospitalized COVID-19 patients are scarce. Objective: To provide a detailed account of hospitalized COVID-19 patients until 180 days after their initial hospitalization. Design: Nationwide cohort study using claims data from the German Local Health Care Funds, the health insurer of one-third of the German population. Setting: Germany. Patients: Adult patients hospitalized in Germany between Feb 1 and April 30, 2020 with PCR-confirmed COVID-19 and a related principal diagnosis. Measurements: Patient characteristics and ventilation status, in-hospital, 30-, 90- and 180-day mortality measured from admission, and 180-day readmission measured from discharge. Multivariable logistic regression model of independent risk factors for 180-day mortality. Results: Of 8679 patients (median age, 72 years), 2161 (24.9\%) died during the index hospitalization. 30-day mortality was 23.9\% (2073/8679), 90-day mortality 27.9\% (2425/8679), and 180-day mortality 29.6\% (2566/8679). The latter was 52.3\% (1472/2817) for patients aged {$\geq$} 80 years, and 53.0\% for patients who had been ventilated invasively (853/1608). Risk factors for 180-day mortality included coagulopathy, BMI {$\geq$} 40, and age. Female sex was a protective factor. Of 6235 patients discharged alive, 1668 patients were readmitted a total of 2551 times within 180 days, resulting in an overall readmission rate of 26.8\%. Limitations: We could not stratify patients by ICU treatment as it is not coded separately. Furthermore, we cannot exclude residual confounding in our analysis of risk factors nor determine causality between risk factors and long-term mortality given the observational nature of this study. Conclusion: This nationwide cohort study of hospitalized COVID-19 patients in Germany found considerable long-term mortality and readmission rates, especially among patients with coagulopathy. Close follow-up after hospital discharge may improve long-term outcome.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KLA8JNUF\\Gnster et al. - 2021 - 6-Month Follow Up of 8679 Hospitalized COVID-19 Pa.pdf}
}

@article{hardingPopulationMobilityInduced2020,
  title = {Population Mobility Induced Phase Separation in {{SIS}} Epidemic and Social Dynamics},
  author = {Harding, Nathan and Spinney, Richard E. and Prokopenko, Mikhail},
  year = {2020},
  month = may,
  journal = {Scientific Reports},
  volume = {10},
  number = {1},
  pages = {1--11},
  publisher = {{Nature Publishing Group}},
  issn = {2045-2322},
  doi = {10.1038/s41598-020-64183-1},
  abstract = {Understanding the impact of behavior dependent mobility in the spread of epidemics and social disorders is an outstanding problem in computational epidemiology. We present a modelling approach for the study of mobility that adapts dynamically according to individual state, epidemic/social-contagion state and network topology in accordance with limited data and/or common behavioral models. We demonstrate that even for simple compartmental network processes, our approach leads to complex spatial patterns of infection in the endemic state dependent on individual behavior. Specifically, we characterize the resulting phenomena in terms of phase separation, highlighting phase transitions between distinct spatial states and determining the systems' phase diagram. The existence of such phases implies that small changes in the populations' perceptions could lead to drastic changes in the spatial extent and morphology of the epidemic/social phenomena.},
  copyright = {2020 The Author(s)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FZ4WGKE6\\Harding et al. - 2020 - Population mobility induced phase separation in SI.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\C62SWTPG\\s41598-020-64183-1.html}
}

@article{harrisonUsingObservationlevelRandom2014,
  title = {Using Observation-Level Random Effects to Model Overdispersion in Count Data in Ecology and Evolution},
  author = {Harrison, Xavier A.},
  year = {2014},
  month = oct,
  journal = {PeerJ},
  volume = {2},
  pages = {e616},
  publisher = {{PeerJ Inc.}},
  issn = {2167-8359},
  doi = {10.7717/peerj.616},
  abstract = {Overdispersion is common in models of count data in ecology and evolutionary biology, and can occur due to missing covariates, non-independent (aggregated) data, or an excess frequency of zeroes (zero-inflation). Accounting for overdispersion in such models is vital, as failing to do so can lead to biased parameter estimates, and false conclusions regarding hypotheses of interest. Observation-level random effects (OLRE), where each data point receives a unique level of a random effect that models the extra-Poisson variation present in the data, are commonly employed to cope with overdispersion in count data. However studies investigating the efficacy of observation-level random effects as a means to deal with overdispersion are scarce. Here I use simulations to show that in cases where overdispersion is caused by random extra-Poisson noise, or aggregation in the count data, observation-level random effects yield more accurate parameter estimates compared to when overdispersion is simply ignored. Conversely, OLRE fail to reduce bias in zero-inflated data, and in some cases increase bias at high levels of overdispersion. There was a positive relationship between the magnitude of overdispersion and the degree of bias in parameter estimates. Critically, the simulations reveal that failing to account for overdispersion in mixed models can erroneously inflate measures of explained variance (r2), which may lead to researchers overestimating the predictive power of variables of interest. This work suggests use of observation-level random effects provides a simple and robust means to account for overdispersion in count data, but also that their ability to minimise bias is not uniform across all types of overdispersion and must be applied judiciously.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8PG82HEA\\Harrison - 2014 - Using observation-level random effects to model ov.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q7D76669\\616.html}
}

@misc{hartGenerationTimeAlpha2021,
  title = {Generation Time of the {{Alpha}} and {{Delta SARS-CoV-2}} Variants},
  author = {Hart, W. S. and Miller, E. and Andrews, N. J. and Waight, P. and Maini, P. K. and Funk, S. and Thompson, R. N.},
  year = {2021},
  month = oct,
  pages = {2021.10.21.21265216},
  institution = {{Cold Spring Harbor Laboratory Press}},
  issn = {2126-5216},
  doi = {10.1101/2021.10.21.21265216},
  abstract = {Background In May 2021, the Delta SARS-CoV-2 variant became dominant in the UK. This variant is associated with increased transmissibility compared to the Alpha variant that was previously dominant. To understand ongoing transmission and interventions, a key question is whether the Delta variant generation time (the time between infections in infector- infectee pairs) is typically shorter\textendash i.e., transmissions are happening more quickly\textendash or whether infected individuals simply generate more infections. Methods We analysed transmission data from a UK Health Security Agency household study. By fitting a mathematical transmission model to the data, we estimated the generation times for the Alpha and Delta variants. Results The mean intrinsic generation time (the generation time if there had been a constant supply of susceptibles throughout infection) was shorter for the Delta variant (4{$\cdot$}6 days, 95\% CrI 4{$\cdot$}0-5{$\cdot$}4 days) than the Alpha variant (5{$\cdot$}5 days, 95\% CrI 4{$\cdot$}6-6{$\cdot$}4 days), although within uncertainty ranges. However, there was a larger difference in the realised mean household generation time between the Delta (3{$\cdot$}2 days, 95\% CrI 2{$\cdot$}4-4{$\cdot$}2 days) and Alpha (4{$\cdot$}5 days, 95\% CrI 3{$\cdot$}7-5{$\cdot$}4 days) variants. This is because higher transmissibility led to faster susceptible depletion in households, in addition to the reduced intrinsic generation time. Conclusions The Delta variant transmits more quickly than previously circulating variants. This has implications for interventions such as contact tracing, testing and isolation, which are less effective if the virus is transmitted quickly. Epidemiological models of interventions should be updated to include the shorter generation time of the Delta variant.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at http://creativecommons.org/licenses/by-nc/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6LVZNUGC\\Hart et al. - 2021 - Generation time of the Alpha and Delta SARS-CoV-2 .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\DFCRQ3FB\\2021.10.21.html}
}

@article{haushoferWhichInterventionsWork2020,
  title = {Which Interventions Work Best in a Pandemic?},
  author = {Haushofer, Johannes and Metcalf, C. Jessica E.},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb6144},
  abstract = {We can exploit randomized controlled trials, compartmental models, and spillovers.},
  chapter = {Policy Forum},
  copyright = {Copyright \textcopyright{} 2020, American Association for the Advancement of Science},
  langid = {english},
  pmid = {32439658},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NTLNHNEY\\Haushofer and Metcalf - 2020 - Which interventions work best in a pandemic.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\RYWBEJ4S\\science.html}
}

@article{haushoferWhichInterventionsWork2020a,
  title = {Which Interventions Work Best in a Pandemic?},
  author = {Haushofer, Johannes and Metcalf, C. Jessica E.},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb6144},
  abstract = {We can exploit randomized controlled trials, compartmental models, and spillovers.},
  chapter = {Policy Forum},
  copyright = {Copyright \textcopyright{} 2020, American Association for the Advancement of Science},
  langid = {english},
  pmid = {32439658},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MHQ3FUPG\\Haushofer and Metcalf - 2020 - Which interventions work best in a pandemic.pdf}
}

@article{hawrylukInferenceCOVID19Epidemiological2020,
  title = {Inference of {{COVID-19}} Epidemiological Distributions from {{Brazilian}} Hospital Data},
  author = {Hawryluk, Iwona and Mellan, Thomas A. and Hoeltgebaum, Henrique and Mishra, Swapnil and Schnekenberg, Ricardo P. and Whittaker, Charles and Zhu, Harrison and Gandy, Axel and Donnelly, Christl A. and Flaxman, Seth and Bhatt, Samir},
  year = {2020},
  month = nov,
  journal = {Journal of The Royal Society Interface},
  volume = {17},
  number = {172},
  pages = {20200596},
  publisher = {{Royal Society}},
  doi = {10.1098/rsif.2020.0596},
  abstract = {Knowing COVID-19 epidemiological distributions, such as the time from patient admission to death, is directly relevant to effective primary and secondary care planning, and moreover, the mathematical modelling of the pandemic generally. We determine epidemiological distributions for patients hospitalized with COVID-19 using a large dataset (N = 21 000 - 157 000) from the Brazilian Sistema de Informa\c{c}\~ao de Vigil\^ancia Epidemiol\'ogica da Gripe database. A joint Bayesian subnational model with partial pooling is used to simultaneously describe the 26 states and one federal district of Brazil, and shows significant variation in the mean of the symptom-onset-to-death time, with ranges between 11.2 and 17.8 days across the different states, and a mean of 15.2 days for Brazil. We find strong evidence in favour of specific probability density function choices: for example, the gamma distribution gives the best fit for onset-to-death and the generalized lognormal for onset-to-hospital-admission. Our results show that epidemiological distributions have considerable geographical variation, and provide the first estimates of these distributions in a low and middle-income setting. At the subnational level, variation in COVID-19 outcome timings are found to be correlated with poverty, deprivation and segregation levels, and weaker correlation is observed for mean age, wealth and urbanicity.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RM8R8WQG\\Hawryluk et al. - 2020 - Inference of COVID-19 epidemiological distribution.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\XS66VT39\\rsif.2020.html}
}

@article{hayEstimatingEpidemiologicDynamics2021,
  title = {Estimating Epidemiologic Dynamics from Cross-Sectional Viral Load Distributions},
  author = {Hay, James A. and {Kennedy-Shaffer}, Lee and Kanjilal, Sanjat and Lennon, Niall J. and Gabriel, Stacey B. and Lipsitch, Marc and Mina, Michael J.},
  year = {2021},
  month = jun,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abh0635},
  abstract = {Estimating an epidemic's trajectory is crucial for developing public health responses to infectious diseases, but case data used for such estimation are confounded by variable testing practices. We show that the population distribution of viral loads observed under random or symptom-based surveillance, in the form of cycle threshold (Ct) values obtained from reverse-transcription quantitative polymerase chain reaction testing, changes during an epidemic. Thus, Ct values from even limited numbers of random samples can provide improved estimates of an epidemic's trajectory. Combining data from multiple such samples improves the precision and robustness of such estimation. We apply our methods to Ct values from surveillance conducted during the SARS-CoV-2 pandemic in a variety of settings and offer alternative approaches for real-time estimates of epidemic trajectories for outbreak management and response.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\767HMBJN\\Hay et al. - 2021 - Estimating epidemiologic dynamics from cross-secti.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\LJJDQUT8\\science.html}
}

@article{hebert-dufresneHeterogeneitySecondaryInfections2020,
  title = {Beyond \${{R}}\_0\$: {{Heterogeneity}} in Secondary Infections and Probabilistic Epidemic Forecasting},
  shorttitle = {Beyond \${{R}}\_0\$},
  author = {{H{\'e}bert-Dufresne}, Laurent and Althouse, Benjamin M. and Scarpino, Samuel V. and Allard, Antoine},
  year = {2020},
  month = apr,
  journal = {arXiv:2002.04004 [physics, q-bio]},
  eprint = {2002.04004},
  eprinttype = {arxiv},
  primaryclass = {physics, q-bio},
  abstract = {The basic reproductive number -- \$R\_0\$ -- is one of the most common and most commonly misapplied numbers in public health. Although often used to compare outbreaks and forecast pandemic risk, this single number belies the complexity that two different pathogens can exhibit, even when they have the same \$R\_0\$. Here, we show how to predict outbreak size using estimates of the distribution of secondary infections, leveraging both its average \$R\_0\$ and the underlying heterogeneity. To do so, we reformulate and extend a classic result from random network theory that relies on contact tracing data to simultaneously determine the first moment (\$R\_0\$) and the higher moments (representing the heterogeneity) in the distribution of secondary infections. Further, we show the different ways in which this framework can be implemented in the data-scarce reality of emerging pathogens. Lastly, we demonstrate that without data on the heterogeneity in secondary infections for emerging infectious diseases like COVID-19, the uncertainty in outbreak size ranges dramatically. Taken together, our work highlights the critical need for contact tracing during emerging infectious disease outbreaks and the need to look beyond \$R\_0\$ when predicting epidemic size.},
  archiveprefix = {arXiv},
  keywords = {Physics - Applied Physics,Physics - Physics and Society,Quantitative Biology - Populations and Evolution},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RQP5X2BV\\Hbert-Dufresne et al. - 2020 - Beyond $R_0$ Heterogeneity in secondary infection.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZVQC983F\\2002.html}
}

@article{heesterbeekHowMathematicalEpidemiology2015,
  title = {How Mathematical Epidemiology Became a Field of Biology: A Commentary on {{Anderson}} and {{May}} (1981) `{{The}} Population Dynamics of Microparasites and Their Invertebrate Hosts'},
  shorttitle = {How Mathematical Epidemiology Became a Field of Biology},
  author = {Heesterbeek, J. a. P. and Roberts, M. G.},
  year = {2015},
  month = apr,
  journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
  volume = {370},
  number = {1666},
  pages = {20140307},
  publisher = {{Royal Society}},
  doi = {10.1098/rstb.2014.0307},
  abstract = {We discuss the context, content and importance of the paper `The population dynamics of microparasites and their invertebrate hosts', by R. M. Anderson and R. M. May, published in the Philosophical Transactions of the Royal Society as a stand-alone issue in 1981. We do this from the broader perspective of the study of infectious disease dynamics, rather than the specific perspective of the dynamics of insect pathogens. We argue that their 1981 paper fits seamlessly in the systematic study of infectious disease dynamics that was initiated by the authors in 1978, combining effective use of simple mathematical models, firmly rooted in biology, with observable or empirically measurable ingredients and quantities, and promoting extensive capacity building. This systematic approach, taking ecology and biology rather than applied mathematics as the motivation for advance, proved essential for the maturation of the field, and culminated in their landmark textbook of 1991. This commentary was written to celebrate the 350th anniversary of the journal Philosophical Transactions of the Royal Society.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\35EUX2VK\\Heesterbeek and Roberts - 2015 - How mathematical epidemiology became a field of bi.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\DGWF5AD8\\rstb.2014.html}
}

@article{heesterbeekModelingInfectiousDisease2015,
  title = {Modeling Infectious Disease Dynamics in the Complex Landscape of Global Health},
  author = {Heesterbeek, Hans and Anderson, Roy M. and Andreasen, Viggo and Bansal, Shweta and Angelis, Daniela De and Dye, Chris and Eames, Ken T. D. and Edmunds, W. John and Frost, Simon D. W. and Funk, Sebastian and Hollingsworth, T. Deirdre and House, Thomas and Isham, Valerie and Klepac, Petra and Lessler, Justin and {Lloyd-Smith}, James O. and Metcalf, C. Jessica E. and Mollison, Denis and Pellis, Lorenzo and Pulliam, Juliet R. C. and Roberts, Mick G. and Viboud, Cecile and Collaboration, Isaac Newton Institute IDD},
  year = {2015},
  month = mar,
  journal = {Science},
  volume = {347},
  number = {6227},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.aaa4339},
  abstract = {Mathematical modeling of infectious diseases The spread of infectious diseases can be unpredictable. With the emergence of antibiotic resistance and worrying new viruses, and with ambitious plans for global eradication of polio and the elimination of malaria, the stakes have never been higher. Anticipation and measurement of the multiple factors involved in infectious disease can be greatly assisted by mathematical methods. In particular, modeling techniques can help to compensate for imperfect knowledge, gathered from large populations and under difficult prevailing circumstances. Heesterbeek et al. review the development of mathematical models used in epidemiology and how these can be harnessed to develop successful control strategies and inform public health policy. Science, this issue 10.1126/science.aaa4339 Structured Abstract BACKGROUND Despite many notable successes in prevention and control, infectious diseases remain an enormous threat to human and animal health. The ecological and evolutionary dynamics of pathogens play out on a wide range of interconnected temporal, organizational, and spatial scales that span hours to months, cells to ecosystems, and local to global spread. Some pathogens are directly transmitted between individuals of a single species, whereas others circulate among multiple hosts, need arthropod vectors, or persist in environmental reservoirs. Many factors, including increasing antimicrobial resistance, human connectivity, population growth, urbanization, environmental and land-use change, as well as changing human behavior, present global challenges for prevention and control. Faced with this complexity, mathematical models offer valuable tools for understanding epidemiological patterns and for developing and evaluating evidence for decision-making in global health. ADVANCES During the past 50 years, the study of infectious disease dynamics has matured into a rich interdisciplinary field at the intersection of mathematics, epidemiology, ecology, evolutionary biology, immunology, sociology, and public health. The practical challenges range from establishing appropriate data collection to managing increasingly large volumes of information. The theoretical challenges require fundamental study of many-layered, nonlinear systems in which infections evolve and spread and where key events can be governed by unpredictable pathogen biology or human behavior. In this Review, we start with an examination of real-time outbreak response using the West African Ebola epidemic as an example. Here, the challenges range from underreporting of cases and deaths, and missing information on the impact of control measures to understanding human responses. The possibility of future zoonoses tests our ability to detect anomalous outbreaks and to estimate human-to-human transmissibility against a backdrop of ongoing zoonotic spillover while also assessing the risk of more dangerous strains evolving. Increased understanding of the dynamics of infections in food webs and ecosystems where host and nonhost species interact is key. Simultaneous multispecies infections are increasingly recognized as a notable public health burden, yet our understanding of how different species of pathogens interact within hosts is rudimentary. Pathogen genomics has become an essential tool for drawing inferences about evolution and transmission and, here but also in general, heterogeneity is the major challenge. Methods that depart from simplistic assumptions about random mixing are yielding new insights into the dynamics of transmission and control. There is rapid growth in estimation of model parameters from mismatched or incomplete data, and in contrasting model output with real-world observations. New data streams on social connectivity and behavior are being used, and combining data collected from very different sources and scales presents important challenges. All these mathematical endeavors have the potential to feed into public health policy and, indeed, an increasingly wide range of models is being used to support infectious disease control, elimination, and eradication efforts. OUTLOOK Mathematical modeling has the potential to probe the apparently intractable complexity of infectious disease dynamics. Coupled to continuous dialogue between decision-makers and the multidisciplinary infectious disease community, and by drawing on new data streams, mathematical models can lay bare mechanisms of transmission and indicate new approaches to prevention and control that help to shape national and international public health policy. {$<$}img class="fragment-image" aria-describedby="F1-caption" src="https://science-sciencemag-org.uaccess.univie.ac.at/content/sci/347/6227/aaa4339/F1.medium.gif"/{$>$} Download high-res image Open in new tab Download Powerpoint Modeling for public health. Policy questions define the model's purpose. Initial model design is based on current scientific understanding and the available relevant data. Model validation and fit to disease data may require further adaptation; sensitivity and uncertainty analysis can point to requirements for collection of additional specific data. Cycles of model testing and analysis thus lead to policy advice and improved scientific understanding. Despite some notable successes in the control of infectious diseases, transmissible pathogens still pose an enormous threat to human and animal health. The ecological and evolutionary dynamics of infections play out on a wide range of interconnected temporal, organizational, and spatial scales, which span hours to months, cells to ecosystems, and local to global spread. Moreover, some pathogens are directly transmitted between individuals of a single species, whereas others circulate among multiple hosts, need arthropod vectors, or can survive in environmental reservoirs. Many factors, including increasing antimicrobial resistance, increased human connectivity and changeable human behavior, elevate prevention and control from matters of national policy to international challenge. In the face of this complexity, mathematical models offer valuable tools for synthesizing information to understand epidemiological patterns, and for developing quantitative evidence for decision-making in global health.},
  chapter = {Review},
  copyright = {Copyright \textcopyright{} 2015, American Association for the Advancement of Science},
  langid = {english},
  pmid = {25766240},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3K6465XC\\Heesterbeek et al. - 2015 - Modeling infectious disease dynamics in the comple.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\XM7BAJ5K\\aaa4339.html}
}

@article{heesterbeekModelingInfectiousDisease2015a,
  title = {Modeling Infectious Disease Dynamics in the Complex Landscape of Global Health},
  author = {Heesterbeek, Hans and Anderson, Roy and Andreasen, Viggo and Bansal, Shweta and De Angelis, Daniela and Dye, Chris and Eames, Ken and Edmunds, John and Frost, Simon and Funk, Sebastian and Hollingsworth, Deirdre and House, Thomas and Isham, Valerie and Klepac, Petra and Lessler, Justin and {Lloyd-Smith}, James and Metcalf, Jessica and Mollison, Denis and Pellis, Lorenzo and Pulliam, Juliet and Roberts, Mick and Viboud, Cecile},
  year = {2015},
  month = mar,
  journal = {Science (New York, N.Y.)},
  volume = {347},
  number = {6227},
  pages = {aaa4339},
  issn = {0036-8075},
  doi = {10.1126/science.aaa4339},
  abstract = {Despite some notable successes in the control of infectious diseases, transmissible pathogens still pose an enormous threat to human and animal health. The ecological and evolutionary dynamics of infections play out on a wide range of interconnected temporal, organizational and spatial scales, which even within a single pathogen often span hours to months, cellular to ecosystem levels, and local to pandemic spread. Some pathogens are directly transmitted between individuals of a single species, while others circulate among multiple hosts, need arthropod vectors, or can survive in environmental reservoirs. Many factors, including increasing antimicrobial resistance, increased human connectivity, and dynamic human behavior, raise prevention and control from formerly national to international issues. In the face of this complexity, mathematical models offer essential tools for synthesizing information to understand epidemiological patterns, and for developing the quantitative evidence base for decision-making in global health.},
  pmcid = {PMC4445966},
  pmid = {25766240},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\W9N233JK\\Heesterbeek et al. - 2015 - Modeling infectious disease dynamics in the comple.pdf}
}

@techreport{hellewellEstimatingEffectivenessRoutine2020,
  type = {Preprint},
  title = {Estimating the Effectiveness of Routine Asymptomatic {{PCR}} Testing at Different Frequencies for the Detection of {{SARS-CoV-2}} Infections},
  author = {Hellewell, Joel and Russell, Timothy W. and {The SAFER Investigators and Field Study Team} and {The Crick COVID-19 Consortium} and {CMMID COVID-19 working group} and Beale, Rupert and Kelly, Gavin and Houlihan, Catherine and Nastouli, Eleni and Kucharski, Adam J.},
  year = {2020},
  month = nov,
  institution = {{Epidemiology}},
  doi = {10.1101/2020.11.24.20229948},
  abstract = {Abstract                        Background             Routine asymptomatic testing using RT-PCR of people who interact with vulnerable populations, such as medical staff in hospitals or care workers in care homes, has been employed to help prevent outbreaks among vulnerable populations. Although the peak sensitivity of RT-PCR can be high, the probability of detecting an infection will vary throughout the course of an infection. The effectiveness of routine asymptomatic testing will therefore depend on testing frequency and how PCR detection varies over time.                                   Methods             We fitted a Bayesian statistical model to a dataset of twice weekly PCR tests of UK healthcare workers performed by self-administered nasopharyngeal swab, regardless of symptoms. We jointly estimated times of infection and the probability of a positive PCR test over time following infection, we then compared asymptomatic testing strategies by calculating the probability that a symptomatic infection is detected before symptom onset and the probability that an asymptomatic infection is detected within 7 days of infection.                                   Findings             We estimated that the probability that the PCR test detected infection peaked at 77\% (54 - 88\%) 4 days after infection, decreasing to 50\% (38 - 65\%) by 10 days after infection. Our results suggest a substantially higher probability of detecting infections 1\textendash 3 days after infection than previously published estimates. We estimated that testing every other day would detect 57\% (33-76\%) of symptomatic cases prior to onset and 94\% (75-99\%) of asymptomatic cases within 7 days if test results were returned within a day.                                   Interpretation             Our results suggest that routine asymptomatic testing can enable detection of a high proportion of infected individuals early in their infection, provided that the testing is frequent and the time from testing to notification of results is sufficiently fast.                                   Funding             Wellcome Trust, National Institute for Health Research (NIHR) Health Protection Research Unit, Medical Research Council (UKRI)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MLFHVKA7\\Hellewell et al. - 2020 - Estimating the effectiveness of routine asymptomat.pdf}
}

@article{hellewellFeasibilityControllingCOVID192020,
  title = {Feasibility of Controlling {{COVID-19}} Outbreaks by Isolation of Cases and Contacts},
  author = {Hellewell, Joel and Abbott, Sam and Gimma, Amy and Bosse, Nikos I and Jarvis, Christopher I and Russell, Timothy W and Munday, James D and Kucharski, Adam J and Edmunds, W John and Funk, Sebastian and Eggo, Rosalind M and Sun, Fiona and Flasche, Stefan and Quilty, Billy J and Davies, Nicholas and Liu, Yang and Clifford, Samuel and Klepac, Petra and Jit, Mark and Diamond, Charlie and Gibbs, Hamish and {van Zandvoort}, Kevin},
  year = {2020},
  month = apr,
  journal = {The Lancet Global Health},
  volume = {8},
  number = {4},
  pages = {e488-e496},
  issn = {2214109X},
  doi = {10.1016/S2214-109X(20)30074-7},
  abstract = {Background Isolation of cases and contact tracing is used to control outbreaks of infectious diseases, and has been used for coronavirus disease 2019 (COVID-19). Whether this strategy will achieve control depends on characteristics of both the pathogen and the response. Here we use a mathematical model to assess if isolation and contact tracing are able to control onwards transmission from imported cases of COVID-19.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9WD5THUR\\Hellewell et al. - 2020 - Feasibility of controlling COVID-19 outbreaks by i.pdf}
}

@misc{hermesautoSouthKoreaRaces2020,
  type = {Text},
  title = {South {{Korea}} Races to Contain New {{Covid-19}} Cluster Linked to Clubs as Infections Swell to 119},
  author = {{hermesauto}},
  year = {2020},
  month = may,
  journal = {The Straits Times},
  abstract = {The promise of anonymous testing has encouraged more people to come forward, with more than 15,000 tests conducted on Wednesday.. Read more at straitstimes.com.},
  howpublished = {https://www.straitstimes.com/asia/east-asia/south-korea-races-to-contain-new-coronavirus-cluster-linked-to-clubs-as-infections},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AMAEBSM9\\south-korea-races-to-contain-new-coronavirus-cluster-linked-to-clubs-as-infections.html}
}

@article{heTemporalDynamicsViral2020,
  title = {Temporal Dynamics in Viral Shedding and Transmissibility of {{COVID-19}}},
  author = {He, Xi and Lau, Eric H. Y. and Wu, Peng and Deng, Xilong and Wang, Jian and Hao, Xinxin and Lau, Yiu Chung and Wong, Jessica Y. and Guan, Yujuan and Tan, Xinghua and Mo, Xiaoneng and Chen, Yanqing and Liao, Baolin and Chen, Weilie and Hu, Fengyu and Zhang, Qing and Zhong, Mingqiu and Wu, Yanrong and Zhao, Lingzhai and Zhang, Fuchun and Cowling, Benjamin J. and Li, Fang and Leung, Gabriel M.},
  year = {2020},
  month = may,
  journal = {Nature Medicine},
  volume = {26},
  number = {5},
  pages = {672--675},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0869-5},
  abstract = {We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector\textendash infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44\% (95\% confidence interval, 25\textendash 69\%) of secondary cases were infected during the index cases' presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HIWT5PZF\\He et al. - 2020 - Temporal dynamics in viral shedding and transmissi.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\4XLN49N3\\s41591-020-0869-5.html}
}

@article{heTemporalDynamicsViral2020a,
  title = {Temporal Dynamics in Viral Shedding and Transmissibility of {{COVID-19}}},
  author = {He, Xi and Lau, Eric H. Y. and Wu, Peng and Deng, Xilong and Wang, Jian and Hao, Xinxin and Lau, Yiu Chung and Wong, Jessica Y. and Guan, Yujuan and Tan, Xinghua and Mo, Xiaoneng and Chen, Yanqing and Liao, Baolin and Chen, Weilie and Hu, Fengyu and Zhang, Qing and Zhong, Mingqiu and Wu, Yanrong and Zhao, Lingzhai and Zhang, Fuchun and Cowling, Benjamin J. and Li, Fang and Leung, Gabriel M.},
  year = {2020},
  month = may,
  journal = {Nature Medicine},
  volume = {26},
  number = {5},
  pages = {672--675},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0869-5},
  abstract = {We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector\textendash infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44\% (95\% confidence interval, 25\textendash 69\%) of secondary cases were infected during the index cases' presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CX8WERIH\\He et al. - 2020 - Temporal dynamics in viral shedding and transmissi.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WRSYXMSX\\s41591-020-0869-5.html}
}

@misc{HighSARSCoV2Seroprevalence,
  title = {High {{SARS-CoV-2 Seroprevalence}} in {{Children}} and {{Adults}} in the {{Austrian Ski Resort Ischgl}} | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.08.20.20178533v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D6P9VIIG\\2020.08.20.html}
}

@article{hippisley-coxRiskThrombocytopeniaThromboembolism2021,
  title = {Risk of Thrombocytopenia and Thromboembolism after Covid-19 Vaccination and {{SARS-CoV-2}} Positive Testing: Self-Controlled Case Series Study},
  shorttitle = {Risk of Thrombocytopenia and Thromboembolism after Covid-19 Vaccination and {{SARS-CoV-2}} Positive Testing},
  author = {{Hippisley-Cox}, Julia and Patone, Martina and Mei, Xue W. and Saatci, Defne and Dixon, Sharon and Khunti, Kamlesh and Zaccardi, Francesco and Watkinson, Peter and {Shankar-Hari}, Manu and Doidge, James and Harrison, David A. and Griffin, Simon J. and Sheikh, Aziz and Coupland, Carol A. C.},
  year = {2021},
  month = aug,
  journal = {BMJ},
  volume = {374},
  pages = {n1931},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.n1931},
  abstract = {Objective To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults. Design Self-controlled case series study using national data on covid-19 vaccination and hospital admissions. Setting Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom's health service (NHS). Participants 29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged {$\geq$}16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study. Main outcome measures The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events. Results The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95\% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test. Conclusion Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.},
  chapter = {Research},
  copyright = {\textcopyright{} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6L7D8J68\\Hippisley-Cox et al. - 2021 - Risk of thrombocytopenia and thromboembolism after.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\RDGCKZTW\\bmj.html}
}

@article{holmdahlWrongUsefulWhat2020,
  title = {Wrong but {{Useful}} \textemdash{} {{What Covid-19 Epidemiologic Models Can}} and {{Cannot Tell Us}}},
  author = {Holmdahl, Inga and Buckee, Caroline},
  year = {2020},
  month = may,
  journal = {New England Journal of Medicine},
  publisher = {{Massachusetts Medical Society}},
  doi = {10.1056/NEJMp2016822},
  abstract = {Perspective from The New England Journal of Medicine \textemdash{} Wrong but Useful \textemdash{} What Covid-19 Epidemiologic Models Can and Cannot Tell Us},
  copyright = {Copyright \textcopyright{} 2020 Massachusetts Medical Society. All rights reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y6IIX8YM\\NEJMp2016822.html}
}

@article{holzerAnwendungsempfehlungenFuerNachweis,
  title = {{Anwendungsempfehlungen f\"ur den Nachweis von Antik\"orpern bei SARS-CoV-2}},
  author = {Holzer, Michael},
  pages = {10},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9NUEFZQ6\\Holzer - Anwendungsempfehlungen fr den Nachweis von Antik.pdf}
}

@article{holzerEmpfehlungUmgangMit,
  title = {{Empfehlung zum Umgang mit SARS-CoV-2 Kategorie I Kontaktpersonen \textendash bei versorgungskritischem Gesundheits- und Schl\"usselpersonal (Stand: 29.03.2020)}},
  author = {Holzer, Michael},
  pages = {5},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AN2F2ULK\\Holzer - Empfehlung zum Umgang mit SARS-CoV-2 Kategorie I K.pdf}
}

@article{holzerEmpfehlungZurEntlassung,
  title = {{Empfehlung zur Entlassung aus dem Krankenhaus bzw. aus der h\"auslichen Absonderung von COVID-19-F\"allen (Stand: 08.05.2020; basierend auf Empfehlungen des Robert-Koch-Instituts}},
  author = {Holzer, Michael},
  pages = {8},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D87RTEPR\\Holzer - Empfehlung zur Entlassung aus dem Krankenhaus bzw..pdf}
}

@article{holzerStrategieZurVirusvariantensurveillance,
  title = {{Strategie zur Virusvariantensurveillance}},
  author = {Holzer, Michael},
  pages = {8},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LYRRWCMA\\Holzer - Strategie zur Virusvariantensurveillance.pdf}
}

@article{honeinSummaryGuidancePublic2020,
  title = {Summary of {{Guidance}} for {{Public Health Strategies}} to {{Address High Levels}} of {{Community Transmission}} of {{SARS-CoV-2}} and {{Related Deaths}}, {{December}} 2020},
  author = {Honein, Margaret A.},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6949e2},
  abstract = {This report describes the need for implementation and adherence to mitigation strategies to reduce SARS-CoV-2 transmission and deaths.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UHRB8E5M\\mm6949e2.html}
}

@article{horbyNERVTAGPaperNote,
  title = {{{NERVTAG}} Paper {{Note}} on Growth Rate of {{SARS-CoV-2 B}}.1.1.7},
  author = {Horby, Peter and Evans, Cariad and Huntley, Catherine and Cevik, Muge and Hiscox, Julian and Edmunds, John and Ferguson, Neil and Hayward, Andrew},
  pages = {14},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MNX65WII\\Horby et al. - NERVTAG paper Note on growth rate of SARS-CoV-2 B..pdf}
}

@article{hsiangEffectLargescaleAnticontagion2020,
  title = {The Effect of Large-Scale Anti-Contagion Policies on the {{COVID-19}} Pandemic},
  author = {Hsiang, Solomon and Allen, Daniel and {Annan-Phan}, S{\'e}bastien and Bell, Kendon and Bolliger, Ian and Chong, Trinetta and Druckenmiller, Hannah and Huang, Luna Yue and Hultgren, Andrew and Krasovich, Emma and Lau, Peiley and Lee, Jaecheol and Rolf, Esther and Tseng, Jeanette and Wu, Tiffany},
  year = {2020},
  month = jun,
  journal = {Nature},
  issn = {0028-0836, 1476-4687},
  doi = {10.1038/s41586-020-2404-8},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XN5ZPIYD\\s41586-020-2404-8_reference.pdf}
}

@article{huang6monthConsequencesCOVID192021,
  title = {6-Month Consequences of {{COVID-19}} in Patients Discharged from Hospital: A Cohort Study},
  shorttitle = {6-Month Consequences of {{COVID-19}} in Patients Discharged from Hospital},
  author = {Huang, Chaolin and Huang, Lixue and Wang, Yeming and Li, Xia and Ren, Lili and Gu, Xiaoying and Kang, Liang and Guo, Li and Liu, Min and Zhou, Xing and Luo, Jianfeng and Huang, Zhenghui and Tu, Shengjin and Zhao, Yue and Chen, Li and Xu, Decui and Li, Yanping and Li, Caihong and Peng, Lu and Li, Yong and Xie, Wuxiang and Cui, Dan and Shang, Lianhan and Fan, Guohui and Xu, Jiuyang and Wang, Geng and Wang, Ying and Zhong, Jingchuan and Wang, Chen and Wang, Jianwei and Zhang, Dingyu and Cao, Bin},
  year = {2021},
  month = jan,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)32656-8},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5\textendash 6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57{$\cdot$}0 (IQR 47{$\cdot$}0\textendash 65{$\cdot$}0) years and 897 (52\%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186{$\cdot$}0 (175{$\cdot$}0\textendash 199{$\cdot$}0) days. Fatigue or muscle weakness (63\%, 1038 of 1655) and sleep difficulties (26\%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23\% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24\% for those at severity scale 3, 22\% for severity scale 4, and 29\% for severity scale 5\textendash 6. The corresponding proportions of patients with diffusion impairment were 22\% for severity scale 3, 29\% for scale 4, and 56\% for scale 5\textendash 6, and median CT scores were 3{$\cdot$}0 (IQR 2{$\cdot$}0\textendash 5{$\cdot$}0) for severity scale 3, 4{$\cdot$}0 (3{$\cdot$}0\textendash 5{$\cdot$}0) for scale 4, and 5{$\cdot$}0 (4{$\cdot$}0\textendash 6{$\cdot$}0) for scale 5\textendash 6. After multivariable adjustment, patients showed an odds ratio (OR) 1{$\cdot$}61 (95\% CI 0{$\cdot$}80\textendash 3{$\cdot$}25) for scale 4 versus scale 3 and 4{$\cdot$}60 (1{$\cdot$}85\textendash 11{$\cdot$}48) for scale 5\textendash 6 versus scale 3 for diffusion impairment; OR 0{$\cdot$}88 (0{$\cdot$}66\textendash 1{$\cdot$}17) for scale 4 versus scale 3 and OR 1{$\cdot$}77 (1{$\cdot$}05\textendash 2{$\cdot$}97) for scale 5\textendash 6 versus scale 3 for anxiety or depression, and OR 0{$\cdot$}74 (0{$\cdot$}58\textendash 0{$\cdot$}96) for scale 4 versus scale 3 and 2{$\cdot$}69 (1{$\cdot$}46\textendash 4{$\cdot$}96) for scale 5\textendash 6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96{$\cdot$}2\% \emph{vs} 58{$\cdot$}5\%) and median titres (19{$\cdot$}0 \emph{vs} 10{$\cdot$}0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1{$\cdot$}73 m\textsuperscript{2} or more at acute phase had eGFR less than 90 mL/min per 1{$\cdot$}73 m\textsuperscript{2} at follow-up.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DB7QTCYX\\Huang et al. - 2021 - 6-month consequences of COVID-19 in patients disch.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IZSSFK5G\\fulltext.html}
}

@article{HumoralCellularImmune,
  title = {Humoral and Cellular Immune Response against {{SARS-CoV-2}} Variants Following Heterologous and Homologous {{ChAdOx1 nCoV-19}}/{{BNT162b2}} Vaccination.},
  pages = {12},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TQHA3KGY\\Humoral and cellular immune response against SARS-.pdf}
}

@article{humphreyFeatureLearningDeep2013,
  title = {Feature Learning and Deep Architectures: New Directions for Music Informatics},
  shorttitle = {Feature Learning and Deep Architectures},
  author = {Humphrey, Eric J. and Bello, Juan P. and Lecun, Yann},
  year = {2013},
  month = dec,
  journal = {Journal of Intelligent Information Systems; New York},
  volume = {41},
  number = {3},
  pages = {461--481},
  issn = {09259902},
  doi = {http://dx.doi.org/10.1007/s10844-013-0248-5},
  abstract = {Issue Title: MIRrors: Music Information Research reflects on its future As we look to advance the state of the art in content-based music informatics, there is a general sense that progress is decelerating throughout the field. On closer inspection, performance trajectories across several applications reveal that this is indeed the case, raising some difficult questions for the discipline: why are we slowing down, and what can we do about it? Here, we strive to address both of these concerns. First, we critically review the standard approach to music signal analysis and identify three specific deficiencies to current methods: hand-crafted feature design is sub-optimal and unsustainable, the power of shallow architectures is fundamentally limited, and short-time analysis cannot encode musically meaningful structure. Acknowledging breakthroughs in other perceptual AI domains, we offer that deep learning holds the potential to overcome each of these obstacles. Through conceptual arguments for feature learning and deeper processing architectures, we demonstrate how deep processing models are more powerful extensions of current methods, and why now is the time for this paradigm shift. Finally, we conclude with a discussion of current challenges and the potential impact to further motivate an exploration of this promising research area.[PUBLICATION ABSTRACT]},
  copyright = {Springer Science+Business Media New York 2013},
  langid = {english},
  keywords = {Analysis,Computers--Artificial Intelligence,Computers--Data Base Management,Information technology,Intelligent systems,Music,Signal processing,Studies},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SGGV8H9X\\Humphrey et al. - 2013 - Feature learning and deep architectures new direc.pdf}
}

@misc{HvdhLytvnvtHsbr,
  title = {  -       .Pdf},
  journal = {Dropbox},
  abstract = {Shared with Dropbox},
  howpublished = {https://www.dropbox.com/s/h2l2tn8rwpzose0/\%C3\%97\%C2\%94\%C3\%97\%C2\%95\%C3\%97\%C2\%93\%C3\%97\%C2\%A2\%C3\%97\%C2\%94\%20\%C3\%97\%C2\%9C\%C3\%97\%C2\%A2\%C3\%97\%C2\%99\%C3\%97\%C2\%AA\%C3\%97\%C2\%95\%C3\%97\%C2\%A0\%C3\%97\%C2\%95\%C3\%97\%C2\%AA\%20-\%20\%C3\%97\%C2\%94\%C3\%97\%C2\%A1\%C3\%97\%C2\%91\%C3\%97\%C2\%A8\%20\%C3\%97\%C2\%9E\%C3\%97\%C2\%95\%C3\%97\%C2\%A2\%C3\%97\%C2\%99\%C3\%97\%C2\%9C\%C3\%97\%C2\%95\%C3\%97\%C2\%AA\%20\%C3\%97\%C2\%94\%C3\%97\%C2\%97\%C3\%97\%C2\%99\%C3\%97\%C2\%A1\%C3\%97\%C2\%95\%C3\%97\%C2\%9F\%20\%C3\%97\%C2\%A0\%C3\%97\%C2\%92\%C3\%97\%C2\%93\%20\%C3\%97\%C2\%A0\%C3\%97\%C2\%92\%C3\%97\%C2\%99\%C3\%97\%C2\%A3\%20\%C3\%97\%C2\%94\%C3\%97\%C2\%A7\%C3\%97\%C2\%95\%C3\%97\%C2\%A8\%C3\%97\%C2\%95\%C3\%97\%C2\%A0\%C3\%97\%C2\%94\%20\%C3\%97\%C2\%91\%C3\%97\%C2\%99\%C3\%97\%C2\%A9\%C3\%97\%C2\%A8\%C3\%97\%C2\%90\%C3\%97\%C2\%9C.pdf?dl=0},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AM3PXV69\\  -       .html}
}

@article{hwangTransmissionDynamicsDelta2021,
  title = {Transmission Dynamics of the {{Delta}} Variant of {{SARS-CoV-2}} Infections in {{South Korea}}},
  author = {Hwang, Hari and Lim, Jun-Sik and Song, Sun-Ah and Achangwa, Chiara and Sim, Woobeom and Kim, Giho and Ryu, Sukhyun},
  year = {2021},
  month = dec,
  journal = {The Journal of Infectious Diseases},
  pages = {jiab586},
  issn = {0022-1899},
  doi = {10.1093/infdis/jiab586},
  abstract = {The Delta variant of SARS-CoV-2 is now the predominant variant worldwide. However, its transmission dynamics remain unclear.We analyzed 405 local case-patients infected with the Delta variant of SARS-CoV-2 and temporal patterns of viral shedding identified between 22 June and 31 July 2021 in Daejeon, South Korea.Overall, 20\% were presymptomatic at the time of epidemiological investigation. We identified six clustered outbreaks, and all were associated with indoor facilities. In 23 household contacts, the secondary attack rate was 63\%. We estimated the mean serial interval as 3.26 days (95\% credible interval, 2.92\textendash 3.60), and 15\% (95\% confidence interval, 13\textendash 18\%) of cases seeded 80\% of all local transmission. Analysis of the nasopharyngeal swab samples identified virus shedding from the presymptomatic patients, and the highest viral load was observed two days after symptom onset.Our findings suggest that the Delta variant is highly transmissible in indoor settings and households. Rapid contact tracing, isolation of the asymptomatic contacts, strict adherence to public health measures, and increased uptake of COVID-19 vaccination including booster doses are needed to reduce the community transmission of the Delta variant.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QP6V9QJ3\\Hwang et al. - 2021 - Transmission dynamics of the Delta variant of SARS.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IWH5KUC3\\6448309.html}
}

@incollection{Index2017,
  title = {Index},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {409--414},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.index},
  abstract = {No Abstract.},
  isbn = {978-1-118-63198-0},
  langid = {english},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.index},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\P5Z3ITA3\\2017 - Index.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\4T5CNBU7\\9781118631980.html}
}

@misc{IndividualQuarantineActive,
  title = {Individual Quarantine versus Active Monitoring of Contacts for the Mitigation of {{COVID-19}}: A Modelling Study - {{The Lancet Infectious Diseases}}},
  howpublished = {https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30361-3/fulltext?dgcid=hubspot\_email\_newsletter\_tlcoronavirus20\&utm\_campaign=tlcoronavirus20\&utm\_source=hs\_email\&utm\_medium=email\&utm\_content=88296112\&\_hsenc=p2ANqtz-9J7\_RYBtHpODsY597QvHdRrQ1mev7yQhrubVE7ElkQ6OC19xftue-zX4BzooMBkypwvgYIWFm8byNumAH5VV7UQOlbsEWmh4rr4z3ZjnKPqW9Guao\&\_hsmi=88296112\&fbclid=IwAR0LkdBR3j5B9Z5\_BwfhFoae\_SM\_ZxSJH232XHdGXSM8QFE6ilYO37zJxs4},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YQ374NUN\\fulltext.html}
}

@misc{IntroductionInfectiousDisease,
  title = {An Introduction to Infectious Disease Modelling \textendash{} {{EMILIA VYNNYCKY}} and {{RICHARD G WHITE}}},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WMMD9UV3\\anintroductiontoinfectiousdiseasemodelling.com.html}
}

@misc{IschglStudie42Prozent,
  title = {{Ischgl-Studie: 42,4 Prozent sind Antik\"orper-positiv - myPoint}},
  shorttitle = {{Ischgl-Studie}},
  copyright = {\textcopyright{} Medical University of Innsbruck, Austria},
  howpublished = {https://www.i-med.ac.at/mypoint/news/746359.html},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2XI8EFZ7\\746359.html}
}

@misc{ItaewonVisitorsUrged08:43,
  title = {{Itaewon Visitors Urged To Get Virus Tests As New Cluster Grows}},
  year = {08:43},
  abstract = {South Korea has reported a steady rise in new virus infections linked to nightclubs and bars in Itaewon, one of Seoul's popular nightlife neighborhood},
  chapter = {tbs},
  howpublished = {http://tbs.seoul.kr/eFm/newsView.do?typ\_800=N\&idx\_800=3387710\&seq\_800=20380287},
  langid = {korean-han},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\88IUVIE4\\newsView.html}
}

@article{jamesHighCOVID19Attack2020,
  title = {High {{COVID-19 Attack Rate Among Attendees}} at {{Events}} at a {{Church}} \textemdash{} {{Arkansas}}, {{March}} 2020},
  author = {James, Allison},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6920e2},
  abstract = {On March 16, 2020, the day that national social distancing guidelines were released (1), the Arkansas Department of Health (ADH) was notified of two cases of coronavirus disease 2019 (COVID-19) ...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NQ2Y94M5\\mm6920e2.html}
}

@article{jangEarlyReleaseCluster,
  title = {Early {{Release}} - {{Cluster}} of {{Coronavirus Disease Associated}} with {{Fitness Dance Classes}}, {{South Korea}} - {{Volume}} 26, {{Number}} 8\textemdash{{August}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Jang, Sukbin and Han, Si Hyun and Rhee, Ji-Young},
  doi = {10.3201/eid2608.200633},
  abstract = {During 24 days in Cheonan, South Korea, 112 persons were infected with severe acute respiratory syndrome coronavirus 2 associated with fitness dance c...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D8GLWUXS\\20-0633_article.html}
}

@article{jansenInvestigationSARSCoV25292021,
  title = {Investigation of a {{SARS-CoV-2 B}}.1.1.529 ({{Omicron}}) {{Variant Cluster}} \textemdash{} {{Nebraska}}, {{November}}\textendash{{December}} 2021},
  author = {Jansen, Lauren},
  year = {2021},
  month = dec,
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {70},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm705152e3},
  abstract = {This report describes an investigation on an Omicron variant cluster in a Nebraska household from November\textendash December 2021.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\S54VTFYS\\Jansen - 2021 - Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\F9S8DAF3\\mm705152e3.html}
}

@article{jefferiesCOVID19NewZealand2020,
  title = {{{COVID-19}} in {{New Zealand}} and the Impact of the National Response: A Descriptive Epidemiological Study},
  shorttitle = {{{COVID-19}} in {{New Zealand}} and the Impact of the National Response},
  author = {Jefferies, Sarah and French, Nigel and Gilkison, Charlotte and Graham, Giles and Hope, Virginia and Marshall, Jonathan and McElnay, Caroline and McNeill, Andrea and Muellner, Petra and Paine, Shevaun and Prasad, Namrata and Scott, Julia and Sherwood, Jillian and Yang, Liang and Priest, Patricia},
  year = {2020},
  month = oct,
  journal = {The Lancet Public Health},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2468-2667},
  doi = {10.1016/S2468-2667(20)30225-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}In early 2020, during the COVID-19 pandemic, New Zealand implemented graduated, risk-informed national COVID-19 suppression measures aimed at disease elimination. We investigated their impacts on the epidemiology of the first wave of COVID-19 in the country and response performance measures.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did a descriptive epidemiological study of all laboratory-confirmed and probable cases of COVID-19 and all patients tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New Zealand from Feb 2 to May 13, 2020, after which time community transmission ceased. We extracted data from the national notifiable diseases database and the national SARS-CoV-2 test results repository. Demographic features and disease outcomes, transmission patterns (source of infection, outbreaks, household transmission), time-to-event intervals, and testing coverage were described over five phases of the response, capturing different levels of non-pharmaceutical interventions. Risk factors for severe outcomes (hospitalisation or death) were examined with multivariable logistic regression and time-to-event intervals were analysed by fitting parametric distributions using maximum likelihood estimation.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}1503 cases were detected over the study period, including 95 (6{$\cdot$}3\%) hospital admissions and 22 (1{$\cdot$}5\%) COVID-19 deaths. The estimated case infection rate per million people per day peaked at 8{$\cdot$}5 (95\% CI 7{$\cdot$}6\textendash 9{$\cdot$}4) during the 10-day period of rapid response escalation, declining to 3{$\cdot$}2 (2{$\cdot$}8\textendash 3{$\cdot$}7) in the start of lockdown and progressively thereafter. 1034 (69\%) cases were imported or import related, tending to be younger adults, of European ethnicity, and of higher socioeconomic status. 702 (47\%) cases were linked to 34 outbreaks. Severe outcomes were associated with locally acquired infection (crude odds ratio [OR] 2{$\cdot$}32 [95\% CI 1{$\cdot$}40\textendash 3{$\cdot$}82] compared with imported), older age (adjusted OR ranging from 2{$\cdot$}72 [1{$\cdot$}40\textendash 5{$\cdot$}30] for 50\textendash 64 year olds to 8{$\cdot$}25 [2{$\cdot$}59\textendash 26{$\cdot$}31] for people aged {$\geq$}80 years compared with 20\textendash 34 year olds), aged residential care residency (adjusted OR 3{$\cdot$}86 [1{$\cdot$}59\textendash 9{$\cdot$}35]), and Pacific peoples (adjusted OR 2{$\cdot$}76 [1{$\cdot$}14\textendash 6{$\cdot$}68]) and Asian (2{$\cdot$}15 [1{$\cdot$}10\textendash 4{$\cdot$}20]) ethnicities relative to European or other. Times from illness onset to notification and isolation progressively decreased and testing increased over the study period, with few disparities and increasing coverage of females, M\=aori, Pacific peoples, and lower socioeconomic groups.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}New Zealand's response resulted in low relative burden of disease, low levels of population disease disparities, and the initial achievement of COVID-19 elimination.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Ministry of Business Innovation and Employment Strategic Scientific Investment Fund, and Ministry of Health, New Zealand.{$<$}/p{$>$}},
  langid = {english},
  pmid = {33065023},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ULNDKFSX\\Jefferies et al. - 2020 - COVID-19 in New Zealand and the impact of the nati.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QRSKDWZT\\fulltext.html}
}

@article{jefferiesCOVID19NewZealand2020a,
  title = {{{COVID-19}} in {{New Zealand}} and the Impact of the National Response: A Descriptive Epidemiological Study},
  shorttitle = {{{COVID-19}} in {{New Zealand}} and the Impact of the National Response},
  author = {Jefferies, Sarah and French, Nigel and Gilkison, Charlotte and Graham, Giles and Hope, Virginia and Marshall, Jonathan and McElnay, Caroline and McNeill, Andrea and Muellner, Petra and Paine, Shevaun and Prasad, Namrata and Scott, Julia and Sherwood, Jillian and Yang, Liang and Priest, Patricia},
  year = {2020},
  month = oct,
  journal = {The Lancet Public Health},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2468-2667},
  doi = {10.1016/S2468-2667(20)30225-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}In early 2020, during the COVID-19 pandemic, New Zealand implemented graduated, risk-informed national COVID-19 suppression measures aimed at disease elimination. We investigated their impacts on the epidemiology of the first wave of COVID-19 in the country and response performance measures.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did a descriptive epidemiological study of all laboratory-confirmed and probable cases of COVID-19 and all patients tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New Zealand from Feb 2 to May 13, 2020, after which time community transmission ceased. We extracted data from the national notifiable diseases database and the national SARS-CoV-2 test results repository. Demographic features and disease outcomes, transmission patterns (source of infection, outbreaks, household transmission), time-to-event intervals, and testing coverage were described over five phases of the response, capturing different levels of non-pharmaceutical interventions. Risk factors for severe outcomes (hospitalisation or death) were examined with multivariable logistic regression and time-to-event intervals were analysed by fitting parametric distributions using maximum likelihood estimation.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}1503 cases were detected over the study period, including 95 (6{$\cdot$}3\%) hospital admissions and 22 (1{$\cdot$}5\%) COVID-19 deaths. The estimated case infection rate per million people per day peaked at 8{$\cdot$}5 (95\% CI 7{$\cdot$}6\textendash 9{$\cdot$}4) during the 10-day period of rapid response escalation, declining to 3{$\cdot$}2 (2{$\cdot$}8\textendash 3{$\cdot$}7) in the start of lockdown and progressively thereafter. 1034 (69\%) cases were imported or import related, tending to be younger adults, of European ethnicity, and of higher socioeconomic status. 702 (47\%) cases were linked to 34 outbreaks. Severe outcomes were associated with locally acquired infection (crude odds ratio [OR] 2{$\cdot$}32 [95\% CI 1{$\cdot$}40\textendash 3{$\cdot$}82] compared with imported), older age (adjusted OR ranging from 2{$\cdot$}72 [1{$\cdot$}40\textendash 5{$\cdot$}30] for 50\textendash 64 year olds to 8{$\cdot$}25 [2{$\cdot$}59\textendash 26{$\cdot$}31] for people aged {$\geq$}80 years compared with 20\textendash 34 year olds), aged residential care residency (adjusted OR 3{$\cdot$}86 [1{$\cdot$}59\textendash 9{$\cdot$}35]), and Pacific peoples (adjusted OR 2{$\cdot$}76 [1{$\cdot$}14\textendash 6{$\cdot$}68]) and Asian (2{$\cdot$}15 [1{$\cdot$}10\textendash 4{$\cdot$}20]) ethnicities relative to European or other. Times from illness onset to notification and isolation progressively decreased and testing increased over the study period, with few disparities and increasing coverage of females, M\=aori, Pacific peoples, and lower socioeconomic groups.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}New Zealand's response resulted in low relative burden of disease, low levels of population disease disparities, and the initial achievement of COVID-19 elimination.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Ministry of Business Innovation and Employment Strategic Scientific Investment Fund, and Ministry of Health, New Zealand.{$<$}/p{$>$}},
  langid = {english},
  pmid = {33065023},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F64GGG7M\\Jefferies et al. - 2020 - COVID-19 in New Zealand and the impact of the nati.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WZF9CKTN\\fulltext.html}
}

@article{jiaPopulationFlowDrives2020,
  title = {Population Flow Drives Spatio-Temporal Distribution of {{COVID-19}} in {{China}}},
  author = {Jia, Jayson S. and Lu, Xin and Yuan, Yun and Xu, Ge and Jia, Jianmin and Christakis, Nicholas A.},
  year = {2020},
  month = apr,
  journal = {Nature},
  pages = {1--11},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-020-2284-y},
  abstract = {Sudden, large-scale, and diffuse human migration can amplify localized outbreaks into widespread epidemics.1\textendash 4 Rapid and accurate tracking of aggregate population flows may therefore be epidemiologically informative. Here, we use mobile-phone-data-based counts of 11,478,484 people egressing or transiting through the prefecture of Wuhan between 1 January and 24 January 2020 as they moved to 296 prefectures throughout China. First, we document the efficacy of quarantine in ceasing movement. Second, we show that the distribution of population outflow from Wuhan accurately predicts the relative frequency and geographic distribution of COVID-19 infections through February 19, 2020, across all of China. Third, we develop a spatio-temporal ``risk source'' model that leverages population flow data (which operationalizes risk emanating from epidemic epicenters) to not only forecast confirmed cases, but also to identify high-transmission-risk locales at an early stage. Fourth, we use this risk source model to statistically derive the geographic spread of COVID-19 and the growth pattern based on the population outflow from Wuhan; the model yields a benchmark trend and an index for assessing COVID-19 community transmission risk over time for different locations. This approach can be used by policy-makers in any nation with available data to make rapid and accurate risk assessments and to plan allocation of limited resources ahead of ongoing outbreaks.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PXYKP2QM\\Jia et al. - 2020 - Population flow drives spatio-temporal distributio.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QMZVKYUQ\\s41586-020-2284-y.html}
}

@article{jonesComputerMethodCalculate1977,
  title = {A Computer Method to Calculate the Convolution of Statistical Distributions},
  author = {Jones, Thomas A.},
  year = {1977},
  month = nov,
  journal = {Journal of the International Association for Mathematical Geology},
  volume = {9},
  number = {6},
  pages = {635--647},
  issn = {1573-8868},
  doi = {10.1007/BF02067218},
  abstract = {It is becoming increasingly important to determine probability distributions of combinations of random variables. Convolution is a technique by which the distribution of a sum of random variables can be determined. This paper presents some simplifications in order to reduce the numerical integrations and computer time. In addition, the method may be used with empirical nonanalytic distributions. While Monte Carlo methods are also appropriate for calculating the distribution, convolution can give at least as much accuracy as Monte Carlo methods with a reduction in computation. Two applications are presented: one approximates the distribution of percent sand in an area, and the other indicates a method of determining sample size when using the distribution of means to approximate normality.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TKW5SBVF\\Jones - 1977 - A computer method to calculate the convolution of .pdf}
}

@article{jordanWhoMostLikely2020,
  title = {Who Is Most Likely to Be Infected with {{SARS-CoV-2}}?},
  author = {Jordan, Rachel E. and Adab, Peymane},
  year = {2020},
  month = may,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30395-9},
  abstract = {Despite the daily updates on number of cases, hospital admissions, and deaths around the world and the increasing number of hospital-based case series, some of the fundamental information about how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads in the population and who is really at risk of both infection and severe consequences is still missing. In The Lancet Infectious Diseases, Simon de Lusignan and colleagues1 report on the characteristics of the first 3802 people tested for SARS-CoV-2 within the Royal College of General Practitioners (RCGP) sentinel primary care surveillance network.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X9K9B4BX\\Jordan and Adab - 2020 - Who is most likely to be infected with SARS-CoV-2.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3HAXJ5KK\\fulltext.html}
}

@techreport{karagiannidisObservationalStudyChanges2021,
  type = {Preprint},
  title = {Observational Study of Changes in Utilization and Outcomes in Non-Invasive Ventilation in {{COVID-19}}},
  author = {Karagiannidis, Christian and Hentschker, Corinna and Westhoff, Michael and {Weber-Carstens}, Steffen and Janssens, Uwe and Kluge, Stefan and Pfeifer, Michael and Spies, Claudia and Welte, Tobias and Rossaint, Rolf and Mostert, Carina and Windisch, Wolfram},
  year = {2021},
  month = mar,
  institution = {{Intensive Care and Critical Care Medicine}},
  doi = {10.1101/2021.03.28.21254477},
  abstract = {Abstract                        Rationale             The role of non-invasive ventilation (NIV) in severe COVID-19 remains a matter of debate.                                   Objectives             To determine the utilization and outcome of NIV in COVID-19 in an unbiased cohort.                                   Methods             Observational study of confirmed COVID-19 cases of claims data of the Local Health Care Funds comparing patients with non-invasive and invasive mechanical ventilation (IMV) between spring versus autumn period 2020.                                   Measurements and Main Results             Nationwide cohort of 7490 cases (median/IQR age 70/60\textendash 79 years, 66\% male) 3851 (51\%) patients primarily received IMV without NIV, 1614 (22\%) patients received NIV without subsequent intubation, and 1247 (17\%) patients had NIV failure (NIV-F), defined by subsequent endotracheal intubation. The proportion of patients who received invasive MV decreased from 74\% to 39\% during the second period. Accordingly, the proportion of patients with NIV exclusively increased from 10\% to 28\%, and those failing NIV increased from 9\% to 21\%. Median length of hospital stay decreased from 26 to 22 days, and duration of MV decreased from 11.6 to 7.6 days. The NIV failure rate decreased from 49\% to 42\%. Overall mortality remained unchanged (51\% versus 53\%). Mortality was 39\% with NIV-only, 52\% with IMV and 66\% with NIV-F with mortality rates steadily increasing from 58\% in early NIV-F (day 1) to 75\% in late NIV-F ({$>$}4 days).                                   Conclusion             Utilization of NIV rapidly increased during the autumn period, which was associated with a reduced duration of MV, but not with overall mortality. High NIV-F rates are associated with increased mortality, particularly in late NIV-F.                                   Funding             Institutional support and physical resources were provided by the University Witten/Herdecke and Kliniken der Stadt K\"oln and the Federal Association of the Local Health Care Funds.                                   At a Glance Commentary                            Scientific Knowledge on the Subject               Current management of ventilatory support in COVID-19 patients with respiratory failure is heterogeneous. Despite increasing use of non-invasive ventilation (NIV), defining intubation criteria still remains a matter of uncertainty and discussion, especially with regard to the balance between the NIV benefits and the risk of NIV failure. In addition, robust data concerning the influence of the duration and failure of NIV on intubation and mortality rates are still missing, although the time span between initiation of NIV and subsequent intubation in case of respiratory failure progression is suggested to influence patient outcome.                                         What This Study Adds to the Field               This is the first large observational study describing differences of ventilatory strategies between the spring and autumn period of the SARS-CoV-2 pandemic in Germany and provides the in-hospital mortality rate of 7,490 patients who received mechanical ventilation. The increased utilization of NIV from 10\% (first period) to 29\% (second period) was associated with overall reduced durations of mechanical ventilation and length of hospital stay, but overall mortality remained comparably high and reached 51\%, 53\% respectively. Patients succeeding with NIV had lower mortality rates than those getting intubated without preceding NIV attempts, but those failing NIV had higher mortality rates, respectively, and this became even more predominant in late NIV failure. The present observational study shows the increasing role of NIV in the concert of ICU medicine related to COVID-19, but also clearly addresses its risks in addition to its benefits, both impacting on mortality.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HW5AAPIZ\\Karagiannidis et al. - 2021 - Observational study of changes in utilization and .pdf}
}

@article{kaufmanMeasuringSignaltonoiseRatios1989,
  title = {Measuring Signal-to-Noise Ratios in {{MR}} Imaging},
  author = {Kaufman, L and Kramer, D M and Crooks, L E and Ortendahl, D A},
  year = {1989},
  month = oct,
  journal = {Radiology},
  volume = {173},
  number = {1},
  pages = {265--267},
  issn = {0033-8419},
  doi = {10.1148/radiology.173.1.2781018},
  abstract = {The signal-to-noise ratio (S/N) in magnetic resonance imagining is one of the variables that must be measured when comparing the relative performance of different techniques. Although various investigators and official groups have proposed different methods for measuring S/N, these are generally not practical for use by a physician working in a clinical situation. The authors present a simple method that should serve for estimating S/N in most cases.},
  langid = {english},
  pmid = {2781018},
  keywords = {Magnetic Resonance Imaging}
}

@misc{keDailySamplingEarly2021,
  title = {Daily Sampling of Early {{SARS-CoV-2}} Infection Reveals Substantial Heterogeneity in Infectiousness},
  author = {Ke, Ruian and Martinez, Pamela P. and Smith, Rebecca L. and Gibson, Laura L. and Mirza, Agha and Conte, Madison and Gallagher, Nicholas and Luo, Chun Huai and Jarrett, Junko and Conte, Abigail and Liu, Tongyu and Farjo, Mireille and Walden, Kimberly K. O. and Rendon, Gloria and Fields, Christopher J. and Wang, Leyi and Fredrickson, Richard and Edmonson, Darci C. and Baughman, Melinda E. and Chiu, Karen K. and Choi, Hannah and Scardina, Kevin R. and Bradley, Shannon and Gloss, Stacy L. and Reinhart, Crystal and Yedetore, Jagadeesh and Quicksall, Jessica and Owens, Alyssa N. and Broach, John and Barton, Bruce and Lazar, Peter and Heetderks, William J. and Robinson, Matthew L. and Mostafa, Heba H. and Manabe, Yukari C. and Pekosz, Andrew and McManus, David D. and Brooke, Christopher B.},
  year = {2021},
  month = jul,
  pages = {2021.07.12.21260208},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.07.12.21260208},
  abstract = {The dynamics of SARS-CoV-2 replication and shedding in humans remain poorly understood. We captured the dynamics of infectious virus and viral RNA shedding during acute infection through daily longitudinal sampling of 60 individuals for up to 14 days. By fitting mechanistic models, we directly estimate viral reproduction and clearance rates, and overall infectiousness for each individual. Significant person-to-person variation in infectious virus shedding suggests that individual-level heterogeneity in viral dynamics contributes to superspreading. Viral genome load often peaked days earlier in saliva than in nasal swabs, indicating strong compartmentalization and suggesting that saliva may serve as a superior sampling site for early detection of infection. Viral loads and clearance kinetics of B.1.1.7 and non-B.1.1.7 viruses in nasal swabs were indistinguishable, however B.1.1.7 exhibited a significantly slower pre-peak growth rate in saliva. These results provide a high-resolution portrait of SARS-CoV-2 infection dynamics and implicate individual-level heterogeneity in infectiousness in superspreading.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4WRMJTQ6\\Ke et al. - 2021 - Daily sampling of early SARS-CoV-2 infection revea.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\897BP9EY\\2021.07.12.html}
}

@techreport{keDailySamplingEarly2021a,
  type = {Preprint},
  title = {Daily Sampling of Early {{SARS-CoV-2}} Infection Reveals Substantial Heterogeneity in Infectiousness},
  author = {Ke, Ruian and Martinez, Pamela P. and Smith, Rebecca L. and Gibson, Laura L. and Mirza, Agha and Conte, Madison and Gallagher, Nicholas and Luo, Chun Huai and Jarrett, Junko and Conte, Abigail and Liu, Tongyu and Farjo, Mireille and Walden, Kimberly K.O. and Rendon, Gloria and Fields, Christopher J. and Wang, Leyi and Fredrickson, Richard and Edmonson, Darci C. and Baughman, Melinda E. and Chiu, Karen K. and Choi, Hannah and Scardina, Kevin R. and Bradley, Shannon and Gloss, Stacy L. and Reinhart, Crystal and Yedetore, Jagadeesh and Quicksall, Jessica and Owens, Alyssa N. and Broach, John and Barton, Bruce and Lazar, Peter and Heetderks, William J. and Robinson, Matthew L. and Mostafa, Heba H. and Manabe, Yukari C. and Pekosz, Andrew and McManus, David D. and Brooke, Christopher B.},
  year = {2021},
  month = jul,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2021.07.12.21260208},
  abstract = {ABSTRACT           The dynamics of SARS-CoV-2 replication and shedding in humans remain poorly understood. We captured the dynamics of infectious virus and viral RNA shedding during acute infection through daily longitudinal sampling of 60 individuals for up to 14 days. By fitting mechanistic models, we directly estimate viral reproduction and clearance rates, and overall infectiousness for each individual. Significant person-to-person variation in infectious virus shedding suggests that individual-level heterogeneity in viral dynamics contributes to superspreading. Viral genome load often peaked days earlier in saliva than in nasal swabs, indicating strong compartmentalization and suggesting that saliva may serve as a superior sampling site for early detection of infection. Viral loads and clearance kinetics of B.1.1.7 and non-B.1.1.7 viruses in nasal swabs were indistinguishable, however B.1.1.7 exhibited a significantly slower pre-peak growth rate in saliva. These results provide a high-resolution portrait of SARS-CoV-2 infection dynamics and implicate individual-level heterogeneity in infectiousness in superspreading.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NCVE7WD7\\Ke et al. - 2021 - Daily sampling of early SARS-CoV-2 infection revea.pdf}
}

@misc{keetonSARSCoV2SpikeCell2021,
  title = {{{SARS-CoV-2}} Spike {{T}} Cell Responses Induced upon Vaccination or Infection Remain Robust against {{Omicron}}},
  author = {Keeton, Roanne and Tincho, Marius B. and Ngomti, Amkele and Baguma, Richard and Benede, Ntombi and Suzuki, Akiko and Khan, Khadija and Cele, Sandile and Bernstein, Mallory and Karim, Farina and Madzorera, Sharon V. and {Moyo-Gwete}, Thandeka and Mennen, Mathilda and Skelem, Sango and Adriaanse, Marguerite and Mutithu, Daniel and Aremu, Olukayode and Stek, Cari and du Bruyn, Elsa and Mescht, Mieke Van Der and de Beer, Zelda and de Villiers, Talita R. and Bodenstein, Annie and van den Berg, Gretha and Mendes, Adriano and Strydom, Amy and Venter, Marietjie and Grifoni, Alba and Weiskopf, Daniela and Sette, Alessandro and Wilkinson, Robert J. and Bekker, Linda-Gail and Gray, Glenda and Ueckermann, Veronica and Rossouw, Theresa and Boswell, Michael T. and Bihman, Jinal and Moore, Penny and Sigal, Alex and Ntusi, Ntobeko A. B. and Burgers, Wendy A. and Riou, Catherine},
  year = {2021},
  month = dec,
  pages = {2021.12.26.21268380},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.12.26.21268380},
  abstract = {The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70). We found that 70-80\% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). These results demonstrate that despite Omicron's extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\K7WET7P5\\Keeton et al. - 2021 - SARS-CoV-2 spike T cell responses induced upon vac.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\2F78ZYRL\\2021.12.26.html}
}

@article{kevadiyaDiagnosticsSARSCoV2Infections2021,
  title = {Diagnostics for {{SARS-CoV-2}} Infections},
  author = {Kevadiya, Bhavesh D. and Machhi, Jatin and Herskovitz, Jonathan and Oleynikov, Maxim D. and Blomberg, Wilson R. and Bajwa, Neha and Soni, Dhruvkumar and Das, Srijanee and Hasan, Mahmudul and Patel, Milankumar and Senan, Ahmed M. and Gorantla, Santhi and McMillan, JoEllyn and Edagwa, Benson and Eisenberg, Robert and Gurumurthy, Channabasavaiah B. and Reid, St Patrick M. and Punyadeera, Chamindie and Chang, Linda and Gendelman, Howard E.},
  year = {2021},
  month = feb,
  journal = {Nature Materials},
  pages = {1--13},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4660},
  doi = {10.1038/s41563-020-00906-z},
  abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to nearly every corner of the globe, causing societal instability. The resultant coronavirus disease 2019 (COVID-19) leads to fever, sore throat, cough, chest and muscle pain, dyspnoea, confusion, anosmia, ageusia and headache. These can progress to life-threatening respiratory insufficiency, also affecting the heart, kidney, liver and nervous systems. The diagnosis of SARS-CoV-2 infection is often confused with that of influenza and seasonal upper respiratory tract viral infections. Due to available treatment strategies and required containments, rapid diagnosis is mandated. This Review brings clarity to the rapidly growing body of available and in-development diagnostic tests, including nanomaterial-based tools. It serves as a resource guide for scientists, physicians, students and the public at large.},
  copyright = {2021 Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2VNK2XST\\Kevadiya et al. - 2021 - Diagnostics for SARS-CoV-2 infections.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\VACYCECV\\s41563-020-00906-z.html}
}

@article{kisslerProjectingTransmissionDynamics2020,
  title = {Projecting the Transmission Dynamics of {{SARS-CoV-2}} through the Postpandemic Period},
  author = {Kissler, Stephen M. and Tedijanto, Christine and Goldstein, Edward and Grad, Yonatan H. and Lipsitch, Marc},
  year = {2020},
  month = apr,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb5793},
  abstract = {It is urgent to understand the future of severe acute respiratory syndrome\textendash coronavirus 2 (SARS-CoV-2) transmission. We used estimates of seasonality, immunity, and cross-immunity for betacoronaviruses OC43 and HKU1 from time series data from the USA to inform a model of SARS-CoV-2 transmission. We projected that recurrent wintertime outbreaks of SARS-CoV-2 will probably occur after the initial, most severe pandemic wave. Absent other interventions, a key metric for the success of social distancing is whether critical care capacities are exceeded. To avoid this, prolonged or intermittent social distancing may be necessary into 2022. Additional interventions, including expanded critical care capacity and an effective therapeutic, would improve the success of intermittent distancing and hasten the acquisition of herd immunity. Longitudinal serological studies are urgently needed to determine the extent and duration of immunity to SARS-CoV-2. Even in the event of apparent elimination, SARS-CoV-2 surveillance should be maintained since a resurgence in contagion could be possible as late as 2024.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32291278},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JWIB4XID\\Kissler et al. - 2020 - Projecting the transmission dynamics of SARS-CoV-2.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QE5ZQV39\\science.html}
}

@article{kleinLongitudinalImmuneProfiling,
  title = {Longitudinal Immune Profiling of a {{SARS-CoV-2}} Reinfection in a Solid Organ Transplant Recipient},
  author = {Klein, Jonathan and Brito, Anderson F and Trubin, Paul and Lu, Peiwen and Wong, Patrick and Alpert, Tara and {Pe{\~n}a-Hern{\'a}ndez}, Mario A and Haynes, Winston and Kamath, Kathy and Liu, Feimei and Fauver, Joseph R and Lucas, Carolina and Oh, Jieun and Mao, Tianyang and Silva, Julio and Muenker, M Catherine and {Casanovas-Massana}, Arnau and Moore, Adam J and Kalinich, Chaney C and Ring, Aaron and Shon, John and Ko, Albert I and Grubaugh, Nathan D and Iwasaki, Akiko and Azar, Marwan M},
  pages = {40},
  abstract = {Prior to the emergence of antigenically distinct SARS-CoV-2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses. However, case reports also suggested that rare, repeated infections may occur as soon as 48 days following initial disease onset. The underlying immunologic deficiencies enabling SARSCoV-2 reinfections are currently unknown. Here we describe a renal transplant recipient who developed recurrent, symptomatic SARS-CoV-2 infection - confirmed by whole virus genome sequencing - 7 months after primary infection. To elucidate the immunological mechanisms responsible for SARS-CoV-2 reinfection, we performed longitudinal profiling of cellular and humoral responses during both primary and recurrent SARS-CoV-2 infection. We found that the patient responded to the primary infection with transient, poor-quality adaptive immune responses. The patient's immune system was further compromised by intervening treatment for acute rejection of the renal allograft prior to reinfection. Importantly, we also identified the development of neutralizing antibodies and the formation of humoral memory responses prior to SARS-CoV-2 reinfection. However, these neutralizing antibodies failed to confer protection against reinfection, suggesting that additional factors are required for efficient prevention of SARS-CoV-2 reinfection. Further, we found no evidence supporting viral evasion of primary adaptive immune responses, suggesting that susceptibility to reinfection may be determined by host factors rather than pathogen adaptation in this patient. In summary, our study suggests that a low neutralizing antibody presence alone is not sufficient to confer resistance against reinfection. Thus, patients with solid organ transplantation, or patients who are otherwise immunosuppressed, who recover from infection with SARS-CoV-2 may not develop sufficient protective immunity and are at risk of reinfection.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QSWF54F7\\Klein et al. - Longitudinal immune profiling of a SARS-CoV-2 rein.pdf}
}

@article{klompasAirborneTransmissionSARSCoV22020,
  title = {Airborne {{Transmission}} of {{SARS-CoV-2}}: {{Theoretical Considerations}} and {{Available Evidence}}},
  shorttitle = {Airborne {{Transmission}} of {{SARS-CoV-2}}},
  author = {Klompas, Michael and Baker, Meghan A. and Rhee, Chanu},
  year = {2020},
  month = jul,
  journal = {JAMA},
  doi = {10.1001/jama.2020.12458},
  abstract = {This Viewpoint discusses physical and epidemiological evidence supporting droplet vs aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and concludes on balance that aerosol transmission seems unlikely to be the dominant mode of coronavirus disease 2019 (COVID-19)...},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5WTML57X\\Klompas et al. - 2020 - Airborne Transmission of SARS-CoV-2 Theoretical C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7QY4TSKA\\2768396.html}
}

@article{knablHighSARSCoV2Seroprevalence2020,
  title = {High {{SARS-CoV-2 Seroprevalence}} in {{Children}} and {{Adults}} in the {{Austrian Ski Resort Ischgl}}},
  author = {Knabl, Ludwig and Mitra, Tanmay and Kimpel, Janine and Roessler, Annika and Volland, Andre and Walser, Andreas and Ulmer, Hanno and Pipperger, Lisa and Binder, Sebastian C. and Riepler, Lydia and Bates, Katie and Bandyopadhyay, Arnab and Schips, Marta and Ranjan, Mrinalini and Falkensammer, Barbara and Borena, Wegene and {Meyer-Hermann}, Michael and von Laer, Dorothee},
  year = {2020},
  month = aug,
  journal = {medRxiv},
  pages = {2020.08.20.20178533},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.08.20.20178533},
  abstract = {{$<$}p{$>$}Background: Early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe. Methods: Between April 21 and 27, a cross-sectional epidemiologic study targeting the full population of Ischgl (n= 1867), of which 79\% could be included (n=1473, incl. 214 children), was performed. For each individual, the study involved a SARS-CoV-2 PCR, antibody testing and structured questionnaires. A mathematical model was used to help understand the influence of the determined seroprevalence on virus transmission. Findings: The seroprevalence was 42.4\% (95\% CI 39.8-44.7). Individuals under 18 showed a significantly lower seroprevalence of 27.1\% (95\% CI 21.3-33.6) than adults (45\%; 95\% CI 42.2-47.7; OR of 0.455, 95\% CI 0.356-0.682, p\&lt;0.001). Of the seropositive individuals, 83.7\% had not been diagnosed to have had SARS-CoV-2 infection previously. The clinical course was generally mild. Over the previous two months, two COVID-19-related deaths had been recorded, corresponding to an infection fatality rate (IFR) of 0.25\% (95\% CI 0.03-0.91). Only 8 (0.5 \%) individuals were newly diagnosed to be infected with SARS-CoV-2 during this study. Interpretation: Ischgl was hit early and hard by SARS-CoV-2 leading to a high local seroprevalence of 42.4\%, which was lower in individuals below the age of 18 than in adults. Mathematical modeling suggests that a drastic decline of newly infected individuals in Ischgl by the end of April occured due to the dual impact from the non-pharmacological interventions (NPIs) and a significant immunization of the Ischgl population. Funding: Helmholtz Association, European Union9s Horizon 2020 research and innovation program, German Research Foundation (DFG), state Tyrol.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DAHW8R96\\Knabl et al. - 2020 - High SARS-CoV-2 Seroprevalence in Children and Adu.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\9G2PABPL\\2020.08.20.html}
}

@techreport{knockReport4120202020,
  title = {Report 41: {{The}} 2020 {{SARS-CoV-2}} Epidemic in {{England}}: Key Epidemiological Drivers and Impact of Interventions},
  shorttitle = {Report 41},
  author = {Knock, E and Whittles, L and Lees, J and Perez Guzman, P and Verity, R and Fitzjohn, R and Gaythorpe, K and Imai, N and Hinsley, W and Okell, L and Rosello, A and Kantas, N and Walters, C and Bhatia, S and Watson, O and Whittaker, C and Cattarino, L and Boonyasiri, A and Djaafara, A and Fraser, K and Fu, H and Wang, H and Xi, X and Donnelly, C and Jauneikaite, E and Laydon, D and White, P and Ghani, A and Ferguson, N and Cori, A and Baguelin, M},
  year = {2020},
  month = dec,
  institution = {{Imperial College London}},
  doi = {10.25561/85146},
  abstract = {England has been severely affected by COVID-19. We fitted a model of SARS-CoV-2 transmission in care homes and the community to regional 2020 surveillance data. Only national lockdown brought the reproduction number below 1 consistently; introduced one week earlier in the first wave it could have reduced mortality by 23,300 deaths on average. The mean infection fatality ratio was initially \textasciitilde 1.3\% across all regions except London and halved following clinical care improvements. The infection fatality ratio was two-fold lower throughout in London, even when adjusting for demographics. The infection fatality ratio in care homes was 2.5-times that in the elderly in the community. Population-level infection-induced immunity in England is still far from herd immunity, with regional mean cumulative attack rates ranging between 4.4\% and 15.8\%.},
  collaborator = {Medical Research Council (MRC)},
  copyright = {\textcopyright{} 2020 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License https://creativecommons.org/licenses/by-nc-nd/4.0/., Creative Commons Attribution Non Commercial No Derivatives 4.0 International, 2021-01-08},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,England,Real Time Modelling,United Kingdom},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AUNNVQ2G\\Knock et al. - 2020 - Report 41 The 2020 SARS-CoV-2 epidemic in England.pdf}
}

@article{koch-institutBerichtVirusvariantenSARSCoV2,
  title = {{2. Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland, insbesondere zur Variant of Concern (VOC) B.1.1.7}},
  author = {{Koch-Institut}, Robert},
  pages = {11},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X3HNFNIA\\Koch-Institut - 2. Bericht zu Virusvarianten von SARS-CoV-2 in Deu.pdf}
}

@article{koch-institutErlaeuterungSchaetzungZeitlich,
  title = {{Erl\"auterung der Sch\"atzung der zeitlich variierenden Reproduktionszahl R}},
  author = {{Koch-Institut}, Robert},
  pages = {7},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YIHL86BP\\Koch-Institut - Erluterung der Schtzung der zeitlich variierende.pdf}
}

@article{koch-institutErlaeuterungSchaetzungZeitlicha,
  title = {{Erl\"auterung der Sch\"atzung der zeitlich variierenden Reproduktionszahl R}},
  author = {{Koch-Institut}, Robert},
  pages = {7},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Z8KB6EZ6\\Koch-Institut - Erluterung der Schtzung der zeitlich variierende.pdf}
}

@article{kraemerEffectHumanMobility2020,
  title = {The Effect of Human Mobility and Control Measures on the {{COVID-19}} Epidemic in {{China}}},
  author = {Kraemer, Moritz U. G. and Yang, Chia-Hung and Gutierrez, Bernardo and Wu, Chieh-Hsi and Klein, Brennan and Pigott, David M. and Group{\textdagger}, Open COVID-19 Data Working and du Plessis, Louis and Faria, Nuno R. and Li, Ruoran and Hanage, William P. and Brownstein, John S. and Layan, Maylis and Vespignani, Alessandro and Tian, Huaiyu and Dye, Christopher and Pybus, Oliver G. and Scarpino, Samuel V.},
  year = {2020},
  month = may,
  journal = {Science},
  volume = {368},
  number = {6490},
  pages = {493--497},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb4218},
  abstract = {Tracing infection from mobility data What sort of measures are required to contain the spread of severe acute respiratory syndrome\textendash coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19)? The rich data from the Open COVID-19 Data Working Group include the dates when people first reported symptoms, not just a positive test date. Using these data and real-time travel data from the internet services company Baidu, Kraemer et al. found that mobility statistics offered a precise record of the spread of SARS-CoV-2 among the cities of China at the start of 2020. The frequency of introductions from Wuhan were predictive of the size of the epidemic sparked in other provinces. However, once the virus had escaped Wuhan, strict local control measures such as social isolation and hygiene, rather than long-distance travel restrictions, played the largest part in controlling SARS-CoV-2 spread. Science, this issue p. 493 The ongoing coronavirus disease 2019 (COVID-19) outbreak expanded rapidly throughout China. Major behavioral, clinical, and state interventions were undertaken to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, affected COVID-19 spread in China. We used real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation in transmission in cities across China and to ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was explained well by human mobility data. After the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases were still indicative of local chains of transmission outside of Wuhan. This study shows that the drastic control measures implemented in China substantially mitigated the spread of COVID-19. Mobile phone data show that the spread of COVID-19 in China was driven by travel and mitigated substantially by local control measures. Mobile phone data show that the spread of COVID-19 in China was driven by travel and mitigated substantially by local control measures.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. http://www.sciencemag.org/about/science-licenses-journal-article-reuseThis is an article distributed under the terms of the Science Journals Default License.},
  langid = {english},
  pmid = {32213647},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EVZPP35V\\Kraemer et al. - 2020 - The effect of human mobility and control measures .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\9U9BF2L6\\493.html}
}

@article{kraemerMappingGlobalVariation2020,
  title = {Mapping Global Variation in Human Mobility},
  author = {Kraemer, Moritz U. G. and Sadilek, Adam and Zhang, Qian and Marchal, Nahema A. and Tuli, Gaurav and Cohn, Emily L. and Hswen, Yulin and Perkins, T. Alex and Smith, David L. and Reiner, Robert C. and Brownstein, John S.},
  year = {2020},
  month = may,
  journal = {Nature Human Behaviour},
  pages = {1--11},
  publisher = {{Nature Publishing Group}},
  issn = {2397-3374},
  doi = {10.1038/s41562-020-0875-0},
  abstract = {The geographic variation of human movement is largely unknown, mainly due to a lack of accurate and scalable data. Here we describe global human mobility patterns, aggregated from over 300 million smartphone users. The data cover nearly all countries and 65\% of Earth's populated surface, including cross-border movements and international migration. This scale and coverage enable us to develop a globally comprehensive human movement typology. We quantify how human movement patterns vary across sociodemographic and environmental contexts and present international movement patterns across national borders. Fitting statistical models, we validate our data and find that human movement laws apply at 10 times shorter distances and movement declines 40\% more rapidly in low-income settings. These results and data are made available to further understanding of the role of human movement in response to rapid demographic, economic and environmental changes.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y45RR6VV\\Kraemer et al. - 2020 - Mapping global variation in human mobility.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\GUW4R3YY\\s41562-020-0875-0.html}
}

@article{kretzschmarImpactDelaysEffectiveness2020,
  title = {Impact of Delays on Effectiveness of Contact Tracing Strategies for {{COVID-19}}: A Modelling Study},
  shorttitle = {Impact of Delays on Effectiveness of Contact Tracing Strategies for {{COVID-19}}},
  author = {Kretzschmar, Mirjam E. and Rozhnova, Ganna and Bootsma, Martin C. J. and van Boven, Michiel and van de Wijgert, Janneke H. H. M. and Bonten, Marc J. M.},
  year = {2020},
  month = jul,
  journal = {The Lancet Public Health},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2468-2667},
  doi = {10.1016/S2468-2667(20)30157-2},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}In countries with declining numbers of confirmed cases of COVID-19, lockdown measures are gradually being lifted. However, even if most physical distancing measures are continued, other public health measures will be needed to control the epidemic. Contact tracing via conventional methods or mobile app technology is central to control strategies during de-escalation of physical distancing. We aimed to identify key factors for a contact tracing strategy to be successful.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We evaluated the impact of timeliness and completeness in various steps of a contact tracing strategy using a stochastic mathematical model with explicit time delays between time of infection and symptom onset, and between symptom onset, diagnosis by testing, and isolation (testing delay). The model also includes tracing of close contacts (eg, household members) and casual contacts, followed by testing regardless of symptoms and isolation if testing positive, with different tracing delays and coverages. We computed effective reproduction numbers of a contact tracing strategy (\emph{R}\textsubscript{CTS}) for a population with physical distancing measures and various scenarios for isolation of index cases and tracing and quarantine of their contacts.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}For the most optimistic scenario (testing and tracing delays of 0 days and tracing coverage of 100\%), and assuming that around 40\% of transmissions occur before symptom onset, the model predicts that the estimated effective reproduction number of 1{$\cdot$}2 (with physical distancing only) will be reduced to 0{$\cdot$}8 (95\% CI 0{$\cdot$}7\textendash 0{$\cdot$}9) by adding contact tracing. The model also shows that a similar reduction can be achieved when testing and tracing coverage is reduced to 80\% (\emph{R}\textsubscript{CTS} 0{$\cdot$}8, 95\% CI 0{$\cdot$}7\textendash 1{$\cdot$}0). A testing delay of more than 1 day requires the tracing delay to be at most 1 day or tracing coverage to be at least 80\% to keep \emph{R}\textsubscript{CTS} below 1. With a testing delay of 3 days or longer, even the most efficient strategy cannot reach \emph{R}\textsubscript{CTS} values below 1. The effect of minimising tracing delay (eg, with app-based technology) declines with decreasing coverage of app use, but app-based tracing alone remains more effective than conventional tracing alone even with 20\% coverage, reducing the reproduction number by 17{$\cdot$}6\% compared with 2{$\cdot$}5\%. The proportion of onward transmissions per index case that can be prevented depends on testing and tracing delays, and given a 0-day tracing delay, ranges from up to 79{$\cdot$}9\% with a 0-day testing delay to 41{$\cdot$}8\% with a 3-day testing delay and 4{$\cdot$}9\% with a 7-day testing delay.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}In our model, minimising testing delay had the largest impact on reducing onward transmissions. Optimising testing and tracing coverage and minimising tracing delays, for instance with app-based technology, further enhanced contact tracing effectiveness, with the potential to prevent up to 80\% of all transmissions. Access to testing should therefore be optimised, and mobile app technology might reduce delays in the contact tracing process and optimise contact tracing coverage.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}ZonMw, Funda\c{c}\~ao para a Ci\^encia e a Tecnologia, and EU Horizon 2020 RECOVER.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZSR7SALA\\Kretzschmar et al. - 2020 - Impact of delays on effectiveness of contact traci.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\XDDZNXBP\\fulltext.html}
}

@incollection{kruschkeStan2015,
  title = {Stan},
  booktitle = {Doing {{Bayesian Data Analysis}}},
  author = {Kruschke, John K.},
  year = {2015},
  pages = {399--416},
  publisher = {{Elsevier}},
  doi = {10.1016/B978-0-12-405888-0.00014-3},
  isbn = {978-0-12-405888-0},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9KNWFGLR\\Kruschke - 2015 - Stan.pdf}
}

@article{kuangDELAYDIFFERENTIALEQUATIONS,
  title = {{{DELAY DIFFERENTIAL EQUATIONS}}},
  author = {Kuang, Yang},
  pages = {4},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5WPZGT7D\\Kuang - DELAY DIFFERENTIAL EQUATIONS.pdf}
}

@article{kucirkaVariationFalseNegativeRate2020,
  title = {Variation in {{False-Negative Rate}} of {{Reverse Transcriptase Polymerase Chain Reaction}}\textendash{{Based SARS-CoV-2 Tests}} by {{Time Since Exposure}}},
  author = {Kucirka, Lauren M. and Lauer, Stephen A. and Laeyendecker, Oliver and Boon, Denali and Lessler, Justin},
  year = {2020},
  month = may,
  journal = {Annals of Internal Medicine},
  issn = {0003-4819},
  doi = {10.7326/M20-1495},
  abstract = {Tests for severe acute respiratory syndrome coronavirus 2 based on reverse transcriptase polymerase chain reaction (RT-PCR) are being used to ``rule out'' infection among high-risk persons, such as exposed inpatients and health care workers, but studies suggest that test sensitivity may be low. This study estimates the false-negative rate by day since exposure to infection by pooling and modeling data from previously published studies on RT-PCR sensitivity of upper respiratory tract samples of persons who were ultimately confirmed to have coronavirus disease 19.},
  pmcid = {PMC7240870},
  pmid = {32422057},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7PRUC7XG\\Kucirka et al. - 2020 - Variation in False-Negative Rate of Reverse Transc.pdf}
}

@misc{kupferschmidtapr.14EndingCoronavirusLockdowns2020,
  title = {Ending Coronavirus Lockdowns Will Be a Dangerous Process of Trial and Error},
  author = {KupferschmidtApr. 14, Kai and {2020} and Pm, 4:10},
  year = {2020},
  month = apr,
  journal = {Science | AAAS},
  abstract = {There's no scientific consensus on when it's safe to reopen schools, businesses, restaurants, and bars},
  howpublished = {http://www.sciencemag.org/news/2020/04/ending-coronavirus-lockdowns-will-be-dangerous-process-trial-and-error},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\66H2BKGT\\ending-coronavirus-lockdowns-will-be-dangerous-process-trial-and-error.html}
}

@misc{kupferschmidtdec.20MutantCoronavirusUnited2020,
  title = {Mutant Coronavirus in the {{United Kingdom}} Sets off Alarms, but Its Importance Remains Unclear},
  author = {KupferschmidtDec. 20, Kai and {2020} and Pm, 5:45},
  year = {2020},
  month = dec,
  journal = {Science | AAAS},
  abstract = {European countries impose travel bans as scientists probe whether new strain spreads faster or causes more severe COVID-19},
  howpublished = {http://www.sciencemag.org/news/2020/12/mutant-coronavirus-united-kingdom-sets-alarms-its-importance-remains-unclear},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MP2JPAHF\\mutant-coronavirus-united-kingdom-sets-alarms-its-importance-remains-unclear.html}
}

@article{laiEffectNonpharmaceuticalInterventions2020,
  title = {Effect of Non-Pharmaceutical Interventions to Contain {{COVID-19}} in {{China}}},
  author = {Lai, Shengjie and Ruktanonchai, Nick W. and Zhou, Liangcai and Prosper, Olivia and Luo, Wei and Floyd, Jessica R. and Wesolowski, Amy and Santillana, Mauricio and Zhang, Chi and Du, Xiangjun and Yu, Hongjie and Tatem, Andrew J.},
  year = {2020},
  month = may,
  journal = {Nature},
  pages = {1--7},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-020-2293-x},
  abstract = {On March 11, 2020, the World Health Organization declared COVID-19 a pandemic1. The outbreak containment strategies in China based on non-pharmaceutical interventions (NPIs) appear to be effective2, but quantitative research is still needed to assess the efficacy of NPIs and their timings3. Using epidemiological and anonymised human movement data4,5, here we develop a modelling framework that uses daily travel networks to simulate different outbreak and intervention scenarios across China. We estimated that there were a total of 114,325 COVID-19 cases (interquartile range 76,776 - 164,576) in mainland China as of February 29, 2020. Without NPIs, the COVID-19 cases would likely have shown a 67-fold increase (interquartile range 44 - 94) by February 29, 2020, with the effectiveness of different interventions varying. The early detection and isolation of cases was estimated to have prevented more infections than travel restrictions and contact reductions, but combined NPIs achieved the strongest and most rapid effect. The lifting of travel restrictions since February 17, 2020 does not appear to lead to an increase in cases across China if the social distancing interventions can be maintained, even at a limited level of 25\% reduction on average through late April. Our findings contribute to an improved understanding of NPIs on COVID-19 and to inform response efforts across the World.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9D3DVH9M\\Lai et al. - 2020 - Effect of non-pharmaceutical interventions to cont.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\EBIC9RB7\\s41586-020-2293-x.html}
}

@article{laiImpactCOVID19Preventative2020,
  title = {The Impact of {{COVID-19}} Preventative Measures on Airborne/Droplet-Transmitted Infectious Diseases in {{Taiwan}}},
  author = {Lai, Chih-Cheng and Chen, Shey-Ying and Yen, Muh-Yong and Lee, Ping-Ing and Ko, Wen-Chien and Hsueh, Po-Ren},
  year = {2020},
  month = nov,
  journal = {Journal of Infection},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0163-4453, 1532-2742},
  doi = {10.1016/j.jinf.2020.11.029},
  abstract = {With immense interest, we read the recent article by de Lusignan et~al.,1 which reported an absolute excess mortality of approximately 2 deaths per 100 person-years in England during the first wave of coronavirus disease 2019 (COVID-19). This report reminds us of the possible collateral damage caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, particularly in countries with high number of COVID-19 cases. In contrast, several recent reports revealed the collateral benefit of implementing infection control and prevention interventions during the COVID-19 pandemic on other respiratory infectious diseases.},
  langid = {english},
  pmid = {33249105},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LSI6RU59\\Lai et al. - 2020 - The impact of COVID-19 preventative measures on ai.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\YT7DQK5M\\fulltext.html}
}

@misc{LandOberoesterreichAktuelles,
  title = {{Land Ober\"osterreich - Aktuelles zum Corona-Virus in Ober\"osterreich}},
  journal = {Land Ober\"osterreich},
  howpublished = {http://www.land-oberoesterreich.gv.at},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8IQQMDXV\\238017.html}
}

@misc{LandOberoesterreichCovid19,
  title = {{Land Ober\"osterreich - Covid-19: Information an Fahrg\"aste der Buslinie Nr. 664 von Wels nach Buchkirchen}},
  shorttitle = {{Land Ober\"osterreich - Covid-19}},
  journal = {Land Ober\"osterreich},
  howpublished = {http://www.land-oberoesterreich.gv.at},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y4M2DY7E\\238053.html}
}

@techreport{larremoreTestSensitivitySecondary2020,
  type = {Preprint},
  title = {Test Sensitivity Is Secondary to Frequency and Turnaround Time for {{COVID-19}} Surveillance},
  author = {Larremore, Daniel B and Wilder, Bryan and Lester, Evan and Shehata, Soraya and Burke, James M and Hay, James A and Tambe, Milind and Mina, Michael J and Parker, Roy},
  year = {2020},
  month = jun,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2020.06.22.20136309},
  abstract = {The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with pre-symptomatic, symptomatic, and asymptomatic infections, the re-opening of societies and the control of virus spread will be facilitated by robust surveillance, for which virus testing will often be central. After infection, individuals undergo a period of incubation during which viral titers are usually too low to detect, followed by an exponential growth of virus, leading to a peak viral load and infectiousness, and ending with declining viral levels and clearance. Given the pattern of viral load kinetics, we model surveillance effectiveness considering test sensitivities, frequency, and sample-to-answer reporting time. These results demonstrate that effective surveillance, including time to first detection and outbreak control, depends largely on frequency of testing and the speed of reporting, and is only marginally improved by high test sensitivity. We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZENBFS3Q\\Larremore et al. - 2020 - Test sensitivity is secondary to frequency and tur.pdf}
}

@article{lashCOVID19CaseInvestigation2021,
  title = {{{COVID-19 Case Investigation}} and {{Contact Tracing}} in the {{US}}, 2020},
  author = {Lash, R. Ryan and Moonan, Patrick K. and Byers, Brittany L. and Bonacci, Robert A. and Bonner, Kimberly E. and Donahue, Matthew and Donovan, Catherine V. and Grome, Heather N. and Janssen, Julia M. and Magleby, Reed and McLaughlin, Heather P. and Miller, James S. and Pratt, Caroline Q. and Steinberg, Jonathan and Varela, Kate and Anschuetz, Greta L. and Cieslak, Paul R. and Fialkowski, Veronica and Fleischauer, Aaron T. and Goddard, Clay and Johnson, Sara Jo and Morris, Michelle and Moses, Jill and Newman, Allison and Prinzing, Lauren and Sulka, Alana C. and Va, Puthiery and Willis, Matthew and Oeltmann, John E. and {COVID-19 Contact Tracing Assessment Team} and Clayton, Joshua  L. and Forbes, Heather  Bailey and DeLuca, Nick and Haddad, Maryam and Harris, Gibbie and Hayes, Susan and Hendrickson, Blake and Honein, Margaret  A. and Hogben, Matthew and Jones, Amanda and Knott, Catherine J. and Leman, Richard  L. and McCurdy, Stephen  A. and McGrath, Alana and Moore, Zack  S. and Ortbahn, Dustin and Paritala, Sai and Pevzner, Eric  S. and Pierce, Rebecca  A. and Raghunathan, Pratima  L. and Rains, Catherine and Rose, Dale  A. and Safranek, Tom and Sathya, Bhavani and Tan, Christina G. and Taylor, Melanie and Thorpe, Phoebe  G. and Walke, Henry and Weisbeck, Andee},
  year = {2021},
  month = jun,
  journal = {JAMA Network Open},
  volume = {4},
  number = {6},
  pages = {e2115850},
  issn = {2574-3805},
  doi = {10.1001/jamanetworkopen.2021.15850},
  langid = {english}
}

@misc{lasserAssessingImpactSARSCoV22021,
  title = {Assessing the Impact of {{SARS-CoV-2}} Prevention Measures in {{Austrian}} Schools by Means of Agent-Based Simulations Calibrated to Cluster Tracing Data},
  author = {Lasser, Jana and Sorger, Johannes and Richter, Lukas and Thurner, Stefan and Schmid, Daniela and Klimek, Peter},
  year = {2021},
  month = sep,
  pages = {2021.04.13.21255320},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.04.13.21255320},
  abstract = {How to safely maintain open schools during a pandemic is still controversial. We aim to identify those measures that effectively control the spread of SARS-CoV-2 in Austrian schools. By control we mean that each source case infects less than one other person on average. We use Austrian data on 616 clusters involving 2,822 student-cases and 676 teacher-cases to calibrate an agent-based epidemiological model in terms of cluster size and transmission risk depending on age and clinical presentation. Considering a situation in which the B1.617.2 (delta) virus strain is dominant and parts of the population are vaccinated, we quantify the impact of non-pharmaceutical intervention measures (NPIs) such as room ventilation, reduction of class size, wearing of masks during lessons, vaccinations, and school entry testing by SARS-CoV2-antigen tests. In the tracing data we find that 40\% of all clusters involved no more than two cases, and 3\% of the clusters only had more than 20 cases. The younger the students, the more likely we found asymptomatic cases and teachers as the source case of the in-school transmissions. Based on this data, the model shows that different school types require different combinations of NPIs to achieve control of the infection spreading: If 80\% of teachers and 50\% of students are vaccinated, in primary schools, it is necessary to combine at least two of the above NPIs. In secondary schools, where contact networks of students and teachers become increasingly large and dense, a combination of at least three NPIs is needed. A sensitivity analysis indicated that poorly executed mitigation measures might increase the cluster size by a factor of more than 17 for primary schools and even higher increases are to be expected for the other school types. Our results suggest that school-type-specific combinations of NPIs together with vaccinations are necessary to allow for a controlled opening of schools under sustained community transmission of the SARS-CoV-2 delta variant. However, large clusters might still occur on an infrequent, however, regular basis.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UG7CP2KA\\Lasser et al. - 2021 - Assessing the impact of SARS-CoV-2 prevention meas.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\GXDM9BSB\\2021.04.13.21255320v2.html}
}

@article{laxminarayanEpidemiologyTransmissionDynamics2020,
  title = {Epidemiology and Transmission Dynamics of {{COVID-19}} in Two {{Indian}} States},
  author = {Laxminarayan, Ramanan and Wahl, Brian and Dudala, Shankar Reddy and Gopal, K. and Mohan, Chandra and Neelima, S. and Reddy, K. S. Jawahar and Radhakrishnan, J. and Lewnard, Joseph A.},
  year = {2020},
  month = sep,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abd7672},
  abstract = {Although most COVID-19 cases have occurred in low-resource countries, little is known about the epidemiology of the disease in such contexts. Data from the Indian states of Tamil Nadu and Andhra Pradesh provide a detailed view into SARS-CoV-2 transmission pathways and mortality in a high-incidence setting. Reported cases and deaths have been concentrated in younger cohorts than expected from observations in higher-income countries, even after accounting for demographic differences across settings. Among 575,071 individuals exposed to 84,965 confirmed cases, infection probabilities ranged from 4.7-10.7\% for low-risk and high-risk contact types. Same-age contacts were associated with the greatest infection risk. Case-fatality ratios spanned 0.05\% at ages 5-17 years to 16.6\% at ages {$\geq$}85 years. Primary data are urgently needed from low-resource countries to guide control measures.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WM5353JF\\Laxminarayan et al. - 2020 - Epidemiology and transmission dynamics of COVID-19.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\W7DWDJQ2\\science.html}
}

@article{leclercImportancePatientBed2021,
  title = {Importance of Patient Bed Pathways and Length of Stay Differences in Predicting {{COVID-19}} Bed Occupancy in {{England}}},
  author = {Leclerc, Quentin J. and Fuller, Naomi M. and Keogh, Ruth H. and {Diaz-Ordaz}, Karla and Sekula, Richard and Semple, Malcolm G. and Investigators, Isaric4c and Group, CMMID COVID-19 Working and Atkins, Katherine E. and Procter, Simon R. and Knight, Gwenan M.},
  year = {2021},
  month = jan,
  journal = {medRxiv},
  pages = {2021.01.14.21249791},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.01.14.21249791},
  abstract = {{$<$}p{$>$}\textbf{Objectives} Predicting bed occupancy for hospitalised patients with COVID-19 requires understanding of length of stay (LoS) in particular bed types. LoS can vary depending on the patient9s "bed pathway" - the sequence of transfers between bed types during a hospital stay. In this study, we characterise these pathways, and their impact on predicted hospital bed occupancy. \textbf{Design} We obtained data from University College Hospital (UCH) and the ISARIC4C COVID-19 Clinical Information Network (CO-CIN) on hospitalised patients with COVID-19 who required care in general ward or critical care (CC) beds to determine possible bed pathways and LoS. We developed a discrete-time model to examine the implications of using either bed pathways or only average LoS by bed type to forecast bed occupancy. We compared model-predicted bed occupancy to publicly available bed occupancy data on COVID-19 in England between March and August 2020. \textbf{Results} In both the UCH and CO-CIN datasets, 82\% of hospitalised patients with COVID-19 only received care in general ward beds. We identified four other bed pathways, present in both datasets: "Ward, CC, Ward", "Ward, CC", "CC" and "CC, Ward". Mean LoS varied by bed type, pathway, and dataset, between 1.78 and 13.53 days. For UCH, we found that using bed pathways improved the accuracy of bed occupancy predictions, while only using an average LoS for each bed type underestimated true bed occupancy. However, using the CO-CIN LoS dataset we were not able to replicate past data on bed occupancy in England, suggesting regional LoS heterogeneities. \textbf{Conclusions} We identified five bed pathways, with substantial variation in LoS by bed type, pathway, and geography. This might be caused by local differences in patient characteristics, clinical care strategies, or resource availability, and suggests that national LoS averages may not be appropriate for local forecasts of bed occupancy for COVID-19.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RQJWDATS\\Leclerc et al. - 2021 - Importance of patient bed pathways and length of s.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\CYDK5ZQ5\\2021.01.14.html}
}

@article{leclercWhatSettingsHave2020,
  title = {What Settings Have Been Linked to {{SARS-CoV-2}} Transmission Clusters?},
  author = {Leclerc, Quentin J. and Fuller, Naomi M. and Knight, Lisa E. and {CMMID COVID-19 Working Group} and Funk, Sebastian and Knight, Gwenan M.},
  year = {2020},
  month = may,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {83},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.15889.1},
  abstract = {Background               : Concern about the health impact of novel coronavirus SARS-CoV-2 has resulted in widespread enforced reductions in people's movement (``lockdowns''). However, there are increasing concerns about the severe economic and wider societal consequences of these measures. Some countries have begun to lift some of the rules on physical distancing in a stepwise manner, with differences in what these ``exit strategies'' entail and their timeframes. The aim of this work was to inform such exit strategies by exploring the types of indoor and outdoor settings where transmission of SARS-CoV-2 has been reported to occur and result in clusters of cases. Identifying potential settings that result in transmission clusters allows these to be kept under close surveillance and/or to remain closed as part of strategies that aim to avoid a resurgence in transmission following the lifting of lockdown measures.                                         Methods               : We performed a systematic review of available literature and media reports to find settings reported in peer reviewed articles and media with these characteristics. These sources are curated and made available in an editable online database.                                         Results               : We found many examples of SARS-CoV-2 clusters linked to a wide range of mostly indoor settings. Few reports came from schools, many from households, and an increasing number were reported in hospitals and elderly care settings across Europe.                                         Conclusions:               We identified possible places that are linked to clusters of COVID-19 cases and could be closely monitored and/or remain closed in the first instance following the progressive removal of lockdown restrictions. However, in part due to the limits in surveillance capacities in many settings, the gathering of information such as cluster sizes and attack rates is limited in several ways: inherent recall bias, biased media reporting and missing data.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AARIEF5U\\5-83.html}
}

@article{leclercWhatSettingsHave2020a,
  title = {What Settings Have Been Linked to {{SARS-CoV-2}} Transmission Clusters?},
  author = {Leclerc, Quentin J. and Fuller, Naomi M. and Knight, Lisa E. and {CMMID COVID-19 Working Group} and Funk, Sebastian and Knight, Gwenan M.},
  year = {2020},
  month = may,
  journal = {Wellcome Open Research},
  volume = {5},
  pages = {83},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.15889.1},
  abstract = {Background               : Concern about the health impact of novel coronavirus SARS-CoV-2 has resulted in widespread enforced reductions in people's movement (``lockdowns''). However, there are increasing concerns about the severe economic and wider societal consequences of these measures. Some countries have begun to lift some of the rules on physical distancing in a stepwise manner, with differences in what these ``exit strategies'' entail and their timeframes. The aim of this work was to inform such exit strategies by exploring the types of indoor and outdoor settings where transmission of SARS-CoV-2 has been reported to occur and result in clusters of cases. Identifying potential settings that result in transmission clusters allows these to be kept under close surveillance and/or to remain closed as part of strategies that aim to avoid a resurgence in transmission following the lifting of lockdown measures.                                         Methods               : We performed a systematic review of available literature and media reports to find settings reported in peer reviewed articles and media with these characteristics. These sources are curated and made available in an editable online database.                                         Results               : We found many examples of SARS-CoV-2 clusters linked to a wide range of mostly indoor settings. Few reports came from schools, many from households, and an increasing number were reported in hospitals and elderly care settings across Europe.                                         Conclusions:               We identified possible places that are linked to clusters of COVID-19 cases and could be closely monitored and/or remain closed in the first instance following the progressive removal of lockdown restrictions. However, in part due to the limits in surveillance capacities in many settings, the gathering of information such as cluster sizes and attack rates is limited in several ways: inherent recall bias, biased media reporting and missing data.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KTMUX3TP\\Leclerc et al. - 2020 - What settings have been linked to SARS-CoV-2 trans.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\RXV4SEVW\\v1.html}
}

@article{lemaitreAssessingImpactNonpharmaceutical2020,
  title = {Assessing the Impact of Non-Pharmaceutical Interventions on {{SARS-CoV-2}} Transmission in {{Switzerland}}},
  author = {Lemaitre, Joseph Chadi and {Perez-Saez}, Javier and Azman, Andrew and Rinaldo, Andrea and Fellay, Jacques},
  year = {2020},
  month = may,
  journal = {medRxiv},
  pages = {2020.05.04.20090639},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.05.04.20090639},
  abstract = {{$<$}p{$>$}Following the rapid dissemination of COVID-19 cases in Switzerland, large-scale non- pharmaceutical interventions (NPIs) were implemented by the cantons and the federal government between February 28 and March 20. Estimates of the impact of these interventions on SARS-CoV-2 transmission are critical for decision making in this and future outbreaks. We here aim to assess the impact of these NPIs on disease transmission by estimating changes in the basic reproduction number (R\textsubscript{0}) at national and cantonal levels in relation to the timing of these NPIs. We estimate the time- varying R\textsubscript{0} nationally and in twelve cantons by fitting a stochastic transmission model explicitly simulating within hospital dynamics. We use individual-level data of \&gt;1,000 hospitalized patients in Switzerland and public daily reports of hospitalizations and deaths. We estimate the national R\textsubscript{0} was 3.15 (95\% CI: 2.13-3.76) at the start of the epidemic. Starting from around March 6, we find a strong reduction in R\textsubscript{0} with an 85\% median decrease (95\% quantile range, QR: 83\%-90\%) to a value of 0.44 (95\% QR: 0.27-0.65) in the period of March 29-April 5. At the cantonal-level R\textsubscript{0} decreased over the course of the epidemic between 71\% and 94\%. We found that reductions in R\textsubscript{0} were synchronous with changes in mobility patterns as estimated through smartphone activity, which started before the official implementation of NPIs. We found that most of the reduction of transmission is due to behavioural changes as opposed to natural immunity, the latter accounting for only about 3\% of the total reduction in effective transmission. As Switzerland considers relaxing some of the restrictions of social mixing, current estimates of R\textsubscript{0} well below one are promising. However most of inferred transmission reduction was due to behaviour change (\&lt;3\% due to natural immunity buildup), with an estimated 97\% (95\% QR: 96.6\%-97.2\%) of the Swiss population still susceptible to SARS-CoV-2 as of April 24. These results warrant a cautious relaxation of social distance practices and close monitoring of changes in both the basic and effective reproduction numbers.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PNNZV4I7\\Lemaitre et al. - 2020 - Assessing the impact of non-pharmaceutical interve.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3RJJRDVC\\2020.05.04.html}
}

@article{levinASSESSINGAGESPECIFICITY2020,
  title = {{{ASSESSING THE AGE SPECIFICITY OF INFECTION FATALITY RATES FOR COVID-19}}: {{SYSTEMATIC REVIEW}}, {{META-ANALYSIS}}, {{AND PUBLIC POLICY IMPLICATIONS}}},
  shorttitle = {{{ASSESSING THE AGE SPECIFICITY OF INFECTION FATALITY RATES FOR COVID-19}}},
  author = {Levin, Andrew T. and Hanage, William P. and {Owusu-Boaitey}, Nana and Cochran, Kensington B. and Walsh, Seamus P. and {Meyerowitz-Katz}, Gideon},
  year = {2020},
  month = sep,
  journal = {medRxiv},
  pages = {2020.07.23.20160895},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  issn = {2016-0895},
  doi = {10.1101/2020.07.23.20160895},
  abstract = {{$<$}p{$>$}This paper assesses the age specificity of the infection fatality rate (IFR) for COVID-19 using results from 28 seroprevalence studies as well as five countries that have engaged in comprehensive tracing of COVID-19 cases. The estimated IFR is close to zero for children and younger adults but rises exponentially with age, reaching 0.4\% at age 55, 1.3\% at age 65, 4.2\% at age 75, and 14\% at age 85. We find that differences in the age structure of the population and the age-specific prevalence of COVID-19 explain nearly 90\% of the geographical variation in population IFR. Consequently, protecting vulnerable age groups could substantially reduce the incidence of mortality.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5A9S5F2F\\Levin et al. - 2020 - ASSESSING THE AGE SPECIFICITY OF INFECTION FATALIT.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MILNX9RJ\\2020.07.23.html}
}

@article{levinAssessingAgeSpecificity2020,
  title = {Assessing the Age Specificity of Infection Fatality Rates for {{COVID-19}}: Systematic Review, Meta-Analysis, and Public Policy Implications},
  shorttitle = {Assessing the Age Specificity of Infection Fatality Rates for {{COVID-19}}},
  author = {Levin, Andrew T. and Hanage, William P. and {Owusu-Boaitey}, Nana and Cochran, Kensington B. and Walsh, Seamus P. and {Meyerowitz-Katz}, Gideon},
  year = {2020},
  month = dec,
  journal = {European Journal of Epidemiology},
  volume = {35},
  number = {12},
  pages = {1123--1138},
  issn = {1573-7284},
  doi = {10.1007/s10654-020-00698-1},
  abstract = {Determine age-specific infection fatality rates for COVID-19 to inform public health policies and communications that help protect vulnerable age groups. Studies of COVID-19 prevalence were collected by conducting an online search of published articles, preprints, and government reports that were publicly disseminated prior to 18 September 2020. The systematic review encompassed 113 studies, of which 27 studies (covering 34 geographical locations) satisfied the inclusion criteria and were included in the meta-analysis. Age-specific IFRs were computed using the prevalence data in conjunction with reported fatalities 4~weeks after the midpoint date of the study, reflecting typical lags in fatalities and reporting. Meta-regression procedures in Stata were used to analyze the infection fatality rate (IFR) by age. Our analysis finds a exponential relationship between age and IFR for COVID-19. The estimated age-specific IFR is very low for children and younger adults (e.g., 0.002\% at age 10 and 0.01\% at age 25) but increases progressively to 0.4\% at age 55, 1.4\% at age 65, 4.6\% at age 75, and 15\% at age 85. Moreover, our results indicate that about 90\% of the variation in population IFR across geographical locations reflects differences in the age composition of the population and the extent to which relatively vulnerable age groups were exposed to the virus. These results indicate that COVID-19 is hazardous not only for the elderly but also for middle-aged adults, for whom the infection fatality rate is two orders of magnitude greater than the annualized risk of a fatal automobile accident and far more dangerous than seasonal influenza. Moreover, the overall IFR for COVID-19 should not be viewed as a fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, public health measures to mitigate infections in older adults could substantially decrease total deaths.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WFZTYZL8\\Levin et al. - 2020 - Assessing the age specificity of infection fatalit.pdf}
}

@misc{levinAssessingBurdenCOVID192021,
  title = {Assessing the {{Burden}} of {{COVID-19}} in {{Developing Countries}}: {{Systematic Review}}, {{Meta-Analysis}}, and {{Public Policy Implications}}},
  shorttitle = {Assessing the {{Burden}} of {{COVID-19}} in {{Developing Countries}}},
  author = {Levin, Andrew and {Owusu-Boaitey}, Nana and Pugh, Sierra and Fosdick, Bailey K. and Zwi, Anthony B. and Malani, Anup and Soman, Satej and Besan{\c c}on, Lonni and Kashnitsky, Ilya and Ganesh, Sachin and McLaughlin, Aloysius and Song, Gayeong and Uhm, Rine and {Meyerowitz-Katz}, Gideon},
  year = {2021},
  month = oct,
  pages = {2021.09.29.21264325},
  institution = {{Cold Spring Harbor Laboratory Press}},
  issn = {2126-4325},
  doi = {10.1101/2021.09.29.21264325},
  abstract = {Introduction The infection-fatality rate (IFR) of COVID-19 has been carefully measured and analyzed in high-income countries, whereas there has been no systematic analysis of age-specific seroprevalence or IFR for developing countries. Indeed, it has been suggested that the death rate in developing countries may be far lower than in high-income countries\textemdash an outcome that would be starkly different from the typical pattern for many other infectious diseases. Methods We systematically reviewed the literature to identify all serology studies in developing countries that were conducted using representative samples of specimens collected by early 2021. For each of the antibody assays used in these serology studies, we identified data on assay characteristics, including the extent of seroreversion over time. We analyzed the serology data using a Bayesian model that incorporates conventional sampling uncertainty as well as uncertainties about assay sensitivity and specificity. We then calculated IFRs using individual case reports or aggregated public health updates, including age-specific estimates whenever feasible. Results Seroprevalence in many developing country locations was markedly higher than in high-income countries but still far short of herd immunity. In most locations, seroprevalence among older adults was similar to that of younger age-groups. Age-specific IFRs were 1.3-2.5x higher than in high-income countries. The median value of population IFR was 0.5\% among developing countries with satisfactory death reporting as of 2016, compared to a median of 0.05\% for other developing countries. Conclusion The burden of COVID-19 is far higher in developing countries than in high-income countries, reflecting a combination of elevated transmission to middle-aged and older adults as well as limited access to adequate healthcare. These results underscore the critical need to accelerate the provision of vaccine doses to vulnerable populations in developing countries. Key Points- Age-specific prevalence and infection fatality rate (IFR) of COVID-19 for developing countries has not been well assessed.- Seroprevalence in developing countries (as measured by antibodies against SARS-CoV-2) is markedly higher than in high-income countries but still far short of herd immunity.- Seroprevalence among older adults is broadly similar to that of younger age-groups.- Age-specific IFRs in developing countries are roughly twice those of high-income countries.- Population IFR in developing countries with satisfactory death reporting (based on UN/WHO data as of 2016) is ten times higher than in other developing countries.- These results underscore the urgency of disseminating vaccines to vulnerable people in developing countries.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DSEQYID9\\Levin et al. - 2021 - Assessing the Burden of COVID-19 in Developing Cou.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MUTPS7DY\\2021.09.29.html}
}

@article{liCharacterisingBackgroundIncidence2021,
  title = {Characterising the Background Incidence Rates of Adverse Events of Special Interest for Covid-19 Vaccines in Eight Countries: Multinational Network Cohort Study},
  shorttitle = {Characterising the Background Incidence Rates of Adverse Events of Special Interest for Covid-19 Vaccines in Eight Countries},
  author = {Li, Xintong and Ostropolets, Anna and Makadia, Rupa and Shoaibi, Azza and Rao, Gowtham and Sena, Anthony G. and {Martinez-Hernandez}, Eugenia and Delmestri, Antonella and Verhamme, Katia and Rijnbeek, Peter R. and {Duarte-Salles}, Talita and Suchard, Marc A. and Ryan, Patrick B. and Hripcsak, George and {Prieto-Alhambra}, Daniel},
  year = {2021},
  month = jun,
  journal = {BMJ},
  volume = {373},
  pages = {n1435},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.n1435},
  abstract = {Objective To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. Design Multinational network cohort study. Setting Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model. Participants 126 661 070 people observed for at least 365 days before 1 January 2017, 2018, or 2019 from 13 databases. Main outcome measures Events of interests were 15 prespecified AESIs (non-haemorrhagic and haemorrhagic stroke, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylaxis, Bell's palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocytopenia, disseminated intravascular coagulation, encephalomyelitis (including acute disseminated encephalomyelitis), Guillain-Barr\'e syndrome, and transverse myelitis). Incidence rates of AESIs were stratified by age, sex, and database. Rates were pooled across databases using random effects meta-analyses and classified according to the frequency categories of the Council for International Organizations of Medical Sciences. Results Background rates varied greatly between databases. Deep vein thrombosis ranged from 387 (95\% confidence interval 370 to 404) per 100 000 person years in UK CPRD GOLD data to 1443 (1416 to 1470) per 100 000 person years in US IBM MarketScan Multi-State Medicaid data among women aged 65 to 74 years. Some AESIs increased with age. For example, myocardial infarction rates in men increased from 28 (27 to 29) per 100 000 person years among those aged 18-34 years to 1400 (1374 to 1427) per 100 000 person years in those older than 85 years in US Optum electronic health record data. Other AESIs were more common in young people. For example, rates of anaphylaxis among boys and men were 78 (75 to 80) per 100 000 person years in those aged 6-17 years and 8 (6 to 10) per 100 000 person years in those older than 85 years in Optum electronic health record data. Meta-analytic estimates of AESI rates were classified according to age and sex. Conclusion This study found large variations in the observed rates of AESIs by age group and sex, showing the need for stratification or standardisation before using background rates for safety surveillance. Considerable population level heterogeneity in AESI rates was found between databases.},
  chapter = {Research},
  copyright = {\textcopyright{} Author(s) (or their employer(s)) 2019. Re-use permitted under CC                 BY. No commercial re-use. See rights and permissions. Published by                 BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PYXRPK6D\\Li et al. - 2021 - Characterising the background incidence rates of a.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\U2929T85\\bmj.html}
}

@article{lindnerHeadtoheadComparisonSARSCoV22020,
  title = {Head-to-Head Comparison of {{SARS-CoV-2}} Antigen-Detecting Rapid Test with Self-Collected Anterior Nasal Swab versus Professional-Collected Nasopharyngeal Swab},
  author = {Lindner, Andreas K. and Nikolai, Olga and Kausch, Franka and Wintel, Mia and Hommes, Franziska and Gertler, Maximilian and Kr{\"u}ger, Lisa J. and Gaeddert, Mary and Tobian, Frank and Lainati, Federica and K{\"o}ppel, Lisa and Seybold, Joachim and Corman, Victor M. and Drosten, Christian and Hofmann, J{\"o}rg and Sacks, Jilian A. and Mockenhaupt, Frank P. and Denkinger, Claudia M.},
  year = {2020},
  month = oct,
  journal = {medRxiv},
  pages = {2020.10.26.20219600},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.10.26.20219600},
  abstract = {{$<$}h3{$>$}Abstract{$<$}/h3{$>$} {$<$}h3{$>$}Background{$<$}/h3{$>$} {$<$}p{$>$}Two antigen-detecting rapid diagnostic tests (Ag-RDTs) are now approved through the WHO Emergency Use Listing procedure and can be performed at the point-of-care. However, both tests use nasopharyngeal (NP) swab samples. NP swab samples must be collected by trained healthcare personnel with protective equipment and are frequently perceived as uncomfortable by patients.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$>$} {$<$}p{$>$}This was a manufacturer-independent, prospective diagnostic accuracy study with comparison of a supervised, self-collected anterior nose (AN) swab sample with a professional-collected NP swab sample, using a WHO-listed SARS-CoV-2 Ag-RDT, STANDARD Q COVID-19 Ag Test (SD Biosensor), which is also being distributed by Roche. The reference standard was RT-PCR from an oro-/nasopharyngeal swab sample. Percent positive and negative agreement as well as sensitivity and specificity were calculated.{$<$}/p{$><$}h3{$>$}Results{$<$}/h3{$>$} {$<$}p{$>$}Among the 289 participants, 39 (13.5\%) tested positive for SARS-CoV-2 by RT-PCR. The positive percent agreement of the two different sampling techniques for the Ag-RDT was 90.6\% (CI 75.8-96.8). The negative percent agreement was 99.2\% (CI 97.2-99.8). The Ag-RDT with AN sampling showed a sensitivity of 74.4\% (29/39 PCR positives detected; CI 58.9-85.4) and specificity of 99.2\% (CI 97.1-99.8) compared to RT-PCR. The sensitivity with NP sampling was 79.5\% (31/39 PCR positives detected; CI 64.5-89.2) and specificity was 99.6\% (CI 97.8-100). In patients with high viral load (\&gt;7.0 log \textsubscript{10} RNA SARS-CoV2/swab), the sensitivity of the Ag-RDT with AN sampling was 96\% and 100\% with NP sampling.{$<$}/p{$><$}h3{$>$}Conclusion{$<$}/h3{$>$} {$<$}p{$>$}Supervised self-sampling from the anterior nose is a reliable alternative to professional nasopharyngeal sampling using a WHO-listed SARS-CoV-2 Ag-RDT. Considering the ease-of-use of Ag-RDTs, self-sampling and potentially patient self-testing at home may be a future use case.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MKLR7A5Z\\Lindner et al. - 2020 - Head-to-head comparison of SARS-CoV-2 antigen-dete.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\V5WC5XTR\\2020.10.26.html}
}

@article{linPolicyDecisionsUse,
  title = {Policy {{Decisions}} and {{Use}} of {{Information Technology}} to {{Fight COVID-19}}, {{Taiwan}} - {{Volume}} 26, {{Number}} 7\textemdash{{July}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Lin, Cheryl and Braund, Wendy E. and Auerbach, John and Chou, Jih-Haw and Teng, Ju-Hsiu and Tu, Pikuei and Mullen, Jewel},
  doi = {10.3201/eid2607.200574},
  abstract = {Because of its proximity to and frequent travelers to and from China, Taiwan faces complex challenges in preventing coronavirus disease (COVID-19). As...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KQ8QT2ZM\\Lin et al. - Policy Decisions and Use of Information Technology.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\SDSTWZXJ\\20-0574_article.html}
}

@article{liPostpandemicTestingSARSCoV22020,
  title = {Post-Pandemic Testing of {{SARS-CoV-2}} in {{Huanan Seafood Market}} Area in {{Wuhan}}, {{China}}},
  author = {Li, Jingwen and Wu, Chengbi and Zhang, Xing and Chen, Lan and Wang, Xinyi and Guan, Xiuli and Li, Jinghong and Lin, Zhicheng and Xiong, Nian},
  year = {2020},
  month = jul,
  journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  issn = {1537-6591},
  doi = {10.1093/cid/ciaa1043},
  abstract = {76 days after the COVID-19 epidemic was contained in Wuhan, the Chinese government carried out a citywide SARS-CoV-2 nucleic acid testing for all the residents from May 14th to June 1st, 2020. Our hospital tested 107,662 residents around Huanan Seafood Market, uncovering a positivity rate of 0.006\%.},
  langid = {english},
  pmcid = {PMC7454404},
  pmid = {32710746},
  keywords = {asymptomatic,COVID-19,Huanan Seafood Market,infectious},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UGAMANWI\\Li et al. - 2020 - Post-pandemic testing of SARS-CoV-2 in Huanan Seaf.pdf}
}

@article{liReviewChangepointDetection2019,
  title = {A {{Review}} of {{Changepoint Detection Models}}},
  author = {Li, Yixiao and Lin, Gloria and Lau, Thomas and Zeng, Ruochen},
  year = {2019},
  month = aug,
  journal = {arXiv:1908.07136 [cs, q-fin, stat]},
  eprint = {1908.07136},
  eprinttype = {arxiv},
  primaryclass = {cs, q-fin, stat},
  abstract = {The objective of the change-point detection is to discover the abrupt property changes lying behind the time-series data. In this paper, we firstly summarize the definition and in-depth implication of the changepoint detection. The next stage is to elaborate traditional and some alternative model-based changepoint detection algorithms. Finally, we try to go a bit further in the theory and look into future research directions.},
  archiveprefix = {arXiv},
  keywords = {Computer Science - Machine Learning,Quantitative Finance - Trading and Market Microstructure,Statistics - Machine Learning},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JQHZYALW\\Li et al. - 2019 - A Review of Changepoint Detection Models.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\48AJJZHQ\\1908.html}
}

@incollection{ListSymbols2017,
  title = {List of {{Symbols}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {407--408},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.symbols},
  abstract = {No Abstract.},
  isbn = {978-1-118-63198-0},
  langid = {english},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.symbols},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8AKPWHQH\\2017 - List of Symbols.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZIB47B98\\9781118631980.html}
}

@article{liTemporalAssociationIntroducing2020,
  title = {The Temporal Association of Introducing and Lifting Non-Pharmaceutical Interventions with the Time-Varying Reproduction Number ({{R}}) of {{SARS-CoV-2}}: A Modelling Study across 131 Countries},
  shorttitle = {The Temporal Association of Introducing and Lifting Non-Pharmaceutical Interventions with the Time-Varying Reproduction Number ({{R}}) of {{SARS-CoV-2}}},
  author = {Li, You and Campbell, Harry and Kulkarni, Durga and Harpur, Alice and Nundy, Madhurima and Wang, Xin and Nair, Harish},
  year = {2020},
  month = oct,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30785-4},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Non-pharmaceutical interventions (NPIs) were implemented by many countries to reduce the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19. A resurgence in COVID-19 cases has been reported in some countries that lifted some of these NPIs. We aimed to understand the association of introducing and lifting NPIs with the level of transmission of SARS-CoV-2, as measured by the time-varying reproduction number (\emph{R}), from a broad perspective across 131 countries.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}In this modelling study, we linked data on daily country-level estimates of \emph{R} from the London School of Hygiene \& Tropical Medicine (London, UK) with data on country-specific policies on NPIs from the Oxford COVID-19 Government Response Tracker, available between Jan 1 and July 20, 2020. We defined a phase as a time period when all NPIs remained the same, and we divided the timeline of each country into individual phases based on the status of NPIs. We calculated the \emph{R} ratio as the ratio between the daily \emph{R} of each phase and the \emph{R} from the last day of the previous phase (ie, before the NPI status changed) as a measure of the association between NPI status and transmission of SARS-CoV-2. We then modelled the \emph{R} ratio using a log-linear regression with introduction and relaxation of each NPI as independent variables for each day of the first 28 days after the change in the corresponding NPI. In an ad-hoc analysis, we estimated the effect of reintroducing multiple NPIs with the greatest effects, and in the observed sequence, to tackle the possible resurgence of SARS-CoV-2.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}790 phases from 131 countries were included in the analysis. A decreasing trend over time in the \emph{R} ratio was found following the introduction of school closure, workplace closure, public events ban, requirements to stay at home, and internal movement limits; the reduction in \emph{R} ranged from 3\% to 24\% on day 28 following the introduction compared with the last day before introduction, although the reduction was significant only for public events ban (\emph{R} ratio 0{$\cdot$}76, 95\% CI 0{$\cdot$}58\textendash 1{$\cdot$}00); for all other NPIs, the upper bound of the 95\% CI was above 1. An increasing trend over time in the \emph{R} ratio was found following the relaxation of school closure, bans on public events, bans on public gatherings of more than ten people, requirements to stay at home, and internal movement limits; the increase in \emph{R} ranged from 11\% to 25\% on day 28 following the relaxation compared with the last day before relaxation, although the increase was significant only for school reopening (\emph{R} ratio 1{$\cdot$}24, 95\% CI 1{$\cdot$}00\textendash 1{$\cdot$}52) and lifting bans on public gatherings of more than ten people (1{$\cdot$}25, 1{$\cdot$}03\textendash 1{$\cdot$}51); for all other NPIs, the lower bound of the 95\% CI was below 1. It took a median of 8 days (IQR 6\textendash 9) following the introduction of an NPI to observe 60\% of the maximum reduction in \emph{R} and even longer (17 days [14\textendash 20]) following relaxation to observe 60\% of the maximum increase in \emph{R}. In response to a possible resurgence of COVID-19, a control strategy of banning public events and public gatherings of more than ten people was estimated to reduce \emph{R}, with an \emph{R} ratio of 0{$\cdot$}71 (95\% CI 0{$\cdot$}55\textendash 0{$\cdot$}93) on day 28, decreasing to 0{$\cdot$}62 (0{$\cdot$}47\textendash 0{$\cdot$}82) on day 28 if measures to close workplaces were added, 0{$\cdot$}58 (0{$\cdot$}41\textendash 0{$\cdot$}81) if measures to close workplaces and internal movement restrictions were added, and 0{$\cdot$}48 (0{$\cdot$}32\textendash 0{$\cdot$}71) if measures to close workplaces, internal movement restrictions, and requirements to stay at home were added.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Individual NPIs, including school closure, workplace closure, public events ban, ban on gatherings of more than ten people, requirements to stay at home, and internal movement limits, are associated with reduced transmission of SARS-CoV-2, but the effect of introducing and lifting these NPIs is delayed by 1\textendash 3 weeks, with this delay being longer when lifting NPIs. These findings provide additional evidence that can inform policy-maker decisions on the timing of introducing and lifting different NPIs, although \emph{R} should be interpreted in the context of its known limitations.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Wellcome Trust Institutional Strategic Support Fund and Data-Driven Innovation initiative.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QLIJL35T\\Li et al. - 2020 - The temporal association of introducing and liftin.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\F5VU527X\\fulltext.html}
}

@article{littleReducingRisksCoronavirus2020,
  title = {Reducing Risks from Coronavirus Transmission in the Home\textemdash the Role of Viral Load},
  author = {Little, Paul and Read, Robert C. and Aml{\^o}t, Richard and Chadborn, Tim and Rice, Cathy and Bostock, Jennifer and Yardley, Lucy},
  year = {2020},
  month = may,
  journal = {BMJ},
  volume = {369},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.m1728},
  abstract = {{$<$}p{$>$}\textbf{Paul Little and colleagues} call for better promotion of simple measures that can help reduce the spread and severity of infection among those living with people who have covid-19 {$<$}/p{$>$}},
  chapter = {Analysis},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},
  langid = {english},
  pmid = {32376669},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CVIFE47X\\Little et al. - 2020 - Reducing risks from coronavirus transmission in th.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\AA599YVL\\bmj.html}
}

@article{liuAssessingGlobalTendency,
  title = {Assessing the {{Global Tendency}} of {{COVID-19 Outbreak}}},
  author = {Liu, Qinghe and Liu, Zhicheng and Zhu, Junkai and Zhu, Yuhao and Li, Deqiang and Gao, Zefei and Zhou, Liuling and Tang, Yuanbo and Zhang, Xiang and Yang, Junyan and Wang, Qiao},
  pages = {21},
  abstract = {COVID-19 is now widely spreading around the world as a global pandemic. In this report, we estimate the global tendency of COVID-19 and analyze the associated global epidemic risk, given that the status quo is continued without further measures being taken.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\C3E49HW4\\Liu et al. - Assessing the Global Tendency of COVID-19 Outbreak.pdf}
}

@techreport{liuSafetyImmunogenicityReport2021,
  type = {{{SSRN Scholarly Paper}}},
  title = {Safety and {{Immunogenicity Report}} from the {{Com-COV Study}} \textendash{} a {{Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules}} with {{An Adenoviral Vectored}} and {{mRNA COVID-19 Vaccine}}},
  author = {Liu, Xinxue and Shaw, Robert H. and Stuart, Arabella SV and Greenland, Melanie and Dinesh, Tanya and {Provstgaard-Morys}, Samuel and Clutterbuck, Elizabeth and Ramasamy, Maheshi N. and Aley, Parvinder K. and Farooq Mujadidi, Yama and Long, Fei and Plested, Emma and Robinson, Hannah and Singh, Nisha and Walker, Laura L. and White, Rachel and Andrews, Nick and Cameron, J. Claire and Collins, Andrea M. and Ferreira, Daniela M. and Hill, Helen C. and Green, Christopher A. and Hallis, Bassam and Heath, Paul T. and Faust, Saul N. and Finn, Adam and Lambe, Teresa and Lazarus, Rajeka and Libri, Vincenzo and Ramsay, Mary E. and Read, Robert C. and Turner, David P. J. and Turner, Paul J. and {Nguyen-Van-Tam}, Jonathan S. and Snape, Matthew D. and Group, Com-COV Study},
  year = {2021},
  month = jun,
  number = {ID 3874014},
  address = {{Rochester, NY}},
  institution = {{Social Science Research Network}},
  doi = {10.2139/ssrn.3874014},
  abstract = {Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation, however we have previously reported that heterologous schedules incorporating an adenoviral-vectored vaccine (ChAd, Vaxzevria, Astrazeneca) and an mRNA vaccine (BNT, Comirnaty, Pfizer) at a 4-week interval are more reactogenic than homologous schedules. Here we report the immunogenicity of these schedules.~Methods: Com-COV (ISRCTN: 69254139, EudraCT: 2020-005085-33) is a participant-blind, non-inferiority trial evaluating vaccine reactogenicity and immunogenicity. Adults {$\geq$} 50 years, including those with well-controlled comorbidities, were randomised across eight groups to receive ChAd/ChAd, ChAd/BNT, BNT/BNT or BNT/ChAd, administered at 28- or 84-day intervals.The primary endpoint is geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG levels (ELISA) at one-month post boost between heterologous and homologous schedules given the same prime vaccine. We tested non-inferiority of GMR using a margin of 0.63. The primary analysis was on a per-protocol population, who were seronegative at baseline. Safety analyses were performed amongst participants receiving at least one dose of study vaccines.Findings: In February 2021, 830 participants were enrolled and randomised, including 463 with a 28-day prime-boost interval whose results are reported in this paper. Participant mean age was 57.8 years, 45.8\% were female, and 25.3\% from ethnic minorities.The geometric mean concentration (GMC) of day 28 post-boost SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients (12,906 ELU/ml) was non-inferior to that in ChAd/ChAd recipients (1,392 ELU/ml) with a geometric mean ratio (GMR) of 9.2 (one-sided 97.5\% CI: 7.5, {$\infty$}). In participants primed with BNT, we failed to show non-inferiority of the heterologous schedule (BNT/ChAd, GMC 7,133 ELU/ml) against the homologous schedule (BNT/BNT, GMC 14,080 ELU/ml) with a GMR of 0.51 (one-sided 97.5\% CI: 0.43, {$\infty$}). Geometric mean of T cell response at 28 days post boost in the ChAd/BNT group was 185 SFC/106  PBMCs (spot forming cells/106 peripheral blood mononuclear cells) compared to 50, 80 and 99 SFC/106 PBMCs for ChAd/ChAd, BNT/BNT, and BNT/ChAd, respectively. There were four serious adverse events across all groups, none of which were considered related to immunisation.Interpretation: Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the GMCs of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation. These data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.Trial Registration: The trial is registered at  www.isrctn.com as ISRCTN: 69254139.Funding: Funded by the UK Vaccine Task Force (VTF) and National Institute for Health Research (NIHR)Declaration of Interest: MDS acts on behalf of the University of Oxford as an Investigator on studies funded or sponsored by vaccine manufacturers including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM vaccines. He receives no personal financial payment for this work. JSN-V-T is seconded to the Department of Health and Social Care, England. AMC and DMF are investigators on studies funded by Pfizer and Unilever. They receive no personal financial payment for this work. AF is a member of the Joint Committee on Vaccination and Immunisation and Chair of the WHO European Technical Advisory Group of Experts (ETAGE) on Immunisation. He is an investigator and/or provides consultative advice on clinical trials and studies of COVID-19 vaccines produced by AstraZeneca, Janssen, Valneva, Pfizer and Sanofi and of other vaccines from these and other manufacturers including GSK, VPI, Takeda and Bionet Asia. He receives no personal remuneration or benefits for any of this work. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an Investigator and/or providing consultative advice on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck and Valneva vaccines and antimicrobials. He receives no personal financial payment for this work. PTH acts on behalf of St. George's University of London as an Investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, Novavax and Valneva. He receives no personal financial payment for this work. CAG acts on behalf of University Hospitals Birmingham NHS Foundation Trust as an Investigator on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, Novavax, CureVac, Moderna, and Valneva vaccines, and receives no personal financial payment for this work. VL acts on behalf of University College London Hospitals NHS Foundation Trust as an Investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers including Pfizer, AstraZeneca and Valneva. He receives no personal financial payment for this work. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and is an occasional consultant to Vaccitech unrelated to this work. Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19Ethical Approval: The trial was reviewed and approved by the South-Central Berkshire Research Ethics Committee (21/SC/0022), the University of Oxford, and the Medicines and Healthcare Products Regulatory Agency MHRA). An independent data safety monitoring board (DSMB) reviewed safety data, and local trial- site physicians provided oversight of all adverse events in real-time.},
  langid = {english},
  keywords = {Adam Finn,Andrea  M. Collins,Arabella  SV Stuart,Bassam Hallis,Christopher  A. Green,Com-COV Study Group,Daniela  M. Ferreira,David  P. J. Turner,Elizabeth Clutterbuck,Emma Plested,Fei Long,Hannah Robinson,Helen  C. Hill,J. Claire Cameron,Jonathan  S. Nguyen-Van-Tam,Laura  L. Walker,Maheshi  N. Ramasamy,Mary E. Ramsay,Matthew  D. Snape,Melanie Greenland,Nick Andrews,Nisha Singh,Parvinder  K. Aley,Paul  J. Turner,Paul  T. Heath,Rachel White,Rajeka Lazarus,Robert  C. Read,Robert  H. Shaw,Safety and Immunogenicity Report from the Com-COV Study  a Single-Blind RandomisedNon-InferiorityTrialComparingHeterologousAnd HomologousPrime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine,Samuel Provstgaard-Morys,Saul N. Faust,SSRN,Tanya Dinesh,Teresa Lambe,Vincenzo Libri,Xinxue Liu,Yama Farooq Mujadidi},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8IZGUMF9\\papers.html}
}

@misc{LongitudinalAssessmentDiagnostic,
  title = {Longitudinal Assessment of Diagnostic Test Performance over the Course of Acute {{SARS-CoV-2}} Infection | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2021.03.19.21253964v1.article-metrics}
}

@misc{LongitudinalMonitoringSARSCoV2,
  title = {Longitudinal Monitoring of {{SARS-CoV-2 RNA}} on High-Touch Surfaces in a Community Setting | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.10.27.20220905v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CYTBHG7Y\\2020.10.27.html}
}

@article{lopezTransmissionDynamicsCOVID192020,
  title = {Transmission {{Dynamics}} of {{COVID-19 Outbreaks Associated}} with {{Child Care Facilities}} \textemdash{} {{Salt Lake City}}, {{Utah}}, {{April}}\textendash{{July}} 2020},
  author = {Lopez, Adriana S.},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6937e3},
  abstract = {Reports suggest that children aged {$\geq$}10 years can efficiently transmit SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XX2FHB4W\\mm6937e3.html}
}

@article{LossSARSCoV2Antibodies2020,
  title = {Loss of {{Anti}}\textendash{{SARS-CoV-2 Antibodies}} in {{Mild Covid-19}}},
  year = {2020},
  month = sep,
  journal = {New England Journal of Medicine},
  volume = {0},
  number = {0},
  pages = {null},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMc2027051},
  abstract = {To the Editor: The results reported in the letter by Ibarrondo et al. (Sept. 10)1 regarding the rapid decay of anti\textendash severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in patients who had recovered from Covid-19 are in contrast to our findings and those of other research groups, such as Wang et al. from China.2 In their study, Wang et al. showed that IgG responses were detected in most patients with either severe disease or mild disease at 9 days after the onset of infection, and the IgG levels remained high throughout the study (35 to 40 days). These findings are . . .},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMc2027051},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3DQ2K9Z5\\2020 - Loss of AntiSARS-CoV-2 Antibodies in Mild Covid-1.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\PTQJGJ8G\\NEJMc2027051.html}
}

@article{lubinEvolutionSARSCoV2Proteome,
  title = {Evolution of the {{SARS-CoV-2}} Proteome in Three Dimensions ({{3D}}) during the First Six Months of the {{COVID-19}} Pandemic},
  author = {Lubin, Joseph},
  pages = {64},
  abstract = {Three-dimensional structures of SARS-CoV-2 and other coronaviral proteins archived in the Protein Data Bank were used to analyze viral proteome evolution during the first six months of the COVID-19 pandemic. Analyses of spatial locations, chemical properties, and structural and energetic impacts of the observed amino acid changes in {$>$}48,000 viral proteome sequences showed how each one of the 29 viral study proteins have undergone amino acid changes. Structural models computed for every unique sequence variant revealed that most substitutions map to protein surfaces and boundary layers with a minority affecting hydrophobic cores. Conservative changes were observed more frequently in cores versus boundary layers/surfaces. Active sites and protein-protein interfaces showed modest numbers of substitutions. Energetics calculations showed that the impact of substitutions on the thermodynamic stability of the proteome follows a universal bi-Gaussian distribution. Detailed results are presented for six drug discovery targets and four structural proteins comprising the virion, highlighting substitutions with the potential to impact protein structure, enzyme activity, and functional interfaces. Characterizing the evolution of the virus in three dimensions provides testable insights into viral protein function and should aid in structure-based drug discovery efforts as well as the prospective identification of amino acid substitutions with potential for drug resistance.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3ARBY7PQ\\Lubin - Evolution of the SARS-CoV-2 proteome in three dime.pdf}
}

@article{luEarlyReleaseCOVID19,
  title = {Early {{Release}} - {{COVID-19 Outbreak Associated}} with {{Air Conditioning}} in {{Restaurant}}, {{Guangzhou}}, {{China}}, 2020 - {{Volume}} 26, {{Number}} 7\textemdash{{July}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Lu, Jianyun and Gu, Jieni and Li, Kuibiao and Xu, Conghui and Su, Wenzhe and Lai, Zhisheng and Zhou, Deqian and Yu, Chao and Xu, Bin and Yang, Zhicong},
  doi = {10.3201/eid2607.200764},
  abstract = {During January 26\textendash February 10, 2020, an outbreak of 2019 novel coronavirus disease in an air-conditioned restaurant in Guangzhou, China, involved 3 fa...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JG27LUYE\\20-0764_article.html}
}

@article{lyngseCOVID19TransmissionDanish2020,
  title = {{{COVID-19 Transmission Within Danish Households}}: {{A Nationwide Study}} from {{Lockdown}} to {{Reopening}}},
  shorttitle = {{{COVID-19 Transmission Within Danish Households}}},
  author = {Lyngse, Frederik Plesner and Kirkeby, Carsten Thure and Halasa, Tariq and Andreasen, Viggo and Skov, Robert Leo and M{\o}ller, Frederik Trier and Krause, Tyra Grove and M{\o}lbak, K{\aa}re},
  year = {2020},
  month = sep,
  journal = {medRxiv},
  pages = {2020.09.09.20191239},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.09.09.20191239},
  abstract = {{$<$}p{$>$}\textbf{Background} The Covid-19 pandemic is one of the most serious global public health threats in recent times. Understanding transmission of SARS-CoV-2 is of utmost importance to be able to respond to outbreaks and take action against spread of the disease. Transmission within the household is a concern, especially because infection control is difficult to apply within the household domain. \textbf{Methods} We used comprehensive administrative register data from Denmark, comprising the full population and all COVID-19 tests, to estimate household transmission risk and attack rate. \textbf{Results} We studied the testing dynamics for COVID-19 and found that the day after receiving a positive test result within the household, 35\% of potential secondary cases were tested and 13\% of these were positive. After a primary case in 6,782 households, 82\% of potential secondary cases were tested within 14 days, of which 17\% tested positive as secondary cases, implying an attack rate of 17\%. Among primary cases, those aged 0-24 were underrepresented when compared with the total population. We found an approximately linearly increasing relationship between attack rate and age. We investigated the transmission risk from primary cases by age, and found an increasing risk with age of primary cases for adults, while the risk seems to decrease with age for children. \textbf{Conclusions} Although there is an increasing attack rate and transmission risk of SARS-CoV-2 with age, children are also able to transmit SARS-CoV-2 within the household.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LEHUV5TC\\Lyngse et al. - 2020 - COVID-19 Transmission Within Danish Households A .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\JR2XHIKE\\2020.09.09.html}
}

@article{lyngseSARSCoV2OmicronVOC,
  title = {{{SARS-CoV-2 Omicron VOC Transmission}} in {{Danish Households}}},
  author = {Lyngse, Frederik Plesner and Mortensen, Laust Hvas and Denwood, Matthew J and Christiansen, Lasse Engbo and M{\o}ller, Camilla Holten and Skov, Robert Leo and Spiess, Katja and Fomsgaard, Anders and Lassauni{\`e}re, Maria Magdalena and Rasmussen, Morten and Stegger, Marc and Nielsen, Claus and Sieber, Raphael Niklaus and Cohen, Arieh Sierra and M{\o}ller, Frederik Trier and Overvad, Maria and M{\o}lbak, K{\aa}re and Krause, Tyra Grove and Kirkeby, Carsten Thure},
  pages = {31},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\T2SGJNMJ\\Lyngse et al. - SARS-CoV-2 Omicron VOC Transmission in Danish Hous.pdf}
}

@misc{lyngseSARSCoV2OmicronVOC2021,
  title = {{{SARS-CoV-2 Omicron VOC Transmission}} in {{Danish Households}}},
  author = {Lyngse, Frederik Plesner and Mortensen, Laust Hvas and Denwood, Matthew J. and Christiansen, Lasse Engbo and M{\o}ller, Camilla Holten and Skov, Robert Leo and Spiess, Katja and Fomsgaard, Anders and Lassauniere, Ria and Rasmussen, Morten and Stegger, Marc and Nielsen, Claus and Sieber, Raphael Niklaus and Cohen, Arieh Sierra and M{\o}ller, Frederik Trier and Overvad, Maria and M{\o}lbak, K{\aa}re and Krause, Tyra Grove and Kirkeby, Carsten Thure},
  year = {2021},
  month = dec,
  pages = {2021.12.27.21268278},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.12.27.21268278},
  abstract = {The Omicron variant of concern (VOC) is a rapidly spreading variant of SARS-CoV-2 that is likely to overtake the previously dominant Delta VOC in many countries by the end of 2021. We estimated the transmission dynamics following the spread of Omicron VOC within Danish households during December 2021. We used data from Danish registers to estimate the household secondary attack rate (SAR). Among 11,937 households (2,225 with the Omicron VOC), we identified 6,397 secondary infections during a 1-7 day follow-up period. The SAR was 31\textbackslash\% and 21\textbackslash\% in households with the Omicron and Delta VOC, respectively. We found an increased transmission for unvaccinated individuals, and a reduced transmission for booster-vaccinated individuals, compared to fully vaccinated individuals. Comparing households infected with the Omicron to Delta VOC, we found an 1.17 (95\textbackslash\%-CI: 0.99-1.38) times higher SAR for unvaccinated, 2.61 times (95\textbackslash\%-CI: 2.34-2.90) higher for fully vaccinated and 3.66 (95\textbackslash\%-CI: 2.65-5.05) times higher for booster-vaccinated individuals, demonstrating strong evidence of immune evasiveness of the Omicron VOC. Our findings confirm that the rapid spread of the Omicron VOC primarily can be ascribed to the immune evasiveness rather than an inherent increase in the basic transmissibility.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RBVT2H4I\\Lyngse et al. - 2021 - SARS-CoV-2 Omicron VOC Transmission in Danish Hous.pdf}
}

@techreport{madewellHouseholdTransmissionSARSCoV22020,
  type = {Preprint},
  title = {Household Transmission of {{SARS-CoV-2}}: A Systematic Review and Meta-Analysis of Secondary Attack Rate},
  shorttitle = {Household Transmission of {{SARS-CoV-2}}},
  author = {Madewell, Zachary J. and Yang, Yang and Longini, Ira M. and Halloran, M. Elizabeth and Dean, Natalie E.},
  year = {2020},
  month = aug,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2020.07.29.20164590},
  abstract = {Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spread by direct, indirect, or close contact with infected people via infected respiratory droplets or saliva. Crowded indoor environments with sustained close contact and conversations are a particularly high-risk setting. Methods: We performed a meta-analysis through July 29, 2020 of SARS-CoV-2 household secondary attack rate (SAR), disaggregating by several covariates (contact type, symptom status, adult/child contacts, contact sex, relationship to index case, index case sex, number of contacts in household, coronavirus).},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q82U7T42\\Madewell et al. - 2020 - Household transmission of SARS-CoV-2 a systematic.pdf}
}

@article{madewellHouseholdTransmissionSARSCoV22020a,
  title = {Household Transmission of {{SARS-CoV-2}}: A Systematic Review and Meta-Analysis of Secondary Attack Rate},
  shorttitle = {Household Transmission of {{SARS-CoV-2}}},
  author = {Madewell, Zachary J. and Yang, Yang and Longini, Ira M. and Halloran, M. Elizabeth and Dean, Natalie E.},
  year = {2020},
  month = aug,
  journal = {medRxiv},
  pages = {2020.07.29.20164590},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.07.29.20164590},
  abstract = {{$<$}p{$>$}Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spread by direct, indirect, or close contact with infected people via infected respiratory droplets or saliva. Crowded indoor environments with sustained close contact and conversations are a particularly high-risk setting. Methods: We performed a meta-analysis through July 29, 2020 of SARS-CoV-2 household secondary attack rate (SAR), disaggregating by several covariates (contact type, symptom status, adult/child contacts, contact sex, relationship to index case, index case sex, number of contacts in household, coronavirus). Findings: We identified 40 relevant published studies that report household secondary transmission. The estimated overall household SAR was 18.8\% (95\% confidence interval [CI]: 15.4\%-22.2\%), which is higher than previously observed SARs for SARS-CoV and MERS-CoV. We observed that household SARs were significantly higher from symptomatic index cases than asymptomatic index cases, to adult contacts than children contacts, to spouses than other family contacts, and in households with one contact than households with three or more contacts. Interpretation: To prevent the spread of SARS-CoV-2, people are being asked to stay at home worldwide. With suspected or confirmed infections referred to isolate at home, household transmission will continue to be a significant source of transmission.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TU7TT9NT\\Madewell et al. - 2020 - Household transmission of SARS-CoV-2 a systematic.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7433FH7G\\2020.07.29.html}
}

@article{makEvaluationRapidAntigen2020,
  title = {Evaluation of Rapid Antigen Test for Detection of {{SARS-CoV-2}} Virus},
  author = {Mak, Gannon CK and Cheng, Peter KC and Lau, Stephen SY and Wong, Kitty KY and Lau, Cs and Lam, Edman TK and Chan, Rickjason CW and Tsang, Dominic NC},
  year = {2020},
  month = aug,
  journal = {Journal of Clinical Virology},
  volume = {129},
  pages = {104500},
  issn = {13866532},
  doi = {10.1016/j.jcv.2020.104500},
  abstract = {Background: The rapid diagnosis of Coronavirus Disease 2019 (COVID-19) patients is essential to reduce the disease spread. Rapid antigen detection (RAD) tests are available, however, there is scanty data on the performance of RAD tests. Objective: To evaluate the performance of the commercially available BIOCREDIT COVID-19 Ag test and compare it with RT-PCR for detecting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Analytical sensitivity for the detection of SARS-CoV-2 virus was determined for the RAD test using viral culture and RT-PCR as reference methods. The RAD test was further evaluated using respiratory samples collected from confirmed COVID-19 patients. The results were compared with RT-PCR test. Results: The detection limits between RAD test, viral culture and RT-PCR varied hugely. RAD was 103 fold less sensitive than viral culture while RAD was 105 fold less sensitive than RT-PCR. The RAD test detected between 11.1 \% and 45.7 \% of RT-PCR-positive samples from COVID-19 patients. Conclusions: This study demonstrated that the RAD test serves only as adjunct to RT-PCR test because of potential for false-negative results.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ADNU3CAL\\Mak et al. - 2020 - Evaluation of rapid antigen test for detection of .pdf}
}

@article{mallapatyHowChildrenSpread2020,
  title = {How Do Children Spread the Coronavirus? {{The}} Science Still Isn't Clear},
  shorttitle = {How Do Children Spread the Coronavirus?},
  author = {Mallapaty, Smriti},
  year = {2020},
  month = may,
  journal = {Nature},
  publisher = {{Nature Publishing Group}},
  doi = {10.1038/d41586-020-01354-0},
  abstract = {Schools are beginning to reopen \textemdash{} but scientists are still trying to understand what the deal is with kids and COVID-19.},
  copyright = {2020 Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GSK6KIYL\\d41586-020-01354-0.html}
}

@article{mallapatyMathematicalStrategyThat2020,
  title = {The Mathematical Strategy That Could Transform Coronavirus Testing},
  author = {Mallapaty, Smriti},
  year = {2020},
  month = jul,
  journal = {Nature},
  publisher = {{Nature Publishing Group}},
  doi = {10.1038/d41586-020-02053-6},
  abstract = {Four charts show how pooling samples from many people can save time or resources.},
  copyright = {2020 Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ACJEND6S\\d41586-020-02053-6.html}
}

@techreport{maraisSalivaSwabsAre2021,
  type = {Preprint},
  title = {Saliva Swabs Are the Preferred Sample for {{Omicron}} Detection},
  author = {Marais, Gert and Hsiao, Nei-yuan and Iranzadeh, Arash and Doolabh, Deelan and Enoch, Annabel and Chu, Chun-yat and Williamson, Carolyn and Brink, Adrian and Hardie, Diana},
  year = {2021},
  month = dec,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2021.12.22.21268246},
  abstract = {Abstract           The Omicron variant is characterised by more than 50 distinct mutations, the majority of which are located in the spike protein. The implications of these mutations for disease transmission, tissue tropism and diagnostic testing are still to be determined. We evaluated the relative performance of saliva and mid-turbinate swabs as RT-PCR samples for the Delta and Omicron variants. The positive percent agreement (PPA) of saliva swabs and mid-turbinate swabs to a composite standard was 71\% (95\% CI: 53-84\%) and 100\% (95\% CI: 89-100\%), respectively, for the Delta variant. However, for the Omicron variant saliva and mid-turbinate swabs had a 100\% (95\% CI: 90-100\%) and 86\% (95\% CI: 71-94\%) PPA, respectively. This finding supports ex-vivo data of altered tissue tropism from other labs for the Omicron variant. Reassessment of the diagnostic testing standard-of-care may be required as the Omicron variant become the dominant variant worldwide.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q9C7NGAX\\Marais et al. - 2021 - Saliva swabs are the preferred sample for Omicron .pdf}
}

@article{markelNonpharmaceuticalInterventionsImplemented2007,
  title = {Nonpharmaceutical {{Interventions Implemented}} by {{US Cities During}} the 1918-1919 {{Influenza Pandemic}}},
  author = {Markel, Howard and Lipman, Harvey B. and Navarro, J. Alexander and Sloan, Alexandra and Michalsen, Joseph R. and Stern, Alexandra Minna and Cetron, Martin S.},
  year = {2007},
  month = aug,
  journal = {JAMA},
  volume = {298},
  number = {6},
  pages = {644--654},
  publisher = {{American Medical Association}},
  issn = {0098-7484},
  doi = {10.1001/jama.298.6.644},
  abstract = {ContextA critical question in pandemic influenza planning is the role nonpharmaceutical interventions might play in delaying the temporal effects of a pandemic, reducing the overall and peak attack rate, and reducing the number of cumulative deaths. Such measures could potentially provide valuable time for pandemic-strain vaccine and antiviral medication production and distribution. Optimally, appropriate implementation of nonpharmaceutical interventions would decrease the burden on health care services and critical infrastructure.ObjectivesTo examine the implementation of nonpharmaceutical interventions for epidemic mitigation in 43 cities in the continental United States from September 8, 1918, through February 22, 1919, and to determine whether city-to-city variation in mortality was associated with the timing, duration, and combination of nonpharmaceutical interventions; altered population susceptibility associated with prior pandemic waves; age and sex distribution; and population size and density.Design and SettingHistorical archival research, and statistical and epidemiological analyses. Nonpharmaceutical interventions were grouped into 3 major categories: school closure; cancellation of public gatherings; and isolation and quarantine.Main Outcome MeasuresWeekly excess death rate (EDR); time from the activation of nonpharmaceutical interventions to the first peak EDR; the first peak weekly EDR; and cumulative EDR during the entire 24-week study period.ResultsThere were 115 340 excess pneumonia and influenza deaths (EDR, 500/100 000 population) in the 43 cities during the 24 weeks analyzed. Every city adopted at least 1 of the 3 major categories of nonpharmaceutical interventions. School closure and public gathering bans activated concurrently represented the most common combination implemented in 34 cities (79\%); this combination had a median duration of 4 weeks (range, 1-10 weeks) and was significantly associated with reductions in weekly EDR. The cities that implemented nonpharmaceutical interventions earlier had greater delays in reaching peak mortality (Spearman r = -0.74, P \&lt; .001), lower peak mortality rates (Spearman r = 0.31, P = .02), and lower total mortality (Spearman r = 0.37, P = .008). There was a statistically significant association between increased duration of nonpharmaceutical interventions and a reduced total mortality burden (Spearman r = -0.39, P = .005).ConclusionsThese findings demonstrate a strong association between early, sustained, and layered application of nonpharmaceutical interventions and mitigating the consequences of the 1918-1919 influenza pandemic in the United States. In planning for future severe influenza pandemics, nonpharmaceutical interventions should be considered for inclusion as companion measures to developing effective vaccines and medications for prophylaxis and treatment.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4GVI2EHJ\\Markel et al. - 2007 - Nonpharmaceutical Interventions Implemented by US .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3VQSYC7Q\\208354.html}
}

@incollection{MarkovChainMonte2017,
  title = {Markov {{Chain Monte Carlo}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {187--220},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch6},
  abstract = {This chapter presents a powerful generic method, called Markov chain Monte Carlo (MCMC), for approximately generating samples from an arbitrary distribution. The prominent MCMC algorithms are the Metropolis\textendash Hastings and the Gibbs samplers, the latter being particularly useful in Bayesian analysis. Finally, MCMC sampling is the main ingredient in the popular simulated annealing technique for discrete and continuous optimization. The main idea behind the Metropolis\textendash Hastings algorithm is to simulate a Markov chain such that the stationary distribution of this chain coincides with the target distribution. The estimates obtained via MCMC samples often tend to have much greater variances than those obtained from independent sampling of the target distribution. Hit-and-run is unique in that it only takes polynomial time to get out of a corner. The distinguishing feature of the Gibbs sampler is that the underlying Markov chain is constructed, in a deterministic or random fashion, from a sequence of conditional distributions.},
  chapter = {6},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {Bayesian analysis,Markov chain Monte Carlo (MCMC),MetropolisHastings algorithm,simulated annealing technique,target distribution},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch6},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3LDDZTUY\\2017 - Markov Chain Monte Carlo.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q8L4YUY4\\9781118631980.html}
}

@book{martchevaIntroductionMathematicalEpidemiology2015,
  title = {An {{Introduction}} to {{Mathematical Epidemiology}}},
  author = {Martcheva, Maia},
  year = {2015},
  series = {Texts in {{Applied Mathematics}}},
  volume = {61},
  publisher = {{Springer US}},
  address = {{Boston, MA}},
  doi = {10.1007/978-1-4899-7612-3},
  isbn = {978-1-4899-7611-6 978-1-4899-7612-3},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CMGXWLTM\\Martcheva - 2015 - An Introduction to Mathematical Epidemiology.pdf}
}

@misc{may4Covid19EstimatesAustria,
  title = {Covid-19: {{Estimates}} for {{Austria}}},
  shorttitle = {Covid-19},
  author = {May 4, Authors Affiliations Published and Doi, 2020},
  journal = {Covid-19},
  abstract = {Identifying changes in the reproduction number, rate of spread, and doubling time during the course of the COVID-19 outbreak whilst accounting for potential biases due to delays in case reporting in Austria. These results are impacted by changes in testing effort, increases and decreases in testing effort will increase and decrease reproduction number estimates respectively (see Methods for further explanation).},
  howpublished = {https://epiforecasts.io/covid/posts/national/austria/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WABNWGT9\\austria.html}
}

@misc{may4Covid19GlobalSummary,
  title = {Covid-19: {{Global}} Summary},
  shorttitle = {Covid-19},
  author = {May 4, Authors Affiliations Published and Doi, 2020},
  journal = {Covid-19},
  abstract = {Identifying changes in the reproduction number, rate of spread, and doubling time during the course of the COVID-19 outbreak whilst accounting for potential biases due to delays in case reporting both nationally and subnationally. These results are impacted by changes in testing effort, increases and decreases in testing effort will increase and decrease reproduction number estimates respectively (see Methods for further explanation).},
  howpublished = {https://epiforecasts.io/covid/posts/global/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5DWN28ZT\\global.html}
}

@misc{MayaBuiltWestern,
  title = {The {{Maya}} Built the {{Western Hemisphere}}'s First Water Filtration System},
  abstract = {A reservoir in the ancient city of Tikal contains traces of zeolite, a volcanic mineral still used for filtration today},
  howpublished = {http://www.science.org/content/article/maya-built-western-hemisphere-s-first-water-filtration-system},
  langid = {english}
}

@article{mcruerPilotInducedOscillationsHuman,
  title = {Pilot-{{Induced Oscillations}} and {{Human Dynamic Behavior}}},
  author = {McRuer, T},
  pages = {106},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\44EYAUNE\\McRuer - Pilot-Induced Oscillations and Human Dynamic Behav.pdf}
}

@article{mcruerPilotInducedOscillationsHumana,
  title = {Pilot-{{Induced Oscillations}} and {{Human Dynamic Behavior}}},
  author = {McRuer, T},
  pages = {106},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PCL3Y5WF\\McRuer - Pilot-Induced Oscillations and Human Dynamic Behav.pdf}
}

@article{mehraHydroxychloroquineChloroquineMacrolide2020,
  title = {Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of {{COVID-19}}: A Multinational Registry Analysis},
  shorttitle = {Hydroxychloroquine or Chloroquine with or without a Macrolide for Treatment of {{COVID-19}}},
  author = {Mehra, Mandeep R. and Desai, Sapan S. and Ruschitzka, Frank and Patel, Amit N.},
  year = {2020},
  month = may,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)31180-6},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}96 032 patients (mean age 53{$\cdot$}8 years, 46{$\cdot$}3\% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11{$\cdot$}1\%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9{$\cdot$}3\%), hydroxychloroquine (18{$\cdot$}0\%; hazard ratio 1{$\cdot$}335, 95\% CI 1{$\cdot$}223\textendash 1{$\cdot$}457), hydroxychloroquine with a macrolide (23{$\cdot$}8\%; 1{$\cdot$}447, 1{$\cdot$}368\textendash 1{$\cdot$}531), chloroquine (16{$\cdot$}4\%; 1{$\cdot$}365, 1{$\cdot$}218\textendash 1{$\cdot$}531), and chloroquine with a macrolide (22{$\cdot$}2\%; 1{$\cdot$}368, 1{$\cdot$}273\textendash 1{$\cdot$}469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0{$\cdot$}3\%), hydroxychloroquine (6{$\cdot$}1\%; 2{$\cdot$}369, 1{$\cdot$}935\textendash 2{$\cdot$}900), hydroxychloroquine with a macrolide (8{$\cdot$}1\%; 5{$\cdot$}106, 4{$\cdot$}106\textendash 5{$\cdot$}983), chloroquine (4{$\cdot$}3\%; 3{$\cdot$}561, 2{$\cdot$}760\textendash 4{$\cdot$}596), and chloroquine with a macrolide (6{$\cdot$}5\%; 4{$\cdot$}011, 3{$\cdot$}344\textendash 4{$\cdot$}812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BPGHFBNH\\Mehra et al. - 2020 - Hydroxychloroquine or chloroquine with or without .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\NQZMNQMW\\fulltext.html}
}

@article{meloCOVID19relatedAnosmiaAssociated2021,
  title = {{{COVID-19-related}} Anosmia Is Associated with Viral Persistence and Inflammation in Human Olfactory Epithelium and Brain Infection in Hamsters},
  author = {de Melo, Guilherme Dias and Lazarini, Fran{\c c}oise and Levallois, Sylvain and Hautefort, Charlotte and Michel, Vincent and Larrous, Florence and Verillaud, Benjamin and Aparicio, Caroline and Wagner, Sebastien and Gheusi, Gilles and Kergoat, Lauriane and Kornobis, Etienne and Donati, Flora and Cokelaer, Thomas and Hervochon, R{\'e}mi and Madec, Yoann and Roze, Emmanuel and Salmon, Dominique and Bourhy, Herv{\'e} and Lecuit, Marc and Lledo, Pierre-Marie},
  year = {2021},
  month = may,
  journal = {Science Translational Medicine},
  publisher = {{American Association for the Advancement of Science}},
  issn = {1946-6234, 1946-6242},
  doi = {10.1126/scitranslmed.abf8396},
  abstract = {Whereas recent investigations have revealed viral, inflammatory and vascular factors involved in SARS-CoV-2 lung pathogenesis, the pathophysiology of neurological disorders in COVID-19 remains poorly understood. Olfactory and taste dysfunction are common in COVID-19, especially in mildly symptomatic patients. Here, we conducted a virologic, molecular, and cellular study of the olfactory neuroepithelium of seven patients with COVID-19 presenting with acute loss of smell. We report evidence that the olfactory neuroepithelium may be a major site of SARS-CoV2 infection with multiple cell types, including olfactory sensory neurons, support cells, and immune cells, becoming infected. SARS-CoV-2 replication in the olfactory neuroepithelium was associated with local inflammation. Furthermore, we showed that SARS-CoV-2 induced acute anosmia and ageusia in golden Syrian hamsters, lasting as long as the virus remained in the olfactory epithelium and the olfactory bulb. Finally, olfactory mucosa sampling from patients showing long-term persistence of COVID-19-associated anosmia revealed the presence of virus transcripts and of SARS-CoV-2-infected cells, together with protracted inflammation. SARS-CoV-2 persistence and associated inflammation in the olfactory neuroepithelium may account for prolonged or relapsing symptoms of COVID-19, such as loss of smell, which should be considered for optimal medical management of this disease. SARS-CoV-2 persists in the olfactory epithelium of hamsters and in individuals with COVID-19 for several months after infection. SARS-CoV-2 persists in the olfactory epithelium of hamsters and in individuals with COVID-19 for several months after infection.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2021, American Association for the Advancement of Science. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EENBSSMM\\scitranslmed.html}
}

@article{menniRealtimeTrackingSelfreported2020,
  title = {Real-Time Tracking of Self-Reported Symptoms to Predict Potential {{COVID-19}}},
  author = {Menni, Cristina and Valdes, Ana M. and Freidin, Maxim B. and Sudre, Carole H. and Nguyen, Long H. and Drew, David A. and Ganesh, Sajaysurya and Varsavsky, Thomas and Cardoso, M. Jorge and {El-Sayed Moustafa}, Julia S. and Visconti, Alessia and Hysi, Pirro and Bowyer, Ruth C. E. and Mangino, Massimo and Falchi, Mario and Wolf, Jonathan and Ourselin, Sebastien and Chan, Andrew T. and Steves, Claire J. and Spector, Tim D.},
  year = {2020},
  month = may,
  journal = {Nature Medicine},
  pages = {1--4},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0916-2},
  abstract = {A total of 2,618,862 participants reported their potential symptoms of COVID-19 on a smartphone-based app. Among the 18,401 who had undergone a SARS-CoV-2 test, the proportion of participants who reported loss of smell and taste was higher in those with a positive test result (4,668 of 7,178 individuals; 65.03\%) than in those with a negative test result (2,436 of 11,223 participants; 21.71\%) (odds ratio\,=\,6.74; 95\% confidence interval\,=\,6.31\textendash 7.21). A model combining symptoms to predict probable infection was applied to the data from all app users who reported symptoms (805,753) and predicted that 140,312 (17.42\%) participants are likely to have COVID-19.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HALI8N49\\Menni et al. - 2020 - Real-time tracking of self-reported symptoms to pr.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\J6BT2P3A\\s41591-020-0916-2.html}
}

@article{mercaldoConfidenceIntervalsPredictive2007,
  title = {Confidence Intervals for Predictive Values with an Emphasis to Case\textendash Control Studies},
  author = {Mercaldo, Nathaniel D. and Lau, Kit F. and Zhou, Xiao H.},
  year = {2007},
  journal = {Statistics in Medicine},
  volume = {26},
  number = {10},
  pages = {2170--2183},
  issn = {1097-0258},
  doi = {10.1002/sim.2677},
  abstract = {The accuracy of a binary-scale diagnostic test can be represented by sensitivity (Se), specificity (Sp) and positive and negative predictive values (PPV and NPV). Although Se and Sp measure the intrinsic accuracy of a diagnostic test that does not depend on the prevalence rate, they do not provide information on the diagnostic accuracy of a particular patient. To obtain this information we need to use PPV and NPV. Since PPV and NPV are functions of both the accuracy of the test and the prevalence of the disease, constructing their confidence intervals for a particular patient is not straightforward. In this paper, a novel method for the estimation of PPV and NPV, as well as their confidence intervals, is developed. For both predictive values, standard, adjusted and their logit transformed-based confidence intervals are compared using coverage probabilities and interval lengths in a simulation study. These methods are then applied to two case\textendash control studies: a diagnostic test assessing the ability of the e4 allele of the apolipoprotein E gene (ApoE.e4) on distinguishing patients with late-onset Alzheimer's disease (AD) and a prognostic test assessing the predictive ability of a 70-gene signature on breast cancer metastasis. Copyright \textcopyright{} 2006 John Wiley \& Sons, Ltd.},
  langid = {english},
  keywords = {Alzheimer's disease,breast cancer,confidence intervals,diagnostic tests,predictive values},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.2677},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2FGSJ28G\\Mercaldo et al. - 2007 - Confidence intervals for predictive values with an.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KYEW2NKV\\sim.html}
}

@article{mesleEstimatedNumberDeaths2021,
  title = {Estimated Number of Deaths Directly Averted in People 60 Years and Older as a Result of {{COVID-19}} Vaccination in the {{WHO European Region}}, {{December}} 2020 to {{November}} 2021},
  author = {Mesl{\'e}, Margaux MI and Brown, Jeremy and Mook, Piers and Hagan, Jos{\'e} and Pastore, Roberta and Bundle, Nick and Spiteri, Gianfranco and Ravasi, Giovanni and Nicolay, Nathalie and Andrews, Nick and Dykhanovska, Tetiana and Mossong, Jo{\"e}l and {Sadkowska-Todys}, Ma{\l}gorzata and Nikiforova, Raina and Riccardo, Flavia and Meijerink, Hinta and Mazagatos, Clara and Kyncl, Jan and McMenamin, Jim and Melillo, Tanya and Kaoustou, Stella and {L{\'e}vy-Bruhl}, Daniel and Haarhuis, Freek and Rich, Rivka and Kall, Meaghan and Nitzan, Dorit and Smallwood, Catherine and Pebody, Richard G.},
  year = {2021},
  month = nov,
  journal = {Eurosurveillance},
  volume = {26},
  number = {47},
  pages = {2101021},
  publisher = {{European Centre for Disease Prevention and Control}},
  issn = {1560-7917},
  doi = {10.2807/1560-7917.ES.2021.26.47.2101021},
  abstract = {Since December 2019, over 1.5 million SARS-CoV-2-related fatalities have been recorded in the World Health Organization European Region - 90.2\% in people {$\geq$} 60 years. We calculated lives saved in this age group by COVID-19 vaccination in 33 countries from December 2020 to November 2021, using weekly reported deaths and vaccination coverage. We estimated that vaccination averted 469,186 deaths (51\% of 911,302 expected deaths; sensitivity range: 129,851\textendash 733,744; 23\textendash 62\%). Impact by country ranged 6\textendash 93\%, largest when implementation was early.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\I4IMESPW\\1560-7917.ES.2021.26.47.html}
}

@techreport{meyerowitz-katzSystematicReviewMetaanalysis2020,
  type = {Preprint},
  title = {A Systematic Review and Meta-Analysis of Published Research Data on {{COVID-19}} Infection-Fatality Rates},
  author = {{Meyerowitz-Katz}, Gideon and Merone, Lea},
  year = {2020},
  month = may,
  institution = {{Epidemiology}},
  doi = {10.1101/2020.05.03.20089854},
  abstract = {Methods Pubmed and Medrxiv were searched using a set of terms and Boolean operators on 25/04/2020. Articles were screened for inclusion by both authors. Meta-analysis was performed in Stata 15.1 using the metan command, based on IFR and confidence intervals extracted from each study. Google/Google Scholar was used to assess the grey literature relating to government reports. Results After exclusions, there were 13 estimates of IFR included in the final meta-analysis, from a wide range of countries, published between February and April 2020. The meta-analysis demonstrated a point-estimate of IFR of 0.75\% (0.49-1.01\%) with high heterogeneity (p{$<$}0.001). Conclusion Based on a systematic review and meta-analysis of published evidence on COVID-19 until the end of April, 2020, the IFR of the disease across populations is 0.75\% (0.49-1.01\%). However, due to very high heterogeneity in the meta-analysis, it is difficult to know if this represents the `true' point estimate. It is likely that different places will experience different IFRs. More research looking at age-stratified IFR is urgently needed to inform policy-making on this front.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XG4PQFU4\\Meyerowitz-Katz and Merone - 2020 - A systematic review and meta-analysis of published.pdf}
}

@article{millerMobilityTrendsProvide2020,
  title = {Mobility Trends Provide a Leading Indicator of Changes in {{SARS-CoV-2}} Transmission},
  author = {Miller, Andrew C. and Foti, Nicholas J. and Lewnard, Joseph A. and Jewell, Nicholas P. and Guestrin, Carlos and Fox, Emily B.},
  year = {2020},
  month = may,
  journal = {medRxiv},
  pages = {2020.05.07.20094441},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.05.07.20094441},
  abstract = {{$<$}p{$>$}Determining the impact of non-pharmaceutical interventions on transmission of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is paramount for the design and deployment of effective public health policies. Incorporating Apple Maps mobility data into an epidemiological model of daily deaths and hospitalizations allowed us to estimate an explicit relationship between human mobility and transmission in the United States. We find that reduced mobility explains a large decrease in the effective reproductive number attained by April 1st and further identify state-to-state variation in the inferred transmission-mobility relationship. These findings indicate that simply relaxing stay-at-home orders can rapidly lead to outbreaks exceeding the scale of transmission that has occurred to date. Our findings provide quantitative guidance on the impact policies must achieve against transmission to safely relax social distancing measures.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SI7TFHUU\\Miller et al. - 2020 - Mobility trends provide a leading indicator of cha.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\NBQYKQV8\\2020.05.07.html}
}

@techreport{millerMobilityTrendsProvide2020a,
  type = {Preprint},
  title = {Mobility Trends Provide a Leading Indicator of Changes in {{SARS-CoV-2}} Transmission},
  author = {Miller, Andrew C and Foti, Nicholas J and Lewnard, Joseph A and Jewell, Nicholas P and Guestrin, Carlos and Fox, Emily B},
  year = {2020},
  month = may,
  institution = {{Epidemiology}},
  doi = {10.1101/2020.05.07.20094441},
  abstract = {Determining the impact of non-pharmaceutical interventions on transmission of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is paramount for the design and deployment of effective public health policies.  Incorporating Apple Maps mobility data into an epidemiological model of daily deaths and hospitalizations allowed us to estimate an explicit relationship between human mobility and transmission in the United States.  We find that reduced mobility explains a large decrease in the effective reproductive number attained by April 1st and further identify state-to-state variation in the inferred transmission-mobility relationship. These findings indicate that simply relaxing stay-at-home orders can rapidly lead to outbreaks exceeding the scale of transmission that has occurred to date. Our findings provide quantitative guidance on the impact policies must achieve against transmission to safely relax social distancing measures.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RUUXIT5L\\Miller et al. - 2020 - Mobility trends provide a leading indicator of cha.pdf}
}

@article{millerMobilityTrendsProvide2020b,
  title = {Mobility Trends Provide a Leading Indicator of Changes in {{SARS-CoV-2}} Transmission},
  author = {Miller, Andrew C. and Foti, Nicholas J. and Lewnard, Joseph A. and Jewell, Nicholas P. and Guestrin, Carlos and Fox, Emily B.},
  year = {2020},
  month = may,
  journal = {medRxiv},
  pages = {2020.05.07.20094441},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.05.07.20094441},
  abstract = {{$<$}p{$>$}Determining the impact of non-pharmaceutical interventions on transmission of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is paramount for the design and deployment of effective public health policies. Incorporating Apple Maps mobility data into an epidemiological model of daily deaths and hospitalizations allowed us to estimate an explicit relationship between human mobility and transmission in the United States. We find that reduced mobility explains a large decrease in the effective reproductive number attained by April 1st and further identify state-to-state variation in the inferred transmission-mobility relationship. These findings indicate that simply relaxing stay-at-home orders can rapidly lead to outbreaks exceeding the scale of transmission that has occurred to date. Our findings provide quantitative guidance on the impact policies must achieve against transmission to safely relax social distancing measures.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\C52KGA2N\\Miller et al. - 2020 - Mobility trends provide a leading indicator of cha.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KXV6HAJY\\2020.05.07.html}
}

@misc{MinimalCommonOutcome,
  title = {A Minimal Common Outcome Measure Set for {{COVID-19}} Clinical Research - {{The Lancet Infectious Diseases}}},
  howpublished = {https://www-thelancet-com.uaccess.univie.ac.at/journals/laninf/article/PIIS1473-3099(20)30483-7/fulltext},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HRIKXHK6\\fulltext.html}
}

@article{mishraCOVID19ModelLocal,
  title = {A {{COVID-19 Model}} for {{Local Authorities}} of the {{United Kingdom}}},
  author = {Mishra, Swapnil and Scott, Jamie and Zhu, Harrison and Ferguson, Neil M and Bhatt, Samir and Gandy, Axel},
  pages = {10},
  abstract = {We propose a new framework to model the COVID-19 epidemic of the United Kingdom at the level of local authorities. The model fits within a general framework for semi-mechanistic Bayesian models of the epidemic, with some important innovations: we model the proportion of infections that result in reported deaths and cases as random variables. This is in contrast to standard frameworks that model the latent infection as a deterministic function of time varying reproduction number, Rt. The model is tailored and designed to be updated daily based on publicly available data. We envisage the model to be useful for now-casting and shortterm projections of the epidemic as well as estimating historical trends. The model fits are available on a public website, https://imperialcollegelondon.github.io/covid19local. The model is currently being used by the Scottish government in their decisions on interventions within Scotland [1, issue 24 to now].},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VM7USGY4\\Mishra et al. - A COVID-19 Model for Local Authorities of the Unit.pdf}
}

@misc{ModelPredictiveControl,
  title = {Model Predictive Control | {{Institute}} for {{Systems Theory}} and {{Automatic Control}} | {{University}} of {{Stuttgart}}},
  howpublished = {https://www.ist.uni-stuttgart.de/research/topics/mpc/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\S25FQGZU\\mpc.html}
}

@article{moghadasImplicationsSilentTransmission2020,
  title = {The Implications of Silent Transmission for the Control of {{COVID-19}} Outbreaks},
  author = {Moghadas, Seyed M. and Fitzpatrick, Meagan C. and Sah, Pratha and Pandey, Abhishek and Shoukat, Affan and Singer, Burton H. and Galvani, Alison P.},
  year = {2020},
  month = jul,
  journal = {Proceedings of the National Academy of Sciences},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.2008373117},
  abstract = {Since the emergence of coronavirus disease 2019 (COVID-19), unprecedented movement restrictions and social distancing measures have been implemented worldwide. The socioeconomic repercussions have fueled calls to lift these measures. In the absence of population-wide restrictions, isolation of infected individuals is key to curtailing transmission. However, the effectiveness of symptom-based isolation in preventing a resurgence depends on the extent of presymptomatic and asymptomatic transmission. We evaluate the contribution of presymptomatic and asymptomatic transmission based on recent individual-level data regarding infectiousness prior to symptom onset and the asymptomatic proportion among all infections. We found that the majority of incidences may be attributable to silent transmission from a combination of the presymptomatic stage and asymptomatic infections. Consequently, even if all symptomatic cases are isolated, a vast outbreak may nonetheless unfold. We further quantified the effect of isolating silent infections in addition to symptomatic cases, finding that over one-third of silent infections must be isolated to suppress a future outbreak below 1\% of the population. Our results indicate that symptom-based isolation must be supplemented by rapid contact tracing and testing that identifies asymptomatic and presymptomatic cases, in order to safely lift current restrictions and minimize the risk of resurgence.},
  chapter = {Biological Sciences},
  copyright = {Copyright \textcopyright{} 2020 the Author(s). Published by PNAS.. https://creativecommons.org/licenses/by/4.0/This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).},
  langid = {english},
  keywords = {case isolation,contact tracing,COVID-19},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BYTE497A\\Moghadas et al. - 2020 - The implications of silent transmission for the co.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\2LEPTNUQ\\2008373117.html}
}

@misc{MoinGrueziServus,
  title = {Moin, {{Gr\"uezi}}, {{Servus}} - Wie Wir Wo Sprechen | {{SPIEGEL ONLINE}}},
  abstract = {K\"onnen wir Sie aufgrund von Spracheigenheiten innerhalb des deutschsprachigen Europas verorten? Sagen Sie uns, wie Sie sprechen, und wir sagen Ihnen, woher Sie stammen.},
  howpublished = {http://sprachatlas.spiegel.de}
}

@misc{MoMo,
  title = {{{MoMo}}},
  howpublished = {https://momo.isciii.es/public/momo/dashboard/momo\_dashboard.html\#datos},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BA8HAXZA\\momo_dashboard.html}
}

@techreport{monodReport32Targeting2020,
  title = {Report 32: {{Targeting}} Interventions to Age Groups That Sustain {{COVID-19}} Transmission in the {{United States}}},
  shorttitle = {Report 32},
  author = {Monod, M and Blenkinsop, A and Xi, X and Herbert, D and Bershan, S and Tietze, S and Bradley, V and Chen, Y and Coupland, H and Filippi, S and {Ish-Horowicz}, J and McManus, M and Mellan, T and Gandy, A and Hutchinson, M and Unwin, H and Vollmer, M and Weber, S and Zhu, H and Bezancon, A and Ferguson, N and Mishra, S and Flaxman, S and Bhatt, S and Ratmann, O and Ainslie, K and Baguelin, M and Boonyasiri, A and Boyd, O and Cattarino, L and Cooper, L and Cucunuba Perez, Z and {Cuomo-Dannenburg}, G and Djaafara, A and Dorigatti, I and Van Elsland, S and Fitzjohn, R and Gaythorpe, K and Geidelberg, L and Green, W and Hamlet, A and Jeffrey, B and Knock, E and Laydon, D and Nedjati Gilani, G and Nouvellet, P and Parag, K and Siveroni, I and Thompson, H and Verity, R and Walters, C and Donnelly, C and Okell, L and Bhatia, S and Brazeau, N and Eales, O and Haw, D and Imai, N and Jauneikaite, E and Lees, J and Mousa, A and Olivera Mesa, D and Skarp, J and Whittles, L},
  year = {2020},
  month = sep,
  institution = {{Imperial College London}},
  doi = {10.25561/82551},
  abstract = {Following ini al declines, in mid 2020, a resurgence in transmission of novel coronavirus disease (COVID-19) has occurred in the United States and parts of Europe. Despite the wide implementa on of non-pharmaceu cal interven ons, it is s ll not known how they are impacted by changing contact pa erns, age and other demographics. As COVID-19 disease control becomes more localised, understanding the age demographics driving transmission and how these impacts the loosening of interven ons such as school reopening is crucial. Considering dynamics for the United States, we analyse aggregated, age-specific mobility trends from more than 10 million individuals and link these mechanis cally to age-specific COVID-19 mortality data. In contrast to previous approaches, we link mobility to mortality via age specific contact pa erns and use this rich rela onship to reconstruct accurate transmission dynamics. Contrary to anecdotal evidence, we find li le support for age-shi s in contact and transmission dynamics over me. We es mate that, un l August, 63.4\% [60.9\%-65.5\%] of SARS-CoV-2 infec ons in the United States originated from adults aged 20-49, while 1.2\% [0.8\%-1.8\%] originated from children aged 0-9. In areas with con nued, community-wide transmission, our transmission model predicts that re-opening kindergartens and elementary schools could facilitate spread and lead to considerable excess COVID-19 a ributable deaths over a 90-day period. These findings indicate that targe ng interven ons to adults aged 20-49 are an important considera on in hal ng resurgent epidemics and preven ng COVID-19-a ributable deaths when kindergartens and elementary schools reopen.},
  collaborator = {Medical Research Council (MRC) and Foundation, Abdul Latif Jameel},
  copyright = {\textcopyright{} 2020 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License https://creativecommons.org/licenses/by-nc-nd/4.0/., Creative Commons Attribution Non Commercial No Derivatives 4.0 International},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,USA},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2WKR66RV\\Monod et al. - 2020 - Report 32 Targeting interventions to age groups t.pdf}
}

@techreport{monodReport32Targeting2020a,
  title = {Report 32: {{Targeting}} Interventions to Age Groups That Sustain {{COVID-19}} Transmission in the {{United States}}},
  shorttitle = {Report 32},
  author = {Monod, M and Blenkinsop, A and Xi, X and Herbert, D and Bershan, S and Tietze, S and Bradley, V and Chen, Y and Coupland, H and Filippi, S and {Ish-Horowicz}, J and McManus, M and Mellan, T and Gandy, A and Hutchinson, M and Unwin, H and Vollmer, M and Weber, S and Zhu, H and Bezancon, A and Ferguson, N and Mishra, S and Flaxman, S and Bhatt, S and Ratmann, O and Ainslie, K and Baguelin, M and Boonyasiri, A and Boyd, O and Cattarino, L and Cooper, L and Cucunuba Perez, Z and {Cuomo-Dannenburg}, G and Djaafara, A and Dorigatti, I and Van Elsland, S and Fitzjohn, R and Gaythorpe, K and Geidelberg, L and Green, W and Hamlet, A and Jeffrey, B and Knock, E and Laydon, D and Nedjati Gilani, G and Nouvellet, P and Parag, K and Siveroni, I and Thompson, H and Verity, R and Walters, C and Donnelly, C and Okell, L and Bhatia, S and Brazeau, N and Eales, O and Haw, D and Imai, N and Jauneikaite, E and Lees, J and Mousa, A and Olivera Mesa, D and Skarp, J and Whittles, L},
  year = {2020},
  month = sep,
  institution = {{Imperial College London}},
  doi = {10.25561/82551},
  abstract = {Following ini al declines, in mid 2020, a resurgence in transmission of novel coronavirus disease (COVID-19) has occurred in the United States and parts of Europe. Despite the wide implementa on of non-pharmaceu cal interven ons, it is s ll not known how they are impacted by changing contact pa erns, age and other demographics. As COVID-19 disease control becomes more localised, understanding the age demographics driving transmission and how these impacts the loosening of interven ons such as school reopening is crucial. Considering dynamics for the United States, we analyse aggregated, age-specific mobility trends from more than 10 million individuals and link these mechanis cally to age-specific COVID-19 mortality data. In contrast to previous approaches, we link mobility to mortality via age specific contact pa erns and use this rich rela onship to reconstruct accurate transmission dynamics. Contrary to anecdotal evidence, we find li le support for age-shi s in contact and transmission dynamics over me. We es mate that, un l August, 63.4\% [60.9\%-65.5\%] of SARS-CoV-2 infec ons in the United States originated from adults aged 20-49, while 1.2\% [0.8\%-1.8\%] originated from children aged 0-9. In areas with con nued, community-wide transmission, our transmission model predicts that re-opening kindergartens and elementary schools could facilitate spread and lead to addi onal COVID-19 a ributable deaths over a 90-day period. These findings indicate that targe ng interven ons to adults aged 20-49 are an important considera on in hal ng resurgent epidemics and preven ng COVID-19-a ributable deaths when kindergartens and elementary schools reopen.},
  collaborator = {Medical Research Council (MRC) and Foundation, Abdul Latif Jameel},
  copyright = {\textcopyright{} 2020 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License https://creativecommons.org/licenses/by-nc-nd/4.0/., Creative Commons Attribution Non Commercial No Derivatives 4.0 International},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,USA},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HIN8BJ5N\\Monod et al. - 2020 - Report 32 Targeting interventions to age groups t.pdf}
}

@article{mooreVaccinationNonpharmaceuticalInterventions,
  title = {Vaccination and Non-Pharmaceutical Interventions for {{COVID-19}}: A Mathematical Modelling Study},
  author = {Moore, Sam},
  pages = {11},
  abstract = {Background The dynamics of vaccination against SARS-CoV-2 are complicated by age-dependent factors, changing levels of infection, and the relaxation of non-pharmaceutical interventions (NPIs) as the perceived risk declines, necessitating the use of mathematical models. Our aims were to use epidemiological data from the UK together with estimates of vaccine efficacy to predict the possible long-term dynamics of SARS-CoV-2 under the planned vaccine rollout.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F5CX2API\\Moore - Vaccination and non-pharmaceutical interventions f.pdf}
}

@article{mooreVaccinationNonpharmaceuticalInterventions2021,
  title = {Vaccination and Non-Pharmaceutical Interventions for {{COVID-19}}: A Mathematical Modelling Study},
  shorttitle = {Vaccination and Non-Pharmaceutical Interventions for {{COVID-19}}},
  author = {Moore, Sam and Hill, Edward M. and Tildesley, Michael J. and Dyson, Louise and Keeling, Matt J.},
  year = {2021},
  month = mar,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(21)00143-2},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}The dynamics of vaccination against SARS-CoV-2 are complicated by age-dependent factors, changing levels of infection, and the relaxation of non-pharmaceutical interventions (NPIs) as the perceived risk declines, necessitating the use of mathematical models. Our aims were to use epidemiological data from the UK together with estimates of vaccine efficacy to predict the possible long-term dynamics of SARS-CoV-2 under the planned vaccine rollout.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}In this study, we used a mathematical model structured by age and UK region, fitted to a range of epidemiological data in the UK, which incorporated the planned rollout of a two-dose vaccination programme (doses 12 weeks apart, protection onset 14 days after vaccination). We assumed default vaccine uptake of 95\% in those aged 80 years and older, 85\% in those aged 50\textendash 79 years, and 75\% in those aged 18\textendash 49 years, and then varied uptake optimistically and pessimistically. Vaccine efficacy against symptomatic disease was assumed to be 88\% on the basis of Pfizer-BioNTech and Oxford-AstraZeneca vaccines being administered in the UK, and protection against infection was varied from 0\% to 85\%. We considered the combined interaction of the UK vaccination programme with multiple potential future relaxations (or removals) of NPIs, to predict the reproduction number (R) and pattern of daily deaths and hospital admissions due to COVID-19 from January, 2021, to January, 2024.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}We estimate that vaccination alone is insufficient to contain the outbreak. In the absence of NPIs, even with our most optimistic assumption that the vaccine will prevent 85\% of infections, we estimate R to be 1{$\cdot$}58 (95\% credible intervals [CI] 1{$\cdot$}36\textendash 1{$\cdot$}84) once all eligible adults have been offered both doses of the vaccine. Under the default uptake scenario, removal of all NPIs once the vaccination programme is complete is predicted to lead to 21 400 deaths (95\% CI 1400\textendash 55 100) due to COVID-19 for a vaccine that prevents 85\% of infections, although this number increases to 96 700 deaths (51 800\textendash 173 200) if the vaccine only prevents 60\% of infections. Although vaccination substantially reduces total deaths, it only provides partial protection for the individual; we estimate that, for the default uptake scenario and 60\% protection against infection, 48{$\cdot$}3\% (95\% CI 48{$\cdot$}1\textendash 48{$\cdot$}5) and 16{$\cdot$}0\% (15{$\cdot$}7\textendash 16{$\cdot$}3) of deaths will be in individuals who have received one or two doses of the vaccine, respectively.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}For all vaccination scenarios we investigated, our predictions highlight the risks associated with early or rapid relaxation of NPIs. Although novel vaccines against SARS-CoV-2 offer a potential exit strategy for the pandemic, success is highly contingent on the precise vaccine properties and population uptake, both of which need to be carefully monitored.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Institute for Health Research, Medical Research Council, and UK Research and Innovation.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DFTAI4VU\\Moore et al. - 2021 - Vaccination and non-pharmaceutical interventions f.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3S2MR3T2\\fulltext.html}
}

@article{moriguchiFirstCaseMeningitis2020,
  title = {A First Case of Meningitis/Encephalitis Associated with {{SARS-Coronavirus-2}}},
  author = {Moriguchi, Takeshi and Harii, Norikazu and Goto, Junko and Harada, Daiki and Sugawara, Hisanori and Takamino, Junichi and Ueno, Masateru and Sakata, Hiroki and Kondo, Kengo and Myose, Natsuhiko and Nakao, Atsuhito and Takeda, Masayuki and Haro, Hirotaka and Inoue, Osamu and {Suzuki-Inoue}, Katsue and Kubokawa, Kayo and Ogihara, Shinji and Sasaki, Tomoyuki and Kinouchi, Hiroyuki and Kojin, Hiroyuki and Ito, Masami and Onishi, Hiroshi and Shimizu, Tatsuya and Sasaki, Yu and Enomoto, Nobuyuki and Ishihara, Hiroshi and Furuya, Shiomi and Yamamoto, Tomoko and Shimada, Shinji},
  year = {2020},
  month = may,
  journal = {International Journal of Infectious Diseases},
  volume = {94},
  pages = {55--58},
  issn = {12019712},
  doi = {10.1016/j.ijid.2020.03.062},
  abstract = {Novel coronavirus (SARS-Coronavirus-2:SARS-CoV-2) which emerged in Wuhan, China, has spread to multiple countries rapidly. We report the first case of meningitis associated with SARS-CoV-2 who was brought in by ambulance due to a convulsion accompanied by unconsciousness. He had never been to any foreign countries. He felt generalized fatigue and fever (day 1). He saw doctors nearby twice (day 2 and 5) and was prescribed Laninamivir and antipyretic agents, His family visited his home and found that he was unconsciousness and lying on the floor in his vomit. He was immediately transported to this hospital by ambulance (day 9). Under emergency transport, he had transient generalized seizures that lasted about a minute. He had obvious neck stiffness. The specific SARS-CoV-2 RNA was not detected in the nasopharyngeal swab but was detected in a CSF. Anti- HSV 1 and varicella-zoster IgM antibodies were not detected in serum samples. A brain MRI showed hyperintensity along the wall of right lateral ventricle and hyperintense signal changes in the right mesial temporal lobe and hippocampus, suggesting the possibility of SARS-CoV-2 meningitis. This case warns the physicians of patients who have CNS symptoms.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2SB8WLR4\\Moriguchi et al. - 2020 - A first case of meningitisencephalitis associated.pdf}
}

@article{moyo-gweteSARSCoV2501YV22021,
  title = {{{SARS-CoV-2 501Y}}.{{V2}} ({{B}}.1.351) Elicits Cross-Reactive Neutralizing Antibodies},
  author = {{Moyo-Gwete}, Thandeka and Madzivhandila, Mashudu and Makhado, Zanele and Ayres, Frances and Mhlanga, Donald and Oosthuysen, Brent and Lambson, Bronwen E. and Kgagudi, Prudence and Tegally, Houriiyah and Iranzadeh, Arash and Doolabh, Deelan and Tyers, Lynn and Chinhoyi, Lionel R. and Mennen, Mathilda and Skelem, Sango and Marais, Gert and Wibmer, Constantinos Kurt and Bhiman, Jinal N. and Ueckermann, Veronica and Rossouw, Theresa and Boswell, Michael and de Oliveira, Tulio and Williamson, Carolyn and Burgers, Wendy A. and Ntusi, Ntobeko and Morris, Lynn and Moore, Penny L.},
  year = {2021},
  month = mar,
  journal = {bioRxiv},
  pages = {2021.03.06.434193},
  publisher = {{Cold Spring Harbor Laboratory}},
  doi = {10.1101/2021.03.06.434193},
  abstract = {{$<$}p{$>$}Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90\% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.{$<$}/p{$>$}},
  chapter = {New Results},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CLIP2HAC\\Moyo-Gwete et al. - 2021 - SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactiv.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\6DIXHFUM\\2021.03.06.html}
}

@article{munroSafetyImmunogenicitySeven2021,
  title = {Safety and Immunogenicity of Seven {{COVID-19}} Vaccines as a Third Dose (Booster) Following Two Doses of {{ChAdOx1 nCov-19}} or {{BNT162b2}} in the {{UK}} ({{COV-BOOST}}): A Blinded, Multicentre, Randomised, Controlled, Phase 2 Trial},
  shorttitle = {Safety and Immunogenicity of Seven {{COVID-19}} Vaccines as a Third Dose (Booster) Following Two Doses of {{ChAdOx1 nCov-19}} or {{BNT162b2}} in the {{UK}} ({{COV-BOOST}})},
  author = {Munro, Alasdair P. S. and Janani, Leila and Cornelius, Victoria and Aley, Parvinder K. and Babbage, Gavin and Baxter, David and Bula, Marcin and Cathie, Katrina and Chatterjee, Krishna and Dodd, Kate and Enever, Yvanne and Gokani, Karishma and Goodman, Anna L. and Green, Christopher A. and Harndahl, Linda and Haughney, John and Hicks, Alexander and van der Klaauw, Agatha A. and Kwok, Jonathan and Libri, Vincenzo and Llewelyn, Martin J. and McGregor, Alastair C. and Minassian, Angela M. and Moore, Patrick and Mughal, Mehmood and Mujadidi, Yama F. and Murira, Jennifer and Osanlou, Orod and Osanlou, Rostam and Owens, Daniel R. and Pacurar, Mihaela and Palfreeman, Adrian and Pan, Daniel and Rampling, Tommy and Regan, Karen and Saich, Stephen and Salkeld, Jo and Saralaya, Dinesh and Sharma, Sunil and Sheridan, Ray and Sturdy, Ann and Thomson, Emma C. and Todd, Shirley and Twelves, Chris and Read, Robert C. and Charlton, Sue and Hallis, Bassam and Ramsay, Mary and Andrews, Nick and {Nguyen-Van-Tam}, Jonathan S. and Snape, Matthew D. and Liu, Xinxue and Faust, Saul N. and Riordan, Andrew and Ustianowski, Andrew and Rogers, Chris A. and Hughes, Stephen and Longshaw, Laura and Stockport, Jane and Hughes, Rachel and Grundy, Lynne and Jones, Lona Tudor and Guha, Arpan and Snashall, Emma and Eadsforth, Tom and Reeder, Sally and Storton, Kim and Munusamy, Malathi and Tandy, Bridget and Egbo, Akamino and Cox, Stephen and Ahmed, Nabeela Nazir and Shenoy, Anil and Bousfield, Rachel and Wixted, Donna and Gutteridge, Helen and Mansfield, Becky and Herbert, Christopher and Holliday, Kyra and Calderwood, James and Barker, Dominique and Brandon, Jacqueline and Tulloch, Hayley and Colquhoun, Suzie and Thorp, Helen and Radford, Helen and Evans, Julie and Baker, Helena and Thorpe, Jeanette and Batham, Sally and Hailstone, Jessica and Phillips, Rachael and Kumar, Dileep and Westwell, Fran and Makia, Fiona and Hopkins, NinaSimone and Barcella, Lara and Mpelembue, Mushiya and Dabagh, Maja and Lang, Matilda and Khan, Farida and Adebambo, Olumide and Chita, Sunder and Corrah, Tumena and Whittington, Ashley and John, Laurence and Roche, Siobhan and Wagstaff, Lynda and Farrier, Adam and Bisnauthsing, Karen and Serafimova, Teona and Nanino, Elisa and Cooney, Enya and {Wilson-Goldsmith}, Jaimie and Nguyen, Hanna and Mazzella, Andrea and Jackson, Beth and Aslam, Suahil and Bawa, Tanveer and Broadhead, Samantha and Farooqi, Sadaf and Piper, Jo and Weighell, Rowena and Pickup, Lorinda and Shamtally, Djamila and Domingo, Jason and Kourampa, Evgenia and Hale, Colin and Gibney, Jennifer and Stackpoole, Michael and {Rashid-Gardner}, Zalina and Lyon, Rebecca and McDonnell, Chloe and Cole, Christine and Stewart, Anna and McMillan, Gillian and Savage, Mary and Beckett, Helen and Moorbey, Chantelle and Desai, Amisha and Brown, Claire and Naker, Kush and Qureshi, Ehsaan and Trinham, Charlotte and Sabine, Charlotte and Moore, Sophie and Hurdover, Steve and Justice, Edwin and Smith, David and Plested, Emma and Silva, Carla Ferreira Da and White, Rachel and Robinson, Hannah and Cifuentes, Liliana and Morshead, Gertraud and {Drake-Brockman}, Rachael and Kinch, Patrick and Kasanyinga, Mwila and Clutterbuck, Elizabeth A. and Bibi, Sagida and Stuart, Arabella SV and Shaw, Robert H. and Singh, Michael and Champaneri, Trishna and Irwin, Margaret and Khan, Mohammed and Kownacka, Alicja and Nabunjo, Martha and Osuji, Carool and Hladkiwskyj, John and Galvin, Dominic and Patel, Gita and Mouland, Johanna and Longhurst, Beverley and Moon, Maria and Giddins, Beth and Alves, Carlota Pereira Dias and Richmond, Leah and Minnis, Christine and Baryschpolec, Sonia and Elliott, Scott and Fox, Lauren and Graham, Victoria and Baker, Natalie and Godwin, Kerry and Buttigieg, Karren and Knight, Chanice and Brown, Phillip and Lall, Paminder and Shaik, Imam and Chiplin, Emily and Brunt, Emily and Leung, Stephanie and Allen, Lauren and Thomas, Steve and Fraser, Sara and Choi, Bea and Gouriet, Jade and Freedman, Andrew and Perkins, Jonathan and Gowland, Andrew and Macdonald, Jonathan and Seenan, John Paul and Starinskij, Igor and Seaton, Andrew and Peters, Erica and Singh, Stephen and Gardside, Ben and Bonnaud, Avril and Davies, Ceri and Gordon, Elizabeth and Keenan, Samantha and Hall, Jane and Wilkins, Suzanne and Tasker, Suzanne and James, Rob and Seath, Ingrid and Littlewood, Kelly and Newman, Joseph and Boubriak, Iryna and Suggitt, Debbie and Haydock, Helen and Bennett, Sara and Woodyatt, Wiesia and Hughes, Kerry and Bell, Judith and Coughlan, Tricia and van Welsenes, Donald and Kamal, Mohammed and Cooper, Chris and Tunstall, Simon and Ronan, Nicholas and Cutts, Rebecca and Dare, Tracey and Yim, Yee Ting Nicole and Whittley, Sarah and Ricamara, Marivic and Hamal, Shama and Adams, Kirsty and Baker, Holly and Driver, Kimberley and Turner, Nicola and Rawlins, Todd and Roy, Subarna and {Merida-Morillas}, Marta and Sakagami, Yukari and Andrews, Antonette and Cordeiro, Lillian Goncalves and Stokes, Matthew and Ambihapathy, Wythehi and Spencer, Joanne and Parungao, Nina and Berry, Lisa and Cullinane, James and Presland, Laura and {Ross-Russell}, Amy and Warren, Sarah and Baker, Jonathan and Oliver, Abigail and Buadi, Amanda and Lee, Kim and Haskell, Louise and Romani, Rossana and Bentley, Ian and Whitbred, Tim and Fowler, Simon and Gavin, John and Magee, Alan and Watson, Tara and Nightingale, Kari and Marius, Phedra and Summerton, Eloise and Locke, Emily and Honey, Thomas and Lingwood, Aidan and de la Haye, Anastasia and Elliott, Ryan Stephen and Underwood, Karen and King, Mikayala and {Davies-Dear}, Sharon and Horsfall, Emily and Chalwin, Olivia and Burton, Holly and Edwards, Christopher J. and Welham, Benjamin and Garrahy, Sarah and Hall, Fran and Ladikou, Eleni and Mullan, Dee and Hansen, Daniel and Campbell, Marion and Santos, Filipa Dos and {Habash-Bailey}, Haniah and Lakeman, Nicki and Branney, Debbie and Vamplew, Luke and Hogan, Alison and Frankham, Jorden and Wiselka, Martin and Vail, Dennyl and Wenn, Victoria and Renals, Valerie and Ellis, Kate and {Lewis-Taylor}, Jessica and Magan, Javier and Hardy, Anna and Appleby, Kim},
  year = {2021},
  month = dec,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(21)02717-3},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\K6DI55KV\\Munro et al. - 2021 - Safety and immunogenicity of seven COVID-19 vaccin.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BZAV6H5R\\fulltext.html}
}

@techreport{murhekarSARSCoV2SeroPrevalenceGeneral2021,
  type = {{{SSRN Scholarly Paper}}},
  title = {{{SARS-CoV-2 Sero-Prevalence Among General Population}} and {{Healthcare Workers}} in {{India}}, {{December}} 2020 - {{January}} 2021},
  author = {Murhekar, Manoj V. and Bhatnagar, Tarun and Thangaraj, Jeromie Wesley Vivian and Saravanakumar, V. and Kumar, Muthusamy Santhosh and Selvaraju, Sriram and Rade, Kiran and Kumar, C. P. Girish and Sabarinathan, R. and Turuk, Alka and Asthana, Smita and Balachandar, Rakesh and Bangar, Sampada Dipak and Bansal, Avi Kumar and Chopra, Vishal and Das, Dasarathi and Deb, Alok Kumar and Devi, Kangjam Rekha and Dhikav, Vikas and Dwivedi, Gaurav Raj and Khan, S. Muhammad Salim and Kumar, M. Sunil and Laxmaiah, Avula and Madhukar, Major and Mahapatra, Amarendra and Rangaraju, Chethana and Turuk, Jyotirmayee and Yadav, Rajiv and Andhalkar, Rushikesh and Arunraj, K. and Baradwaj, Dinesh Kumar and Bharti, Pravin and Bhattacharya, Debdutta and Bhat, Jyothi and Chahal, Ashrafjit S. and Chakraborty, Debjit and Chaudhury, Anshuman and Deval, Hirawati and Dhatrak, Sarang and Dayal, Rakesh and Elantamilan, D. and Giridharan, Prathiksha and Haq, Inaamul and Hudda, Ramesh Kumar and Jagjeevan, Babu and Kalliath, Arshad and Kanungo, Srikanta and Krishnan, Nivethitha N. and Kshatri, Jaya Singh and Kumar, Alok and Kumar, Niraj and Kumar, V. G. Vinoth and Naga Lakshmi, Gangeti Gandhi Jayanthi and Mehta, Ganesh and Mishra, Nandan Kumar and Mitra, Anindya and Nagbhushanam, K. and Nimmathota, Arlappa and Nirmala, A. R. and Pandey, Ashok Kumar and Prasad, Ganta Venkata and Qurieshi, Mariya Amin and Reddy, Sirasanambatti Devarajulu and Robinson, Aby and Sahay, Seema and Saxena, Rochak and Sekar, Krithikaa and Shukla, Vijay Kumar and Singh, Hari Bhan and Singh, Prashant Kumar and Singh, Pushpendra and Singh, Rajeev and Srinivasan, Nivetha and Varma, Dantuluri Sheethal and Viramgami, Ankit and Wilson, Vimith Cheruvathoor and Yadav, Surabhi and Yadav, Suresh and Zaman, Kamran and Chakrabarti, Amit and Das, Aparup and Dhaliwal, R. S. and Dutta, Shanta and Kant, Rajni and Khan, A. M. and Narain, Kanwar and Narasimhaiah, Somashekar and Padmapriyadarshini, Chandrasekaran and Pandey, Krishna and Pati, Sanghamitra and Patil, Shripad and Rajkumar, Hemalatha and Ramarao, Tekumalla and Sharma, Y. K. and Singh, Shalini and Panda, Samiran and Reddy, D. C. S. and Bhargava, Balram},
  year = {2021},
  month = mar,
  number = {ID 3797589},
  address = {{Rochester, NY}},
  institution = {{Social Science Research Network}},
  doi = {10.2139/ssrn.3797589},
  abstract = {Background: Repeated cross-sectional serosurveys in the same geographic area establish the trend of the evolving pandemic. We present the findings of the third round of a national serosurvey to estimate the seroprevalence of SARS-CoV-2 infection among the general population and health care workers of India.~Methods: We conducted the third population-based serosurvey between Dec 18, 2020 and Jan 6, 2021 in the same 700 villages or wards from 70 districts in 21 states across India, which were selected for the first and second serosurveys. We enrolled from each district, at least 400 individuals aged {$\geq$} 10 years from general population and 100 HCWs from sub-district level public health facilities. Serum samples from general population were tested for the presence of IgG antibodies against nucleocapsid (N) and spike protein (S1-RBD) of SARS-CoV-2 using the Abbott and Siemens assays respectively, whereas sera from HCWs were tested for anti-S1-RBD. For general population, sera positive for either of the antibodies were considered positive, while sera positive for anti-S1-RBD were considered as positive for HCW. Weighted seroprevalence estimates were adjusted for sensitivity and specificity of respective assays.~Findings: Of the 28,598 sera from general population, 4585 (16\%) had IgG antibodies against N, 6647 (23.2\%) against S1-RBD and 7436 (26\%) against either. The weighted and assay characteristic adjusted seroprevalence against either of the antibodies was 24.1 (95\%CI: 23.0\% to 25.3\%). Seroprevalence was lower in rural areas (21.4\%, 95\% CI: 20.3\% to 22.6\%) compared to urban non-slum (29.4\%, 95\% CI: 26.9\% - 32.1\%) and slum areas (34.6\%, 95\% CI: 31.0\% to 38.3\%). Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6\% (95\% CI: 23.5\% to 27.8\%).~Interpretation: Nearly one in four individuals aged 10 years or older from general population as well as HCWs were exposed to SARS-CoV-2 by December 2020 amounting to 271 million infections in India.Funding Statement: Indian Council of Medical ResearchDeclaration of Interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare no competing interestsEthics Approval Statement: The project was approved by Institutional Human Ethics Committee at ICMR-National Institute of Epidemiology.},
  langid = {english},
  keywords = {COVID-19,IgG,India,SARS-CoV-2,seroprevalence},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HBDLXPGU\\papers.html}
}

@article{mutesaStrategyFindingPeople2020,
  title = {A Strategy for Finding People Infected with {{SARS-CoV-2}}: Optimizing Pooled Testing at Low Prevalence},
  shorttitle = {A Strategy for Finding People Infected with {{SARS-CoV-2}}},
  author = {Mutesa, Leon and Ndishimye, Pacifique and Butera, Yvan and Souopgui, Jacob and Uwineza, Annette and Rutayisire, Robert and Musoni, Emile and Rujeni, Nadine and Nyatanyi, Thierry and Ntagwabira, Edouard and Semakula, Muhammed and Musanabaganwa, Clarisse and Nyamwasa, Daniel and Ndashimye, Maurice and Ujeneza, Eva and Mwikarago, Ivan Emile and Muvunyi, Claude Mambo and Mazarati, Jean Baptiste and Nsanzimana, Sabin and Turok, Neil and Ndifon, Wilfred},
  year = {2020},
  month = may,
  journal = {arXiv:2004.14934 [q-bio]},
  eprint = {2004.14934},
  eprinttype = {arxiv},
  primaryclass = {q-bio},
  abstract = {Suppressing SARS-CoV-2 will likely require the rapid identification and isolation of infected individuals, on an ongoing basis. RT-PCR (reverse transcription polymerase chain reaction) tests are accurate but costly, making regular testing of every individual expensive. The costs are a challenge for all countries and particularly for developing countries. Cost reductions can be achieved by combining samples and testing them in groups. We propose an algorithm for grouping subsamples, prior to testing, based on the geometry of a hypercube. At low prevalence, this testing procedure uniquely identifies infected individuals in a small number of tests. We discuss the optimal group size and explain why, given the highly infectious nature of the disease, parallel searches are preferred. We report proof of concept experiments in which a positive sample was detected even when diluted a hundred-fold with negative samples. Using these methods, the costs of mass testing could be reduced by a factor of ten to a hundred or more. If infected individuals are quickly and effectively quarantined, the prevalence will fall and so will the costs of regularly testing everyone. Such a strategy provides a possible pathway to the longterm elimination of SARS-CoV-2. Field trials of our approach are now under way in Rwanda and initial data from these are reported here.},
  archiveprefix = {arXiv},
  keywords = {Quantitative Biology - Populations and Evolution,Quantitative Biology - Quantitative Methods},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D37U5TPK\\Mutesa et al. - 2020 - A strategy for finding people infected with SARS-C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\HSG2UAZP\\2004.html}
}

@misc{MuzzledTrumpCDC,
  title = {Muzzled {{By Trump}}, {{The CDC Releases Watered Down Guidelines For Reopening}} - {{YouTube}}},
  howpublished = {https://www.youtube.com/watch?v=zio9QCbprrI},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LCFWZI2G\\watch.html}
}

@article{nagelSodiumMRIUsing2009,
  title = {Sodium {{MRI}} Using a Density-Adapted {{3D}} Radial Acquisition Technique},
  author = {Nagel, Armin M. and Laun, Frederik B. and Weber, Marc-Andr{\'e} and Matthies, Christian and Semmler, Wolfhard and Schad, Lothar R.},
  year = {2009},
  month = dec,
  journal = {Magnetic Resonance in Medicine},
  volume = {62},
  number = {6},
  pages = {1565--1573},
  issn = {1522-2594},
  doi = {10.1002/mrm.22157},
  abstract = {A density-adapted three-dimensional radial projection reconstruction pulse sequence is presented which provides a more efficient k-space sampling than conventional three-dimensional projection reconstruction sequences. The gradients of the density-adapted three-dimensional radial projection reconstruction pulse sequence are designed such that the averaged sampling density in each spherical shell of k-space is constant. Due to hardware restrictions, an inner sphere of k-space is sampled without density adaption. This approach benefits from both the straightforward handling of conventional three-dimensional projection reconstruction sequence trajectories and an enhanced signal-to-noise ratio (SNR) efficiency akin to the commonly used three-dimensional twisted projection imaging trajectories. Benefits for low SNR applications, when compared to conventional three-dimensional projection reconstruction sequences, are demonstrated with the example of sodium imaging. In simulations of the point-spread function, the SNR of small objects is increased by a factor 1.66 for the density-adapted three-dimensional radial projection reconstruction pulse sequence sequence. Using analytical and experimental phantoms, it is shown that the density-adapted three-dimensional radial projection reconstruction pulse sequence allows higher resolutions and is more robust in the presence of field inhomogeneities. High-quality in vivo images of the healthy human leg muscle and the healthy human brain are acquired. For equivalent scan times, the SNR is up to a factor of 1.8 higher and anatomic details are better resolved using density-adapted three-dimensional radial projection reconstruction pulse sequence. Magn Reson Med, 2009. \textcopyright{} 2009 Wiley-Liss, Inc.},
  copyright = {Copyright \textcopyright{} 2009 Wiley-Liss, Inc.},
  langid = {english},
  keywords = {density-adapted sampling,field inhomogeneities,projection reconstruction,radial imaging,sampling density,sodium magnetic resonance imaging},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WZHDNBTR\\Nagel et al. - 2009 - Sodium MRI using a density-adapted 3D radial acqui.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7R2JQTZC\\abstract.html}
}

@article{nalbandianPostacuteCOVID19Syndrome2021,
  title = {Post-Acute {{COVID-19}} Syndrome},
  author = {Nalbandian, Ani and Sehgal, Kartik and Gupta, Aakriti and Madhavan, Mahesh V. and McGroder, Claire and Stevens, Jacob S. and Cook, Joshua R. and Nordvig, Anna S. and Shalev, Daniel and Sehrawat, Tejasav S. and Ahluwalia, Neha and Bikdeli, Behnood and Dietz, Donald and {Der-Nigoghossian}, Caroline and {Liyanage-Don}, Nadia and Rosner, Gregg F. and Bernstein, Elana J. and Mohan, Sumit and Beckley, Akinpelumi A. and Seres, David S. and Choueiri, Toni K. and Uriel, Nir and Ausiello, John C. and Accili, Domenico and Freedberg, Daniel E. and Baldwin, Matthew and Schwartz, Allan and Brodie, Daniel and Garcia, Christine Kim and Elkind, Mitchell S. V. and Connors, Jean M. and Bilezikian, John P. and Landry, Donald W. and Wan, Elaine Y.},
  year = {2021},
  month = mar,
  journal = {Nature Medicine},
  pages = {1--15},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-021-01283-z},
  abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4\,weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\74WLMY2L\\Nalbandian et al. - 2021 - Post-acute COVID-19 syndrome.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\485S6XW2\\s41591-021-01283-z.html}
}

@misc{NaturalHistoryTransmission,
  title = {Natural History and Transmission Potential of Asymptomatic {{SARS-CoV-2}} Infection | {{Clinical Infectious Diseases}} | {{Oxford Academic}}},
  howpublished = {https://academic-oup-com.uaccess.univie.ac.at/cid/advance-article/doi/10.1093/cid/ciaa711/5851471},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KP5CJRWA\\5851471.html}
}

@misc{NaturalHistoryTransmissiona,
  title = {Natural History and Transmission Potential of Asymptomatic {{SARS-CoV-2}} Infection | {{Clinical Infectious Diseases}} | {{Oxford Academic}}},
  howpublished = {https://academic-oup-com.uaccess.univie.ac.at/cid/advance-article/doi/10.1093/cid/ciaa711/5851471},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\I65A6PXG\\5851471.html}
}

@misc{NeuartigesCoronavirus,
  title = {Neuartiges {{Coronavirus}}},
  howpublished = {https://www.sozialministerium.at/Themen/Gesundheit/Uebertragbare-Krankheiten/Infektionskrankheiten-A-Z/Neuartiges-Coronavirus.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KBRYYUM3\\Neuartiges-Coronavirus.html}
}

@misc{NeueErkenntnisseUber,
  title = {{Neue Erkenntnisse \"uber Superspreader-Ereignisse}},
  journal = {DER STANDARD},
  abstract = {Forscher vermuten, dass bis zu 80 Prozent der Covid-19-Ansteckungen auf nur zehn Prozent der Infizierten zur\"uckgehen k\"onnten},
  howpublished = {https://www.derstandard.at/story/2000117603498/neue-erkenntnisse-ueber-superspreader-ereignisse},
  langid = {austrian},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CQ99C8RK\\neue-erkenntnisse-ueber-superspreader-ereignisse.html}
}

@article{ngPreexistingNovoHumoral2020,
  title = {Preexisting and de Novo Humoral Immunity to {{SARS-CoV-2}} in Humans},
  author = {Ng, Kevin W. and Faulkner, Nikhil and Cornish, Georgina H. and Rosa, Annachiara and Harvey, Ruth and Hussain, Saira and Ulferts, Rachel and Earl, Christopher and Wrobel, Antoni G. and Benton, Donald J. and Roustan, Chloe and Bolland, William and Thompson, Rachael and {Agua-Doce}, Ana and Hobson, Philip and Heaney, Judith and Rickman, Hannah and Paraskevopoulou, Stavroula and Houlihan, Catherine F. and Thomson, Kirsty and Sanchez, Emilie and Shin, Gee Yen and Spyer, Moira J. and Joshi, Dhira and O'Reilly, Nicola and Walker, Philip A. and Kjaer, Svend and Riddell, Andrew and Moore, Catherine and Jebson, Bethany R. and Wilkinson, Meredyth and Marshall, Lucy R. and Rosser, Elizabeth C. and Radziszewska, Anna and Peckham, Hannah and Ciurtin, Coziana and Wedderburn, Lucy R. and Beale, Rupert and Swanton, Charles and Gandhi, Sonia and Stockinger, Brigitta and McCauley, John and Gamblin, Steve J. and McCoy, Laura E. and Cherepanov, Peter and Nastouli, Eleni and Kassiotis, George},
  year = {2020},
  month = nov,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abe1107},
  abstract = {Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detect preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable by a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the IgG class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies, targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. Notably, SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LKAWCKGR\\Ng et al. - 2020 - Preexisting and de novo humoral immunity to SARS-C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\9U9DQ5CM\\science.html}
}

@article{nishiuraClosedEnvironmentsFacilitate2020,
  title = {Closed Environments Facilitate Secondary Transmission of Coronavirus Disease 2019 ({{COVID-19}})},
  author = {Nishiura, Hiroshi and Oshitani, Hitoshi and Kobayashi, Tetsuro and Saito, Tomoya and Sunagawa, Tomimasa and Matsui, Tamano and Wakita, Takaji and Team, MHLW COVID-19 Response and Suzuki, Motoi},
  year = {2020},
  month = apr,
  journal = {medRxiv},
  pages = {2020.02.28.20029272},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.02.28.20029272},
  abstract = {{$<$}p{$>$}Objective: To identify common features of cases with novel coronavirus disease (COVID-19) so as to better understand what factors promote secondary transmission including superspreading events. Methods: A total of 110 cases were examined among eleven clusters and sporadic cases, and investigated who acquired infection from whom. The clusters included four in Tokyo and one each in Aichi, Fukuoka, Hokkaido, Ishikawa, Kanagawa and Wakayama prefectures. The number of secondary cases generated by each primary case was calculated using contact tracing data. Results: Of the 110 cases examined, 27 (24.6\%) were primary cases who generated secondary cases. The odds that a primary case transmitted COVID-19 in a closed environment was 18.7 times greater compared to an open-air environment (95\% confidence interval [CI]: 6.0, 57.9). Conclusions: It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events. Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MNTAG397\\Nishiura et al. - 2020 - Closed environments facilitate secondary transmiss.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\QZXAENLP\\2020.02.28.html}
}

@misc{NPGEOCorona,
  title = {{{NPGEO Corona}}},
  abstract = {Auf dem Corona Hub von Esri finden Sie die offiziellen Daten rund um die Ausbreitung des Coronavirus.},
  howpublished = {https://npgeo-corona-npgeo-de.hub.arcgis.com/},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8DZIZNQR\\dd4580c810204019a7b8eb3e0b329dd6_0.html}
}

@article{nybergRiskHospitalAdmission2021,
  title = {Risk of Hospital Admission for Patients with {{SARS-CoV-2}} Variant {{B}}.1.1.7: Cohort Analysis},
  shorttitle = {Risk of Hospital Admission for Patients with {{SARS-CoV-2}} Variant {{B}}.1.1.7},
  author = {Nyberg, Tommy and Twohig, Katherine A. and Harris, Ross J. and Seaman, Shaun R. and Flannagan, Joe and Allen, Hester and Charlett, Andre and Angelis, Daniela De and Dabrera, Gavin and Presanis, Anne M.},
  year = {2021},
  month = jun,
  journal = {BMJ},
  volume = {373},
  pages = {n1412},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.n1412},
  abstract = {Objective To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission compared with diagnosis with wild-type SARS-CoV-2 variants. Design Retrospective cohort analysis. Setting Community based SARS-CoV-2 testing in England, individually linked with hospital admission data. Participants 839 278 patients with laboratory confirmed covid-19, of whom 36 233 had been admitted to hospital within 14 days, tested between 23 November 2020 and 31 January 2021 and analysed at a laboratory with an available TaqPath assay that enables assessment of S-gene target failure (SGTF), a proxy test for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity, deprivation, region of residence, and date of positive test. Main outcome measures Hospital admission between one and 14 days after the first positive SARS-CoV-2 test. Results 27 710 (4.7\%) of 592 409 patients with SGTF variants and 8523 (3.5\%) of 246 869 patients without SGTF variants had been admitted to hospital within one to 14 days. The stratum adjusted hazard ratio of hospital admission was 1.52 (95\% confidence interval 1.47 to 1.57) for patients with covid-19 infected with SGTF variants, compared with those infected with non-SGTF variants. The effect was modified by age (P{$<$}0.001), with hazard ratios of 0.93-1.21 in patients younger than 20 years with versus without SGTF variants, 1.29 in those aged 20-29, and 1.45-1.65 in those aged {$\geq$}30 years. The adjusted absolute risk of hospital admission within 14 days was 4.7\% (95\% confidence interval 4.6\% to 4.7\%) for patients with SGTF variants and 3.5\% (3.4\% to 3.5\%) for those with non-SGTF variants. Conclusions The results suggest that the risk of hospital admission is higher for people infected with the B.1.1.7 variant compared with wild-type SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to adults older than 30 years.},
  chapter = {Research},
  copyright = {\textcopyright{} Author(s) (or their employer(s)) 2019. Re-use permitted under CC                 BY. No commercial re-use. See rights and permissions. Published by                 BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  pmid = {34130987},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\H977ZCZZ\\Nyberg et al. - 2021 - Risk of hospital admission for patients with SARS-.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\5LRUCUVX\\bmj.html}
}

@article{offedduEffectivenessMasksRespirators2017,
  title = {Effectiveness of {{Masks}} and {{Respirators Against Respiratory Infections}} in {{Healthcare Workers}}: {{A Systematic Review}} and {{Meta-Analysis}}},
  shorttitle = {Effectiveness of {{Masks}} and {{Respirators Against Respiratory Infections}} in {{Healthcare Workers}}},
  author = {Offeddu, Vittoria and Yung, Chee Fu and Low, Mabel Sheau Fong and Tam, Clarence C},
  year = {2017},
  month = dec,
  journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  volume = {65},
  number = {11},
  pages = {1934--1942},
  issn = {1058-4838},
  doi = {10.1093/cid/cix681},
  abstract = {In this systematic review and meta-analysis, we found evidence for a protective effect of facemasks and respirators against clinical respiratory infection among healthcare workers, and limited evidence for superiority of respirators. However, the existing evidence is sparse and findings inconsistent., This systematic review and meta-analysis quantified the protective effect of facemasks and respirators against respiratory infections among healthcare workers. Relevant articles were retrieved from Pubmed, EMBASE, and Web of Science. Meta-analyses were conducted to calculate pooled estimates. Meta-analysis of randomized controlled trials (RCTs) indicated a protective effect of masks and respirators against clinical respiratory illness (CRI) (risk ratio [RR] = 0.59; 95\% confidence interval [CI]:0.46\textendash 0.77) and influenza-like illness (ILI) (RR = 0.34; 95\% CI:0.14\textendash 0.82). Compared to masks, N95 respirators conferred superior protection against CRI (RR = 0.47; 95\% CI: 0.36\textendash 0.62) and laboratory-confirmed bacterial (RR = 0.46; 95\% CI: 0.34\textendash 0.62), but not viral infections or ILI. Meta-analysis of observational studies provided evidence of a protective effect of masks (OR = 0.13; 95\% CI: 0.03\textendash 0.62) and respirators (OR = 0.12; 95\% CI: 0.06\textendash 0.26) against severe acute respiratory syndrome (SARS). This systematic review and meta-analysis supports the use of respiratory protection. However, the existing evidence is sparse and findings are inconsistent within and across studies. Multicentre RCTs with standardized protocols conducted outside epidemic periods would help to clarify the circumstances under which the use of masks or respirators is most warranted.},
  pmcid = {PMC7108111},
  pmid = {29140516},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZA2SH6QW\\Offeddu et al. - 2017 - Effectiveness of Masks and Respirators Against Res.pdf}
}

@article{okellHaveDeathsCOVID192020,
  title = {Have Deaths from {{COVID-19}} in {{Europe}} Plateaued Due to Herd Immunity?},
  author = {Okell, Lucy C. and Verity, Robert and Watson, Oliver J. and Mishra, Swapnil and Walker, Patrick and Whittaker, Charlie and Katzourakis, Aris and Donnelly, Christl A. and Riley, Steven and Ghani, Azra C. and Gandy, Axel and Flaxman, Seth and Ferguson, Neil M. and Bhatt, Samir},
  year = {2020},
  month = jun,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)31357-X},
  abstract = {Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently in marked decline in many countries in Europe, North America, and parts of Asia, following unprecedented governmental interventions aiming to substantially reduce travel and physical contact between individuals. There are two possible and very different explanations for this decline.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CLCH8AFK\\Okell et al. - 2020 - Have deaths from COVID-19 in Europe plateaued due .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\LZSEFMC6\\fulltext.html}
}

@book{OrganisationAcademicYear2019,
  title = {The Organisation of the Academic Year in {{Europe}}: 2019/20.},
  shorttitle = {The Organisation of the Academic Year in {{Europe}}},
  year = {2019},
  publisher = {{Publications Office}},
  address = {{LU}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3TE2AB3I\\2019 - The organisation of the academic year in Europe 2.pdf}
}

@article{parkEarlyReleaseCoronavirus,
  title = {Early {{Release}} - {{Coronavirus Disease Outbreak}} in {{Call Center}}, {{South Korea}} - {{Volume}} 26, {{Number}} 8\textemdash{{August}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Park, Shin Young and Kim, Young-Man and Yi, Seonju and Lee, Sangeun and Na, Baeg-Ju and Kim, Chang Bo and Kim, Jung-il and Kim, Hea Sook and Kim, Young Bok and Park, Yoojin and Huh, In Sil and Kim, Hye Kyung and Yoon, Hyung Jun and Jang, Hanaram and Kim, Kyungnam and Chang, Yeonhwa and Kim, Inhye and Lee, Hyeyoung and Gwack, Jin and Kim, Seong Sun and Kim, Miyoung and Kweon, Sanghui and Choe, Young June and Park, Ok and Park, Young Joon and Jeong, Eun Kyeong},
  doi = {10.3201/eid2608.201274},
  abstract = {We describe the epidemiology of a coronavirus disease (COVID-19) outbreak in a call center in South Korea. We obtained information on demographic char...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9ZBTW5RX\\20-1274_article.html}
}

@article{pastor-barriusoInfectionFatalityRisk2020,
  title = {Infection Fatality Risk for {{SARS-CoV-2}} in Community Dwelling Population of {{Spain}}: Nationwide Seroepidemiological Study},
  shorttitle = {Infection Fatality Risk for {{SARS-CoV-2}} in Community Dwelling Population of {{Spain}}},
  author = {{Pastor-Barriuso}, Roberto and {P{\'e}rez-G{\'o}mez}, Beatriz and Hern{\'a}n, Miguel A. and {P{\'e}rez-Olmeda}, Mayte and Yotti, Raquel and {Oteo-Iglesias}, Jes{\'u}s and Sanmart{\'i}n, Jose L. and {Le{\'o}n-G{\'o}mez}, Inmaculada and {Fern{\'a}ndez-Garc{\'i}a}, Aurora and {Fern{\'a}ndez-Navarro}, Pablo and Cruz, Israel and Mart{\'i}n, Mariano and {Delgado-Sanz}, Concepci{\'o}n and de Larrea, Nerea Fern{\'a}ndez and Paniagua, Jose Le{\'o}n and {Mu{\~n}oz-Montalvo}, Juan F. and Blanco, Faustino and Larrauri, Amparo and Poll{\'a}n, Marina},
  year = {2020},
  month = nov,
  journal = {BMJ},
  volume = {371},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.m4509},
  abstract = {Objective To estimate the infection fatality risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on deaths with confirmed coronavirus disease 2019 (covid-19) and excess deaths from all causes. Design Nationwide seroepidemiological study. Setting First wave of covid-19 pandemic in Spain. Participants Community dwelling individuals of all ages. Main outcome measures The main outcome measure was overall, and age and sex specific, infection fatality risk for SARS-CoV-2 (the number of covid-19 deaths and excess deaths divided by the estimated number of SARS-CoV-2 infections) in the community dwelling Spanish population. Deaths with laboratory confirmed covid-19 were obtained from the National Epidemiological Surveillance Network (RENAVE) and excess all cause deaths from the Monitoring Mortality System (MoMo), up to 15 July 2020. SARS-CoV-2 infections in Spain were derived from the estimated seroprevalence by a chemiluminescent microparticle immunoassay for IgG antibodies in 61 098 participants in the ENE-COVID nationwide seroepidemiological survey between 27 April and 22 June 2020. Results The overall infection fatality risk was 0.8\% (19 228 of 2.3 million infected individuals, 95\% confidence interval 0.8\% to 0.9\%) for confirmed covid-19 deaths and 1.1\% (24 778 of 2.3 million infected individuals, 1.0\% to 1.2\%) for excess deaths. The infection fatality risk was 1.1\% (95\% confidence interval 1.0\% to 1.2\%) to 1.4\% (1.3\% to 1.5\%) in men and 0.6\% (0.5\% to 0.6\%) to 0.8\% (0.7\% to 0.8\%) in women. The infection fatality risk increased sharply after age 50, ranging from 11.6\% (8.1\% to 16.5\%) to 16.4\% (11.4\% to 23.2\%) in men aged 80 or more and from 4.6\% (3.4\% to 6.3\%) to 6.5\% (4.7\% to 8.8\%) in women aged 80 or more. Conclusion The increase in SARS-CoV-2 infection fatality risk after age 50 appeared to be more noticeable in men than in women. Based on the results of this study, fatality from covid-19 was greater than that reported for other common respiratory diseases, such as seasonal influenza.},
  chapter = {Research},
  copyright = {\textcopyright{} Author(s) (or their employer(s)) 2019. Re-use permitted under CC                 BY-NC. No commercial re-use. See rights and permissions. Published by                 BMJ.. http://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.},
  langid = {english},
  pmid = {33246972},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MT7JKV6U\\Pastor-Barriuso et al. - 2020 - Infection fatality risk for SARS-CoV-2 in communit.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BU7HZ2U4\\bmj.html}
}

@article{paulsWeekendEffectHospitalized2017,
  title = {The {{Weekend Effect}} in {{Hospitalized Patients}}: {{A Meta-Analysis}}},
  shorttitle = {The {{Weekend Effect}} in {{Hospitalized Patients}}},
  author = {Pauls, Lynn A. and {Johnson-Paben}, Rebecca and McGready, John and Murphy, Jamie D. and Pronovost, Peter J. and Wu, Christopher L.},
  year = {2017},
  month = sep,
  journal = {Journal of Hospital Medicine},
  volume = {12},
  number = {9},
  pages = {760--766},
  issn = {1553-5606},
  doi = {10.12788/jhm.2815},
  abstract = {BACKGROUND: The presence of a "weekend effect" (increased mortality rate during Saturday and/or Sunday admissions) for hospitalized inpatients is uncertain. PURPOSE: We performed a systematic review to examine the presence of a weekend effect on hospital inpatient mortality. DATA SOURCES: PubMed, EMBASE, SCOPUS, and Cochrane databases (January 1966-April 2013) were utilized for our search. STUDY SELECTION: We examined the mortality rate for hospital inpatients admitted during the weekend compared with those admitted during the workweek. To be included, the study had to provide discrete mortality data around the weekends (including holidays) versus weekdays, include patients who were admitted as inpatients over the weekend, and be published in English. DATA EXTRACTION: The primary outcome was all-cause weekend versus weekday mortality with subgroup analysis by personnel staffing levels, rates and times to procedures rates and delays, or illness severity. DATA SYNTHESIS: A total of 97 studies (N = 51,114,109 patients) were examined. Patients admitted on the weekends had a significantly higher overall mortality (relative risk, 1.19; 95\% confidence interval, 1.14-1.23). With regard to the subgroup analyses, patients admitted on the weekends consistently had higher mortality than those admitted during the week, regardless of the levels of weekend/weekday differences in staffing, procedure rates and delays, and illness severity. CONCLUSIONS: Hospital inpatients admitted during weekends may have a higher mortality rate compared with inpatients admitted during the weekdays.},
  langid = {english},
  pmid = {28914284},
  keywords = {Hospital Mortality,Hospitalization,Humans,Inpatients,Patient Admission,Personnel Staffing and Scheduling,Severity of Illness Index,Time Factors},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RM95Z2F5\\Pauls et al. - 2017 - The Weekend Effect in Hospitalized Patients A Met.pdf}
}

@article{pavelkaEffectivenessPopulationwideRapid,
  title = {The Effectiveness of Population-Wide, Rapid Antigen Test-Based Screening in Reducing {{SARS-CoV-2}} Infection Prevalence in {{Slovakia}}},
  author = {Pavelka, Martin and {Van-Zandvoort}, Kevin and Abbott, Sam and Sherratt, Katharine and Covid, Cmmid and Funk, Sebastian},
  pages = {25},
  abstract = {Background: With the development of rapid antigen tests, population screening for SARSCoV-2 infection has become logistically feasible and could reduce transmission with limited burden on the uninfected. We report the effects of mass testing on the prevalence of SARS-CoV-2 in Slovakia, the first country to implement such an approach. Methods: Mass testing was conducted in three rounds: a pilot in four counties, a first national round, and a second round in 45 counties with remaining high infection prevalence. Restrictions on movement and contacts were put in place in the preceding week. We estimated the crude change in the prevalence of infectious infections between tests (cPR). Quasi Poisson regression was used to adjust for covariates (aPR) and mathematical models to adjust for trends preceding mass testing (saPR), and to disentangle the impact of lockdown from that of mass testing. Results: A total of 5,276,832 tests were conducted of which 50,466 were positive. Between rounds 1 and 2 infection prevalence decreased by 58\% (57-58\%) in the crude analysis; aPR: 0.39 (0.30-0.50) and saPR: 0.30 (0.26-0.33). In the two weeks between the pilot and round 2 infection prevalence decreased by 82\%(81\%-83\%). In the microsimulation model this was best explained by a combination of the effects of restrictions and highly effective mass testing combined with quarantine of household contacts of test positives. Conclusions: Mass testing combined with other control measures was highly successful in rapidly reducing SARS-CoV-2 infection prevalence in Slovakia.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8HFW64PE\\Pavelka et al. - The effectiveness of population-wide, rapid antige.pdf}
}

@article{peakIndividualQuarantineActive2020,
  title = {Individual Quarantine versus Active Monitoring of Contacts for the Mitigation of {{COVID-19}}: A Modelling Study},
  shorttitle = {Individual Quarantine versus Active Monitoring of Contacts for the Mitigation of {{COVID-19}}},
  author = {Peak, Corey M and Kahn, Rebecca and Grad, Yonatan H and Childs, Lauren M and Li, Ruoran and Lipsitch, Marc and Buckee, Caroline O},
  year = {2020},
  month = may,
  journal = {The Lancet Infectious Diseases},
  pages = {S1473309920303613},
  issn = {14733099},
  doi = {10.1016/S1473-3099(20)30361-3},
  abstract = {Background Voluntary individual quarantine and voluntary active monitoring of contacts are core disease control strategies for emerging infectious diseases such as COVID-19. Given the impact of quarantine on resources and individual liberty, it is vital to assess under what conditions individual quarantine can more effectively control COVID-19 than active monitoring. As an epidemic grows, it is also important to consider when these interventions are no longer feasible and broader mitigation measures must be implemented.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YCZZW4BR\\PIIS1473-3099(20)30361-3.pdf}
}

@article{peakIndividualQuarantineActive2020a,
  title = {Individual Quarantine versus Active Monitoring of Contacts for the Mitigation of {{COVID-19}}: A Modelling Study},
  shorttitle = {Individual Quarantine versus Active Monitoring of Contacts for the Mitigation of {{COVID-19}}},
  author = {Peak, Corey M. and Kahn, Rebecca and Grad, Yonatan H. and Childs, Lauren M. and Li, Ruoran and Lipsitch, Marc and Buckee, Caroline O.},
  year = {2020},
  month = may,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30361-3},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Voluntary individual quarantine and voluntary active monitoring of contacts are core disease control strategies for emerging infectious diseases such as COVID-19. Given the impact of quarantine on resources and individual liberty, it is vital to assess under what conditions individual quarantine can more effectively control COVID-19 than active monitoring. As an epidemic grows, it is also important to consider when these interventions are no longer feasible and broader mitigation measures must be implemented.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}To estimate the comparative efficacy of individual quarantine and active monitoring of contacts to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we fit a stochastic branching model to reported parameters for the dynamics of the disease. Specifically, we fit a model to the incubation period distribution (mean 5{$\cdot$}2 days) and to two estimates of the serial interval distribution: a shorter one with a mean serial interval of 4{$\cdot$}8 days and a longer one with a mean of 7{$\cdot$}5 days. To assess variable resource settings, we considered two feasibility settings: a high-feasibility setting with 90\% of contacts traced, a half-day average delay in tracing and symptom recognition, and 90\% effective isolation; and a low-feasibility setting with 50\% of contacts traced, a 2-day average delay, and 50\% effective isolation.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Model fitting by sequential Monte Carlo resulted in a mean time of infectiousness onset before symptom onset of 0{$\cdot$}77 days (95\% CI -1{$\cdot$}98 to 0{$\cdot$}29) for the shorter serial interval, and for the longer serial interval it resulted in a mean time of infectiousness onset after symptom onset of 0{$\cdot$}51 days (95\% CI -0{$\cdot$}77 to 1{$\cdot$}50). Individual quarantine in high-feasibility settings, where at least 75\% of infected contacts are individually quarantined, contains an outbreak of SARS-CoV-2 with a short serial interval (4{$\cdot$}8 days) 84\% of the time. However, in settings where the outbreak continues to grow (eg, low-feasibility settings), so too will the burden of the number of contacts traced for active monitoring or quarantine, particularly uninfected contacts (who never develop symptoms). When resources are prioritised for scalable interventions such as physical distancing, we show active monitoring or individual quarantine of high-risk contacts can contribute synergistically to mitigation efforts. Even under the shorter serial interval, if physical distancing reduces the reproductive number to 1{$\cdot$}25, active monitoring of 50\% of contacts can result in overall outbreak control (ie, effective reproductive number {$<$}1).{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Our model highlights the urgent need for more data on the serial interval and the extent of presymptomatic transmission to make data-driven policy decisions regarding the cost\textendash benefit comparisons of individual quarantine versus active monitoring of contacts. To the extent that these interventions can be implemented, they can help mitigate the spread of SARS-CoV-2.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Institute of General Medical Sciences, National Institutes of Health.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32445710},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\M6GEI62E\\Peak et al. - 2020 - Individual quarantine versus active monitoring of .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\F7LRBVZZ\\fulltext.html}
}

@article{perkmannAntiSpikeProteinAssays2021,
  title = {Anti-{{Spike}} Protein Assays to Determine Post-Vaccination Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays},
  shorttitle = {Anti-{{Spike}} Protein Assays to Determine Post-Vaccination Antibody Levels},
  author = {Perkmann, Thomas and {Perkmann-Nagele}, Nicole and Koller, Thomas and Mucher, Patrick and Radakovics, Astrid and Marculescu, Rodrig and Wolzt, Michael and Wagner, Oswald F. and Binder, Christoph J. and Haslacher, Helmuth},
  year = {2021},
  month = mar,
  journal = {medRxiv},
  pages = {2021.03.05.21252977},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.03.05.21252977},
  abstract = {{$<$}h3{$>$}Abstract{$<$}/h3{$>$} {$<$}h3{$>$}Background{$<$}/h3{$>$} {$<$}p{$>$}Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant for identifying possible vaccine failure and estimating the time of protection. Therefore, we aimed to evaluate the performance of five different Anti-SARS-CoV-2 antibody assays regarding the quantification of anti-spike (S) antibodies induced after a single dose of BNT162b2.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$>$} {$<$}p{$>$}Sera of n=69 SARS-CoV-2 na\"ive individuals 21{$\pm$}1 days after vaccination with BNT162b2 (Pfizer/BioNTech) were tested using the following quantitative SARS-CoV-2 antibody assays: Roche S total antibody, DiaSorin trimeric spike IgG, DiaSorin S1/S2 IgG, Abbott II IgG, and Serion/Virion IgG. Test agreement was assessed by Passing-Bablok regression. Results were further compared to the percent inhibition calculated from a surrogate virus neutralization test (sVNT) by correlation and ROC (receiver-operating-characteristics) analysis.{$<$}/p{$><$}h3{$>$}Results{$<$}/h3{$>$} {$<$}p{$>$}Individual values were distributed over several orders of magnitude for all assays evaluated. Although the assays were in good overall agreement ({$\rho$}=0.80-0.94), Passing-Bablok regression revealed systematic and proportional differences, which could not be eliminated by converting the results to BAU/mL as suggested by the manufacturers. 7 (10\%) individuals had a negative sVNT results (i.e. \&lt;30\% inhibition). These samples were reliably identified by most assays and yielded low binding antibody levels (ROC-AUCs 0.84-0.93).{$<$}/p{$><$}h3{$>$}Conclusions{$<$}/h3{$>$} {$<$}p{$>$}Although all assays evaluated showed good correlation, readings from different assays were not interchangeable, even when converted to BAU/mL using the WHO international standard for SARS-CoV-2 immunoglobulin. This highlights the need for further standardization of SARS-CoV-2 serology.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IWECFABZ\\Perkmann et al. - 2021 - Anti-Spike protein assays to determine post-vaccin.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\676XHSBF\\2021.03.05.21252977v1.html}
}

@techreport{perkmannAntiSpikeProteinAssays2021a,
  type = {Preprint},
  title = {Anti-{{Spike}} Protein Assays to Determine Post-Vaccination Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays},
  shorttitle = {Anti-{{Spike}} Protein Assays to Determine Post-Vaccination Antibody Levels},
  author = {Perkmann, Thomas and {Perkmann-Nagele}, Nicole and Koller, Thomas and Mucher, Patrick and Radakovics, Astrid and Marculescu, Rodrig and Wolzt, Michael and Wagner, Oswald F. and Binder, Christoph J. and Haslacher, Helmuth},
  year = {2021},
  month = mar,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2021.03.05.21252977},
  abstract = {Abstract                        Background             Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant for identifying possible vaccine failure and estimating the time of protection. Therefore, we aimed to evaluate the performance of five different Anti-SARS-CoV-2 antibody assays regarding the quantification of anti-spike (S) antibodies induced after a single dose of BNT162b2.                                   Methods             Sera of n=69 SARS-CoV-2 na\"ive individuals 21{$\pm$}1 days after vaccination with BNT162b2 (Pfizer/BioNTech) were tested using the following quantitative SARS-CoV-2 antibody assays: Roche S total antibody, DiaSorin trimeric spike IgG, DiaSorin S1/S2 IgG, Abbott II IgG, and Serion/Virion IgG. Test agreement was assessed by Passing-Bablok regression. Results were further compared to the percent inhibition calculated from a surrogate virus neutralization test (sVNT) by correlation and ROC (receiver-operating-characteristics) analysis.                                   Results             Individual values were distributed over several orders of magnitude for all assays evaluated. Although the assays were in good overall agreement ({$\rho$}=0.80-0.94), Passing-Bablok regression revealed systematic and proportional differences, which could not be eliminated by converting the results to BAU/mL as suggested by the manufacturers. 7 (10\%) individuals had a negative sVNT results (i.e. {$<$}30\% inhibition). These samples were reliably identified by most assays and yielded low binding antibody levels (ROC-AUCs 0.84-0.93).                                   Conclusions             Although all assays evaluated showed good correlation, readings from different assays were not interchangeable, even when converted to BAU/mL using the WHO international standard for SARS-CoV-2 immunoglobulin. This highlights the need for further standardization of SARS-CoV-2 serology.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\56768NI8\\Perkmann et al. - 2021 - Anti-Spike protein assays to determine post-vaccin.pdf}
}

@techreport{perkmannSideSideComparison2020,
  type = {Preprint},
  title = {Side by Side Comparison of Three Fully Automated {{SARS-CoV-2}} Antibody Assays with a Focus on Specificity},
  author = {Perkmann, Thomas and {Perkmann-Nagele}, Nicole and Breyer, Marie-Kathrin and {Breyer-Kohansal}, Robab and Burghuber, Otto C and Hartl, Sylvia and Aletaha, Daniel and Sieghart, Daniela and Quehenberger, Peter and Marculescu, Rodrig and Mucher, Patrick and Strassl, Robert and Wagner, Oswald F and Binder, Christoph J and Haslacher, Helmuth},
  year = {2020},
  month = jun,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2020.06.04.20117911},
  abstract = {Background: In the context of the COVID-19 pandemic, numerous new serological test systems for the detection of anti-SARS-CoV-2 antibodies have become available quickly. However, the clinical performance of many of them is still insufficiently described. Therefore we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side. Methods: We included a total of 1,154 specimens from pre-COVID-19 times and 65 samples from COVID-19 patients ({$\geq$}14 days after symptom onset) to evaluate the test performance of SARS-CoV-2 serological assays by Abbott, Roche, and DiaSorin. Results: All three assays presented with high specificities: 99.2\% (98.6-99.7) for Abbott, 99.7\% (99.2-100.0) for Roche, and 98.3\% (97.3-98.9) for DiaSorin. In contrast to the manufacturers' specifications, sensitivities only ranged from 83.1\% to 89.2\%. Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar's test revealed significant differences between results obtained from Roche and DiaSorin. However, at low seroprevalences, the minor differences in specificity resulted in profound discrepancies of positive predictability at 1\% seroprevalence: 52.3\% (36.2-67.9), 77.6\% (52.8-91.5), and 32.6\% (23.6-43.1) for Abbott, Roche, and DiaSorin, respectively. Conclusion: We find diagnostically relevant differences in specificities for the anti-SARS-CoV2 antibody assays by Abbott, Roche, and DiaSorin that have a significant impact on the positive predictability of these tests.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4ZGEHD39\\Perkmann et al. - 2020 - Side by side comparison of three fully automated S.pdf}
}

@article{phamFirst100Days2020,
  title = {The First 100 Days of {{SARS-CoV-2}} Control in {{Vietnam}}},
  author = {Pham, Quang Thai and Rabaa, Maia A and Duong, Huy Luong and Dang, Quang Tan and Tran, Dai Quang and Quach, Ha-Linh and Hoang, Ngoc-Anh Thi and Phung, Cong Dinh and Ngu, Duy Nghia and Tran, Anh Tu and La, Ngoc Quang and Tran, My Phuc and Vinh, Chau and Nguyen, Cong Khanh and Dang, Duc Anh and Tran, Nhu Duong and Thwaites, Guy and {van Doorn}, H Rogier and Choisy, Marc},
  year = {2020},
  month = aug,
  journal = {Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America},
  issn = {1058-4838},
  doi = {10.1093/cid/ciaa1130},
  abstract = {Background One hundred days after SARS-CoV-2 was first reported in Vietnam on January 23rd, 270 cases were confirmed, with no deaths. We describe the control measures used by the Government and their relationship with imported and domestically-acquired case numbers, with the aim of identifying the measures associated with successful SARS-CoV-2 control. Methods Clinical and demographic data on the first 270 SARS-CoV-2 infected cases and the timing and nature of Government control measures, including numbers of tests and quarantined individuals, were analysed. Apple and Google mobility data provided proxies for population movement. Serial intervals were calculated from 33 infector-infectee pairs and used to estimate the proportion of pre-symptomatic transmission events and time-varying reproduction numbers. Results A national lockdown was implemented between April 1st and 22nd. Around 200 000 people were quarantined and 266 122 RT-PCR tests conducted. Population mobility decreased progressively before lockdown. 60\% (163/270) of cases were imported; 43\% (89/208) of resolved infections remained asymptomatic for the duration of infection. The serial interval was 3{$\cdot$}24 days, and 27{$\cdot$}5\% (95\% confidence interval, 15{$\cdot$}7\%-40{$\cdot$}0\%) of transmissions occurred pre-symptomatically. Limited transmission amounted to a maximum reproduction number of 1{$\cdot$}15 (95\% confidence interval, 0{$\cdot$}37-2{$\cdot$}36). No community transmission has been detected since April 15th. Conclusions Vietnam has controlled SARS-CoV-2 spread through the early introduction of mass communication, meticulous contact-tracing with strict quarantine, and international travel restrictions. The value of these interventions is supported by the high proportion of asymptomatic and imported cases, and evidence for substantial pre-symptomatic transmission.},
  pmcid = {PMC7454342},
  pmid = {32738143},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PDNJDXXN\\Pham et al. - 2020 - The first 100 days of SARS-CoV-2 control in Vietna.pdf}
}

@misc{PhysicalDistancingFace,
  title = {Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of {{SARS-CoV-2}} and {{COVID-19}}: A Systematic Review and Meta-Analysis - {{The Lancet}}},
  howpublished = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31142-9/fulltext},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FS28R9J6\\fulltext.html}
}

@misc{PinkbookCourseBook2021,
  title = {Pinkbook {{Course Book}}: {{Epidemiology}} of {{Vaccine Preventable Diseases}} | {{CDC}}},
  shorttitle = {Pinkbook {{Course Book}}},
  year = {2021},
  month = mar,
  abstract = {Pinkbook: (Epidemiology and Prevention of Vaccine-Preventable Diseases)},
  howpublished = {https://www.cdc.gov/vaccines/pubs/pinkbook/index.html},
  langid = {american}
}

@article{planasConsiderableEscapeSARSCoV22021,
  title = {Considerable Escape of {{SARS-CoV-2 Omicron}} to Antibody Neutralization},
  author = {Planas, Delphine and Saunders, Nell and Maes, Piet and {Guivel-Benhassine}, Florence and Planchais, Cyril and Buchrieser, Julian and Bolland, William-Henry and Porrot, Fran{\c c}oise and Staropoli, Isabelle and Lemoine, Frederic and P{\'e}r{\'e}, H{\'e}l{\`e}ne and Veyer, David and Puech, Julien and Rodary, Julien and Baela, Guy and Dellicour, Simon and Raymenants, Joren and Gorissen, Sarah and Geenen, Caspar and Vanmechelen, Bert and {Wawina-Bokalanga}, Tony and {Mart{\'i}-Carrerasi}, Joan and Cuypers, Lize and S{\`e}ve, Aymeric and Hocqueloux, Laurent and Prazuck, Thierry and Rey, F{\'e}lix and {Simon-Lorri{\`e}re}, Etienne and Bruel, Timoth{\'e}e and Mouquet, Hugo and Andr{\'e}, Emmanuel and Schwartz, Olivier},
  year = {2021},
  month = dec,
  journal = {Nature},
  pages = {d41586-021-03827-2},
  issn = {0028-0836, 1476-4687},
  doi = {10.1038/d41586-021-03827-2},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\L5TASZNU\\Planas et al. - 2021 - Considerable escape of SARS-CoV-2 Omicron to antib.pdf}
}

@techreport{planasSensitivityInfectiousSARSCoV22021,
  type = {Preprint},
  title = {Sensitivity of Infectious {{SARS-CoV-2 B}}.1.1.7 and {{B}}.1.351 Variants to Neutralizing Antibodies},
  author = {Planas, Delphine and Bruel, Timothee and Grzelak, Ludivine and {Guivel-Benhassine}, Florence and Staropoli, Isabelle and Porrot, Francoise and Planchais, Cyril and Buchrieser, Julian and Rajah, Maaran Michael and Bishop, Elodie and Albert, Melanie and Donati, Flora and Behillil, Sylvie and Enouf, Vincent and Marianne, Maquart and Gonzalez, Maria and De Seze, Jerome and Pere, Helene and Veyer, David and Seve, Aymeric and {Simon-Loriere}, Etienne and {Fafi-Kremer}, Samira and Stefic, Karl and Mouquet, Hugo and Hocqueloux, Laurent and {van der Werf}, Sylvie and Prazuck, Thierry and Schwartz, Olivier},
  year = {2021},
  month = feb,
  institution = {{Immunology}},
  doi = {10.1101/2021.02.12.430472},
  abstract = {SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries. Here, we isolated infectious B.1.1.7 and B.1.351 strains and examined their sensitivity to anti-SARS-CoV-2 antibodies present in sera and nasal swabs, in comparison with a D614G reference virus. We established a novel rapid neutralization assay, based on reporter cells that become GFP+ after overnight infection. B.1.1.7 was neutralized by 79/83 sera from convalescent patients collected up to 9 months post symptoms, almost similar to D614G. There was a mean 6-fold reduction in titers and even loss of activity against B.1.351 in 40\% of convalescent sera after 9 months. Early sera from 19 vaccinated individuals were almost as potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Nasal swabs from vaccine recipients were not neutralizing, except in individuals who were diagnosed COVID-19+ before vaccination. Thus, faster-spreading variants acquired a partial resistance to humoral immunity generated by natural infection or vaccination, mostly visible in individuals with low antibody levels.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HKSJVXFR\\Planas et al. - 2021 - Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.pdf}
}

@article{planasSensitivityInfectiousSARSCoV22021a,
  title = {Sensitivity of Infectious {{SARS-CoV-2 B}}.1.1.7 and {{B}}.1.351 Variants to Neutralizing Antibodies},
  author = {Planas, Delphine and Bruel, Timoth{\'e}e and Grzelak, Ludivine and {Guivel-Benhassine}, Florence and Staropoli, Isabelle and Porrot, Fran{\c c}oise and Planchais, Cyril and Buchrieser, Julian and Rajah, Maaran Michael and Bishop, Elodie and Albert, M{\'e}lanie and Donati, Flora and Prot, Matthieu and Behillil, Sylvie and Enouf, Vincent and Maquart, Marianne and {Smati-Lafarge}, Mounira and Varon, Emmanuelle and Schortgen, Fr{\'e}d{\'e}rique and Yahyaoui, Layla and Gonzalez, Maria and S{\`e}ze, J{\'e}r{\^o}me De and P{\'e}r{\'e}, H{\'e}l{\`e}ne and Veyer, David and S{\`e}ve, Aymeric and {Simon-Lori{\`e}re}, Etienne and {Fafi-Kremer}, Samira and Stefic, Karl and Mouquet, Hugo and Hocqueloux, Laurent and van der Werf, Sylvie and Prazuck, Thierry and Schwartz, Olivier},
  year = {2021},
  month = mar,
  journal = {Nature Medicine},
  pages = {1--8},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-021-01318-5},
  abstract = {Sera from convalescent individuals with coronavirus disease 2019 and from individuals vaccinated with BNT162b2 have reduced ability to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351, but antibody potency against the variants increases after two vaccine doses.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NSGXE4T6\\Planas et al. - 2021 - Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KF547M2F\\s41591-021-01318-5.html}
}

@article{pollanPrevalenceSARSCoV2Spain2020,
  title = {Prevalence of {{SARS-CoV-2}} in {{Spain}} ({{ENE-COVID}}): A Nationwide, Population-Based Seroepidemiological Study},
  shorttitle = {Prevalence of {{SARS-CoV-2}} in {{Spain}} ({{ENE-COVID}})},
  author = {Poll{\'a}n, Marina and {P{\'e}rez-G{\'o}mez}, Beatriz and {Pastor-Barriuso}, Roberto and Oteo, Jes{\'u}s and Hern{\'a}n, Miguel A. and {P{\'e}rez-Olmeda}, Mayte and Sanmart{\'i}n, Jose L. and {Fern{\'a}ndez-Garc{\'i}a}, Aurora and Cruz, Israel and de Larrea, Nerea Fern{\'a}ndez and Molina, Marta and {Rodr{\'i}guez-Cabrera}, Francisco and Mart{\'i}n, Mariano and {Merino-Amador}, Paloma and Paniagua, Jose Le{\'o}n and {Mu{\~n}oz-Montalvo}, Juan F. and Blanco, Faustino and Yotti, Raquel and Blanco, Faustino and Fern{\'a}ndez, Rodrigo Guti{\'e}rrez and Mart{\'i}n, Mariano and Navarro, Saturnino Mezcua and Molina, Marta and {Mu{\~n}oz-Montalvo}, Juan F. and Hern{\'a}ndez, Mat{\'i}as Salinero and Sanmart{\'i}n, Jose L. and {Cuenca-Estrella}, Manuel and Yotti, Raquel and Paniagua, Jos{\'e} Le{\'o}n and de Larrea, Nerea Fern{\'a}ndez and {Fern{\'a}ndez-Navarro}, Pablo and {Pastor-Barriuso}, Roberto and {P{\'e}rez-G{\'o}mez}, Beatriz and Poll{\'a}n, Marina and Avell{\'o}n, Ana and Fedele, Giovanni and {Fern{\'a}ndez-Garc{\'i}a}, Aurora and Iglesias, Jes{\'u}s Oteo and Olmeda, Mar{\'i}a Teresa P{\'e}rez and Cruz, Israel and Martinez, Maria Elena Fernandez and {Rodr{\'i}guez-Cabrera}, Francisco D. and Hern{\'a}n, Miguel A. and Fern{\'a}ndez, Susana Padrones and Aguirre, Jos{\'e} Manuel Rumbao and Mar{\'i}, Jos{\'e} M. Navarro and Borr{\'a}s, Bego{\~n}a Palop and Jim{\'e}nez, Ana Bel{\'e}n P{\'e}rez and {Rodr{\'i}guez-Iglesias}, Manuel and Gasc{\'o}n, Ana Mar{\'i}a Calvo and Alcaine, Mar{\'i}a Luz Lou and Su{\'a}rez, Ignacio Donate and {\'A}lvarez, Oscar Su{\'a}rez and P{\'e}rez, Mercedes Rodr{\'i}guez and Sanch{\'i}s, Margarita Cases and Gomila, Carlos Javier Villaf{\'a}fila and Saladrigas, Lluis Carbo and Fern{\'a}ndez, Adoraci{\'o}n Hurtado and Oliver, Antonio and Feliciano, El{\'i}as Castro and Quintana, Mar{\'i}a Noem{\'i} Gonz{\'a}lez and Fern{\'a}ndez, Jos{\'e} Mar{\'i}a Barrasa and Betancor, Mar{\'i}a Araceli Hern{\'a}ndez and Febles, Melisa Hern{\'a}ndez and Mart{\'i}n, Leopoldo Mart{\'i}n and L{\'o}pez, Luis-Mariano L{\'o}pez and Miota, Teresa Ugarte and Poblaci{\'o}n, In{\'e}s De Benito and P{\'e}rez, Mar{\'i}a Sagrario Celada and Fern{\'a}ndez, Mar{\'i}a Natalia Vall{\'e}s and Enr{\'i}quez, Tom{\'a}s Mat{\'e} and Arranz, Miguel Villa and Gonz{\'a}lez, Marta Dom{\'i}nguez-Gil and {Fern{\'a}ndez-Natal}, Isabel and Lob{\'o}n, Gregoria Meg{\'i}as and Bellido, Juan Luis Mu{\~n}oz and Ciruela, Pilar and i Casals, Ariadna Mas and Bot{\'i}as, Maria Dolad{\'e} and Maeso, M. Angeles Marcos and del Campo, D{\'u}nia P{\'e}rez and de Castro, Antonio F{\'e}lix and Ram{\'i}rez, Ram{\'o}n Lim{\'o}n and Retamosa, Maria Francisca El{\'i}as and Gonz{\'a}lez, Manuela Rubio and Lobeiras, Mar{\'i}a Sinda Blanco and Losada, Alberto Fuentes and Aguilera, Antonio and Bou, German and Caro, Yolanda and Marauri, Noem{\'i} and Blanco, Luis Miguel Soria and Gonz{\'a}lez, Isabel del Cura and Pascual, Montserrat Hern{\'a}ndez and Fern{\'a}ndez, Roberto Alonso and {Merino-Amador}, Paloma and Castro, Natalia Cabrera and Lizcano, Aurora Tom{\'a}s and Almagro, Crist{\'o}bal Ram{\'i}rez and Hern{\'a}ndez, Manuel Segovia and Elizaga, Nieves Ascunce and Sanz, Mar{\'i}a Ederra and Baquedano, Carmen Ezpeleta and Bascaran, Ana Bustinduy and Tamayo, Susana Iglesias and Otazua, Luis Elorduy and Benarroch, Rebeca Benarroch and Flores, Jes{\'u}s Lopera and de la Villa, Antonia V{\'a}zquez},
  year = {2020},
  month = jul,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)31483-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Spain is one of the European countries most affected by the COVID-19 pandemic. Serological surveys are a valuable tool to assess the extent of the epidemic, given the existence of asymptomatic cases and little access to diagnostic tests. This nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}35 883 households were selected from municipal rolls using two-stage random sampling stratified by province and municipality size, with all residents invited to participate. From April 27 to May 11, 2020, 61 075 participants (75{$\cdot$}1\% of all contacted individuals within selected households) answered a questionnaire on history of symptoms compatible with COVID-19 and risk factors, received a point-of-care antibody test, and, if agreed, donated a blood sample for additional testing with a chemiluminescent microparticle immunoassay. Prevalences of IgG antibodies were adjusted using sampling weights and post-stratification to allow for differences in non-response rates based on age group, sex, and census-tract income. Using results for both tests, we calculated a seroprevalence range maximising either specificity (positive for both tests) or sensitivity (positive for either test).{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Seroprevalence was 5{$\cdot$}0\% (95\% CI 4{$\cdot$}7\textendash 5{$\cdot$}4) by the point-of-care test and 4{$\cdot$}6\% (4{$\cdot$}3\textendash 5{$\cdot$}0) by immunoassay, with a specificity\textendash sensitivity range of 3{$\cdot$}7\% (3{$\cdot$}3\textendash 4{$\cdot$}0; both tests positive) to 6{$\cdot$}2\% (5{$\cdot$}8\textendash 6{$\cdot$}6; either test positive), with no differences by sex and lower seroprevalence in children younger than 10 years ({$<$}3{$\cdot$}1\% by the point-of-care test). There was substantial geographical variability, with higher prevalence around Madrid ({$>$}10\%) and lower in coastal areas ({$<$}3\%). Seroprevalence among 195 participants with positive PCR more than 14 days before the study visit ranged from 87{$\cdot$}6\% (81{$\cdot$}1\textendash 92{$\cdot$}1; both tests positive) to 91{$\cdot$}8\% (86{$\cdot$}3\textendash 95{$\cdot$}3; either test positive). In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15{$\cdot$}3\% (13{$\cdot$}8\textendash 16{$\cdot$}8) to 19{$\cdot$}3\% (17{$\cdot$}7\textendash 21{$\cdot$}0). Around a third of seropositive participants were asymptomatic, ranging from 21{$\cdot$}9\% (19{$\cdot$}1\textendash 24{$\cdot$}9) to 35{$\cdot$}8\% (33{$\cdot$}1\textendash 38{$\cdot$}5). Only 19{$\cdot$}5\% (16{$\cdot$}3\textendash 23{$\cdot$}2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas. Most PCR-confirmed cases have detectable antibodies, but a substantial proportion of people with symptoms compatible with COVID-19 did not have a PCR test and at least a third of infections determined by serology were asymptomatic. These results emphasise the need for maintaining public health measures to avoid a new epidemic wave.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Spanish Ministry of Health, Institute of Health Carlos III, and Spanish National Health System.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5GTICZZQ\\Polln et al. - 2020 - Prevalence of SARS-CoV-2 in Spain (ENE-COVID) a n.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UIWD3ENG\\fulltext.html}
}

@article{pollanPrevalenceSARSCoV2Spain2020a,
  title = {{Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study}},
  shorttitle = {{Prevalence of SARS-CoV-2 in Spain (ENE-COVID)}},
  author = {Poll{\'a}n, Marina and {P{\'e}rez-G{\'o}mez}, Beatriz and {Pastor-Barriuso}, Roberto and Oteo, Jes{\'u}s and Hern{\'a}n, Miguel A and {P{\'e}rez-Olmeda}, Mayte and Sanmart{\'i}n, Jose L and {Fern{\'a}ndez-Garc{\'i}a}, Aurora and Cruz, Israel and {Fern{\'a}ndez de Larrea}, Nerea and Molina, Marta and {Rodr{\'i}guez-Cabrera}, Francisco and Mart{\'i}n, Mariano and {Merino-Amador}, Paloma and Le{\'o}n Paniagua, Jose and {Mu{\~n}oz-Montalvo}, Juan F and Blanco, Faustino and Yotti, Raquel and Blanco, Faustino and Guti{\'e}rrez Fern{\'a}ndez, Rodrigo and Mart{\'i}n, Mariano and Mezcua Navarro, Saturnino and Molina, Marta and {Mu{\~n}oz-Montalvo}, Juan F. and Salinero Hern{\'a}ndez, Mat{\'i}as and Sanmart{\'i}n, Jose L. and {Cuenca-Estrella}, Manuel and Yotti, Raquel and Le{\'o}n Paniagua, Jos{\'e} and {Fern{\'a}ndez de Larrea}, Nerea and {Fern{\'a}ndez-Navarro}, Pablo and {Pastor-Barriuso}, Roberto and {P{\'e}rez-G{\'o}mez}, Beatriz and Poll{\'a}n, Marina and Avell{\'o}n, Ana and Fedele, Giovanni and {Fern{\'a}ndez-Garc{\'i}a}, Aurora and Oteo Iglesias, Jes{\'u}s and P{\'e}rez Olmeda, Mar{\'i}a Teresa and Cruz, Israel and Fernandez Martinez, Maria Elena and {Rodr{\'i}guez-Cabrera}, Francisco D. and Hern{\'a}n, Miguel A. and Padrones Fern{\'a}ndez, Susana and Rumbao Aguirre, Jos{\'e} Manuel and Navarro Mar{\'i}, Jos{\'e} M. and Palop Borr{\'a}s, Bego{\~n}a and P{\'e}rez Jim{\'e}nez, Ana Bel{\'e}n and {Rodr{\'i}guez-Iglesias}, Manuel and Calvo Gasc{\'o}n, Ana Mar{\'i}a and Lou Alcaine, Mar{\'i}a Luz and Donate Su{\'a}rez, Ignacio and Su{\'a}rez {\'A}lvarez, Oscar and Rodr{\'i}guez P{\'e}rez, Mercedes and Cases Sanch{\'i}s, Margarita and Villaf{\'a}fila Gomila, Carlos Javier and Carbo Saladrigas, Lluis and Hurtado Fern{\'a}ndez, Adoraci{\'o}n and Oliver, Antonio and Castro Feliciano, El{\'i}as and Gonz{\'a}lez Quintana, Mar{\'i}a Noem{\'i} and Barrasa Fern{\'a}ndez, Jos{\'e} Mar{\'i}a and Hern{\'a}ndez Betancor, Mar{\'i}a Araceli and Hern{\'a}ndez Febles, Melisa and Mart{\'i}n Mart{\'i}n, Leopoldo and L{\'o}pez L{\'o}pez, Luis-Mariano and Ugarte Miota, Teresa and De Benito Poblaci{\'o}n, In{\'e}s and Celada P{\'e}rez, Mar{\'i}a Sagrario and Vall{\'e}s Fern{\'a}ndez, Mar{\'i}a Natalia and Mat{\'e} Enr{\'i}quez, Tom{\'a}s and Villa Arranz, Miguel and {Dom{\'i}nguez-Gil Gonz{\'a}lez}, Marta and {Fern{\'a}ndez-Natal}, Isabel and Meg{\'i}as Lob{\'o}n, Gregoria and Mu{\~n}oz Bellido, Juan Luis and Ciruela, Pilar and {Mas i Casals}, Ariadna and Dolad{\'e} Bot{\'i}as, Maria and Marcos Maeso, M. Angeles and {P{\'e}rez del Campo}, D{\'u}nia and {F{\'e}lix de Castro}, Antonio and Lim{\'o}n Ram{\'i}rez, Ram{\'o}n and El{\'i}as Retamosa, Maria Francisca and Rubio Gonz{\'a}lez, Manuela and Blanco Lobeiras, Mar{\'i}a Sinda and Fuentes Losada, Alberto and Aguilera, Antonio and Bou, German and Caro, Yolanda and Marauri, Noem{\'i} and Soria Blanco, Luis Miguel and {del Cura Gonz{\'a}lez}, Isabel and Hern{\'a}ndez Pascual, Montserrat and Alonso Fern{\'a}ndez, Roberto and {Merino-Amador}, Paloma and Cabrera Castro, Natalia and Tom{\'a}s Lizcano, Aurora and Ram{\'i}rez Almagro, Crist{\'o}bal and Segovia Hern{\'a}ndez, Manuel and Ascunce Elizaga, Nieves and Ederra Sanz, Mar{\'i}a and Ezpeleta Baquedano, Carmen and Bustinduy Bascaran, Ana and Iglesias Tamayo, Susana and Elorduy Otazua, Luis and Benarroch Benarroch, Rebeca and Lopera Flores, Jes{\'u}s and {V{\'a}zquez de la Villa}, Antonia},
  year = {2020},
  month = jul,
  journal = {The Lancet},
  pages = {S0140673620314835},
  issn = {01406736},
  doi = {10.1016/S0140-6736(20)31483-5},
  langid = {spanish},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\G5ZA87FY\\informe_final.pdf}
}

@article{pollardGuideVaccinologyBasic2021,
  title = {A Guide to Vaccinology: From Basic Principles to New Developments},
  shorttitle = {A Guide to Vaccinology},
  author = {Pollard, Andrew J. and Bijker, Else M.},
  year = {2021},
  month = feb,
  journal = {Nature Reviews Immunology},
  volume = {21},
  number = {2},
  pages = {83--100},
  publisher = {{Nature Publishing Group}},
  issn = {1474-1741},
  doi = {10.1038/s41577-020-00479-7},
  abstract = {Immunization is a cornerstone of public health policy and is demonstrably highly cost-effective when used to protect child health. Although it could be argued that immunology has not thus far contributed much to vaccine development, in that most of the vaccines we use today were developed and tested empirically, it is clear that there are major challenges ahead to develop new vaccines for difficult-to-target pathogens, for which we urgently need a better understanding of protective immunity. Moreover, recognition of the huge potential and challenges for vaccines to control disease outbreaks and protect the older population, together with the availability of an array of new technologies, make it the perfect time for immunologists to be involved in designing the next generation of powerful immunogens. This Review provides an introductory overview of vaccines, immunization and related issues and thereby aims to inform a broad scientific audience about the underlying immunological concepts.},
  copyright = {2020 Springer Nature Limited},
  langid = {english},
  annotation = {Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype: Reviews Subject\_term: Infectious diseases;Vaccines Subject\_term\_id: infectious-diseases;vaccines},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\A67CAPRN\\Pollard and Bijker - 2021 - A guide to vaccinology from basic principles to n.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\Q8Q4CQF4\\s41577-020-00479-7.html}
}

@article{poschVerbreitungUndVorkommen,
  title = {{Verbreitung und Vorkommen von Coronavirusvarianten}},
  author = {Posch, Wilfried and Rizzoli, Elmar and Allerberger, Franz},
  pages = {15},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WU6YF3TP\\Posch et al. - Verbreitung und Vorkommen von Coronavirusvarianten.pdf}
}

@article{powell-jacksonInfectionPreventionControl2020,
  title = {Infection Prevention and Control Compliance in {{Tanzanian}} Outpatient Facilities: A Cross-Sectional Study with Implications for the Control of {{COVID-19}}},
  shorttitle = {Infection Prevention and Control Compliance in {{Tanzanian}} Outpatient Facilities},
  author = {{Powell-Jackson}, Timothy and King, Jessica J C and Makungu, Christina and Spieker, Nicole and Woodd, Susannah and Risha, Peter and Goodman, Catherine},
  year = {2020},
  month = may,
  journal = {The Lancet Global Health},
  issn = {2214-109X},
  doi = {10.1016/S2214-109X(20)30222-9},
  abstract = {Background As coronavirus disease 2019 (COVID-19) spreads, weak health systems must not become a vehicle for transmission through poor infection prevention and control practices. We assessed the compliance of health workers with infection prevention and control practices relevant to COVID-19 in outpatient settings in Tanzania, before the pandemic. Methods This study was based on a secondary analysis of cross-sectional data collected as part of a randomised controlled trial in private for-profit dispensaries and health centres and in faith-based dispensaries, health centres, and hospitals, in 18 regions. We observed provider\textendash patient interactions in outpatient consultation rooms, laboratories, and dressing rooms, and categorised infection prevention and control practices into four domains: hand hygiene, glove use, disinfection of reusable equipment, and waste management. We calculated compliance as the proportion of indications (infection risks) in which a health worker performed a correct action, and examined associations between compliance and health worker and facility characteristics using multilevel mixed-effects logistic regression models. Findings Between Feb 7 and April 5, 2018, we visited 228 health facilities, and observed at least one infection prevention and control indication in 220 facilities (118 [54\%] dispensaries, 66 [30\%] health centres, and 36 [16\%] hospitals). 18\hphantom{,}710 indications were observed across 734 health workers (49 [7\%] medical doctors, 214 [29\%] assistant medical officers or clinical officers, 106 [14\%] nurses or midwives, 126 [17\%] clinical assistants, and 238 [32\%] laboratory technicians or assistants). Compliance was 6{$\cdot$}9\% for hand hygiene (n=8655 indications), 74{$\cdot$}8\% for glove use (n=4915), 4{$\cdot$}8\% for disinfection of reusable equipment (n=841), and 43{$\cdot$}3\% for waste management (n=4299). Facility location was not associated with compliance in any of the infection prevention and control domains. Facility level and ownership were also not significantly associated with compliance, except for waste management. For hand hygiene, nurses and midwives (odds ratio 5{$\cdot$}80 [95\% CI 3{$\cdot$}91\textendash 8{$\cdot$}61]) and nursing and medical assistants (2{$\cdot$}65 [1{$\cdot$}67\textendash 4{$\cdot$}20]) significantly outperformed the reference category of assistant medical officers or clinical officers. For glove use, nurses and midwives (10{$\cdot$}06 [6{$\cdot$}68\textendash 15{$\cdot$}13]) and nursing and medical assistants (5{$\cdot$}93 [4{$\cdot$}05\textendash 8{$\cdot$}71]) also significantly outperformed the reference category. Laboratory technicians performed significantly better in glove use (11{$\cdot$}95 [8{$\cdot$}98\textendash 15{$\cdot$}89]), but significantly worse in hand hygiene (0{$\cdot$}27 [0{$\cdot$}17\textendash 0{$\cdot$}43]) and waste management (0{$\cdot$}25 [0{$\cdot$}14\textendash 0{$\cdot$}44] than the reference category. Health worker age was negatively associated with correct glove use and female health workers were more likely to comply with hand hygiene. Interpretation Health worker infection prevention and control compliance, particularly for hand hygiene and disinfection, was inadequate in these outpatient settings. Improvements in provision of supplies and health worker behaviours are urgently needed in the face of the current pandemic. Funding UK Medical Research Council, Economic and Social Research Council, Department for International Development, Global Challenges Research Fund, Wellcome Trust.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\I467Z64Y\\Powell-Jackson et al. - 2020 - Infection prevention and control compliance in Tan.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\6NH432WA\\S2214109X20302229.html}
}

@article{pratherReducingTransmissionSARSCoV22020,
  title = {Reducing Transmission of {{SARS-CoV-2}}},
  author = {Prather, Kimberly A. and Wang, Chia C. and Schooley, Robert T.},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc6197},
  abstract = {Masks and testing are necessary to combat asymptomatic spread in aerosols and droplets},
  chapter = {Perspective},
  copyright = {Copyright \textcopyright{} 2020, American Association for the Advancement of Science},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EZCGBKMC\\Prather et al. - 2020 - Reducing transmission of SARS-CoV-2.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\65VSNPID\\science.html}
}

@incollection{Preliminaries2017,
  title = {Preliminaries},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {1--47},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch1},
  abstract = {This chapter reviews the basic concepts of probability, stochastic processes, information theory, and convex optimization. The most fundamental example is the experiment where a fair coin is tossed a number of times. Independence is of crucial importance in probability and statistics. The chapter recommends considering different kinds of numerical characteristics of a random variable. Another useful quantity is the variance, which measures the spread or dispersion of the distribution. The square root of the variance is called the standard deviation. The theory for multiple random variables is similar to that for a single random variable. The proofs follow directly from the definitions of covariance and variance and the properties of the expectation. All transforms share an important uniqueness property, which states that two distributions are the same if and only if their respective transforms are the same. The chapter also discusses two of the main results in probability, which include the law of large numbers and the central limit theorem. Both are associated with sums of independent random variables.},
  chapter = {1},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {convex optimization,information theory,preliminaries,random variable,stochastic processes},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9C7J43RP\\2017 - Preliminaries.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\GF895JEU\\9781118631980.html}
}

@misc{PreliminaryFindingsMRNA,
  title = {Preliminary {{Findings}} of {{mRNA Covid-19 Vaccine Safety}} in {{Pregnant Persons}} | {{NEJM}}},
  howpublished = {https://www.nejm.org/doi/full/10.1056/NEJMoa2104983},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HTYZMWY6\\NEJMoa2104983.html}
}

@article{premEffectControlStrategies2020,
  title = {The Effect of Control Strategies to Reduce Social Mixing on Outcomes of the {{COVID-19}} Epidemic in {{Wuhan}}, {{China}}: A Modelling Study},
  shorttitle = {The Effect of Control Strategies to Reduce Social Mixing on Outcomes of the {{COVID-19}} Epidemic in {{Wuhan}}, {{China}}},
  author = {Prem, Kiesha and Liu, Yang and Russell, Timothy W. and Kucharski, Adam J. and Eggo, Rosalind M. and Davies, Nicholas and Flasche, Stefan and Clifford, Samuel and Pearson, Carl A. B. and Munday, James D. and Abbott, Sam and Gibbs, Hamish and Rosello, Alicia and Quilty, Billy J. and Jombart, Thibaut and Sun, Fiona and Diamond, Charlie and Gimma, Amy and van Zandvoort, Kevin and Funk, Sebastian and Jarvis, Christopher I. and Edmunds, W. John and Bosse, Nikos I. and Hellewell, Joel and Jit, Mark and Klepac, Petra},
  year = {2020},
  month = mar,
  journal = {The Lancet Public Health},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2468-2667},
  doi = {10.1016/S2468-2667(20)30073-6},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}In December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in Wuhan, China. Since then, the city of Wuhan has taken unprecedented measures in response to the outbreak, including extended school and workplace closures. We aimed to estimate the effects of physical distancing measures on the progression of the COVID-19 epidemic, hoping to provide some insights for the rest of the world.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}To examine how changes in population mixing have affected outbreak progression in Wuhan, we used synthetic location-specific contact patterns in Wuhan and adapted these in the presence of school closures, extended workplace closures, and a reduction in mixing in the general community. Using these matrices and the latest estimates of the epidemiological parameters of the Wuhan outbreak, we simulated the ongoing trajectory of an outbreak in Wuhan using an age-structured susceptible-exposed-infected-removed (SEIR) model for several physical distancing measures. We fitted the latest estimates of epidemic parameters from a transmission model to data on local and internationally exported cases from Wuhan in an age-structured epidemic framework and investigated the age distribution of cases. We also simulated lifting of the control measures by allowing people to return to work in a phased-in way and looked at the effects of returning to work at different stages of the underlying outbreak (at the beginning of March or April).{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Our projections show that physical distancing measures were most effective if the staggered return to work was at the beginning of April; this reduced the median number of infections by more than 92\% (IQR 66\textendash 97) and 24\% (13\textendash 90) in mid-2020 and end-2020, respectively. There are benefits to sustaining these measures until April in terms of delaying and reducing the height of the peak, median epidemic size at end-2020, and affording health-care systems more time to expand and respond. However, the modelled effects of physical distancing measures vary by the duration of infectiousness and the role school children have in the epidemic.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Restrictions on activities in Wuhan, if maintained until April, would probably help to delay the epidemic peak. Our projections suggest that premature and sudden lifting of interventions could lead to an earlier secondary peak, which could be flattened by relaxing the interventions gradually. However, there are limitations to our analysis, including large uncertainties around estimates of \emph{R}\textsubscript{0} and the duration of infectiousness.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}Bill \& Melinda Gates Foundation, National Institute for Health Research, Wellcome Trust, and Health Data Research UK.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32220655},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DLMNG4R4\\Prem et al. - 2020 - The effect of control strategies to reduce social .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\USDL2SMQ\\fulltext.html}
}

@misc{PresenceSARSCoV2Reactive,
  title = {Presence of {{SARS-CoV-2}} Reactive {{T}} Cells in {{COVID-19}} Patients and Healthy Donors | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.04.17.20061440v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2YD24J92\\2020.04.17.html}
}

@misc{Presse,
  title = {Presse},
  howpublished = {http://www.statistik.at/web\_de/presse/123051.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\C3VS9X62\\123051.html}
}

@misc{Pressea,
  title = {Presse},
  howpublished = {https://www.statistik.at/web\_de/presse/124846.html},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PM5SAAZI\\124846.html}
}

@misc{PrevalenceOngoingSymptoms,
  title = {Prevalence of Ongoing Symptoms Following Coronavirus ({{COVID-19}}) Infection in the {{UK}} - {{Office}} for {{National Statistics}}},
  howpublished = {https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F4XS9W6F\\1april2021.html}
}

@misc{PrevalenciaCoronavirusConjunto,
  title = {{Prevalencia coronavirus - Conjunto de datos}},
  abstract = {El dato de prevalencia indica las personas que cada d\'ia siguen siendo compatibles con COVID19. Datos diarios en cada zona b\'asica de salud. El dataset se ...},
  howpublished = {http://datos.gob.es/es/catalogo/a07002862-prevalencia-coronavirus},
  langid = {spanish},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\22AWYX74\\a07002862-prevalencia-coronavirus.html}
}

@book{PreventingTransmissionPandemic2011,
  title = {Preventing {{Transmission}} of {{Pandemic Influenza}} and {{Other Viral Respiratory Diseases}}: {{Personal Protective Equipment}} for {{Healthcare Personnel}}: {{Update}} 2010},
  shorttitle = {Preventing {{Transmission}} of {{Pandemic Influenza}} and {{Other Viral Respiratory Diseases}}},
  year = {2011},
  month = apr,
  pages = {13027},
  publisher = {{National Academies Press}},
  address = {{Washington, D.C.}},
  doi = {10.17226/13027},
  isbn = {978-0-309-16254-8},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ESGS6UR9\\2011 - Preventing Transmission of Pandemic Influenza and .pdf}
}

@article{pritchardImpactVaccinationSARSCoV2,
  title = {Impact of Vaccination on {{SARS-CoV-2}} Cases in the Community: A Population-Based Study Using the {{UK}}'s {{COVID-19 Infection Survey}}},
  author = {Pritchard, Emma and Matthews, Philippa C and Stoesser, Nicole and Eyre, David W and Vihta, Karina-Doris and Jones, Joel and House, Thomas and VanSteenHouse, Harper and Bell, Iain and Bell, John I and Newton, John N and Farrar, Jeremy and Diamond, Ian and Rourke, Emma and Studley, Ruth and Peto, Tim and Walker, A Sarah and Pouwels, Koen B},
  pages = {37},
  abstract = {Objectives To assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV-2 infection in the community. Design Prospective cohort study. Setting The UK population-representative longitudinal COVID-19 Infection Survey. Participants 373,402 participants aged {$\geq$}16 years contributing 1,610,562 RT-PCR results from nose and throat swabs between 1 December 2020 and 3 April 2021. Main outcome measures New RT-PCR-positive episodes for SARS-CoV-2 overall, by self-reported symptoms, by cycle threshold (Ct) value ({$<$}30 versus {$\geq$}30), and by gene positivity (compatible with the B.1.1.7 variant versus not). Results Odds of new SARS-CoV-2 infection were reduced 65\% (95\% CI 60 to 70\%; P{$<$}0.001) in those {$\geq$}21 days since first vaccination with no second dose versus unvaccinated individuals without evidence of prior infection (RT-PCR or antibody). In those vaccinated, the largest reduction in odds was seen post second dose (70\%, 95\% CI 62 to 77\%; P{$<$}0.001).There was no evidence that these benefits varied between Oxford-AstraZeneca and Pfizer-BioNTech vaccines (P{$>$}0.9).There was no evidence of a difference in odds of new SARS-CoV-2 infection for individuals having received two vaccine doses and with evidence of prior infection but not vaccinated (P=0.89). Vaccination had a greater impact on reducing SARS-CoV-2 infections with evidence of high viral shedding Ct{$<$}30 (88\% reduction after two doses; 95\% CI 80 to 93\%; P{$<$}0.001) and with self-reported symptoms (90\% reduction after two doses; 95\% CI 82 to 94\%; P{$<$}0.001); effects were similar for different gene positivity patterns. Conclusion Vaccination with a single dose of Oxford-AstraZeneca or Pfizer-BioNTech vaccines, or two doses of Pfizer-BioNTech, significantly reduced new SARS-CoV-2 infections in this large community surveillance study. Greater reductions in symptomatic infections and/or infections with a higher viral burden are reflected in reduced rates of hospitalisations/deaths, but highlight the potential for limited ongoing transmission from asymptomatic infections in vaccinated individuals.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IHUEASRS\\Pritchard et al. - Impact of vaccination on SARS-CoV-2 cases in the c.pdf}
}

@misc{ProjectsNewsworthyJpp,
  title = {Projects {$\cdot$} {{Newsworthy}} / Jpp.2005.Excess.Deaths.Data},
  journal = {GitLab},
  abstract = {GitLab.com},
  howpublished = {https://gitlab.com/newsworthy/jpp.2005.excess.deaths.data},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VET22IIB\\jpp.2005.excess.deaths.html}
}

@misc{ProthromboticThrombocytopenicDisorder2021,
  title = {A {{Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination}}},
  year = {2021},
  month = mar,
  doi = {10.21203/rs.3.rs-362354/v1},
  abstract = {Research Square is a preprint platform that makes research communication faster, fairer, and more useful.},
  howpublished = {https://www.researchsquare.com},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2N4Q3YY7\\2021 - A Prothrombotic Thrombocytopenic Disorder Resembli.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZFCPUQMY\\v1.html}
}

@article{prunasVaccinationBNT162b2Reduces2021,
  title = {Vaccination with {{BNT162b2}} Reduces Transmission of {{SARS-CoV-2}} to Household Contacts in {{Israel}}},
  author = {Prunas, Ottavia and Warren, Joshua L and Crawford, Forrest W and Gazit, Sivan and Weinberger, Daniel M and Pitzer, Virginia E},
  year = {2021},
  pages = {26},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F7DDAQ2B\\Prunas et al. - 2021 - Vaccination with BNT162b2 reduces transmission of .pdf}
}

@misc{QuantifyingPopulationContact,
  title = {Quantifying Population Contact Patterns in the {{United States}} during the {{COVID-19}} Pandemic | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.04.13.20064014v2},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SE9V6ZKC\\2020.04.13.html}
}

@article{raderCrowdingShapeCOVID192020,
  title = {Crowding and the Shape of {{COVID-19}} Epidemics},
  author = {Rader, Benjamin and Scarpino, Samuel V. and Nande, Anjalika and Hill, Alison L. and Adlam, Ben and Reiner, Robert C. and Pigott, David M. and Gutierrez, Bernardo and Zarebski, Alexander E. and Shrestha, Munik and Brownstein, John S. and Castro, Marcia C. and Dye, Christopher and Tian, Huaiyu and Pybus, Oliver G. and Kraemer, Moritz U. G.},
  year = {2020},
  month = oct,
  journal = {Nature Medicine},
  pages = {1--6},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-1104-0},
  abstract = {The coronavirus disease 2019 (COVID-19) pandemic is straining public health systems worldwide, and major non-pharmaceutical interventions have been implemented to slow its spread1\textendash 4. During the initial phase of the outbreak, dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was primarily determined by human mobility from Wuhan, China5,6. Yet empirical evidence on the effect of key geographic factors on local epidemic transmission is lacking7. In this study, we analyzed highly resolved spatial variables in cities, together with case count data, to investigate the role of climate, urbanization and variation in interventions. We show that the degree to which cases of COVID-19 are compressed into a short period of time (peakedness of the epidemic) is strongly shaped by population aggregation and heterogeneity, such that epidemics in crowded cities are more spread over time, and crowded cities have larger total attack rates than less populated cities. Observed differences in the peakedness of epidemics are consistent with a meta-population model of COVID-19 that explicitly accounts for spatial hierarchies. We paired our estimates with globally comprehensive data on human mobility and predict that crowded cities worldwide could experience more prolonged epidemics.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QSSNKN4C\\Rader et al. - 2020 - Crowding and the shape of COVID-19 epidemics.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\EJWXTR9F\\s41591-020-1104-0.html}
}

@article{ramdasTestRetestRetest2020,
  title = {`{{Test}}, Re-Test, Re-Test': Using Inaccurate Tests to Greatly Increase the Accuracy of {{COVID-19}} Testing},
  shorttitle = {`{{Test}}, Re-Test, Re-Test'},
  author = {Ramdas, Kamalini and Darzi, Ara and Jain, Sanjay},
  year = {2020},
  month = may,
  journal = {Nature Medicine},
  pages = {1--2},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0891-7},
  copyright = {2020 Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DDDUGMH7\\Ramdas et al. - 2020 - Test, re-test, re-test using inaccurate tests t.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\YI6HXUJP\\s41591-020-0891-7.html}
}

@incollection{RandomNumberRandom2017,
  title = {Random {{Number}}, {{Random Variable}}, and {{Stochastic Process Generation}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {49--90},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch2},
  abstract = {This chapter describes the computer generation of random numbers, random variables, and stochastic processes. A good random number generator captures all the important statistical properties of true random sequences, even though the sequence is generated by a deterministic algorithm. For this reason these generators are sometimes called pseudorandom, with most computer languages already containing a built-in pseudorandom number generator. The simplest methods for generating pseudorandom sequences use the so-called linear congruential generators. Good random generators must have very large state spaces. The chapter also discusses various general methods for generating one-dimensional random variables from a prescribed distribution by considering the inverse-transform method and the acceptance\textendash rejection method. The inverse-transform and composition methods are direct methods in the sense that they deal directly with the cdf of the random variable to be generated. The acceptance\textendash rejection method is an indirect method due to Stan Ulam and John von Neumann.},
  chapter = {2},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {John von Neumann,number generator,random generators,random variables,stochastic process},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch2},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\US8TGJPD\\2017 - Random Number, Random Variable, and Stochastic Pro.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\AS8TWUN9\\9781118631980.html}
}

@misc{RapidImplementationMobile,
  title = {Rapid Implementation of Mobile Technology for Real-Time Epidemiology of {{COVID-19}} | {{Science}}},
  howpublished = {https://science-sciencemag-org.uaccess.univie.ac.at/content/early/2020/05/05/science.abc0473},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UIP66P49\\science.html}
}

@article{rauscherBehoerdlicheVorgangsweiseBei,
  title = {{Beh\"ordliche Vorgangsweise bei SARS-CoV-2 Kontaktpersonen: Kontaktpersonennachverfolgung}},
  author = {Rauscher, Julia},
  pages = {12},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZH94B23Z\\Rauscher - Behrdliche Vorgangsweise bei SARS-CoV-2 Kontaktpe.pdf}
}

@article{rauscherEmpfehlungBMSGPKZur,
  title = {{Empfehlung des BMSGPK zur Erstellung einer individuellen COVID-19 Risikoanalyse bez\"uglich eines schweren Krankheitsverlaufs}},
  author = {Rauscher, Julia},
  pages = {4},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4JILGEYP\\Rauscher - Empfehlung des BMSGPK zur Erstellung einer individ.pdf}
}

@article{rauscherEmpfehlungenBMSGPKSchutzmassnahmen,
  title = {{Empfehlungen des BMSGPK zu Schutzma\ss nahmen in Kinderg\"arten}},
  author = {Rauscher, Julia},
  pages = {4},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FZVWN2FB\\Rauscher - Empfehlungen des BMSGPK zu Schutzmanahmen in Kind.pdf}
}

@misc{redCoVClusterBetrifftBisher2020,
  title = {{CoV-Cluster betrifft bisher keine weiteren Firmen}},
  author = {at/Agenturen {red}, wien ORF},
  year = {2020},
  month = may,
  journal = {wien.ORF.at},
  abstract = {Post-Bedienstete haben in Wien und Nieder\"osterreich rund 50 Familien mit dem Coronavirus angesteckt. Alle werden jenem Cluster zugerechnet, um den zuletzt auch politisch gestritten wurde. Auf weitere Unternehmen hat er sich bislang nicht ausgeweitet.},
  howpublished = {https://wien.orf.at/stories/3050942/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ES58ZWKU\\3050942.html}
}

@misc{redGrosserCoVClusterWien2020,
  title = {{Gro\ss er CoV-Cluster in Wien}},
  author = {at/Agenturen {red}, wien ORF},
  year = {2020},
  month = may,
  journal = {wien.ORF.at},
  abstract = {Es gibt einen gro\ss en Coronavirus-Cluster in Wien: Die Ansteckungen im Asylheim Erdberg, bei der Post und in einem Liesinger Kindergarten h\"angen zusammen. Dabei gibt es stets einen Konnex zu Leiharbeitsfirmen. An die 80 Menschen sind allein in Wien infiziert.},
  howpublished = {https://wien.orf.at/stories/3048973/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YNM5BCSZ\\3048973.html}
}

@misc{redPostNetzNicht2020,
  title = {{Post: ,,Netz nicht zu 100 Prozent gespannt``}},
  shorttitle = {{Post}},
  author = {at/Agenturen {red}, noe ORF},
  year = {2020},
  month = may,
  journal = {noe.ORF.at},
  abstract = {Die Post ist rund um den Coronavirus-Ausbruch im Verteilzentrum Hagenbrunn (Bezirk Korneuburg) unter Druck geraten. Post-Chef Georg P\"olzl sprach nun von einer Vorsichtsma\ss nahme, man habe ,,das Netz aber nicht zu 100 Prozent gespannt``. Im Logistikzentrum Inzersdorf d\"urfte es bald den n\"achsten Bundesheer-Einsatz geben.},
  howpublished = {https://noe.orf.at/stories/3049235/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UAUQIVVV\\3049235.html}
}

@misc{redStatistikAustriaSchickt2020,
  title = {{Statistik Austria schickt Aussendungen vorab ins Kanzleramt}},
  author = {at/Agenturen {red}, ORF},
  year = {2020},
  month = may,
  journal = {news.ORF.at},
  howpublished = {https://orf.at/stories/3165949/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SL5WDDZG\\3165949.html}
}

@article{ReducingBetweenhouseholdTransmission2021,
  title = {Reducing Within- and between-Household Transmission in Light of New Variant {{SARS-CoV-2}}},
  year = {2021},
  pages = {24},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\P4HL9578\\2021 - Reducing within- and between-household transmissio.pdf}
}

@misc{ReichLabCOVID19,
  title = {Reich {{Lab COVID-19 Forecast Hub}}},
  abstract = {COVID-19 Forecasts - Cumulative Deaths},
  howpublished = {https://reichlab.io/covid19-forecast-hub/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6UA2T59M\\covid19-forecast-hub.html}
}

@article{rentelnFoolproofSamplingMathematical2005,
  title = {Foolproof: {{A Sampling}} of {{Mathematical Folk Humor}}},
  author = {Renteln, Paul and Dundes, Alan},
  year = {2005},
  volume = {52},
  number = {1},
  pages = {11},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\T9724EGN\\Renteln and Dundes - 2005 - Foolproof A Sampling of Mathematical Folk Humor.pdf}
}

@misc{RepeatedSeroprevalenceAntiSARSCoV2,
  title = {Repeated Seroprevalence of Anti-{{SARS-CoV-2 IgG}} Antibodies in a Population-Based Sample from {{Geneva}}, {{Switzerland}} | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.05.02.20088898v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4C5Y6VEA\\2020.05.02.html}
}

@misc{Report34COVID19,
  title = {Report 34 - {{COVID-19 Infection Fatality Ratio Estimates}} from {{Seroprevalence}}},
  journal = {Imperial College London},
  abstract = {Report 34 - COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence},
  howpublished = {http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/},
  langid = {british},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7X7ZG6T6\\report-34-ifr.html}
}

@misc{Report412020,
  title = {Report 41 - {{The}} 2020 {{SARS-CoV-2}} Epidemic in {{England}}: Key Epidemiological Drivers and Impact of Interventions},
  shorttitle = {Report 41 - {{The}} 2020 {{SARS-CoV-2}} Epidemic in {{England}}},
  journal = {Imperial College London},
  abstract = {Report 41 - The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact of interventions},
  howpublished = {http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-41-rtm/},
  langid = {british},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UKYWFD6C\\report-41-rtm.html}
}

@misc{Report43Quantifying,
  title = {Report 43 - {{Quantifying}} the Impact of Vaccine Hesitancy in Prolonging the Need for {{Non-Pharmaceutical Interventions}} to Control the {{COVID-19}} Pandemic},
  journal = {Imperial College London},
  abstract = {Report 43 - Quantifying the impact of vaccine hesitancy in prolonging the need for Non-Pharmaceutical Interventions to control the COVID-19 pandemic},
  howpublished = {http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-43-vaccine-hesitancy/},
  langid = {british},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\M3AI37GY\\report-43-vaccine-hesitancy.html}
}

@article{ReportEpidemiologicalFeatures2020,
  title = {Report on the {{Epidemiological Features}} of {{Coronavirus Disease}} 2019 ({{COVID-19}}) {{Outbreak}} in the {{Republic}} of {{Korea}} from {{January}} 19 to {{March}} 2, 2020},
  year = {2020},
  month = mar,
  journal = {Journal of Korean Medical Science},
  volume = {35},
  number = {10},
  issn = {1011-8934},
  doi = {10.3346/jkms.2020.35.e112},
  abstract = {Since the first case of coronavirus disease19 (COVID-19) was reported in Wuhan, China, as of March 2, 2020, the total number of confirmed cases of COVID-19 was 89,069 cases in 67 countries and regions. As of 0 am, March 2, 2020, the Republic of Korea had the second-largest number of confirmed cases (n = 4,212) after China (n = 80,026). This report summarizes the epidemiologic features and the snapshots of the outbreak in the Republic of Korea from January 19 and March 2, 2020.},
  pmcid = {PMC7073313},
  pmid = {32174069},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UWIDAICD\\2020 - Report on the Epidemiological Features of Coronavi.pdf}
}

@article{ReproductionNumberGrowth2020,
  title = {Reproduction Number ({{R}}) and Growth Rate (r) of the {{COVID-19}} Epidemic in the {{UK}}},
  year = {2020},
  pages = {86},
  langid = {english}
}

@article{ReproductionNumberStructured2009,
  title = {The Reproduction Number \${{R}}\_t\$ in Structured and Nonstructured Populations},
  year = {2009},
  journal = {Mathematical Biosciences and Engineering},
  volume = {6},
  number = {2},
  pages = {239--259},
  issn = {1551-0018},
  doi = {10.3934/mbe.2009.6.239},
  abstract = {Using daily counts of newly infected individuals, Wallinga and Teunis (WT) introduced a conceptually simple method to estimate the number of secondary cases per primary case (Rt) for a given day. The method requires an estimate of the generation interval probability density function (pdf), which specifies the probabilities for the times between symptom onset in a primary case and symptom onset in a corresponding secondary case. Other methods to estimate Rt are based on explicit models such as the SIR model; therefore, one might expect the WT method to be more robust to departures from SIRtype behavior. This paper uses simulated data to compare the quality of daily Rt estimates based on a SIR model to those using the WT method for both structured (classical SIR assumptions are violated) and nonstructured (classical SIR assumptions hold) populations. By using detailed simulations that record the infection day of each new infection and the donor-recipient identities, the true Rt and the generation interval pdf is known with negligible error. We find that the generation interval pdf is time dependent in all cases, which agrees with recent results reported elsewhere. We also find that the WT method performs essentially the same in the structured populations (except for a spatial network) as it does in the nonstructured population. And, the WT method does as well or better than a SIR-model based method in three of the four structured populations. Therefore, even if the contact patterns are heterogeneous as in the structured populations evaluated here, the WT method provides reasonable estimates of Rt, as does the SIR method.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZFMUKV3J\\2009 - The reproduction number $R_t$ in structured and no.pdf}
}

@article{ReproductionNumberStructured2009a,
  title = {The Reproduction Number \${{R}}\_t\$ in Structured and Nonstructured Populations},
  year = {2009},
  journal = {Mathematical Biosciences and Engineering},
  volume = {6},
  number = {2},
  pages = {239},
  publisher = {{AIMS Press}},
  doi = {10.3934/mbe.2009.6.239},
  abstract = {Using daily counts of newly infected individuals, Wallinga and Teunis  (WT) introduced a conceptually simple method to estimate the number of secondary cases per primary case (\$R\_t\$) for a given day. The method requires an estimate of the generation interval probability density function (pdf), which specifies the probabilities for the times between symptom onset in a primary case and symptom onset in a corresponding secondary case. Other methods to estimate \$R\_t\$ are based on explicit models such as the SIR model; therefore, one might expect the WT method to be more robust to departures from SIR-type behavior. This paper uses simulated data to compare the quality of daily \$R\_t\$ estimates based on a SIR model to those using the WT method for both structured (classical SIR assumptions are violated) and nonstructured (classical SIR assumptions hold) populations. By using detailed simulations that record the infection day of each new infection and the donor-recipient identities, the true \$R\_t\$ and the generation interval pdf is known with negligible error. We find that the generation interval pdf is time dependent in all cases, which  agrees with recent results reported elsewhere. We also find that the WT method performs essentially the same in the structured populations (except for a spatial network)  as it does in the nonstructured population. And, the WT method does as well or better than a SIR-model based method in three of the four structured populations. Therefore, even if the contact patterns are  heterogeneous as in the structured populations evaluated here, the WT method provides reasonable estimates of \$R\_t\$, as does the SIR method.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LRKJ74KT\\mbe.2009.6.html}
}

@misc{ResearchersNearlyHalf,
  title = {Researchers: {{Nearly Half Of Accounts Tweeting About Coronavirus Are Likely Bots}}},
  shorttitle = {Researchers},
  journal = {NPR.org},
  abstract = {Researchers culled through more than 200 million tweets  discussing the virus since January and found that about 45\% were sent by accounts that behave more like computerized robots than humans.},
  howpublished = {https://www.npr.org/sections/coronavirus-live-updates/2020/05/20/859814085/researchers-nearly-half-of-accounts-tweeting-about-coronavirus-are-likely-bots},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\URYIZE7M\\researchers-nearly-half-of-accounts-tweeting-about-coronavirus-are-likely-bots.html}
}

@article{restifVaccinationDynamicsImmune2007,
  title = {Vaccination and the Dynamics of Immune Evasion},
  author = {Restif, Olivier and Grenfell, Bryan T},
  year = {2007},
  month = feb,
  journal = {Journal of The Royal Society Interface},
  volume = {4},
  number = {12},
  pages = {143--153},
  publisher = {{Royal Society}},
  doi = {10.1098/rsif.2006.0167},
  abstract = {Vaccines exert strong selective pressures on pathogens, favouring the spread of antigenic variants. We propose a simple mathematical model to investigate the dynamics of a novel pathogenic strain that emerges in a population where a previous strain is maintained at low endemic level by a vaccine. We compare three methods to assess the ability of the novel strain to invade and persist: algebraic rate of invasion; deterministic dynamics; and stochastic dynamics. These three techniques provide complementary predictions on the fate of the system. In particular, we emphasize the importance of stochastic simulations, which account for the possibility of extinctions of either strain. More specifically, our model suggests that the probability of persistence of an invasive strain (i) can be minimized for intermediate levels of vaccine cross-protection (i.e. immune protection against the novel strain) and (ii) is lower if cross-immunity acts through a reduced infectious period rather than through reduced susceptibility.},
  keywords = {antigenic diversity,Bordetella pertussis,cross-immunity},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YH4EU8GT\\Restif and Grenfell - 2007 - Vaccination and the dynamics of immune evasion.pdf}
}

@misc{RestrictionsNonessentialTravel,
  type = {Text},
  title = {Restrictions on Non-Essential Travel to the {{EU}}},
  journal = {European Commission - European Commission},
  abstract = {Coronavirus: Commission proposes to ease restrictions on non-essential travel to the EU while addressing variants through new `emergency brake' mechanism},
  howpublished = {https://ec.europa.eu/commission/presscorner/detail/en/ip\_21\_2121},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BIGIQ6I7\\ip_21_2121.html}
}

@article{richterEpidemiologischeParameterCOVID19,
  title = {{Epidemiologische Parameter des COVID19 Ausbruchs - Update 24.04.2020, \"Osterreich, 2020}},
  author = {Richter, Lukas and Schmid, Daniela and Chakeri, Ali and Maritschnik, Sabine and Pfeiffer, Sabine and Stadlober, Ernst},
  pages = {5},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GFGIJH9M\\Richter et al. - Epidemiologische Parameter des COVID19 Ausbruchs -.pdf}
}

@article{richterEpidemiologischeParameterCOVID19a,
  title = {{Epidemiologische Parameter des COVID19 Ausbruchs - Update 30.04.2020, \"Osterreich, 2020}},
  author = {Richter, Lukas and Schmid, Daniela and Chakeri, Ali and Maritschnik, Sabine and Pfeiffer, Sabine and Stadlober, Ernst},
  pages = {14},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2LN72UBT\\Richter et al. - Epidemiologische Parameter des COVID19 Ausbruchs -.pdf}
}

@article{richterMethodenbeschreibungFuerSchaetzung,
  title = {{Methodenbeschreibung f\"ur die Sch\"atzung von epidemiologischen Parametern des COVID19 Ausbruchs, \"Osterreich}},
  author = {Richter, Lukas and Schmid, Daniela and Stadlober, Ernst},
  pages = {4},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JJ9HA8MZ\\Richter et al. - Methodenbeschreibung fr die Schtzung von epidemi.pdf}
}

@article{richterMethodenbeschreibungFurSchatzung,
  title = {{Methodenbeschreibung f\"ur die Sch\"atzung von epidemiologischen Parametern des COVID19 Ausbruchs, \"Osterreich}},
  author = {Richter, Lukas and Schmid, Daniela and Stadlober, Ernst},
  pages = {4},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\A3SPLRH3\\Richter et al. - Methodenbeschreibung fr die Schtzung von epidemi.pdf}
}

@article{richterSchaetzungSeriellenIntervalles,
  title = {{Sch\"atzung des seriellen Intervalles von COVID19, \"Osterreich}},
  author = {Richter, Lukas and Schmid, Daniela and Chakeri, Ali and Maritschnik, Sabine and Pfeiffer, Sabine and Stadlober, Ernst},
  pages = {3},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XVGSI6RD\\Richter et al. - Schtzung des seriellen Intervalles von COVID19, .pdf}
}

@article{rileyResurgenceSARSCoV2Detection2021,
  title = {Resurgence of {{SARS-CoV-2}}: Detection by Community Viral Surveillance},
  shorttitle = {Resurgence of {{SARS-CoV-2}}},
  author = {Riley, Steven and Ainslie, Kylie E. C. and Eales, Oliver and Walters, Caroline E. and Wang, Haowei and Atchison, Christina and Fronterre, Claudio and Diggle, Peter J. and Ashby, Deborah and Donnelly, Christl A. and Cooke, Graham and Barclay, Wendy and Ward, Helen and Darzi, Ara and Elliott, Paul},
  year = {2021},
  month = apr,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abf0874},
  abstract = {Surveillance of the SARS-CoV-2 epidemic has mainly relied on case reporting which is biased by health service performance, test availability and test-seeking behaviors. We report a community-wide national representative surveillance program in England involving self-administered swab results from 594,000 individuals tested for SARS-CoV-2, regardless of symptoms, from May to beginning of September 2020. The epidemic declined between May and July 2020 but then increased gradually from mid-August, accelerating into early September 2020 at the start of the second wave. When compared to cases detected through routine surveillance, we report here a longer period of decline and a younger age distribution. Representative community sampling for SARS-CoV-2 can substantially improve situational awareness and feed into the public health response even at low prevalence.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {33893241},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5FTK5AJP\\Riley et al. - 2021 - Resurgence of SARS-CoV-2 detection by community v.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\I67SI2GS\\science.html}
}

@techreport{rippingerEvaluationUndetectedCases2020,
  type = {{{SSRN Scholarly Paper}}},
  title = {Evaluation of {{Undetected Cases During}} the {{COVID-19 Epidemic}} in {{Austria}}},
  author = {Rippinger, Claire and Bicher, Martin and Urach, Christoph and Brunmeir, Dominik and Zauner, G{\"u}nther and Sroczynski, Gabi and Jahn, B. and M{\"u}hlberger, Nikolai and Siebert, Uwe and Popper, Niki},
  year = {2020},
  month = oct,
  number = {ID 3689596},
  address = {{Rochester, NY}},
  institution = {{Social Science Research Network}},
  doi = {10.2139/ssrn.3689596},
  abstract = {Background: Knowing the number of undetected cases of COVID-19 is important for a better understanding of the spread of the disease. This study analyses the temporal dynamic of detected vs. undetected cases to provide guidance for the interpretation of prevalence and incidence studies performed to estimate the detection rate.Methods: We used an agent-based model to evaluate assumptions on the detection probability ranging from 0{$\cdot$}1 to 0{$\cdot$}9. For each general detection probability, we derived age-dependent detection probabilities and calibrated the model to reproduce the epidemic wave of COVID-19 in Austria from March 2020 to June 2020. We categorized infected individuals into presymptomatic, symptomatic unconfirmed, confirmed and never detected to observe the simulated dynamic of the detected and undetected cases.Findings: The calculation of the age-dependent detection probability ruled values lower than 0{$\cdot$}4 as most likely. Furthermore, the proportion of undetected cases depends strongly on the dynamic of the epidemic wave: during the initial upswing, the undetected cases account for a major part of all infected individuals, whereas their share decreases around the peak of the confirmed cases.Interpretation: The results of prevalence studies performed to determine the detection rate of COVID-19 patients should always be interpreted with regard to the current dynamic of the epidemic wave. Applying the method proposed in our analysis, the prevalence study performed in Austria in April 2020 could indicate a detection rate of 0{$\cdot$}13, instead of the prevalent ratio of 0{$\cdot$}29 between detected and estimated undetected cases at that time.Funding: This study has been partially funded by The Austrian Research Promotion Agency (FFG) Covid19 Emergency Call, the WWTF-COVID-19 Rapid Response Funding, the Medizinisch-Wissenschaftlicher Fonds des B\"urgermeisters der Bundeshauptstadt Wien, and the Society for Medical Decision Making (SMDM) Covid-19 Decision Modeling Initiative.Declaration of Interests: The authors declare that they have no competing interests.},
  langid = {english},
  keywords = {agent-based,COVID-19,Detection,Simulation},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QNBJD4EU\\papers.html}
}

@misc{RISRundfunkgebuhrengesetzBundesrecht,
  title = {{{RIS}} - {{Rundfunkgeb\"uhrengesetz}} - {{Bundesrecht}} Konsolidiert, {{Fassung}} Vom 06.03.2021},
  howpublished = {https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen\&Gesetzesnummer=10012892},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EGAWQX82\\GeltendeFassung.html}
}

@misc{RoutineAsymptomaticTesting,
  title = {Routine Asymptomatic Testing Strategies for Airline Travel during the {{COVID-19}} Pandemic: A Simulation Study - {{The Lancet Infectious Diseases}}},
  howpublished = {https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00134-1/fulltext},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RAPBLT9D\\fulltext.html}
}

@book{rubinsteinSimulationMonteCarlo2017,
  title = {Simulation and the {{Monte Carlo}} Method},
  author = {Rubinstein, Reuven Y. and Kroese, Dirk P.},
  year = {2017},
  series = {Wiley Series in Probability and Statistics},
  edition = {Third edition},
  publisher = {{John Wiley \& Sons, Inc}},
  address = {{Hoboken, New Jersey}},
  isbn = {978-1-118-63220-8 978-1-118-63238-3},
  langid = {english},
  lccn = {QA298},
  keywords = {Digital computer simulation,Mathematical statistics,Monte Carlo method,Sampling (Statistics)},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MU69F73P\\Rubinstein and Kroese - 2017 - Simulation and the Monte Carlo method.pdf}
}

@article{ruktanonchaiAssessingImpactCoordinated2020,
  title = {Assessing the Impact of Coordinated {{COVID-19}} Exit Strategies across {{Europe}}},
  author = {Ruktanonchai, N. W. and Floyd, J. R. and Lai, S. and Ruktanonchai, C. W. and Sadilek, A. and {Rente-Lourenco}, P. and Ben, X. and Carioli, A. and Gwinn, J. and Steele, J. E. and Prosper, O. and Schneider, A. and Oplinger, A. and Eastham, P. and Tatem, A. J.},
  year = {2020},
  month = sep,
  journal = {Science},
  volume = {369},
  number = {6510},
  pages = {1465--1470},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc5096},
  abstract = {Better relaxing lockdown together Even during a pandemic, all countries\textemdash even islands\textemdash are dependent in one way or another on their neighbors. Without coordinated relaxation of nonpharmaceutical interventions (NPIs) among the most closely connected countries, it is difficult to envisage maintaining control of infectious viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ruktanonchai et al. used mobility data from smartphones to estimate movements between administrative units across Europe before and after the implementation of NPIs for coronavirus disease 2019 (COVID-19). Modeling disease dynamics under alternative scenarios of countries releasing NPIs, in particular stay-at-home orders, showed that if countries do not coordinate their NPIs when they relax lockdown, resurgence of disease occurs sooner. Coordination of on-off NPIs would significantly increase their effectiveness at reducing transmission across Europe. Science, this issue p. 1465 As rates of new coronavirus disease 2019 (COVID-19) cases decline across Europe owing to nonpharmaceutical interventions such as social distancing policies and lockdown measures, countries require guidance on how to ease restrictions while minimizing the risk of resurgent outbreaks. We use mobility and case data to quantify how coordinated exit strategies could delay continental resurgence and limit community transmission of COVID-19. We find that a resurgent continental epidemic could occur as many as 5 weeks earlier when well-connected countries with stringent existing interventions end their interventions prematurely. Further, we find that appropriate coordination can greatly improve the likelihood of eliminating community transmission throughout Europe. In particular, synchronizing intermittent lockdowns across Europe means that half as many lockdown periods would be required to end continent-wide community transmission. Coordination among countries in easing restrictions is key to preventing resurgent COVID-19 outbreaks and stopping community transmission. Coordination among countries in easing restrictions is key to preventing resurgent COVID-19 outbreaks and stopping community transmission.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32680881},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RXXP6RMZ\\Ruktanonchai et al. - 2020 - Assessing the impact of coordinated COVID-19 exit .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\F7EYGPSS\\1465.html}
}

@article{salisburyHelenSalisburyBattening2020,
  title = {Helen {{Salisbury}}: {{Battening}} down the Hatches for a Second Wave},
  shorttitle = {Helen {{Salisbury}}},
  author = {Salisbury, Helen},
  year = {2020},
  month = may,
  journal = {BMJ},
  volume = {369},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.m2076},
  abstract = {Autonomy is one of the four pillars of Western medical ethics. People have a right to make their own decisions about what treatment to accept, as long as they have capacity to do so.1 My patients can\textemdash and often do\textemdash stop taking the tablets I prescribe for their diabetes or hypertension, refuse surgery that could be curative, and ignore advice about alcohol, exercise, or smoking. It's my job to provide\textemdash accurately, clearly, and to the best of my knowledge\textemdash the information on which to base their decisions, and it's their right to ignore it. Infectious diseases are an exception to the rules \ldots},
  chapter = {Views \&amp; Reviews},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KSM2C4KQ\\Salisbury - 2020 - Helen Salisbury Battening down the hatches for a .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WGGQNVCH\\bmj.html}
}

@article{saljeEstimatingBurdenSARSCoV22020,
  title = {Estimating the Burden of {{SARS-CoV-2}} in {{France}}},
  author = {Salje, Henrik and Kiem, C{\'e}cile Tran and Lefrancq, No{\'e}mie and Courtejoie, No{\'e}mie and Bosetti, Paolo and Paireau, Juliette and Andronico, Alessio and Hoz{\'e}, Nathana{\"e}l and Richet, Jehanne and Dubost, Claire-Lise and Strat, Yann Le and Lessler, Justin and {Levy-Bruhl}, Daniel and Fontanet, Arnaud and Opatowski, Lulla and Boelle, Pierre-Yves and Cauchemez, Simon},
  year = {2020},
  month = may,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc3517},
  abstract = {France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 3.6\% of infected individuals are hospitalized and 0.7\% die, ranging from 0.001\% in those {$<$}20 years of age (ya) to 10.1\% in those {$>$}80ya. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77\% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project 2.8 million (range: 1.8\textendash 4.7) people, or 4.4\% (range: 2.8\textendash 7.2) of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32404476},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IX3NEBNR\\Salje et al. - 2020 - Estimating the burden of SARS-CoV-2 in France.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\K8XR2M7C\\science.html}
}

@article{saljeEstimatingBurdenSARSCoV22020a,
  title = {Estimating the Burden of {{SARS-CoV-2}} in {{France}}},
  author = {Salje, Henrik and Tran Kiem, C{\'e}cile and Lefrancq, No{\'e}mie and Courtejoie, No{\'e}mie and Bosetti, Paolo and Paireau, Juliette and Andronico, Alessio and Hoz{\'e}, Nathana{\"e}l and Richet, Jehanne and Dubost, Claire-Lise and Le Strat, Yann and Lessler, Justin and {Levy-Bruhl}, Daniel and Fontanet, Arnaud and Opatowski, Lulla and Boelle, Pierre-Yves and Cauchemez, Simon},
  year = {2020},
  month = may,
  journal = {Science},
  pages = {eabc3517},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abc3517},
  abstract = {France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 3.6\% of infected individuals are hospitalized and 0.7\% die, ranging from 0.001\% in those {$<$}20 years of age (ya) to 10.1\% in those {$>$}80ya. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77\% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project 2.8 million (range: 1.8\textendash 4.7) people, or 4.4\% (range: 2.8\textendash 7.2) of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VS4MGXY9\\Salje et al. - 2020 - Estimating the burden of SARS-CoV-2 in France.pdf}
}

@misc{salvatoreTransmissionPotentialVaccinated2021,
  title = {Transmission Potential of Vaccinated and Unvaccinated Persons Infected with the {{SARS-CoV-2 Delta}} Variant in a Federal Prison, {{July-August}} 2021},
  author = {Salvatore, Phillip P. and Lee, Christine C. and Sleweon, Sadia and McCormick, David W. and Nicolae, Lavinia and Knipe, Kristen and Dixon, Thomas and Banta, Robert and Ogle, Isaac and Young, Cristen and Dusseau, Charles and Salmonson, Shawn and Ogden, Charles and Godwin, Eric and Ballom, TeCora and Ross, Tara and Wynn, Nhien Tran and David, Ebenezer and Bessey, Theresa K. and Kim, Gimin and Suppiah, Suganthi and Tamin, Azaibi and Harcourt, Jennifer L. and Sheth, Mili and Lowe, Luis and Browne, Hannah and Tate, Jacqueline E. and Kirking, Hannah L. and Hagan, Liesl M.},
  year = {2021},
  month = nov,
  pages = {2021.11.12.21265796},
  institution = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2021.11.12.21265796},
  abstract = {Background The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons. Methods Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis. Results A total of 978 specimens were provided by 95 participants, of whom 78 (82\%) were fully vaccinated and 17 (18\%) were not fully vaccinated. No significant differences were detected in duration of RT-PCR positivity among fully vaccinated participants (median: 13 days) versus those not fully vaccinated (median: 13 days; p=0.50), or in duration of culture positivity (medians: 5 days and 5 days; p=0.29). Among fully vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p=0.048) or Janssen (p=0.003) vaccine recipients. Conclusions As this field continues to develop, clinicians and public health practitioners should consider vaccinated persons who become infected with SARS-CoV-2 to be no less infectious than unvaccinated persons. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks.},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\77K9YTFN\\Salvatore et al. - 2021 - Transmission potential of vaccinated and unvaccina.pdf}
}

@article{samsuzzohaNumericalStudyInfluenza2010,
  title = {Numerical Study of an Influenza Epidemic Model with Diffusion},
  author = {Samsuzzoha, Md. and Singh, Manmohan and Lucy, David},
  year = {2010},
  month = dec,
  journal = {Applied Mathematics and Computation},
  volume = {217},
  number = {7},
  pages = {3461--3479},
  issn = {0096-3003},
  doi = {10.1016/j.amc.2010.09.017},
  abstract = {A diffusive epidemic model is investigated with a view to describe the transmission of influenza as an epidemic. The equations are solved numerically using the splitting method under different initial distribution of population density. It is shown that the initial population distribution and diffusion play an important role for spread of disease. It is also shown that interventions (medical and nonmedical) significantly slow down the spread of disease. Stability of equilibria of the numerical solutions are also established.},
  langid = {english},
  keywords = {Diffusion,Epidemic model,Infectious diseases,Influenza,Initial condition,RouthHurwitz stability conditions,Splitting method},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2A8JGAXY\\Samsuzzoha et al. - 2010 - Numerical study of an influenza epidemic model wit.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\WWQVSFYI\\S0096300310009641.html}
}

@article{SARSCoV2VariantData,
  title = {{{SARS-CoV-2}} Variant Data Update, {{England Version}} 17: 12 {{November}} 2021},
  pages = {30},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DPWDS9BI\\SARS-CoV-2 variant data update, England Version 17.pdf}
}

@misc{SARSCov2VariantenOesterreich,
  title = {{SARS-Cov-2-Varianten in \"Osterreich}},
  journal = {AGES - \"Osterreichische Agentur f\"ur Gesundheit und Ern\"ahrungssicherheit},
  abstract = {Die AGES informiert: SARS-Cov-2-Varianten in \"Osterreich},
  howpublished = {https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-oesterreich/},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IADWQSPH\\sars-cov-2-varianten-in-oesterreich.html}
}

@misc{SARSCoV2VariantOmicron,
  title = {The {{SARS-CoV-2}} Variant, {{Omicron}}, Shows Rapid Replication in Human Primary Nasal Epithelial Cultures and Efficiently Uses the Endosomal Route of Entry..Pdf},
  journal = {Google Docs},
  howpublished = {https://drive.google.com/file/d/1vam2PVMWvfRBczqs\_uZbnUixGja1QPZD/view?usp=sharing\&usp=embed\_facebook},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\K7KCPIJZ\\view.html}
}

@article{SARSCoV2VariantsConcern,
  title = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation in {{England}} - {{Technical}} Briefing 28},
  pages = {52},
  abstract = {This report has been published to continue to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOC) and variants under investigation (VUI). The specialist technical briefings contain early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MQSBM63A\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{SARSCoV2VariantsConcerna,
  title = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation},
  pages = {42},
  abstract = {This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOCs) and variants under investigation (VUIs). This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XJYGQVRC\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{SARSCoV2VariantsConcernb,
  title = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation},
  pages = {42},
  abstract = {This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOCs) and variants under investigation (VUIs). This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\R2IBPC8S\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{SARSCoV2VariantsConcernc,
  title = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation},
  pages = {42},
  abstract = {This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOC) and variants under investigation (VUI). This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4RAYQHWG\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{SARSCoV2VariantsConcernd,
  title = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation},
  pages = {17},
  abstract = {This report has been published to share the detailed variant surveillance analyses which contribute to the Omicron risk assessment. This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VSTFI94Q\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{sbarraEmotionalSequelaeNonmarital2005,
  title = {The Emotional Sequelae of Nonmarital Relationship Dissolution: {{Analysis}} of Change and Intraindividual Variability over Time},
  shorttitle = {The Emotional Sequelae of Nonmarital Relationship Dissolution},
  author = {Sbarra, David A. and Emery, Robert E.},
  year = {2005},
  month = jun,
  journal = {Personal Relationships},
  volume = {12},
  number = {2},
  pages = {213--232},
  issn = {1475-6811},
  doi = {10.1111/j.1350-4126.2005.00112.x},
  abstract = {This paper examined the emotional sequelae of nonmarital relationship dissolution among 58 young adults. Participants were recruited while in a serious dating relationship, and when it ended, were signaled randomly with beepers for 28 days to complete an emotions diary. Compared to participants in intact dating relationships, dissolution participants reported more emotional volatility, especially immediately following the breakup. Multilevel growth modeling showed a linear decline in love and curvilinear patterns for sadness, anger, and relief. Contact with a former partner slowed the decline for love and sadness, and attachment style and the impact of the breakup predicted the emotional start-points and rate(s) of change over time. The results are discussed in terms of the functional role of postrelationship emotions as well as the importance of understanding patterns of intraindividual variability and differential predictors of emotional change.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2KF4DB8B\\Sbarra and Emery - 2005 - The emotional sequelae of nonmarital relationship .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\67WWGCQ7\\Sbarra and Emery - 2005 - The emotional sequelae of nonmarital relationship .html}
}

@misc{SchatzungAktuellenEntwicklung,
  title = {Sch\"atzung Der Aktuellen {{Entwicklung}} Der {{SARS-CoV-2-Epidemie}} in {{Deutschland}} \textendash{} {{Nowcasting}}},
  howpublished = {https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/17\_20\_SARS-CoV2\_vorab.pdf?\_\_blob=publicationFile},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\F2RKRA7E\\17_20_SARS-CoV2_vorab.pdf}
}

@article{schlosserCOVID19LockdownInduces2020,
  title = {{{COVID-19}} Lockdown Induces Disease-Mitigating Structural Changes in Mobility Networks},
  author = {Schlosser, Frank and Maier, Benjamin F. and Jack, Olivia and Hinrichs, David and Zachariae, Adrian and Brockmann, Dirk},
  year = {2020},
  month = dec,
  journal = {Proceedings of the National Academy of Sciences},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.2012326117},
  abstract = {In the wake of the COVID-19 pandemic many countries implemented containment measures to reduce disease transmission. Studies using digital data sources show that the mobility of individuals was effectively reduced in multiple countries. However, it remains unclear whether these reductions caused deeper structural changes in mobility networks and how such changes may affect dynamic processes on the network. Here we use movement data of mobile phone users to show that mobility in Germany has not only been reduced considerably: Lockdown measures caused substantial and long-lasting structural changes in the mobility network. We find that long-distance travel was reduced disproportionately strongly. The trimming of long-range network connectivity leads to a more local, clustered network and a moderation of the ``small-world'' effect. We demonstrate that these structural changes have a considerable effect on epidemic spreading processes by ``flattening'' the epidemic curve and delaying the spread to geographically distant regions.},
  chapter = {Physical Sciences},
  copyright = {Copyright \textcopyright{} 2020 the Author(s). Published by PNAS.. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).},
  langid = {english},
  keywords = {COVID-19,human mobility,mobile phones},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SLJHH8YZ\\Schlosser et al. - 2020 - COVID-19 lockdown induces disease-mitigating struc.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\3UEAWMWH\\2012326117.html}
}

@article{schultzThrombosisThrombocytopeniaChAdOx12021,
  title = {Thrombosis and {{Thrombocytopenia}} after {{ChAdOx1 nCoV-19 Vaccination}}},
  author = {Schultz, Nina H. and S{\o}rvoll, Ingvild H. and Michelsen, Annika E. and Munthe, Ludvig A. and {Lund-Johansen}, Fridtjof and Ahlen, Maria T. and Wiedmann, Markus and Aamodt, Anne-Hege and Skatt{\o}r, Thor H. and Tj{\o}nnfjord, Geir E. and Holme, P{\aa}l A.},
  year = {2021},
  month = apr,
  journal = {New England Journal of Medicine},
  volume = {0},
  number = {0},
  pages = {null},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2104882},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa2104882},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QE77ZCH9\\Schultz et al. - 2021 - Thrombosis and Thrombocytopenia after ChAdOx1 nCoV.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\6MGP8S3N\\NEJMoa2104882.html}
}

@article{schwartzAdolescentCOVID19Source2020,
  title = {Adolescent with {{COVID-19}} as the {{Source}} of an {{Outbreak}} at a 3-{{Week Family Gathering}} \textemdash{} {{Four States}}, {{June}}\textendash{{July}} 2020},
  author = {Schwartz, Noah G.},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6940e2},
  abstract = {This report describes an investigation of a COVID-19 outbreak during a 3-week family gathering of five households at which an adolescent aged 13 years was the index patient.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\98A3K7FS\\mm6940e2.html}
}

@article{schwartzAdolescentCOVID19Source2020a,
  title = {Adolescent with {{COVID-19}} as the {{Source}} of an {{Outbreak}} at a 3-{{Week Family Gathering}} \textemdash{} {{Four States}}, {{June}}\textendash{{July}} 2020},
  author = {Schwartz, Noah G.},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6940e2},
  abstract = {This report describes an investigation of a COVID-19 outbreak during a 3-week family gathering of five households at which an adolescent aged 13 years was the index patient.},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LURFVBW3\\Schwartz - 2020 - Adolescent with COVID-19 as the Source of an Outbr.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7DNSU2AI\\mm6940e2.html}
}

@misc{ScienceVsVirus,
  title = {Science vs. {{Virus}}},
  journal = {Hopkins Bloomberg Public Health Magazine},
  abstract = {Virologist Andy Pekosz surveys some of the strategies in the works to stop SARS-CoV-2.},
  howpublished = {https://magazine.jhsph.edu/2020/science-vs-virus},
  langid = {english}
}

@misc{ScienceVsVirusa,
  title = {Science vs. {{Virus}}},
  journal = {Hopkins Bloomberg Public Health Magazine},
  abstract = {Virologist Andy Pekosz surveys some of the strategies in the works to stop SARS-CoV-2.},
  howpublished = {https://magazine.jhsph.edu/2020/science-vs-virus},
  langid = {english}
}

@misc{ScienceVsVirusb,
  title = {Science vs. {{Virus}}},
  journal = {Hopkins Bloomberg Public Health Magazine},
  abstract = {Virologist Andy Pekosz surveys some of the strategies in the works to stop SARS-CoV-2.},
  howpublished = {https://magazine.jhsph.edu/2020/science-vs-virus},
  langid = {english}
}

@article{scireReproductiveNumberCOVID192020,
  title = {Reproductive Number of the {{COVID-19}} Epidemic in {{Switzerland}} with a Focus on the {{Cantons}} of {{Basel-Stadt}} and {{Basel-Landschaft}}},
  author = {Scire, Jeremie and Nadeau, Sarah and Vaughan, Timothy and Brupbacher, Gavin and Fuchs, Simon and Sommer, J{\"u}rg and Koch, Katrin N. and Misteli, Reto and Mundorff, Lukas and G{\"o}tz, Thomas and Eichenberger, Tobias and Quinto, Carlos and Savic, Miodrag and Meienberg, Andrea and Burkard, Thilo and Mayr, Michael and Meier, Christoph A. and Widmer, Andreas and Kuehl, Richard and Egli, Adrian and Hirsch, Hans H. and Bassetti, Stefano and Nickel, Christian H. and Rentsch, Katharina S. and K{\"u}bler, Werner and Bingisser, Roland and Battegay, Manuel and {Tschudin-Sutter}, Sarah and Stadler, Tanja},
  year = {2020},
  month = may,
  journal = {Swiss Medical Weekly},
  volume = {150},
  number = {1920},
  publisher = {{EMH Media}},
  doi = {10.4414/smw.2020.20271},
  abstract = {The reproductive number in Switzerland was between 1.5 and 2 during the first third of March, and has consistently decreased to around 1. After the announcement of the latest strict measure on 20 March 2020, namely that gatherings of more than five people in public spaces are prohibited, the reproductive number dropped significantly below 1; the authors of this study estimate the reproductive number to be between 0.6 and 0.8 in the first third of April.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZITZ6N62\\Scire et al. - 2020 - Reproductive number of the COVID-19 epidemic in Sw.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MWPTNZEN\\smw.2020.html}
}

@article{scohyLowPerformanceRapid2020,
  title = {Low Performance of Rapid Antigen Detection Test as Frontline Testing for {{COVID-19}} Diagnosis},
  author = {Scohy, Ana{\"i}s and Anantharajah, Ahalieyah and Bod{\'e}us, Monique and {Kabamba-Mukadi}, Beno{\^i}t and Verroken, Alexia and {Rodriguez-Villalobos}, Hector},
  year = {2020},
  month = aug,
  journal = {Journal of Clinical Virology},
  volume = {129},
  pages = {104455},
  issn = {1386-6532},
  doi = {10.1016/j.jcv.2020.104455},
  abstract = {Background Ensuring accurate diagnosis is essential to limit the spread of SARS-CoV-2 and for the clinical management of COVID-19. Although real-time reverse transcription polymerase chain reaction (RT- qPCR) is the current recommended laboratory method to diagnose SARS-CoV-2 acute infection, several factors such as requirement of special equipment and skilled staff limit the use of these time-consuming molecular techniques. Recently, several easy to perform rapid antigen detection tests were developed and recommended in some countries as the first line of diagnostic. Objectives The aim of this study was to evaluate the performances of the Coris COVID-19 Ag Respi-Strip test, a rapid immunochromatographic test for the detection of SARS-CoV-2 antigen, in comparison to RT-qPCR. Results 148 nasopharyngeal swabs were tested. Amongst the 106 positive RT-qPCR samples, 32 were detected by the rapid antigen test, given an overall sensitivity of 30.2\%. All the samples detected positive with the antigen rapid test were also positive with RT-qPCR. Conclusions Higher viral loads are associated with better antigen detection rates. Unfortunately, the overall poor sensitivity of the COVID-19 Ag Respi-Strip does not allow using it alone as the frontline testing for COVID-19 diagnosis.},
  langid = {english},
  keywords = {COVID-19,Rapid antigen detection test,SARS-CoV-2},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Y8F9CVSI\\Scohy et al. - 2020 - Low performance of rapid antigen detection test as.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BA9VFIB8\\S1386653220301979.html}
}

@article{scortichiniExcessMortalityCOVID19,
  title = {Excess Mortality during the {{COVID-19}} Outbreak in {{Italy}}: A Two-Stage Interrupted Time-Series Analysis},
  shorttitle = {Excess Mortality during the {{COVID-19}} Outbreak in {{Italy}}},
  author = {Scortichini, Matteo and {Schneider dos Santos}, Rochelle and De' Donato, Francesca and De Sario, Manuela and Michelozzi, Paola and Davoli, Marina and Masselot, Pierre and Sera, Francesco and Gasparrini, Antonio},
  journal = {International Journal of Epidemiology},
  doi = {10.1093/ije/dyaa169},
  abstract = {AbstractBackground.  Italy was the first country outside China to experience the impact of the COVID-19 pandemic, which resulted in a significant health burden.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JZWQ6FVZ\\Scortichini et al. - Excess mortality during the COVID-19 outbreak in I.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\XIATDKRT\\5923437.html}
}

@article{seesslePersistentSymptomsAdult2021,
  title = {Persistent Symptoms in Adult Patients One Year after {{COVID-19}}: A Prospective Cohort Study},
  shorttitle = {Persistent Symptoms in Adult Patients One Year after {{COVID-19}}},
  author = {See{\ss}le, Jessica and Waterboer, Tim and Hippchen, Theresa and Simon, Julia and Kirchner, Marietta and Lim, Adeline and M{\"u}ller, Barbara and Merle, Uta},
  year = {2021},
  month = jul,
  journal = {Clinical Infectious Diseases},
  number = {ciab611},
  issn = {1058-4838},
  doi = {10.1093/cid/ciab611},
  abstract = {Long COVID is defined as the persistence of symptoms beyond 3 months after SARS-CoV-2 infection. To better understand the long-term course and etiology of symptoms we analyzed a cohort of COVID-19 patients prospectively.Patients were included at 5 months after acute COVID-19 in this prospective, non-interventional follow-up study. Patients followed until 12 months after COVID-19 symptom onset (n=96, 32.3\% hospitalised, 55.2\% females) were included in this analysis of symptoms, quality of life (based on a SF-12 survey), laboratory parameters including antinuclear antibodies (ANA), and SARS-CoV-2 antibody levels.At month 12, only 22.9\% of patients were completely free of symptoms and the most frequent symptoms were reduced exercise capacity (56.3\%), fatigue (53.1\%), dyspnoea (37.5\%), concentration problems (39.6\%), problems finding words (32.3\%), and sleeping problems (26.0\%). Females showed significantly more neurocognitive symptoms than males.ANA titres were {$\geq$}1:160 in 43.6\% of patients at 12 months post COVID-19 symptom onset, and neurocognitive symptom frequency was significantly higher in the group with an ANA titre {$\geq$}1:160 compared to \&lt;1:160. Compared to patients without symptoms, patients with at least one long COVID symptom at 12 months did not differ significantly with respect to their SARS-CoV-2-antibody levels, but had a significantly reduced physical and mental life quality compared to patients without symptoms.Neurocognitive long COVID symptoms can persist at least for one year after COVID-19 symptom onset, and reduce life quality significantly. Several neurocognitive symptoms were associated with ANA titre elevations. This may indicate autoimmunity as cofactor in aetiology of long COVID.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3ZFPPAIA\\Seele et al. - 2021 - Persistent symptoms in adult patients one year aft.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\E2GB36TU\\6315216.html}
}

@incollection{SensitivityAnalysisMonte2017,
  title = {Sensitivity {{Analysis}} and {{Monte Carlo Optimization}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {221--256},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch7},
  abstract = {This chapter presents a discrete-event system that can be classified as either static or dynamic, with the former being discrete-event static systems (DESS). Sensitivity analysis can be employed to minimize the mean shortest path in the network with respect to network link parameters, subject to certain constraints. Program Evaluation and Review Technique (PERT) networks and flow networks are common examples. The performance measure might be a vehicle's average delay as it proceeds from a given origin to a given destination or the average number of vehicles waiting for a green light at a given intersection. Particular emphasis is placed on sensitivity analysis with respect to the distributional parameters of Markov chains using the dynamic version of the SF method. The main difference between Case A and Case B is that the former is associated with an on-line optimization approach, called stochastic approximation, while the latter is associated with an off-line optimization approach, called stochastic counterpart optimization or sample average approximation. The underlying idea in the stochastic counterpart approach is to replace all the expected value functions in the deterministic program by their sample average equivalents and then solve the latter by standard mathematical programming techniques.},
  chapter = {7},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {discrete-event static systems (DESS),off-line optimization approach,Program Evaluation and Review Technique (PERT),sample average approximation,standard mathematical programming techniques},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch7},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\73QX479D\\2017 - Sensitivity Analysis and Monte Carlo Optimization.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\JQXMLW45\\9781118631980.html}
}

@misc{SeoulMayorReiterates10:47,
  title = {{Seoul Mayor Reiterates Anonymous COVID-19 Testing For All Itaewon Visitors}},
  year = {10:47},
  abstract = {Seoul Mayor Park Won-soon says over 24,000 people have been tested for the novel coronavirus in connection to the Itaewon cluster, but risks remain an},
  chapter = {tbs},
  howpublished = {http://tbs.seoul.kr/eFm/newsView.do?typ\_800=O\&idx\_800=3387586\&seq\_800=20380163},
  langid = {korean-han},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BZVMT5IP\\newsView.html}
}

@misc{SerialIntervalBasic,
  title = {Serial Interval and Basic Reproduction Number of {{SARS-CoV-2 Omicron}} Variant in {{South Korea}} | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2021.12.25.21268301v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\NQGMAHQX\\2021.12.25.html}
}

@article{SeroepidemiologiskaStudierEfter,
  title = {{Seroepidemiologiska studier efter genomg\aa ngen covid-19 (Delrapport 1)}},
  pages = {3},
  langid = {swedish},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\H6V2XCLX\\Seroepidemiologiska studier efter genomgngen covi.pdf}
}

@techreport{sharmaUnderstandingEffectivenessGovernment2021,
  type = {{preprint}},
  title = {{Understanding the effectiveness of government interventions in Europe's second wave of COVID-19}},
  author = {Sharma, Mrinank and Mindermann, S{\"o}ren and {Rogers-Smith}, Charlie and Leech, Gavin and Snodin, Benedict and Ahuja, Janvi and Sandbrink, Jonas B. and Monrad, Joshua Teperowski and Altman, George and Dhaliwal, Gurpreet and Finnveden, Lukas and Norman, Alexander John and Oehm, Sebastian B. and Sandk{\"u}hler, Julia Fabienne and Mellan, Thomas and Kulveit, Jan and Chindelevitch, Leonid and Flaxman, Seth and Gal, Yarin and Mishra, Swapnil and Brauner, Jan Markus and Bhatt, Samir},
  year = {2021},
  month = mar,
  institution = {{Epidemiology}},
  doi = {10.1101/2021.03.25.21254330},
  abstract = {Abstract           As European governments face resurging waves of COVID-19, non-pharmaceutical interventions (NPIs) continue to be the primary tool for infection control. However, updated estimates of their relative effectiveness have been absent for Europe's second wave, largely due to a lack of collated data that considers the increased subnational variation and diversity of NPIs. We collect the largest dataset of NPI implementation dates in Europe, spanning 114 subnational areas in 7 countries, with a systematic categorisation of interventions tailored to the second wave. Using a hierarchical Bayesian transmission model, we estimate the effectiveness of 17 NPIs from local case and death data. We manually validate the data, address limitations in modelling from previous studies, and extensively test the robustness of our estimates. The combined effect of all NPIs was smaller relative to estimates from the first half of 2020, indicating the strong influence of safety measures and individual protective behaviours--such as distancing--that persisted after the first wave. Closing specific businesses was highly effective. Gathering restrictions were highly effective but only for the strictest limits. We find smaller effects for closing educational institutions compared to the first wave, suggesting that safer operation of schools was possible with a set of stringent safety measures including testing and tracing, preventing mixing, and smaller classes. These results underscore that effectiveness estimates from the early stage of an epidemic are measured relative to pre-pandemic behaviour. Updated estimates are required to inform policy in an ongoing pandemic.},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CH83CU6I\\Sharma et al. - 2021 - Understanding the effectiveness of government inte.pdf}
}

@article{sharmaUnderstandingEffectivenessGovernment2021a,
  title = {Understanding the Effectiveness of Government Interventions against the Resurgence of {{COVID-19}} in {{Europe}}},
  author = {Sharma, Mrinank and Mindermann, S{\"o}ren and {Rogers-Smith}, Charlie and Leech, Gavin and Snodin, Benedict and Ahuja, Janvi and Sandbrink, Jonas B. and Monrad, Joshua Teperowski and Altman, George and Dhaliwal, Gurpreet and Finnveden, Lukas and Norman, Alexander John and Oehm, Sebastian B. and Sandk{\"u}hler, Julia Fabienne and Aitchison, Laurence and Gaven{\v c}iak, Tom{\'a}{\v s} and Mellan, Thomas and Kulveit, Jan and Chindelevitch, Leonid and Flaxman, Seth and Gal, Yarin and Mishra, Swapnil and Bhatt, Samir and Brauner, Jan Markus},
  year = {2021},
  month = oct,
  journal = {Nature Communications},
  volume = {12},
  number = {1},
  pages = {5820},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-021-26013-4},
  abstract = {European governments use non-pharmaceutical interventions (NPIs) to control resurging waves of COVID-19. However, they only have outdated estimates for how effective individual NPIs were in the first wave. We estimate the effectiveness of 17 NPIs in Europe's second wave from subnational case and death data by introducing a flexible hierarchical Bayesian transmission model and collecting the largest dataset of NPI implementation dates across Europe. Business closures, educational institution closures, and gathering bans reduced transmission, but reduced it less than they did in the first wave. This difference is likely due to organisational safety measures and individual protective behaviours\textemdash such as distancing\textemdash which made various areas of public life safer and thereby reduced the effect of closing them. Specifically, we find smaller effects for closing educational institutions, suggesting that stringent safety measures made schools safer compared to the first wave. Second-wave estimates outperform previous estimates at predicting transmission in Europe's third wave.},
  copyright = {2021 The Author(s)},
  langid = {english},
  keywords = {Epidemiology},
  annotation = {Bandiera\_abtest: a Cc\_license\_type: cc\_by Cg\_type: Nature Research Journals Primary\_atype: Research Subject\_term: Epidemiology Subject\_term\_id: epidemiology},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\L6PF4TNJ\\Sharma et al. - 2021 - Understanding the effectiveness of government inte.pdf}
}

@article{sheikhSARSCoV2DeltaVOC2021,
  title = {{{SARS-CoV-2 Delta VOC}} in {{Scotland}}: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness},
  shorttitle = {{{SARS-CoV-2 Delta VOC}} in {{Scotland}}},
  author = {Sheikh, Aziz and McMenamin, Jim and Taylor, Bob and Robertson, Chris},
  year = {2021},
  month = jun,
  journal = {The Lancet},
  volume = {397},
  number = {10293},
  pages = {2461--2462},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(21)01358-1},
  abstract = {On May 19, 2021, the Delta Variant of Concern (VOC), formerly known as the Indian VOC or B 1.617.2, became the dominant strain of SARS-CoV-2 in Scotland. The Alpha VOC (formerly known as the Kent VOC, B.1.1.7, or S gene negative) had been the dominant strain previously, but it has rapidly been replaced (appendix p 1).},
  langid = {english},
  pmid = {34139198},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\43X7IZNY\\Sheikh et al. - 2021 - SARS-CoV-2 Delta VOC in Scotland demographics, ri.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\5MGDZPW9\\fulltext.html}
}

@article{shimabukuroCOVID19VaccineSafety,
  title = {{{COVID-19}} Vaccine Safety Update},
  author = {Shimabukuro, Tom and Covid, Cdc},
  pages = {40},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\W9Y34S3B\\Shimabukuro and Covid - COVID-19 vaccine safety update.pdf}
}

@article{simbana-riveraInterimAnalysisPandemic2020,
  title = {Interim {{Analysis}} of {{Pandemic Coronavirus Disease}} 2019 ({{COVID-19}}) and the {{SARS-CoV-2}} Virus in {{Latin America}} and the {{Caribbean}}: {{Morbidity}}, {{Mortality}} and {{Molecular Testing Trends}} in the {{Region}}},
  shorttitle = {Interim {{Analysis}} of {{Pandemic Coronavirus Disease}} 2019 ({{COVID-19}}) and the {{SARS-CoV-2}} Virus in {{Latin America}} and the {{Caribbean}}},
  author = {{Simbana-Rivera}, Katherine and {Gomez-Barreno}, Lenin and Guerrero, Jhon and {Simbana-Guaycha}, Fernanda and Fernandez, Raul and {Lopez-Cortes}, Andres and Lister, Alex and {Ortiz-Prado}, Esteban},
  year = {2020},
  month = apr,
  journal = {medRxiv},
  pages = {2020.04.25.20079863},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.04.25.20079863},
  abstract = {{$<$}p{$>$}Background: The relentless advance of the SARS-CoV-2 virus pandemic has resulted in a significant burden on countries, regardless of their socio-economic conditions. The virus has infected more than 2.5 million people worldwide, causing to date more than 150,000 deaths in over 210 countries. Objective: The aim of this study was to describe the trends in cases, tests and deaths related to novel coronavirus disease (COVID-19) in Latin American and Caribbean (LAC) countries. Methodology: Data were retrieved from the WHO-Coronavirus Disease (COVID-2019) situation reports and the Center for Systems Science and Engineering (CSSE) databases from Johns Hopkins University. Descriptive statistics including death rates, cumulative mortality and incidence rates, as well as testing rates per population at risk were performed. A comparison analysis among countries with {$\geq$}50 confirmed cases was performed from February 26th, 2020 to April 8th, 2020. Results: Brazil had the greatest number of cases and deaths in the region. Panama experienced a rapid increase in the number of confirmed cases with Trinidad and Tobago, Bolivia and Honduras having the highest case fatality rates. Panama and Chile conducted more tests per million inhabitants and more tests per day per million inhabitants, followed by Uruguay and El Salvador. Dominican Republic, Bolivia, Ecuador and Brazil had the highest positive test rates. Conclusions: The COVID-19 disease pandemic caused by the SARS-CoV-2 virus has progressed rapidly in LAC countries. Some countries have been affected more severely than others, with some adopting similar disease control methods to help slow down the spread of the virus. With limited testing and other resources, social distancing is needed to help alleviate the strain on already stretched health systems.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\MX63JSMN\\Simbana-Rivera et al. - 2020 - Interim Analysis of Pandemic Coronavirus Disease 2.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\LPSH7EKA\\2020.04.25.html}
}

@incollection{SimulationDiscreteEventSystems2017,
  title = {Simulation of {{Discrete-Event Systems}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {91--106},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch3},
  abstract = {This chapter introduces the art and science of computer simulation, in particular with regard to discrete-event systems. The chapter is solely concerned with discrete-event systems, to wit, those systems in which the state variables change instantaneously through jumps at discrete points in time, as opposed to continuous systems, where the state variables change continuously with respect to time. The fourth test is the so-called retrospective test. It involves using historical data to reconstruct the past and then determining how well the resulting solution would have performed if it had been used. An analytical solution is usually obtained directly from its mathematical representation in the form of formulas. The system may be so complex that a formulation in terms of a simple mathematical equation may be impossible. The knowledge obtained in designing a simulation study serves to crystallize the analyst's thinking and often suggests changes in the system being simulated.},
  chapter = {3},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {computer simulation,discrete-event systems,mathematical representation,retrospective test,state variables},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch3},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9YJD3N2T\\2017 - Simulation of Discrete-Event Systems.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\MISNH2D2\\9781118631980.html}
}

@book{SimulationMonteCarlo,
  title = {Simulation and the {{Monte Carlo Method}}, {{Third Edition}}}
}

@article{singanayagamDurationInfectiousnessCorrelation2020,
  title = {Duration of Infectiousness and Correlation with {{RT-PCR}} Cycle Threshold Values in Cases of {{COVID-19}}, {{England}}, {{January}} to {{May}} 2020},
  author = {Singanayagam, Anika and Patel, Monika and Charlett, Andre and Bernal, Jamie Lopez and Saliba, Vanessa and Ellis, Joanna and Ladhani, Shamez and Zambon, Maria and Gopal, Robin},
  year = {2020},
  month = aug,
  journal = {Eurosurveillance},
  volume = {25},
  number = {32},
  pages = {2001483},
  publisher = {{European Centre for Disease Prevention and Control}},
  issn = {1560-7917},
  doi = {10.2807/1560-7917.ES.2020.25.32.2001483},
  abstract = {Severe acute respiratory syndrome coronavirus 2 viral load in the upper respiratory tract peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate coronavirus disease (n = 324 samples analysed). RT-PCR cycle threshold (Ct) values correlate strongly with cultivable virus. Probability of culturing virus declines to 8\% in samples with Ct \&gt; 35 and to 6\% 10 days after onset; it is similar in asymptomatic and symptomatic persons. Asymptomatic persons represent a source of transmissible virus.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DWGAFDDB\\Singanayagam et al. - 2020 - Duration of infectiousness and correlation with RT.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KLFZPSYH\\1560-7917.ES.2020.25.32.html}
}

@article{singanayagamDurationInfectiousnessCorrelation2020a,
  title = {Duration of Infectiousness and Correlation with {{RT-PCR}} Cycle Threshold Values in Cases of {{COVID-19}}, {{England}}, {{January}} to {{May}} 2020},
  author = {Singanayagam, Anika and Patel, Monika and Charlett, Andre and Bernal, Jamie Lopez and Saliba, Vanessa and Ellis, Joanna and Ladhani, Shamez and Zambon, Maria and Gopal, Robin},
  year = {2020},
  month = aug,
  journal = {Eurosurveillance},
  volume = {25},
  number = {32},
  pages = {2001483},
  publisher = {{European Centre for Disease Prevention and Control}},
  issn = {1560-7917},
  doi = {10.2807/1560-7917.ES.2020.25.32.2001483},
  abstract = {Severe acute respiratory syndrome coronavirus 2 viral load in the upper respiratory tract peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate coronavirus disease (n = 324 samples analysed). RT-PCR cycle threshold (Ct) values correlate strongly with cultivable virus. Probability of culturing virus declines to 8\% in samples with Ct \&gt; 35 and to 6\% 10 days after onset; it is similar in asymptomatic and symptomatic persons. Asymptomatic persons represent a source of transmissible virus.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5VR8A9H9\\Singanayagam et al. - 2020 - Duration of infectiousness and correlation with RT.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\LKB7L9IP\\1560-7917.ES.2020.25.32.html}
}

@article{sipahiStabilityStabilizationSystems2011,
  title = {Stability and {{Stabilization}} of {{Systems}} with {{Time Delay}}},
  author = {Sipahi, Rifat and Niculescu, Silviu-Iulian and Abdallah, Chaouki and Michiels, Wim and Gu, Keqin},
  year = {2011},
  month = mar,
  journal = {Control Systems, IEEE},
  volume = {31},
  pages = {38--65},
  doi = {10.1109/MCS.2010.939135},
  abstract = {Time-delays are important components of many dynamical systems that describe coupling or interconnection between dynamics, propagation, or transport phenomena in shared environments, in heredity, and in competition in population dynamics. This monograph addresses the problem of stability analysis and the stabilisation of dynamical systems subjected to time-delays. It presents a wide and self-contained panorama of analytical methods and computational algorithms using a unified eigenvalue-based approach illustrated by examples and applications in electrical and mechanical engineering, biology, and complex network analysis.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\73S9WYSZ\\Sipahi et al. - 2011 - Stability and Stabilization of Systems with Time D.pdf}
}

@article{smithEffectivenessN95Respirators2016,
  title = {Effectiveness of {{N95}} Respirators versus Surgical Masks in Protecting Health Care Workers from Acute Respiratory Infection: A Systematic Review and Meta-Analysis},
  shorttitle = {Effectiveness of {{N95}} Respirators versus Surgical Masks in Protecting Health Care Workers from Acute Respiratory Infection},
  author = {Smith, Jeffrey D. and MacDougall, Colin C. and Johnstone, Jennie and Copes, Ray A. and Schwartz, Brian and Garber, Gary E.},
  year = {2016},
  month = may,
  journal = {CMAJ : Canadian Medical Association Journal},
  volume = {188},
  number = {8},
  pages = {567--574},
  issn = {0820-3946},
  doi = {10.1503/cmaj.150835},
  abstract = {Background: Conflicting recommendations exist related to which facial protection should be used by health care workers to prevent transmission of acute respiratory infections, including pandemic influenza. We performed a systematic review of both clinical and surrogate exposure data comparing N95 respirators and surgical masks for the prevention of transmissible acute respiratory infections. Methods: We searched various electronic databases and the grey literature for relevant studies published from January 1990 to December 2014. Randomized controlled trials (RCTs), cohort studies and case\textendash control studies that included data on health care workers wearing N95 respirators and surgical masks to prevent acute respiratory infections were included in the meta-analysis. Surrogate exposure studies comparing N95 respirators and surgical masks using manikins or adult volunteers under simulated conditions were summarized separately. Outcomes from clinical studies were laboratory-confirmed respiratory infection, influenza-like illness and workplace absenteeism. Outcomes from surrogate exposure studies were filter penetration, face-seal leakage and total inward leakage. Results: We identified 6 clinical studies (3 RCTs, 1 cohort study and 2 case\textendash control studies) and 23 surrogate exposure studies. In the meta-analysis of the clinical studies, we found no significant difference between N95 respirators and surgical masks in associated risk of (a) laboratory-confirmed respiratory infection (RCTs: odds ratio [OR] 0.89, 95\% confidence interval [CI] 0.64\textendash 1.24; cohort study: OR 0.43, 95\% CI 0.03\textendash 6.41; case\textendash control studies: OR 0.91, 95\% CI 0.25\textendash 3.36); (b) influenza-like illness (RCTs: OR 0.51, 95\% CI 0.19\textendash 1.41); or (c) reported workplace absenteeism (RCT: OR 0.92, 95\% CI 0.57\textendash 1.50). In the surrogate exposure studies, N95 respirators were associated with less filter penetration, less face-seal leakage and less total inward leakage under laboratory experimental conditions, compared with surgical masks. Interpretation: Although N95 respirators appeared to have a protective advantage over surgical masks in laboratory settings, our meta-analysis showed that there were insufficient data to determine definitively whether N95 respirators are superior to surgical masks in protecting health care workers against transmissible acute respiratory infections in clinical settings.},
  pmcid = {PMC4868605},
  pmid = {26952529},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AIEDXF5R\\Smith et al. - 2016 - Effectiveness of N95 respirators versus surgical m.pdf}
}

@article{sonabendNonpharmaceuticalInterventionsVaccination2021,
  title = {Non-Pharmaceutical Interventions, Vaccination, and the {{SARS-CoV-2}} Delta Variant in {{England}}: A Mathematical Modelling Study},
  shorttitle = {Non-Pharmaceutical Interventions, Vaccination, and the {{SARS-CoV-2}} Delta Variant in {{England}}},
  author = {Sonabend, Raphael and Whittles, Lilith K. and Imai, Natsuko and {Perez-Guzman}, Pablo N. and Knock, Edward S. and Rawson, Thomas and Gaythorpe, Katy A. M. and Djaafara, Bimandra A. and Hinsley, Wes and FitzJohn, Richard G. and Lees, John A. and Kanapram, Divya Thekke and Volz, Erik M. and Ghani, Azra C. and Ferguson, Neil M. and Baguelin, Marc and Cori, Anne},
  year = {2021},
  month = oct,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(21)02276-5},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7K4DSLU6\\Sonabend et al. - 2021 - Non-pharmaceutical interventions, vaccination, and.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\FHVCFWR3\\fulltext.html}
}

@misc{sozialministeriumCOVID19AlleVerfuegbaren,
  title = {{COVID-19: Alle verf\"ugbaren Dateien (gezippt) - data.gv.at}},
  shorttitle = {{COVID-19}},
  author = {Sozialministerium},
  abstract = {Details zu in der ZIP-Datei inkludierten Dateien siehe https://www.data.gv.at/covid-19/ Aktualisierungszyklus: Daten, die aus dem EMS bezogen werden, werden st\"undlich aktualisiert.  Daten der...},
  howpublished = {https://www.data.gv.at/katalog/dataset/4a9d9ef1-3790-44e2-8316-397c5e862813},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CCJ6A3IH\\4a9d9ef1-3790-44e2-8316-397c5e862813.html}
}

@incollection{SplittingMethod2017,
  title = {Splitting {{Method}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {307--350},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch9},
  abstract = {This chapter explains the fundamental ideas behind the splitting method, demonstrating a variety of splitting algorithms and showcasing a wide range of applications. The chapter asserts how a more practical approach is to determine the levels adaptively, which is similar to what is done in the cross-entropy (CE) method. The adaptive splitting algorithm presented in the chapter is quite similar to the CE algorithm. The Boolean satisfiability (SAT) problem plays a central role in combinatorial optimization and computational complexity. Any NP-complete problem, such as the max-cut problem, the graph-coloring problem, and the TSP, can be translated in polynomial time into a SAT problem. Pairs of vertices are connected by an edge if and only if the corresponding binary vectors differ by one component. The probability that under the null-hypothesis (uniformity) the test statistic takes a value greater than or equal to the one observed. The resulting algorithm is suitable for solving both discrete and continuous optimization problems, and thus can be considered as an alternative to the standard cross-entropy and MinxEnt methods.},
  chapter = {9},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {binary vectors,Boolean satisfiability (SAT),continuous optimization problems,cross-entropy (CE),graph-coloring problem,MinxEnt methods},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch9},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XL4F95G2\\2017 - Splitting Method.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\W9RXKHWP\\9781118631980.html}
}

@article{SpreadSARSCoV2Austria,
  title = {Spread of {{SARS-CoV-2}} in {{Austria}}},
  pages = {41},
  abstract = {The number of confirmed infections with SARS-CoV-2 is a central figure for decision-makers and the public. For most countries, it is safe to assume that the number of unreported cases (``dark figure'') is a multiple of the confirmed cases. It is essential to estimate a total prevalence including unreported cases \textendash{} on the one hand to learn more about central parameters such as case fatality rate, on the other hand to plan and refine decisions about measures with regards to the pandemic.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EGXBT2PZ\\Spread of SARS-CoV-2 in Austria.pdf}
}

@misc{staffWNYSetReopen2020,
  title = {{{WNY}} Set to Reopen {{Tuesday}}; Thousands of {{COVID-19}} Test Kits Heading to {{NY}} Nursing Homes},
  author = {Staff, Jana Barnello \& WHAM},
  year = {2020},
  month = may,
  journal = {WSTM},
  abstract = {In a signal that Western New York has met reopening requirements, Gov. Andrew Cuomo held his daily coronavirus briefing in Buffalo on Monday. Western New York and the Capital Region have met six of seven of the requirements to reopen. Both of those regions were working to increase the number of tracers per 100,000 residents or based on the infection rate.},
  howpublished = {https://cnycentral.com/news/local/watch-gov-cuomo-is-in-buffalo-for-daily-briefing-will-western-new-york-reopen},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QNDLUIX2\\watch-gov-cuomo-is-in-buffalo-for-daily-briefing-will-western-new-york-reopen.html}
}

@misc{StatelevelTrackingCOVID19,
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}} | {{medRxiv}}},
  howpublished = {https://www.medrxiv.org/content/10.1101/2020.07.13.20152355v1},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZQUHWCY4\\2020.07.13.html}
}

@incollection{StatisticalAnalysisDiscreteEvent2017,
  title = {Statistical {{Analysis}} of {{Discrete-Event Systems}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {107--131},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch4},
  abstract = {This chapter examines the statistical analysis of the output data from static and dynamic simulation models, discussing the batch means and regenerative methods for estimating steady-state performance measures. The program evaluation and review technique (PERT) is a frequently used tool for project management. A PERT network is a directed graph where the arcs represent the activities and the vertices represent specific milestones. A milestone is completed when all activities pointing to that milestone are completed. Dynamic simulation models deal with systems that evolve over time. Steady-state simulation is used for systems that exhibit some form of stationary or long-run behavior. Special care must be taken when making inferences concerning steady-state performances, with the reason being that the output data are typically correlated. The main strengths of the concept of regenerative processes are that the existence of limiting distributions is guaranteed under very mild conditions and the behavior of the limiting distribution depends only on the behavior of the process during a typical cycle.},
  chapter = {4},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {dynamic simulation models,output data,program evaluation and review technique (PERT),project management,regenerative methods},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch4},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GKV835CJ\\2017 - Statistical Analysis of Discrete-Event Systems.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\4BQSVIZU\\9781118631980.html}
}

@misc{StatisticsBiologists,
  title = {Statistics for {{Biologists}}},
  howpublished = {https://www-nature-com.uaccess.univie.ac.at/collections/qghhqm},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6NBFVHTL\\qghhqm.html}
}

@article{stephensCOVID19PathImmunity2020,
  title = {{{COVID-19}} and the {{Path}} to {{Immunity}}},
  author = {Stephens, David S. and McElrath, M. Juliana},
  year = {2020},
  month = sep,
  journal = {JAMA},
  doi = {10.1001/jama.2020.16656},
  abstract = {This Viewpoint reviews what is known about acute and long-term B-cell, antibody, and T-cell responses to SARS-CoV-2 infection and explains how each are implicated in vaccine candidates likely to be effective and durably protective again COVID-19.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\T3CA3IHF\\Stephens and McElrath - 2020 - COVID-19 and the Path to Immunity.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UD59JUEF\\2770758.html}
}

@incollection{StochasticEnumerationMethod2017,
  title = {Stochastic {{Enumeration Method}}},
  booktitle = {Simulation and the {{Monte Carlo Method}}},
  year = {2017},
  pages = {351--376},
  publisher = {{John Wiley \& Sons, Ltd}},
  doi = {10.1002/9781118631980.ch10},
  abstract = {This chapter introduces a new generic Monte Carlo technique, called stochastic enumeration (SE), to solve the counting problems that can be formulated in terms of estimating the cost of a tree. The SE method is a sequential importance sampling technique in which random paths are generated through the tree, in a parallel fashion. Two of the most useful algorithms for searching trees or more generally, graphs or networks, are the depth-first search (DFS) and breadth-first search (BFS) methods. Starting from a root of the tree, the algorithm enumerates all the vertices of the tree in a certain order. A systematic way to determine this is to sequentially construct a tree of paths of various lengths, all of which start from the top vertex and end either at the bottom-left vertex or at a vertex whose neighbors. The stochastic enumeration (SE) algorithm generalizes Knuth's algorithm by simulating multiple paths through the tree simultaneously. These paths are also allowed to interact, in the sense that paths avoid each other and therefore explore a larger part of the tree.},
  chapter = {10},
  isbn = {978-1-118-63198-0},
  langid = {english},
  keywords = {breadth-first search (BFS) methods,depth-first search (DFS),Monte Carlo technique,stochastic enumeration (SE),stochastic enumeration (SE) algorithm},
  annotation = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118631980.ch10},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AR8H3YFX\\2017 - Stochastic Enumeration Method.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZKF8FWWN\\9781118631980.html}
}

@misc{StochasticModelPredictive,
  title = {Stochastic Model Predictive Control \textemdash{} How Does It Work? | {{Elsevier Enhanced Reader}}},
  shorttitle = {Stochastic Model Predictive Control \textemdash{} How Does It Work?},
  doi = {10.1016/j.compchemeng.2017.10.026},
  howpublished = {https://reader.elsevier.com/reader/sd/pii/S0098135417303812?token=491D9E5737C51F1D2774226B4F1DFBB847B8E5E9B50FAA29F81FD3140CA9827ADA4A513063EAACC225B6A1AAC87FD17A},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\UQDKD54B\\Stochastic model predictive control  how does it .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BEV3ETAQ\\S0098135417303812.html}
}

@article{sunImpactContactTracing2020,
  title = {Impact of Contact Tracing on {{SARS-CoV-2}} Transmission},
  author = {Sun, Kaiyuan and Viboud, C{\'e}cile},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30357-1},
  abstract = {As the far-reaching impacts of the coronavirus disease 2019 (COVID-19) pandemic expand to more and more countries, key questions about transmission dynamics and optimal intervention strategies remain unanswered. In particular, the age profile of susceptibility and infectivity, the frequency of super-spreading events, the amount of transmission in the household, and the contribution of asymptomatic individuals to transmission remain debated. The study by Qifang Bi and colleagues1 in The Lancet Infectious Diseases explores some of these questions by analysing detailed contact tracing data from Shenzhen, a large and affluent city in southern China at the border with Hong Kong.},
  langid = {english},
  pmid = {32353350},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EUPQMU23\\Sun and Viboud - 2020 - Impact of contact tracing on SARS-CoV-2 transmissi.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IH2T287C\\fulltext.html}
}

@article{tahamtanRealtimeRTPCRCOVID192020,
  title = {Real-Time {{RT-PCR}} in {{COVID-19}} Detection: Issues Affecting the Results},
  shorttitle = {Real-Time {{RT-PCR}} in {{COVID-19}} Detection},
  author = {Tahamtan, Alireza and Ardebili, Abdollah},
  year = {2020},
  month = apr,
  journal = {Expert Review of Molecular Diagnostics},
  pages = {1--2},
  issn = {1473-7159},
  doi = {10.1080/14737159.2020.1757437},
  pmcid = {PMC7189409},
  pmid = {32297805},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BQ4ZPG9F\\Tahamtan and Ardebili - 2020 - Real-time RT-PCR in COVID-19 detection issues aff.pdf}
}

@article{takizawaRobustUltrashortTE2013,
  title = {A {{Robust Ultrashort TE}} ({{UTE}}) {{Imaging Method With Corrected}} k-{{Space Trajectory}} by {{Using Parametric Multiple Function Model}} of {{Gradient Waveform}}},
  author = {Takizawa, M. and Hanada, H. and Oka, K. and Takahashi, T. and Yamamoto, E. and Fujii, M.},
  year = {2013},
  month = feb,
  journal = {IEEE Transactions on Medical Imaging},
  volume = {32},
  number = {2},
  pages = {306--316},
  issn = {0278-0062},
  doi = {10.1109/TMI.2012.2226050},
  abstract = {Ultra-short TE (UTE) sequences with radial sampling make it possible to visualize tissues with very short T2 decay times. The UTE sequence acquires an echo signal from the central to the outer parts of k-space and is very sensitive to small trajectory errors. Therefore, k-space errors caused by imperfections in the gradient system performance, such as gradient delay and waveform distortion, must be corrected. During normal clinical use, these errors must be corrected to account for any gradient strength, or image obliquity. Because of time limitation on clinical examination, a simple, robust, and time-efficient correction method for use with UTE is needed. We demonstrated image degradation due to k-space errors by simulation and found that uncontrolled gradient time delays were the dominant cause of image degradation. They could be corrected by using a pre-scan calibration that works by comparison of half and full echo signals. Further improvements in image quality were achieved by using a one-time calibration of gradient waveform approximations that were built from multiple exponential functions and were used during image reconstruction. We have developed a robust UTE correction method that consists of a gradient waveform approximation that follows a short pre-scan for estimating gradient time delay errors.},
  keywords = {Algorithms,biological tissues,Biomedical imaging,biomedical MRI,calibration,Correction method,Delay,full echo signals,gradient delay,gradient hardware,gradient system performance,gradient time delay error,gradient waveform,half echo signals,image degradation,Image Enhancement,Image Interpretation; Computer-Assisted,image reconstruction,Image reconstruction,k-space errors,k-space trajectory,magnetic resonance imaging (MRI),medical image processing,parametric multiple function model,Phantoms; Imaging,pre-scan calibration,Reproducibility of Results,Robustness,Sensitivity and Specificity,Shape,T2 decay times,tissue visualization,Trajectory,ultrashort echo time,ultrashort TE imaging,Ultrasonography,UTE imaging,waveform distortion},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SGBQWHHE\\Takizawa et al. - 2013 - A Robust Ultrashort TE (UTE) Imaging Method With C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IIJEU9PW\\Takizawa et al. - 2013 - A Robust Ultrashort TE (UTE) Imaging Method With C.html}
}

@article{takizawaRobustUltrashortTE2013a,
  title = {A {{Robust Ultrashort TE}} ({{UTE}}) {{Imaging Method With Corrected}} k-{{Space Trajectory}} by {{Using Parametric Multiple Function Model}} of {{Gradient Waveform}}},
  author = {Takizawa, M. and Hanada, H. and Oka, K. and Takahashi, T. and Yamamoto, E. and Fujii, M.},
  year = {2013},
  month = feb,
  journal = {IEEE Transactions on Medical Imaging},
  volume = {32},
  number = {2},
  pages = {306--316},
  issn = {0278-0062},
  doi = {10.1109/TMI.2012.2226050},
  abstract = {Ultra-short TE (UTE) sequences with radial sampling make it possible to visualize tissues with very short T2 decay times. The UTE sequence acquires an echo signal from the central to the outer parts of k-space and is very sensitive to small trajectory errors. Therefore, k-space errors caused by imperfections in the gradient system performance, such as gradient delay and waveform distortion, must be corrected. During normal clinical use, these errors must be corrected to account for any gradient strength, or image obliquity. Because of time limitation on clinical examination, a simple, robust, and time-efficient correction method for use with UTE is needed. We demonstrated image degradation due to k-space errors by simulation and found that uncontrolled gradient time delays were the dominant cause of image degradation. They could be corrected by using a pre-scan calibration that works by comparison of half and full echo signals. Further improvements in image quality were achieved by using a one-time calibration of gradient waveform approximations that were built from multiple exponential functions and were used during image reconstruction. We have developed a robust UTE correction method that consists of a gradient waveform approximation that follows a short pre-scan for estimating gradient time delay errors.},
  keywords = {Algorithms,biological tissues,Biomedical imaging,biomedical MRI,calibration,Correction method,Delay,full echo signals,gradient delay,gradient hardware,gradient system performance,gradient time delay error,gradient waveform,half echo signals,image degradation,Image Enhancement,Image Interpretation; Computer-Assisted,image reconstruction,Image reconstruction,k-space errors,k-space trajectory,magnetic resonance imaging (MRI),medical image processing,parametric multiple function model,Phantoms; Imaging,pre-scan calibration,Reproducibility of Results,Robustness,Sensitivity and Specificity,Shape,T2 decay times,tissue visualization,Trajectory,ultrashort echo time,ultrashort TE imaging,Ultrasonography,UTE imaging,waveform distortion},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JFF2KN8K\\Takizawa et al. - 2013 - A Robust Ultrashort TE (UTE) Imaging Method With C.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UX83QB9I\\Takizawa et al. - 2013 - A Robust Ultrashort TE (UTE) Imaging Method With C.html}
}

@article{tankersleyZeoliteWaterPurification2020,
  title = {Zeolite Water Purification at {{Tikal}}, an Ancient {{Maya}} City in {{Guatemala}}},
  author = {Tankersley, Kenneth Barnett and Dunning, Nicholas P. and Carr, Christopher and Lentz, David L. and Scarborough, Vernon L.},
  year = {2020},
  month = oct,
  journal = {Scientific Reports},
  volume = {10},
  number = {1},
  pages = {18021},
  publisher = {{Nature Publishing Group}},
  issn = {2045-2322},
  doi = {10.1038/s41598-020-75023-7},
  abstract = {Evidence for the oldest known zeolite water purification filtration system occurs in the undisturbed sediments of the Corriental reservoir at the Maya city of Tikal, in northern Guatemala. The Corriental reservoir was an important source of drinking water at Tikal during the Late Preclassic to Late Classic cultural periods. X-ray diffraction analysis (XRD) and six AMS radiocarbon ages show that between\,\textasciitilde\,2185 and 965~cal~yr B.P. the drinking water in the Corriental reservoir water was filtered through a mixture of zeolite and coarse, sand-sized crystalline quartz. Zeolite is a non-toxic, three-dimensionally porous, crystalline, hydrated aluminosilicate with natural adsorbent and ion exchange properties, which removes harmful microbes as well as dispersed insoluble and soluble toxins from drinking water. The occurrence of zeolite in Corriental reservoir sediments expands our understanding of the earliest history of water purification and the long-term sustainability of an ancient Maya city.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Environmental social sciences,Natural hazards,Sustainability},
  annotation = {Bandiera\_abtest: a Cc\_license\_type: cc\_by Cg\_type: Nature Research Journals Primary\_atype: Research Subject\_term: Environmental social sciences;Natural hazards;Sustainability Subject\_term\_id: environmental-social-sciences;natural-hazards;sustainability},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\P9E7KWDA\\Tankersley et al. - 2020 - Zeolite water purification at Tikal, an ancient Ma.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IA66SVRW\\s41598-020-75023-7.html}
}

@article{taquet6monthNeurologicalPsychiatric2021,
  title = {6-Month Neurological and Psychiatric Outcomes in 236 379 Survivors of {{COVID-19}}: A Retrospective Cohort Study Using Electronic Health Records},
  shorttitle = {6-Month Neurological and Psychiatric Outcomes in 236 379 Survivors of {{COVID-19}}},
  author = {Taquet, Maxime and Geddes, John R. and Husain, Masud and Luciano, Sierra and Harrison, Paul J.},
  year = {2021},
  month = apr,
  journal = {The Lancet Psychiatry},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {2215-0366, 2215-0374},
  doi = {10.1016/S2215-0366(21)00084-5},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}Neurological and psychiatric sequelae of COVID-19 have been reported, but more data are needed to adequately assess the effects of COVID-19 on brain health. We aimed to provide robust estimates of incidence rates and relative risks of neurological and psychiatric diagnoses in patients in the 6 months following a COVID-19 diagnosis.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}For this retrospective cohort study and time-to-event analysis, we used data obtained from the TriNetX electronic health records network (with over 81 million patients). Our primary cohort comprised patients who had a COVID-19 diagnosis; one matched control cohort included patients diagnosed with influenza, and the other matched control cohort included patients diagnosed with any respiratory tract infection including influenza in the same period. Patients with a diagnosis of COVID-19 or a positive test for SARS-CoV-2 were excluded from the control cohorts. All cohorts included patients older than 10 years who had an index event on or after Jan 20, 2020, and who were still alive on Dec 13, 2020. We estimated the incidence of 14 neurological and psychiatric outcomes in the 6 months after a confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; parkinsonism; Guillain-Barr\'e syndrome; nerve, nerve root, and plexus disorders; myoneural junction and muscle disease; encephalitis; dementia; psychotic, mood, and anxiety disorders (grouped and separately); substance use disorder; and insomnia. Using a Cox model, we compared incidences with those in propensity score-matched cohorts of patients with influenza or other respiratory tract infections. We investigated how these estimates were affected by COVID-19 severity, as proxied by hospitalisation, intensive therapy unit (ITU) admission, and encephalopathy (delirium and related disorders). We assessed the robustness of the differences in outcomes between cohorts by repeating the analysis in different scenarios. To provide benchmarking for the incidence and risk of neurological and psychiatric sequelae, we compared our primary cohort with four cohorts of patients diagnosed in the same period with additional index events: skin infection, urolithiasis, fracture of a large bone, and pulmonary embolism.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Among 236 379 patients diagnosed with COVID-19, the estimated incidence of a neurological or psychiatric diagnosis in the following 6 months was 33{$\cdot$}62\% (95\% CI 33{$\cdot$}17\textendash 34{$\cdot$}07), with 12{$\cdot$}84\% (12{$\cdot$}36\textendash 13{$\cdot$}33) receiving their first such diagnosis. For patients who had been admitted to an ITU, the estimated incidence of a diagnosis was 46{$\cdot$}42\% (44{$\cdot$}78\textendash 48{$\cdot$}09) and for a first diagnosis was 25{$\cdot$}79\% (23{$\cdot$}50\textendash 28{$\cdot$}25). Regarding individual diagnoses of the study outcomes, the whole COVID-19 cohort had estimated incidences of 0{$\cdot$}56\% (0{$\cdot$}50\textendash 0{$\cdot$}63) for intracranial haemorrhage, 2{$\cdot$}10\% (1{$\cdot$}97\textendash 2{$\cdot$}23) for ischaemic stroke, 0{$\cdot$}11\% (0{$\cdot$}08\textendash 0{$\cdot$}14) for parkinsonism, 0{$\cdot$}67\% (0{$\cdot$}59\textendash 0{$\cdot$}75) for dementia, 17{$\cdot$}39\% (17{$\cdot$}04\textendash 17{$\cdot$}74) for anxiety disorder, and 1{$\cdot$}40\% (1{$\cdot$}30\textendash 1{$\cdot$}51) for psychotic disorder, among others. In the group with ITU admission, estimated incidences were 2{$\cdot$}66\% (2{$\cdot$}24\textendash 3{$\cdot$}16) for intracranial haemorrhage, 6{$\cdot$}92\% (6{$\cdot$}17\textendash 7{$\cdot$}76) for ischaemic stroke, 0{$\cdot$}26\% (0{$\cdot$}15\textendash 0{$\cdot$}45) for parkinsonism, 1{$\cdot$}74\% (1{$\cdot$}31\textendash 2{$\cdot$}30) for dementia, 19{$\cdot$}15\% (17{$\cdot$}90\textendash 20{$\cdot$}48) for anxiety disorder, and 2{$\cdot$}77\% (2{$\cdot$}31\textendash 3{$\cdot$}33) for psychotic disorder. Most diagnostic categories were more common in patients who had COVID-19 than in those who had influenza (hazard ratio [HR] 1{$\cdot$}44, 95\% CI 1{$\cdot$}40\textendash 1{$\cdot$}47, for any diagnosis; 1{$\cdot$}78, 1{$\cdot$}68\textendash 1{$\cdot$}89, for any first diagnosis) and those who had other respiratory tract infections (1{$\cdot$}16, 1{$\cdot$}14\textendash 1{$\cdot$}17, for any diagnosis; 1{$\cdot$}32, 1{$\cdot$}27\textendash 1{$\cdot$}36, for any first diagnosis). As with incidences, HRs were higher in patients who had more severe COVID-19 (eg, those admitted to ITU compared with those who were not: 1{$\cdot$}58, 1{$\cdot$}50\textendash 1{$\cdot$}67, for any diagnosis; 2{$\cdot$}87, 2{$\cdot$}45\textendash 3{$\cdot$}35, for any first diagnosis). Results were robust to various sensitivity analyses and benchmarking against the four additional index health events.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Our study provides evidence for substantial neurological and psychiatric morbidity in the 6 months after COVID-19 infection. Risks were greatest in, but not limited to, patients who had severe COVID-19. This information could help in service planning and identification of research priorities. Complementary study designs, including prospective cohorts, are needed to corroborate and explain these findings.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CG25FXSX\\Taquet et al. - 2021 - 6-month neurological and psychiatric outcomes in 2.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KEDAIQSU\\fulltext.html}
}

@article{TeachTeachTeach,
  title = {Teach, and Teach and Teach: Does the Average Citizen Use Masks Correctly during Daily Activities? {{Results}} from an Observational Study with More than 12,000 Participants},
  pages = {9},
  abstract = {COVID-19 is a new disease with no treatment and no vaccine so far. The pandemic is still growing in many areas. Among the core measures to prevent disease spread is the use of face masks. We observed 12,588 people in five Brazilian cities within the Baixada Santista metropolitan area. Even though this is densely populated region and heavily impacted by COVID-19 with a high risk population, only 45.1\% of the observed population wore in face masks in a correct way, and another 15.5\% simply did not use masks at all. The remainder used masks incorrectly, which is evidence of the worst scenario of people believing that they are protected when they are not. This is among the first studies, to the best of our knowledge, that measures real life compliance with face masks during this COVID-19 pandemic. It is our conclusion that it is paramount to first control the virus before allowing people back in the streets. We should not assume that people will wear masks properly. Equally important is to instruct and sensitize people on how to use face masks and why it is important.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KIJH267N\\Teach, and teach and teach does the average citiz.pdf}
}

@book{teamStanUserGuide,
  title = {Stan {{User}}'s {{Guide}}},
  author = {Team, Stan Development},
  abstract = {Stan user's guide with examples and programming techniques.},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7EAJUPGZ\\change-point-section.html}
}

@article{tellierRecognitionAerosolTransmission2019,
  title = {Recognition of Aerosol Transmission of Infectious Agents: A Commentary},
  shorttitle = {Recognition of Aerosol Transmission of Infectious Agents},
  author = {Tellier, Raymond and Li, Yuguo and Cowling, Benjamin J. and Tang, Julian W.},
  year = {2019},
  month = jan,
  journal = {BMC Infectious Diseases},
  volume = {19},
  number = {1},
  pages = {101},
  issn = {1471-2334},
  doi = {10.1186/s12879-019-3707-y},
  abstract = {Although short-range large-droplet transmission is possible for most respiratory infectious agents, deciding on whether the same agent is also airborne has a potentially huge impact on the types (and costs) of infection control interventions that are required.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\VNNUDUSA\\Tellier et al. - 2019 - Recognition of aerosol transmission of infectious .pdf}
}

@article{tenfordeSymptomDurationRisk2020,
  title = {Symptom {{Duration}} and {{Risk Factors}} for {{Delayed Return}} to {{Usual Health Among Outpatients}} with {{COVID-19}} in a {{Multistate Health Care Systems Network}} \textemdash{} {{United States}}, {{March}}\textendash{{June}} 2020},
  author = {Tenforde, Mark W.},
  year = {2020},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {69},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm6930e1},
  abstract = {Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 (COVID-19). Characterizing return to baseline health among outpatients with milder...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6PU99I5M\\mm6930e1.html}
}

@misc{TerminologieBrowser,
  title = {Terminologie-{{Browser}}},
  howpublished = {https://termpub.gesundheit.gv.at/TermBrowser/gui/main/main.zul},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\X7FGW66X\\main.html}
}

@article{thompsonEpidemiologicalModelsAre2020,
  title = {Epidemiological Models Are Important Tools for Guiding {{COVID-19}} Interventions},
  author = {Thompson, Robin N.},
  year = {2020},
  month = may,
  journal = {BMC Medicine},
  volume = {18},
  number = {1},
  pages = {152},
  issn = {1741-7015},
  doi = {10.1186/s12916-020-01628-4},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\A84HE5AJ\\s12916-020-01628-4.html}
}

@article{thompsonImprovedInferenceTimevarying2019,
  title = {Improved Inference of Time-Varying Reproduction Numbers during Infectious Disease Outbreaks},
  author = {Thompson, R. N. and Stockwin, J. E. and {van Gaalen}, R. D. and Polonsky, J. A. and Kamvar, Z. N. and Demarsh, P. A. and Dahlqwist, E. and Li, S. and Miguel, E. and Jombart, T. and Lessler, J. and Cauchemez, S. and Cori, A.},
  year = {2019},
  month = dec,
  journal = {Epidemics},
  volume = {29},
  pages = {100356},
  issn = {1755-4365},
  doi = {10.1016/j.epidem.2019.100356},
  abstract = {Accurate estimation of the parameters characterising infectious disease transmission is vital for optimising control interventions during epidemics. A valuable metric for assessing the current threat posed by an outbreak is the time-dependent reproduction number, i.e. the expected number of secondary cases caused by each infected individual. This quantity can be estimated using data on the numbers of observed new cases at successive times during an epidemic and the distribution of the serial interval (the time between symptomatic cases in a transmission chain). Some methods for estimating the reproduction number rely on pre-existing estimates of the serial interval distribution and assume that the entire outbreak is driven by local transmission. Here we show that accurate inference of current transmissibility, and the uncertainty associated with this estimate, requires: (i) up-to-date observations of the serial interval to be included, and; (ii) cases arising from local transmission to be distinguished from those imported from elsewhere. We demonstrate how pathogen transmissibility can be inferred appropriately using datasets from outbreaks of H1N1 influenza, Ebola virus disease and Middle-East Respiratory Syndrome. We present a tool for estimating the reproduction number in real-time during infectious disease outbreaks accurately, which is available as an R software package (EpiEstim 2.2). It is also accessible as an interactive, user-friendly online interface (EpiEstim App), permitting its use by non-specialists. Our tool is easy to apply for assessing the transmission potential, and hence informing control, during future outbreaks of a wide range of invading pathogens.},
  langid = {english},
  keywords = {Disease control,Infectious disease epidemiology,Mathematical modelling,Parameter inference,Reproduction number,Serial interval},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\AQ7MCYSY\\Thompson et al. - 2019 - Improved inference of time-varying reproduction nu.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\FHY7I9X2\\S1755436519300350.html}
}

@article{thompsonInterimEstimatesVaccine2021,
  title = {Interim {{Estimates}} of {{Vaccine Effectiveness}} of {{BNT162b2}} and {{mRNA-1273 COVID-19 Vaccines}} in {{Preventing SARS-CoV-2 Infection Among Health Care Personnel}}, {{First Responders}}, and {{Other Essential}} and {{Frontline Workers}} \textemdash{} {{Eight U}}.{{S}}. {{Locations}}, {{December}} 2020\textendash{{March}} 2021},
  author = {Thompson, Mark G.},
  year = {2021},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  volume = {70},
  issn = {0149-21951545-861X},
  doi = {10.15585/mmwr.mm7013e3},
  abstract = {mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PWGVWGXB\\Thompson - 2021 - Interim Estimates of Vaccine Effectiveness of BNT1.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\L94AL39M\\mm7013e3.html}
}

@misc{ThreatAssessmentBrief2020,
  title = {Threat {{Assessment Brief}}: {{Rapid}} Increase of a {{SARS-CoV-2}} Variant with Multiple Spike Protein Mutations Observed in the {{United Kingdom}}},
  shorttitle = {Threat {{Assessment Brief}}},
  year = {2020},
  month = dec,
  journal = {European Centre for Disease Prevention and Control},
  abstract = {Over the last few weeks, the United Kingdom (UK) has faced a rapid increase in COVID-19 cases in South East England, leading to enhanced epidemiological and virological investigations.},
  howpublished = {https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-rapid-increase-sars-cov-2-variant-united-kingdom},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QJH3X4K9\\threat-assessment-brief-rapid-increase-sars-cov-2-variant-united-kingdom.html}
}

@book{tolonenChapterSummarizingPosterior,
  title = {Chapter 3 {{Summarizing}} the Posterior Distribution | {{Bayesian Inference}} 2019},
  author = {Tolonen, Ville Hyv{\"o}nen \& Topias},
  abstract = {Lecture notes for Bayesian Inference course lectured at University of Helsinki Spring 2019},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\Z8M6PDKV\\summarizing-the-posterior-distribution.html}
}

@misc{TotalQuarantineSantiago2020,
  title = {Total Quarantine in {{Santiago}} de {{Chile}} after Coronavirus Spike -},
  year = {2020},
  month = may,
  abstract = {SANTIAGO \textendash{} Chile ordered a mandatory total quarantine for the capital Santiago's seven million people on Wednesday, after authorities reported a 60\% spike in coronavirus infections in 24 hours, dealing a stunning blow to hopes [...]},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CKAHSUTS\\total-quarantine-in-santiago-de-chile-after-coronavirus-spike-2.html}
}

@article{townsendPersistentFatigueFollowing2020,
  title = {Persistent Fatigue Following {{SARS-CoV-2}} Infection Is Common and Independent of Severity of Initial Infection},
  author = {Townsend, Liam and Dyer, Adam H. and Jones, Karen and Dunne, Jean and Mooney, Aoife and Gaffney, Fiona and O'Connor, Laura and Leavy, Deirdre and O'Brien, Kate and Dowds, Joanne and Sugrue, Jamie A. and Hopkins, David and {Martin-Loeches}, Ignacio and Cheallaigh, Cliona Ni and Nadarajan, Parthiban and McLaughlin, Anne Marie and Bourke, Nollaig M. and Bergin, Colm and O'Farrelly, Cliona and Bannan, Ciaran and Conlon, Niall},
  year = {2020},
  month = nov,
  journal = {PLOS ONE},
  volume = {15},
  number = {11},
  pages = {e0240784},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0240784},
  abstract = {Fatigue is a common symptom in those presenting with symptomatic COVID-19 infection. However, it is unknown if COVID-19 results in persistent fatigue in those recovered from acute infection. We examined the prevalence of fatigue in individuals recovered from the acute phase of COVID-19 illness using the Chalder Fatigue Score (CFQ-11). We further examined potential predictors of fatigue following COVID-19 infection, evaluating indicators of COVID-19 severity, markers of peripheral immune activation and circulating pro-inflammatory cytokines. Of 128 participants (49.5 {$\pm$} 15 years; 54\% female), more than half reported persistent fatigue (67/128; 52.3\%) at median of 10 weeks after initial COVID-19 symptoms. There was no association between COVID-19 severity (need for inpatient admission, supplemental oxygen or critical care) and fatigue following COVID-19. Additionally, there was no association between routine laboratory markers of inflammation and cell turnover (leukocyte, neutrophil or lymphocyte counts, neutrophil-to-lymphocyte ratio, lactate dehydrogenase, C-reactive protein) or pro-inflammatory molecules (IL-6 or sCD25) and fatigue post COVID-19. Female gender and those with a pre-existing diagnosis of depression/anxiety were over-represented in those with fatigue. Our findings demonstrate a significant burden of post-viral fatigue in individuals with previous SARS-CoV-2 infection after the acute phase of COVID-19 illness. This study highlights the importance of assessing those recovering from COVID-19 for symptoms of severe fatigue, irrespective of severity of initial illness, and may identify a group worthy of further study and early intervention.},
  langid = {english},
  keywords = {C-reactive proteins,Chronic fatigue syndrome,COVID 19,Cytokines,Fatigue,Outpatients,Respiratory infections,SARS CoV 2},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\46HWMTV4\\Townsend et al. - 2020 - Persistent fatigue following SARS-CoV-2 infection .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\PGL6NZ8T\\article.html}
}

@misc{TransmissionCOVID19,
  title = {Transmission of {{COVID-19}}},
  journal = {European Centre for Disease Prevention and Control},
  abstract = {Viral shedding, virus and substances of human origin (SoHO), role of asymptomatic and pre-symptomatic individuals and transmission risks in different settings},
  howpublished = {https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\H5Y4MTYX\\transmission.html}
}

@article{trias-llimosMonitoringLifeExpectancy2020,
  title = {Monitoring Life Expectancy Levels during the {{COVID-19}} Pandemic: {{Example}} of the Unequal Impact of the First Wave on {{Spanish}} Regions},
  shorttitle = {Monitoring Life Expectancy Levels during the {{COVID-19}} Pandemic},
  author = {{Trias-Llim{\'o}s}, Sergi and Riffe, Tim and Bilal, Usama},
  year = {2020},
  month = nov,
  journal = {PLOS ONE},
  volume = {15},
  number = {11},
  pages = {e0241952},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0241952},
  abstract = {Background To provide an interpretable summary of the impact on mortality of the COVID-19 pandemic we estimate weekly and annual life expectancies at birth in Spain and its regions. Methods We used daily death count data from the Spanish Daily Mortality Monitoring System (MoMo), and death counts from 2018, and population on July 1st, 2019 by region (CCAA), age groups, and sex from the Spanish National Statistics Institute. We estimated weekly and annual (2019 and 2020*, the shifted annual calendar period up to 5 July 2020) life expectancies at birth as well as their differences with respect to 2019. Results Weekly life expectancies at birth in Spain were lower in weeks 11\textendash 20, 2020 compared to the same weeks in 2019. This drop in weekly life expectancy was especially strong in weeks 13 and 14 (March 23rd to April 5th), with national declines ranging between 6.1 and 7.6 years and maximum regional weekly declines of up to 15 years in Madrid. Annual life expectancy differences between 2019 and 2020 also reflected an overall drop in annual life expectancy of 0.9 years for both men and women. These drops ranged between 0 years in several regions (e.g. Canary and Balearic Islands) to 2.8 years among men in Madrid. Conclusions Life expectancy is an easy to interpret measure for understanding the heterogeneity of mortality patterns across Spanish regions. Weekly and annual life expectancy are sensitive and useful indicators for understanding disparities and communicating the gravity of the situation because differences are expressed in intuitive year units.},
  langid = {english},
  keywords = {Age groups,COVID 19,Death rates,England,Life expectancy,Pandemics,Spain,Sweden},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4R3NXMNC\\Trias-Llims et al. - 2020 - Monitoring life expectancy levels during the COVID.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\NR3ZPR5B\\article.html}
}

@article{ukhealthsecurityagencyOmicronVOC21NOV015292021,
  title = {Omicron {{VOC-21NOV-01}} ({{B}}.1.1.529) Technical Briefing: Hospitalisation and Vaccine Effectiveness},
  author = {{UK Health Security Agency}},
  year = {2021},
  month = dec,
  series = {{{SARS-CoV-2}} Variants of Concern and Variants under Investigation in {{England}}},
  pages = {17},
  abstract = {This report has been published to share the detailed variant surveillance analyses which contribute to the Omicron risk assessment. This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\SXH8FBPE\\SARS-CoV-2 variants of concern and variants under .pdf}
}

@article{unwinReport23Statelevel,
  title = {Report 23: {{State-level}} Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H Juliette T and Mishra, Swapnil and Bradley, Valerie C and Gandy, Axel and Vollmer, Michaela and Mellan, Thomas and Coup, Helen},
  pages = {37},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\242YDBV3\\Unwin et al. - Report 23 State-level tracking of COVID-19 in the.pdf}
}

@techreport{unwinReport23Statelevel2020,
  title = {Report 23: {{State-level}} Tracking of {{COVID-19}} in the {{United States}}},
  shorttitle = {Report 23},
  author = {Unwin, H and Mishra, S and Bradley, VC and Gandy, A and Vollmer, M and Mellan, T and Coupland, H and Ainslie, K and Whittaker, C and {Ish-Horowicz}, J and Filippi, S and Xi, X and Monod, M and Ratmann, O and Hutchinson, M and Valka, F and Zhu, H and Hawryluk, I and Milton, P and Baguelin, M and Boonyasiri, A and Brazeau, N and Cattarino, L and Charles, G and Cooper, L and Cucunuba Perez, Z and {Cuomo-Dannenburg}, G and Djaafara, A and Dorigatti, I and Eales, O and Eaton, J and Van Elsland, S and Fitzjohn, R and Gaythorpe, K and Green, W and Hallett, T and Hinsley, W and Imai, N and Jeffrey, B and Knock, E and Laydon, D and Lees, J and Nedjati Gilani, G and Nouvellet, P and Okell, L and Ower, A and Parag, K and Siveroni, I and Thompson, H and Verity, R and Walker, P and Walters, C and Wang, Y and Watson, O and Whittles, L and Ghani, A and Ferguson, N and Riley, S and Donnelly, C and Bhatt, S and Flaxman, S},
  year = {2020},
  month = may,
  institution = {{Imperial College London}},
  doi = {10.25561/79231},
  abstract = {our estimates show that the percentage of individuals that have been infected is 4.1\% [3.7\%-4.5\%], with wide variation between states. For all states, even for the worst affected states, we estimate that less than a quarter of the population has been infected; in New York, for example, we estimate that 16.6\% [12.8\%-21.6\%] of individuals have been infected to date. Our attack rates for New York are in line with those from recent serological studies [1] broadly supporting our choice of infection fatality rate. There is variation in the initial reproduction number, which is likely due to a range of factors; we find a strong association between the initial reproduction number with both population density (measured at the state level) and the chronological date when 10 cumulative deaths occurred (a crude estimate of the date of locally sustained transmission). Our estimates suggest that the epidemic is not under control in much of the US: as of 17 May 2020 the reproduction number is above the critical threshold (1.0) in 24 [95\% CI: 20-30] states. Higher reproduction numbers are geographically clustered in the South and Midwest, where epidemics are still developing, while we estimate lower reproduction numbers in states that have already suffered high COVID-19 mortality (such as the Northeast). These estimates suggest that caution must be taken in loosening current restrictions if effective additional measures are not put in place. We predict that increased mobility following relaxation of social distancing will lead to resurgence of transmission, keeping all else constant. We predict that deaths over the next two-month period could exceed current cumulative deaths by greater than two-fold, if the relationship between mobility and transmission remains unchanged. Our results suggest that factors modulating transmission such as rapid testing, contact tracing and behavioural precautions are crucial to offset the rise of transmission associated with loosening of social distancing. Overall, we show that while all US states have substantially reduced their reproduction numbers, there is little evidence that any states are approaching herd immunity and thus the epidemic is close to over in any state.},
  collaborator = {Medical Research Council (MRC)},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,United States},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5J226LQ8\\Unwin et al. - 2020 - Report 23 State-level tracking of COVID-19 in the.pdf}
}

@techreport{unwinReport23Statelevel2020a,
  title = {Report 23: {{State-level}} Tracking of {{COVID-19}} in the {{United States}}},
  shorttitle = {Report 23},
  author = {Unwin, H and Mishra, S and Bradley, VC and Gandy, A and Vollmer, M and Mellan, T and Coupland, H and Ainslie, K and Whittaker, C and {Ish-Horowicz}, J and Filippi, S and Xi, X and Monod, M and Ratmann, O and Hutchinson, M and Valka, F and Zhu, H and Hawryluk, I and Milton, P and Baguelin, M and Boonyasiri, A and Brazeau, N and Cattarino, L and Charles, G and Cooper, L and Cucunuba Perez, Z and {Cuomo-Dannenburg}, G and Djaafara, A and Dorigatti, I and Eales, O and Eaton, J and Van Elsland, S and Fitzjohn, R and Gaythorpe, K and Green, W and Hallett, T and Hinsley, W and Imai, N and Jeffrey, B and Knock, E and Laydon, D and Lees, J and Nedjati Gilani, G and Nouvellet, P and Okell, L and Ower, A and Parag, K and Siveroni, I and Thompson, H and Verity, R and Walker, P and Walters, C and Wang, Y and Watson, O and Whittles, L and Ghani, A and Ferguson, N and Riley, S and Donnelly, C and Bhatt, S and Flaxman, S},
  year = {2020},
  month = may,
  institution = {{Imperial College London}},
  doi = {10.25561/79231},
  abstract = {our estimates show that the percentage of individuals that have been infected is 4.1\% [3.7\%-4.5\%], with wide variation between states. For all states, even for the worst affected states, we estimate that less than a quarter of the population has been infected; in New York, for example, we estimate that 16.6\% [12.8\%-21.6\%] of individuals have been infected to date. Our attack rates for New York are in line with those from recent serological studies [1] broadly supporting our choice of infection fatality rate. There is variation in the initial reproduction number, which is likely due to a range of factors; we find a strong association between the initial reproduction number with both population density (measured at the state level) and the chronological date when 10 cumulative deaths occurred (a crude estimate of the date of locally sustained transmission). Our estimates suggest that the epidemic is not under control in much of the US: as of 17 May 2020 the reproduction number is above the critical threshold (1.0) in 24 [95\% CI: 20-30] states. Higher reproduction numbers are geographically clustered in the South and Midwest, where epidemics are still developing, while we estimate lower reproduction numbers in states that have already suffered high COVID-19 mortality (such as the Northeast). These estimates suggest that caution must be taken in loosening current restrictions if effective additional measures are not put in place. We predict that increased mobility following relaxation of social distancing will lead to resurgence of transmission, keeping all else constant. We predict that deaths over the next two-month period could exceed current cumulative deaths by greater than two-fold, if the relationship between mobility and transmission remains unchanged. Our results suggest that factors modulating transmission such as rapid testing, contact tracing and behavioural precautions are crucial to offset the rise of transmission associated with loosening of social distancing. Overall, we show that while all US states have substantially reduced their reproduction numbers, there is little evidence that any states are approaching herd immunity and thus the epidemic is close to over in any state.},
  collaborator = {Medical Research Council (MRC)},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,United States},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\QUENQVUH\\Unwin et al. - 2020 - Report 23 State-level tracking of COVID-19 in the.pdf}
}

@article{unwinStatelevelTrackingCOVID192020,
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H. Juliette T. and Mishra, Swapnil and Bradley, Valerie C. and Gandy, Axel and Mellan, Thomas A. and Coupland, Helen and {Ish-Horowicz}, Jonathan and Vollmer, Michaela Andrea Christine and Whittaker, Charles and Filippi, Sarah L. and Xi, Xiaoyue and Monod, M{\'e}lodie and Ratmann, Oliver and Hutchinson, Michael and Valka, Fabian and Zhu, Harrison and Hawryluk, Iwona and Milton, Philip and Ainslie, Kylie E. C. and Baguelin, Marc and Boonyasiri, Adhiratha and Brazeau, Nick F. and Cattarino, Lorenzo and Cucunub{\'a}, Zulma M. and {Cuomo-Dannenburg}, Gina and Dorigatti, Ilaria and Eales, Oliver D. and Eaton, Jeffrey W. and van Elsland, Sabinee L. and FitzJohn, Richard G. and Gaythorpe, Katy A. M. and Green, William and Hinsley, Wes and Jeffrey, Benjamin and Knock, Edward and Laydon, Daniel J. and Lees, John and {Nedjati-Gilani}, Gemma and Nouvellet, Pierre and Okell, Lucy C. and Parag, Kris V. and Siveroni, Igor and Thompson, Hayley A. and Walker, Patrick and Walters, Caroline E. and Watson, Oliver J. and Whittles, Lilith K. and Ghani, Azra and Ferguson, Neil M. and Riley, Steven and Donnelly, Christl A. and Bhatt, Samir and Flaxman, Seth},
  year = {2020},
  month = jul,
  journal = {medRxiv},
  pages = {2020.07.13.20152355},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.07.13.20152355},
  abstract = {{$<$}p{$>$}As of 1st June 2020, the US Centers for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly modelled the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We used changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. Nationally, we estimated 3.7\% [3.4\%-4.0\%] of the population had been infected by 1st June 2020, with wide variation between states, and approximately 0.01\% of the population was infectious. We also demonstrated that good model forecasts of deaths for the next 3 weeks with low error and good coverage of our credible intervals.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\EDGSSUB8\\Unwin et al. - 2020 - State-level tracking of COVID-19 in the United Sta.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\KHPEK4RN\\2020.07.13.html}
}

@techreport{unwinStatelevelTrackingCOVID192020a,
  type = {Preprint},
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H Juliette T and Mishra, Swapnil and Bradley, Valerie C and Gandy, Axel and Mellan, Thomas A and Coupland, Helen and {Ish-Horowicz}, Jonathan and Vollmer, Michaela Andrea Christine and Whittaker, Charles and Filippi, Sarah L and Xi, Xiaoyue and Monod, M{\'e}lodie and Ratmann, Oliver and Hutchinson, Michael and Valka, Fabian and Zhu, Harrison and Hawryluk, Iwona and Milton, Philip and Ainslie, Kylie E C and Baguelin, Marc and Boonyasiri, Adhiratha and Brazeau, Nick F and Cattarino, Lorenzo and Cucunub{\'a}, Zulma M and {Cuomo-Dannenburg}, Gina and Dorigatti, Ilaria and Eales, Oliver D and Eaton, Jeffrey W and {van Elsland}, Sabinee L and FitzJohn, Richard G and Gaythorpe, Katy A M and Green, William and Hinsley, Wes and Jeffrey, Benjamin and Knock, Edward and Laydon, Daniel J and Lees, John and {Nedjati-Gilani}, Gemma and Nouvellet, Pierre and Okell, Lucy C and Parag, Kris V and Siveroni, Igor and Thompson, Hayley A and Walker, Patrick and Walters, Caroline E and Watson, Oliver J and Whittles, Lilith K and Ghani, Azra and Ferguson, Neil M and Riley, Steven and Donnelly, Christl A. and Bhatt, Samir and Flaxman, Seth},
  year = {2020},
  month = jul,
  institution = {{Public and Global Health}},
  doi = {10.1101/2020.07.13.20152355},
  abstract = {As of 1st June 2020, the US Centers for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly modelled the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We used changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. Nationally, we estimated 3.7\% [3.4\%-4.0\%] of the population had been infected by 1st June 2020, with wide variation between states, and approximately 0.01\% of the population was infectious. We also demonstrated that good model forecasts of deaths for the next 3 weeks with low error and good coverage of our credible intervals.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8ZMIXVNS\\Unwin et al. - 2020 - State-level tracking of COVID-19 in the United Sta.pdf}
}

@techreport{unwinStatelevelTrackingCOVID192020b,
  type = {Preprint},
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H. Juliette T. and Mishra, Swapnil and Bradley, Valerie C. and Gandy, Axel and Mellan, Thomas A. and Coupland, Helen and {Ish-Horowicz}, Jonathan and Vollmer, Michaela A. C. and Whittaker, Charles and Filippi, Sarah L. and Xi, Xiaoyue and Monod, M{\'e}lodie and Ratmann, Oliver and Hutchinson, Michael and Harrison Zhu, Fabian Valka and Hawryluk, Iwona and Milton, Philip and Ainslie, Kylie E. C. and Baguelin, Marc and Boonyasiri, Adhiratha and Brazeau, Nick F. and Cattarino, Lorenzo and Cucunuba, Zulma and {Cuomo-Dannenburg}, Gina and Dorigatti, Ilaria and Eales, Oliver D. and Eaton, Jeffrey W. and {van Elsland}, Sabine L. and FitzJohn, Richard G. and Gaythorpe, Katy A. M. and Green, William and Hinsley, Wes and Jeffrey, Benjamin and Knock, Edward and Laydon, Daniel J. and Lees, John and {Nedjati-Gilani}, Gemma and Nouvellet, Pierre and Okell, Lucy and Parag, Kris V. and Siveroni, Igor and Thompson, Hayley A. and Walker, Patrick and Walters, Caroline E. and Watson, Oliver J. and Whittles, Lilith K. and Ghani, Azra C. and Ferguson, Neil M. and Riley, Steven and Donnelly, Christl A. and Bhatt, Samir and Flaxman, Seth},
  year = {2020},
  month = jul,
  institution = {{Public and Global Health}},
  doi = {10.1101/2020.07.13.20152355},
  abstract = {Abstract                        As of 1st June 2020, the US Centers for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly modelled the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We used changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. On 1st June, we estimated that             R                            t                          was only below one in 23 states. We also estimated that 3.7\% [3.4\%-4.0\%] of the total population of the US had been infected, with wide variation between states, and approximately 0.01\% of the population was infectious. We demonstrate good 3 week model forecasts of deaths with low error and good coverage of our credible intervals.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3X38WIUG\\Unwin et al. - 2020 - State-level tracking of COVID-19 in the United Sta.pdf}
}

@article{unwinStatelevelTrackingCOVID192020c,
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H. Juliette T. and Mishra, Swapnil and Bradley, Valerie C. and Gandy, Axel and Mellan, Thomas A. and Coupland, Helen and {Ish-Horowicz}, Jonathan and Vollmer, Michaela A. C. and Whittaker, Charles and Filippi, Sarah L. and Xi, Xiaoyue and Monod, M{\'e}lodie and Ratmann, Oliver and Hutchinson, Michael and Valka, Fabian and Zhu, Harrison and Hawryluk, Iwona and Milton, Philip and Ainslie, Kylie E. C. and Baguelin, Marc and Boonyasiri, Adhiratha and Brazeau, Nick F. and Cattarino, Lorenzo and Cucunuba, Zulma and {Cuomo-Dannenburg}, Gina and Dorigatti, Ilaria and Eales, Oliver D. and Eaton, Jeffrey W. and {van Elsland}, Sabine L. and FitzJohn, Richard G. and Gaythorpe, Katy A. M. and Green, William and Hinsley, Wes and Jeffrey, Benjamin and Knock, Edward and Laydon, Daniel J. and Lees, John and {Nedjati-Gilani}, Gemma and Nouvellet, Pierre and Okell, Lucy and Parag, Kris V. and Siveroni, Igor and Thompson, Hayley A. and Walker, Patrick and Walters, Caroline E. and Watson, Oliver J. and Whittles, Lilith K. and Ghani, Azra C. and Ferguson, Neil M. and Riley, Steven and Donnelly, Christl A. and Bhatt, Samir and Flaxman, Seth},
  year = {2020},
  month = dec,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {6189},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-19652-6},
  abstract = {As of 1st June 2020, the US Centres for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly model the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We use changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. We estimate that Rt was only below one in 23 states on 1st June. We also estimate that 3.7\% [3.4\%\textendash 4.0\%] of the total population of the US had been infected, with wide variation between states, and approximately 0.01\% of the population was infectious. We demonstrate good 3 week model forecasts of deaths with low error and good coverage of our credible intervals.},
  copyright = {2020 The Author(s)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HR7I4XIC\\Unwin et al. - 2020 - State-level tracking of COVID-19 in the United Sta.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\FYEASCRA\\s41467-020-19652-6.html}
}

@article{unwinStatelevelTrackingCOVID192020d,
  title = {State-Level Tracking of {{COVID-19}} in the {{United States}}},
  author = {Unwin, H. Juliette T. and Mishra, Swapnil and Bradley, Valerie C. and Gandy, Axel and Mellan, Thomas A. and Coupland, Helen and {Ish-Horowicz}, Jonathan and Vollmer, Michaela A. C. and Whittaker, Charles and Filippi, Sarah L. and Xi, Xiaoyue and Monod, M{\'e}lodie and Ratmann, Oliver and Hutchinson, Michael and Valka, Fabian and Zhu, Harrison and Hawryluk, Iwona and Milton, Philip and Ainslie, Kylie E. C. and Baguelin, Marc and Boonyasiri, Adhiratha and Brazeau, Nick F. and Cattarino, Lorenzo and Cucunuba, Zulma and {Cuomo-Dannenburg}, Gina and Dorigatti, Ilaria and Eales, Oliver D. and Eaton, Jeffrey W. and {van Elsland}, Sabine L. and FitzJohn, Richard G. and Gaythorpe, Katy A. M. and Green, William and Hinsley, Wes and Jeffrey, Benjamin and Knock, Edward and Laydon, Daniel J. and Lees, John and {Nedjati-Gilani}, Gemma and Nouvellet, Pierre and Okell, Lucy and Parag, Kris V. and Siveroni, Igor and Thompson, Hayley A. and Walker, Patrick and Walters, Caroline E. and Watson, Oliver J. and Whittles, Lilith K. and Ghani, Azra C. and Ferguson, Neil M. and Riley, Steven and Donnelly, Christl A. and Bhatt, Samir and Flaxman, Seth},
  year = {2020},
  month = dec,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {6189},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-19652-6},
  abstract = {As of 1st June 2020, the US Centres for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly model the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We use changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. We estimate that Rt was only below one in 23 states on 1st June. We also estimate that 3.7\% [3.4\%\textendash 4.0\%] of the total population of the US had been infected, with wide variation between states, and approximately 0.01\% of the population was infectious. We demonstrate good 3 week model forecasts of deaths with low error and good coverage of our credible intervals.},
  copyright = {2020 The Author(s)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2ZXCC7CV\\Unwin et al. - 2020 - State-level tracking of COVID-19 in the United Sta.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\ABRUAC55\\s41467-020-19652-6.html}
}

@article{UsingFaceMasks,
  title = {Using Face Masks in the Community},
  pages = {6},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\53P2ZFAM\\Using face masks in the community.pdf}
}

@article{valkaEstimationInteractiveVisualization2020,
  title = {Estimation and {{Interactive Visualization}} of the {{Time-Varying Reproduction Number Rt}} and the {{Time-Delay}} from {{Infection}} to {{Estimation}}},
  author = {Valka, Fabian and Schuler, Carla},
  year = {2020},
  month = may,
  abstract = {Rt plays a key role in the development of the COVID-19 pandemic. The methods used for building an interactive website for the visualization of the time-varying reproduction number Rt and a novel way to visualize the time delay from infection to estimation overlayed with the Rt estimate are described and analyzed with regards to the influence of parameters chosen and compared to published estimates for Austria. Visualizing the time delays enables the interactive exploration of suspected changes in transmission and their effect on the Rt estimate.},
  copyright = {Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KA9QEF6E\\Valka and Schuler - ESTIMATION AND INTERACTIVE VISUALIZATION OF THE TI.pdf}
}

@article{valkaEstimationInteractiveVisualization2020a,
  title = {Estimation and {{Interactive Visualization}} of the {{Time-Varying Reproduction Number Rt}} and the {{Time-Delay}} from {{Infection}} to {{Estimation}}},
  author = {Valka, Fabian and Schuler, Carla},
  year = {2020},
  month = sep,
  journal = {medRxiv},
  pages = {2020.09.19.20197970},
  publisher = {{Cold Spring Harbor Laboratory Press}},
  doi = {10.1101/2020.09.19.20197970},
  abstract = {{$<$}p{$>$}Rt plays a key role in the development of the COVID-19 pandemic. The methods used for building an interactive website for the visualization of the time-varying reproduction number Rt and a novel way to visualize the time delay from infection to estimation overlayed with the Rt estimate are described and analyzed with regards to the influence of parameters chosen and compared to published estimates for Austria. Visualizing the time delays enables the interactive exploration of suspected changes in transmission and their effect on the Rt estimate.{$<$}/p{$>$}},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\3DC4P6WX\\Valka and Schuler - 2020 - Estimation and Interactive Visualization of the Ti.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\U5EPE7HR\\2020.09.19.html}
}

@article{vansmedenSampleSizeBinary2019,
  title = {Sample Size for Binary Logistic Prediction Models: {{Beyond}} Events per Variable Criteria},
  shorttitle = {Sample Size for Binary Logistic Prediction Models},
  author = {{van Smeden}, Maarten and Moons, Karel GM and {de Groot}, Joris AH and Collins, Gary S and Altman, Douglas G and Eijkemans, Marinus JC and Reitsma, Johannes B},
  year = {2019},
  month = aug,
  journal = {Statistical Methods in Medical Research},
  volume = {28},
  number = {8},
  pages = {2455--2474},
  publisher = {{SAGE Publications Ltd STM}},
  issn = {0962-2802},
  doi = {10.1177/0962280218784726},
  abstract = {Binary logistic regression is one of the most frequently applied statistical approaches for developing clinical prediction models. Developers of such models often rely on an Events Per Variable criterion (EPV), notably EPV {$\geq$}10, to determine the minimal sample size required and the maximum number of candidate predictors that can be examined. We present an extensive simulation study in which we studied the influence of EPV, events fraction, number of candidate predictors, the correlations and distributions of candidate predictor variables, area under the ROC curve, and predictor effects on out-of-sample predictive performance of prediction models. The out-of-sample performance (calibration, discrimination and probability prediction error) of developed prediction models was studied before and after regression shrinkage and variable selection. The results indicate that EPV does not have a strong relation with metrics of predictive performance, and is not an appropriate criterion for (binary) prediction model development studies. We show that out-of-sample predictive performance can better be approximated by considering the number of predictors, the total sample size and the events fraction. We propose that the development of new sample size criteria for prediction models should be based on these three parameters, and provide suggestions for improving sample size determination.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\4Q3CMKEE\\van Smeden et al. - 2019 - Sample size for binary logistic prediction models.pdf}
}

@article{vasquezAccountingBothRandom2005,
  title = {Accounting for Both Random Errors and Systematic Errors in Uncertainty Propagation Analysis of Computer Models Involving Experimental Measurements with {{Monte Carlo}} Methods},
  author = {Vasquez, Victor R and Whiting, Wallace B},
  year = {2005},
  month = dec,
  journal = {Risk analysis: an official publication of the Society for Risk Analysis},
  volume = {25},
  number = {6},
  pages = {1669--1681},
  issn = {0272-4332},
  doi = {10.1111/j.1539-6924.2005.00704.x},
  abstract = {A Monte Carlo method is presented to study the effect of systematic and random errors on computer models mainly dealing with experimental data. It is a common assumption in this type of models (linear and nonlinear regression, and nonregression computer models) involving experimental measurements that the error sources are mainly random and independent with no constant background errors (systematic errors). However, from comparisons of different experimental data sources evidence is often found of significant bias or calibration errors. The uncertainty analysis approach presented in this work is based on the analysis of cumulative probability distributions for output variables of the models involved taking into account the effect of both types of errors. The probability distributions are obtained by performing Monte Carlo simulation coupled with appropriate definitions for the random and systematic errors. The main objectives are to detect the error source with stochastic dominance on the uncertainty propagation and the combined effect on output variables of the models. The results from the case studies analyzed show that the approach is able to distinguish which error type has a more significant effect on the performance of the model. Also, it was found that systematic or calibration errors, if present, cannot be neglected in uncertainty analysis of models dependent on experimental measurements such as chemical and physical properties. The approach can be used to facilitate decision making in fields related to safety factors selection, modeling, experimental data measurement, and experimental design.},
  langid = {english},
  pmid = {16506991}
}

@article{vinerSusceptibilitySARSCoV2Infection2020,
  title = {Susceptibility to {{SARS-CoV-2 Infection Among Children}} and {{Adolescents Compared With Adults}}: {{A Systematic Review}} and {{Meta-analysis}}},
  shorttitle = {Susceptibility to {{SARS-CoV-2 Infection Among Children}} and {{Adolescents Compared With Adults}}},
  author = {Viner, Russell M. and Mytton, Oliver T. and Bonell, Chris and {Melendez-Torres}, G. J. and Ward, Joseph and Hudson, Lee and Waddington, Claire and Thomas, James and Russell, Simon and {van der Klis}, Fiona and Koirala, Archana and Ladhani, Shamez and {Panovska-Griffiths}, Jasmina and Davies, Nicholas G. and Booy, Robert and Eggo, Rosalind M.},
  year = {2020},
  month = sep,
  journal = {JAMA pediatrics},
  issn = {2168-6211},
  doi = {10.1001/jamapediatrics.2020.4573},
  abstract = {Importance: The degree to which children and adolescents are infected by and transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. The role of children and adolescents in transmission of SARS-CoV-2 is dependent on susceptibility, symptoms, viral load, social contact patterns, and behavior. Objective: To systematically review the susceptibility to and transmission of SARS-CoV-2 among children and adolescents compared with adults. Data Sources: PubMed and medRxiv were searched from database inception to July 28, 2020, and a total of 13 926 studies were identified, with additional studies identified through hand searching of cited references and professional contacts. Study Selection: Studies that provided data on the prevalence of SARS-CoV-2 in children and adolescents (younger than 20 years) compared with adults (20 years and older) derived from contact tracing or population screening were included. Single-household studies were excluded. Data Extraction and Synthesis: PRISMA guidelines for abstracting data were followed, which was performed independently by 2 reviewers. Quality was assessed using a critical appraisal checklist for prevalence studies. Random-effects meta-analysis was undertaken. Main Outcomes and Measures: Secondary infection rate (contact-tracing studies) or prevalence or seroprevalence (population screening studies) among children and adolescents compared with adults. Results: A total of 32 studies comprising 41 640 children and adolescents and 268 945 adults met inclusion criteria, including 18 contact-tracing studies and 14 population screening studies. The pooled odds ratio of being an infected contact in children compared with adults was 0.56 (95\% CI, 0.37-0.85), with substantial heterogeneity (I2\,=\,94.6\%). Three school-based contact-tracing studies found minimal transmission from child or teacher index cases. Findings from population screening studies were heterogenous and were not suitable for meta-analysis. Most studies were consistent with lower seroprevalence in children compared with adults, although seroprevalence in adolescents appeared similar to adults. Conclusions and Relevance: In this meta-analysis, there is preliminary evidence that children and adolescents have lower susceptibility to SARS-CoV-2, with an odds ratio of 0.56 for being an infected contact compared with adults. There is weak evidence that children and adolescents play a lesser role than adults in transmission of SARS-CoV-2 at a population level. This study provides no information on the infectivity of children.},
  langid = {english},
  pmcid = {PMC7519436},
  pmid = {32975552},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\FKQVEN3A\\Viner et al. - 2020 - Susceptibility to SARS-CoV-2 Infection Among Child.pdf}
}

@article{vinetzLackEfficacyHydroxychloroquine2020,
  title = {Lack of Efficacy of Hydroxychloroquine in Covid-19},
  author = {Vinetz, Joseph M.},
  year = {2020},
  month = may,
  journal = {BMJ},
  volume = {369},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj.m2018},
  abstract = {{$<$}p{$>$}Studies in mild-to-moderate cases as well as severe disease leave us still searching for a magic pill{$<$}/p{$>$}},
  chapter = {Editorial},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},
  langid = {english},
  pmid = {32430461},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZWPBBLJ9\\Vinetz - 2020 - Lack of efficacy of hydroxychloroquine in covid-19.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BRAPFH4N\\bmj.html}
}

@techreport{vollmerReport20Subnational2020,
  title = {Report 20: {{A}} Sub-National Analysis of the Rate of Transmission of {{Covid-19}} in {{Italy}}},
  shorttitle = {Report 20},
  author = {Vollmer, M and Mishra, S and Unwin, H and Gandy, A and Melan, T and Bradley, V and Zhu, H and Coupland, H and Hawryluk, I and Hutchinson, M and Ratmann, O and Monod, M and Walker, P and Whittaker, C and Cattarino, L and Ciavarella, C and Cilloni, L and Ainslie, K and Baguelin, M and Bhatia, S and Boonyasiri, A and Brazeau, N and Charles, G and Cooper, L and Cucunuba Perez, Z and {Cuomo-Dannenburg}, G and Dighe, A and Djaafara, A and Eaton, J and Van Elsland, S and Fitzjohn, R and Fraser, K and Gaythorpe, K and Green, W and Hayes, S and Imai, N and Jeffrey, B and Knock, E and Laydon, D and Lees, J and Mangal, T and Mousa, A and Nedjati Gilani, G and Nouvellet, P and Olivera Mesa, D and Parag, K and Pickles, M and Thompson, H and Verity, R and Walters, C and Wang, H and Wang, Y and Watson, O and Whittles, L and Xi, X and Ghani, A and Riley, S and Okell, L and Donnelly, C and Ferguson, N and Dorigatti, I and Flaxman, S and Bhatt, S},
  year = {2020},
  month = may,
  institution = {{Imperial College London}},
  doi = {10.25561/78677},
  abstract = {Italy was the first European country to experience sustained local transmission of COVID-19. As of 1st May 2020, the Italian health authorities reported 28; 238 deaths nationally. To control the epidemic, the Italian government implemented a suite of non-pharmaceutical interventions (NPIs), including school and university closures, social distancing and full lockdown involving banning of public gatherings and non essential movement. In this report, we model the effect of NPIs on transmission using data on average mobility. We estimate that the average reproduction number (a measure of transmission intensity) is currently below one for all Italian regions, and significantly so for the majority of the regions. Despite the large number of deaths, the proportion of population that has been infected by SARS-CoV-2 (the attack rate) is far from the herd immunity threshold in all Italian regions, with the highest attack rate observed in Lombardy (13.18\% [10.66\%-16.70\%]). Italy is set to relax the currently implemented NPIs from 4th May 2020. Given the control achieved by NPIs, we consider three scenarios for the next 8 weeks: a scenario in which mobility remains the same as during the lockdown, a scenario in which mobility returns to pre-lockdown levels by 20\%, and a scenario in which mobility returns to pre-lockdown levels by 40\%. The scenarios explored assume that mobility is scaled evenly across all dimensions, that behaviour stays the same as before NPIs were implemented, that no pharmaceutical interventions are introduced, and it does not include transmission reduction from contact tracing, testing and the isolation of confirmed or suspected cases. We find that, in the absence of additional interventions, even a 20\% return to pre-lockdown mobility could lead to a resurgence in the number of deaths far greater than experienced in the current wave in several regions. Future increases in the number of deaths will lag behind the increase in transmission intensity and so a second wave will not be immediately apparent from just monitoring of the daily number of deaths. Our results suggest that SARS-CoV-2 transmission as well as mobility should be closely monitored in the next weeks and months. To compensate for the increase in mobility that will occur due to the relaxation of the currently implemented NPIs, enhanced community surveillance including swab testing, contact tracing and the early isolation of infections are of paramount importance to reduce the risk of resurgence in transmission.},
  collaborator = {Medical Research Council (MRC)},
  copyright = {\textcopyright{} 2020 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).},
  langid = {english},
  keywords = {Coronavirus,COVID-19,COVID19,Italy,Lockdown,Transmission},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D4PKENJF\\Vollmer et al. - 2020 - Report 20 A sub-national analysis of the rate of .pdf}
}

@article{wakefieldSpatialDiscreteTimeInfectious,
  title = {Spatial {{Discrete-Time Infectious Disease Models}} for {{Surveillance Data}}},
  author = {Wakefield, Jon},
  pages = {37},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LDAKCE3V\\Wakeeld - Spatial Discrete-Time Infectious Disease Models fo.pdf}
}

@article{wallingaHowGenerationIntervals2007,
  title = {How Generation Intervals Shape the Relationship between Growth Rates and Reproductive Numbers},
  author = {Wallinga, J and Lipsitch, M},
  year = {2007},
  month = feb,
  journal = {Proceedings of the Royal Society B: Biological Sciences},
  volume = {274},
  number = {1609},
  pages = {599--604},
  issn = {0962-8452},
  doi = {10.1098/rspb.2006.3754},
  abstract = {Mathematical models of transmission have become invaluable management tools in planning for the control of emerging infectious diseases. A key variable in such models is the reproductive number R. For new emerging infectious diseases, the value of the reproductive number can only be inferred indirectly from the observed exponential epidemic growth rate r. Such inference is ambiguous as several different equations exist that relate the reproductive number to the growth rate, and it is unclear which of these equations might apply to a new infection. Here, we show that these different equations differ only with respect to their assumed shape of the generation interval distribution. Therefore, the shape of the generation interval distribution determines which equation is appropriate for inferring the reproductive number from the observed growth rate. We show that by assuming all generation intervals to be equal to the mean, we obtain an upper bound to the range of possible values that the reproductive number may attain for a given growth rate. Furthermore, we show that by taking the generation interval distribution equal to the observed distribution, it is possible to obtain an empirical estimate of the reproductive number.},
  pmcid = {PMC1766383},
  pmid = {17476782},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\GIJZZZQ4\\Wallinga and Lipsitch - 2007 - How generation intervals shape the relationship be.pdf}
}

@article{wallNeutralisingAntibodyActivity2021,
  title = {Neutralising Antibody Activity against {{SARS-CoV-2 VOCs B}}.1.617.2 and {{B}}.1.351 by {{BNT162b2}} Vaccination},
  author = {Wall, Emma C. and Wu, Mary and Harvey, Ruth and Kelly, Gavin and Warchal, Scott and Sawyer, Chelsea and Daniels, Rodney and Hobson, Philip and Hatipoglu, Emine and Ngai, Yenting and Hussain, Saira and Nicod, Jerome and Goldstone, Robert and Ambrose, Karen and Hindmarsh, Steve and Beale, Rupert and Riddell, Andrew and Gamblin, Steve and Howell, Michael and Kassiotis, George and Libri, Vincenzo and Williams, Bryan and Swanton, Charles and Gandhi, Sonia and Bauer, David LV},
  year = {2021},
  month = jun,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(21)01290-3},
  abstract = {The SARS-CoV-2 B.1.617.2 Variant of Concern (VOC), first detected in India, is now dominant in the UK, having rapidly1 displaced the B.1.1.7 strain2 that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently licensed COVID-19 vaccines against B.1.617.2 is unknown; although it possesses 12 mutations in its spike protein relative to the wildtype SARS-CoV-2 first detected in Wuhan, China, in December, 2019, B.1.617.2 lacks mutations at amino acid positions 501 or 484 in its ACE2 receptor-binding domain, commonly associated with VOCs (appendix p 2) or escape from neutralising antibodies (NAbs).},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\WMPCXQMB\\Wall et al. - 2021 - Neutralising antibody activity against SARS-CoV-2 .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\8SB4PIPN\\fulltext.html}
}

@article{wangAssociationUniversalMasking2020,
  title = {Association {{Between Universal Masking}} in a {{Health Care System}} and {{SARS-CoV-2 Positivity Among Health Care Workers}}},
  author = {Wang, Xiaowen and Ferro, Enrico G. and Zhou, Guohai and Hashimoto, Dean and Bhatt, Deepak L.},
  year = {2020},
  month = jul,
  journal = {JAMA},
  doi = {10.1001/jama.2020.12897},
  abstract = {This study describes SARS-CoV-2 PCR test positivity among health care workers before, during, and after implementation of a policy requiring universal masking of all health care workers and patients in a large health care system in Massachusetts.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\BISG4NEI\\Wang et al. - 2020 - Association Between Universal Masking in a Health .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\45B4DW39\\2768533.html}
}

@article{wangEarlyReleaseImpact,
  title = {Early {{Release}} - {{Impact}} of {{Social Distancing Measures}} on {{Coronavirus Disease Healthcare Demand}}, {{Central Texas}}, {{USA}} - {{Volume}} 26, {{Number}} 10\textemdash{{October}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Wang, Xutong and Pasco, Remy F. and Du, Zhanwei and Petty, Michaela and Fox, Spencer J. and Galvani, Alison P. and Pignone, Michael and Johnston, S. Claiborne and Meyers, Lauren Ancel},
  doi = {10.3201/eid2610.201702},
  abstract = {Social distancing orders have been enacted worldwide to slow the coronavirus disease (COVID-19) pandemic, reduce strain on healthcare systems, and pre...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HWF5QA2A\\20-1702_article.html}
}

@article{wangReductionSecondaryTransmission2020,
  title = {Reduction of Secondary Transmission of {{SARS-CoV-2}} in Households by Face Mask Use, Disinfection and Social Distancing: A Cohort Study in {{Beijing}}, {{China}}},
  shorttitle = {Reduction of Secondary Transmission of {{SARS-CoV-2}} in Households by Face Mask Use, Disinfection and Social Distancing},
  author = {Wang, Yu and Tian, Huaiyu and Zhang, Li and Zhang, Man and Guo, Dandan and Wu, Wenting and Zhang, Xingxing and Kan, Ge Lin and Jia, Lei and Huo, Da and Liu, Baiwei and Wang, Xiaoli and Sun, Ying and Wang, Quanyi and Yang, Peng and MacIntyre, C. Raina},
  year = {2020},
  month = may,
  journal = {BMJ Global Health},
  volume = {5},
  number = {5},
  pages = {e002794},
  issn = {2059-7908},
  doi = {10.1136/bmjgh-2020-002794},
  abstract = {Introduction: Transmission of Coronavirus disease 2019 (COVID-19) within families and close contacts accounts for the majority of epidemic growth. Community mask wearing, hand washing and social distancing are thought to be effective but there is little evidence to inform or support community members on COVID-19 risk reduction within families. Methods: A retrospective cohort study of 335 people in 124 families and with at least one laboratory confirmed COVID-19 case was conducted from 28 February to 27 March, 2020 in Beijing, China. The outcome of interest was secondary transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the family. Characteristics and practices of primary cases, of well family contacts and household hygiene practices were analyzed as predictors of secondary transmission. Results: The secondary attack rate in families was 23.0\% (77/335). Face mask use by the primary case and family contacts before the primary case developed symptoms was 79\% effective in reducing transmission (OR=0.21, 95\% CI: 0.06 to 0.79). Daily use of chlorine or ethanol based disinfectant in households was 77\% effective (OR=0.23, 95\% CI: 0.07 to 0.84). Wearing a mask after illness onset of primary case was not significantly protective. The risk of household transmission was 18 times higher with frequent daily close contact with the primary case (OR=18.26, 95\% CI: 3.93 to 84.79), and four times higher if the primary case had diarrhea (OR=4.10, 95\% CI: 1.08 to 15.60). Household crowding was not significant. Conclusion: The study confirms the highest risk of transmission prior to symptom onset, and provides the first evidence of effectiveness of mask use, disinfection and social distancing in preventing COVID-19. We also show evidence of fecal transmission. This can inform guidelines for community prevention in settings of intense COVID-19 epidemics.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2QISM7YA\\Wang et al. - 2020 - Reduction of secondary transmission of SARS-CoV-2 .pdf}
}

@article{wangTransmissionViralKinetics2021,
  title = {Transmission, Viral Kinetics and Clinical Characteristics of the Emergent {{SARS-CoV-2 Delta VOC}} in {{Guangzhou}}, {{China}}},
  author = {Wang, Yaping and Chen, Ruchong and Hu, Fengyu and Lan, Yun and Yang, Zhaowei and Zhan, Chen and Shi, Jingrong and Deng, Xizi and Jiang, Mei and Zhong, Shuxin and Liao, Baolin and Deng, Kai and Tang, Jingyan and Guo, Liliangzi and Jiang, Mengling and Fan, Qinghong and Li, Meiyu and Liu, Jinxin and Shi, Yaling and Deng, Xilong and Xiao, Xincai and Kang, Min and Li, Yan and Guan, Weijie and Li, Yimin and Li, Shiyue and Li, Feng and Zhong, Nanshan and Tang, Xiaoping},
  year = {2021},
  month = oct,
  journal = {EClinicalMedicine},
  volume = {40},
  publisher = {{Elsevier}},
  issn = {2589-5370},
  doi = {10.1016/j.eclinm.2021.101129},
  langid = {english},
  pmid = {34541481},
  keywords = {COVID-19,Delta variant,Risk factor,Transmission},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PGHAK4WE\\Wang et al. - 2021 - Transmission, viral kinetics and clinical characte.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\V8PWEW7Y\\fulltext.html}
}

@article{wardREACT2IncreasingPrevalence,
  title = {{{REACT-2 Round}} 5: Increasing Prevalence of {{SARS-CoV-2}} Antibodies Demonstrate Impact of the Second Wave and of Vaccine Roll-out in {{England}}},
  author = {Ward, Helen and Cooke, Graham and Whitaker, Matt and Redd, Rozlyn and Brown, Jonathan C and Collet, Katharine and Cooper, Emily and Daunt, Anna and Moshe, Maya and Willicombe, Michelle and Day, Sophie and Atchison, Christina and Donnelly, Christl A and Riley, Steven and Ashby, Deborah and Barclay, Wendy S},
  pages = {29},
  abstract = {Background England has experienced high rates of SARS-CoV-2 infection during the COVID-19 pandemic, affecting in particular minority ethnic groups and more deprived communities. A vaccination programme began in England in December 2020, with priority given to administering the first dose to the largest number of older individuals, healthcare and care home workers. Methods A cross-sectional community survey in England undertaken between 26 January and 8 February 2021 as the fifth round of the REal-time Assessment of Community Transmission-2 (REACT-2) programme. Participants completed questionnaires, including demographic details and clinical and COVID-19 vaccination histories, and self-administered a lateral flow immunoassay (LFIA) test to detect IgG against SARS-CoV-2 spike protein. There were sufficient numbers of participants to analyse antibody positivity after 21 days from vaccination with the PfizerBioNTech but not the AstraZeneca/Oxford vaccine which was introduced slightly later. Results The survey comprised 172,099 people, with valid IgG antibody results from 155,172. The overall prevalence of antibodies (weighted to be representative of the population of England and adjusted for test sensitivity and specificity) in England was 13.9\% (95\% CI 13.7, 14.1) overall, 37.9\% (37.2, 38.7) in vaccinated and 9.8\% (9.6, 10.0) in unvaccinated people. The prevalence of antibodies (weighted) in unvaccinated people was highest in London at 16.9\% (16.3, 17.5), and higher in people of Black (22.4\%, 20.8, 24.1) and Asian (20.0\%, 19.0, 21.0) ethnicity compared to white (8.5\%, 8.3, 8.7) people. The uptake of vaccination by age was highest in those aged 80 years or older (93.5\%). Vaccine confidence was high with 92.0\% (91.9, 92.1) of people saying that they had accepted or intended to accept the offer. Vaccine confidence varied by age and ethnicity, with lower confidence in young people and those of Black ethnicity. Particular concerns were identified around pregnancy, fertility and allergies. In 971 individuals who received two doses of the Pfizer-BioNTech vaccine, the proportion testing positive was high across all age groups. Following a single dose of PfizerBioNTech vaccine after 21 days or more, 84.1\% (82.2, 85.9) of people under 60 years tested positive (unadjusted) with a decreasing trend with increasing age, but high responses to a single dose in those with confirmed or suspected prior COVID at 90.1\% (87.2, 92.4) across all age groups. Conclusions There is uneven distribution of SARS-CoV-2 antibodies in the population with a higher burden in key workers and some minority ethnic groups, similar to the pattern in the first wave. Confidence in the vaccine programme is high overall although it was lower in some of the higher prevalence groups which suggests the need for improved communication about specific perceived risks. Two doses of Pfizer-BioNTech vaccine, or a single dose following previous infection, confers high levels of antibody positivity across all ages. Further work is needed to understand the relationship between antibody positivity, clinical outcomes such as hospitalisation, and transmission.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\CZKTCXHW\\Ward et al. - REACT-2 Round 5 increasing prevalence of SARS-CoV.pdf}
}

@article{weberHintergrundInformationenZurBettenauslastung,
  title = {{Hintergrund-Informationen zur Bettenauslastung auf Intensivstationen}},
  author = {Weber, Karin},
  pages = {7},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8MQ7QV4L\\Weber - Hintergrund-Informationen zur Bettenauslastung auf.pdf}
}

@misc{WeiShengFuLiBuPosts,
  title = { - {{Posts}}},
  howpublished = {https://www.facebook.com/mohw.gov.tw/posts/1565429836956762},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\6M3IMJZB\\1565429836956762.html}
}

@article{westreichTableFallacyPresenting2013,
  title = {The {{Table}}~2 {{Fallacy}}: {{Presenting}} and {{Interpreting Confounder}} and {{Modifier Coefficients}}},
  shorttitle = {The {{Table}}~2 {{Fallacy}}},
  author = {Westreich, Daniel and Greenland, Sander},
  year = {2013},
  month = feb,
  journal = {American Journal of Epidemiology},
  volume = {177},
  number = {4},
  pages = {292--298},
  issn = {0002-9262},
  doi = {10.1093/aje/kws412},
  abstract = {It is common to present multiple adjusted effect estimates from a single model in a single table. For example, a table might show odds ratios for one or more exposures and also for several confounders from a single logistic regression. This can lead to mistaken interpretations of these estimates. We use causal diagrams to display the sources of the problems. Presentation of exposure and confounder effect estimates from a single model may lead to several interpretative difficulties, inviting confusion of direct-effect estimates with total-effect estimates for covariates in the model. These effect estimates may also be confounded even though the effect estimate for the main exposure is not confounded. Interpretation of these effect estimates is further complicated by heterogeneity (variation, modification) of the exposure effect measure across covariate levels. We offer suggestions to limit potential misunderstandings when multiple effect estimates are presented, including precise distinction between total and direct effect measures from a single model, and use of multiple models tailored to yield total-effect estimates for covariates.},
  pmcid = {PMC3626058},
  pmid = {23371353},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\D5IQMPNV\\Westreich and Greenland - 2013 - The Table2 Fallacy Presenting and Interpreting C.pdf}
}

@article{whittlesPotentialProfileCOVID19,
  title = {Potential Profile of the {{COVID-19}} Epidemic in the {{UK}} under Different Vaccination Roll out Strategies [{{Ver}} 2.]},
  author = {Whittles, Lilith K and Imai, Natsuko and Knock, Edward S and {Perez-Guzman}, Pablo N and Ghani, Azra and Ferguson, Neil M and Baguelin, Marc and Cori, Anne},
  pages = {15},
  abstract = {Vaccination will have a large positive impact on the number of COVID-19 deaths with the doses administered to date (\textasciitilde 2M) having a noticeable effect already. \textbullet{} There is uncertainty around the total number of deaths. However, the impact will be substantially higher if optimistic, or even central vaccine roll out can be achieved, compared to pessimistic roll out (i.e. if vaccination can be rapidly ramped up from 1 to 2 or 3 million doses a week). \textbullet{} For all gradual easing of NPI scenarios explored, unless vaccination is rapidly ramped up to 3 million doses a week, gradual lifting of NPIs from 1st March to 1st July will lead to a third wave of hospitalisations which will exceed our indicative threshold of 25,000 beds national hospital capacity.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\E8SPB6YV\\Whittles et al. - Potential profile of the COVID-19 epidemic in the .pdf}
}

@article{whittlesUnlockingRoadmapScenarios,
  title = {``{{Unlocking}}'' {{Roadmap Scenarios}} for {{England}} V2},
  author = {Whittles, Lilith K and Imai, Natsuko and Knock, Edward S and {Perez-Guzman}, Pablo N and Sonabend, Raphael and Ghani, Azra and Ferguson, Neil M and Baguelin, Marc and Cori, Anne},
  pages = {15},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\2L2BJX9G\\Whittles et al. - Unlocking Roadmap Scenarios for England v2.pdf}
}

@article{wibmerSARSCoV2501YV22021,
  title = {{{SARS-CoV-2 501Y}}.{{V2}} Escapes Neutralization by {{South African COVID-19}} Donor Plasma},
  author = {Wibmer, Constantinos Kurt and Ayres, Frances and Hermanus, Tandile and Madzivhandila, Mashudu and Kgagudi, Prudence and Oosthuysen, Brent and Lambson, Bronwen E. and {de Oliveira}, Tulio and Vermeulen, Marion and {van der Berg}, Karin and Rossouw, Theresa and Boswell, Michael and Ueckermann, Veronica and Meiring, Susan and {von Gottberg}, Anne and Cohen, Cheryl and Morris, Lynn and Bhiman, Jinal N. and Moore, Penny L.},
  year = {2021},
  month = mar,
  journal = {Nature Medicine},
  pages = {1--4},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-021-01285-x},
  abstract = {SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\YQ2CY3QH\\Wibmer et al. - 2021 - SARS-CoV-2 501Y.V2 escapes neutralization by South.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\A7MKDSKD\\s41591-021-01285-x.html}
}

@article{wiersingaPathophysiologyTransmissionDiagnosis2020,
  title = {Pathophysiology, {{Transmission}}, {{Diagnosis}}, and {{Treatment}} of {{Coronavirus Disease}} 2019 ({{COVID-19}}): {{A Review}}},
  shorttitle = {Pathophysiology, {{Transmission}}, {{Diagnosis}}, and {{Treatment}} of {{Coronavirus Disease}} 2019 ({{COVID-19}})},
  author = {Wiersinga, W. Joost and Rhodes, Andrew and Cheng, Allen C. and Peacock, Sharon J. and Prescott, Hallie C.},
  year = {2020},
  month = jul,
  journal = {JAMA},
  doi = {10.1001/jama.2020.12839},
  abstract = {{$<$}h3{$>$}Importance{$<$}/h3{$><$}p{$>$}The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.{$<$}/p{$><$}h3{$>$}Observations{$<$}/h3{$><$}p{$>$}SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, presymptomatic, and symptomatic carriers. The average time from exposure to symptom onset is 5 days, and 97.5\% of people who develop symptoms do so within 11.5 days. The most common symptoms are fever, dry cough, and shortness of breath. Radiographic and laboratory abnormalities, such as lymphopenia and elevated lactate dehydrogenase, are common, but nonspecific. Diagnosis is made by detection of SARS-CoV-2 via reverse transcription polymerase chain reaction testing, although false-negative test results may occur in up to 20\% to 67\% of patients; however, this is dependent on the quality and timing of testing. Manifestations of COVID-19 include asymptomatic carriers and fulminant disease characterized by sepsis and acute respiratory failure. Approximately 5\% of patients with COVID-19, and 20\% of those hospitalized, experience severe symptoms necessitating intensive care. More than 75\% of patients hospitalized with COVID-19 require supplemental oxygen. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care (21.6\% vs 24.6\%; age-adjusted rate ratio, 0.83 [95\% CI, 0.74-0.92]) and that remdesivir improves time to recovery (hospital discharge or no supplemental oxygen requirement) from 15 to 11 days. In a randomized trial of 103 patients with COVID-19, convalescent plasma did not shorten time to recovery. Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulants. The case-fatality rate for COVID-19 varies markedly by age, ranging from 0.3 deaths per 1000 cases among patients aged 5 to 17 years to 304.9 deaths per 1000 cases among patients aged 85 years or older in the US. Among patients hospitalized in the intensive care unit, the case fatality is up to 40\%. At least 120 SARS-CoV-2 vaccines are under development. Until an effective vaccine is available, the primary methods to reduce spread are face masks, social distancing, and contact tracing. Monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies.{$<$}/p{$><$}h3{$>$}Conclusions and Relevance{$<$}/h3{$><$}p{$>$}As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. Many aspects of transmission, infection, and treatment remain unclear. Advances in prevention and effective management of COVID-19 will require basic and clinical investigation and public health and clinical interventions.{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8FPI5IAY\\Wiersinga et al. - 2020 - Pathophysiology, Transmission, Diagnosis, and Trea.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\BAHRDGDU\\2768391.html}
}

@techreport{wilhelmReducedNeutralizationSARSCoV22021,
  type = {Preprint},
  title = {Reduced {{Neutralization}} of {{SARS-CoV-2 Omicron Variant}} by {{Vaccine Sera}} and {{Monoclonal Antibodies}}},
  author = {Wilhelm, Alexander and Widera, Marek and Grikscheit, Katharina and Toptan, Tuna and Schenk, Barbara and Pallas, Christiane and Metzler, Melinda and Kohmer, Niko and Hoehl, Sebastian and Helfritz, Fabian A. and Wolf, Timo and Goetsch, Udo and Ciesek, Sandra},
  year = {2021},
  month = dec,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2021.12.07.21267432},
  abstract = {Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RK3V2L83\\Wilhelm et al. - 2021 - Reduced Neutralization of SARS-CoV-2 Omicron Varia.pdf}
}

@misc{WissenAktuellEpidemiologische,
  title = {Wissen {{Aktuell}}: {{Epidemiologische Parameter}} Des {{COVID19 Ausbruchs}}, {{\"Osterreich}}, 2020},
  howpublished = {https://www.ages.at/en/wissen-aktuell/publikationen/epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RXR7275M\\epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020.html}
}

@misc{WissenAktuellEpidemiologischea,
  title = {Wissen {{Aktuell}}: {{Epidemiologische Parameter}} Des {{COVID19 Ausbruchs}}, {{\"Osterreich}}, 2020},
  howpublished = {https://www.ages.at/en/wissen-aktuell/publikationen/epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\JUQLJWTN\\epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020.html}
}

@misc{WissenAktuellEpidemiologischeb,
  title = {Wissen {{Aktuell}}: {{Epidemiologische Parameter}} Des {{COVID19 Ausbruchs}}, {{\"Osterreich}}, 2020},
  howpublished = {https://www.ages.at/en/wissen-aktuell/publikationen/epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DHL64BJC\\epidemiologische-parameter-des-covid19-ausbruchs-oesterreich-2020.html}
}

@article{wolfelVirologicalAssessmentHospitalized2020,
  title = {Virological Assessment of Hospitalized Patients with {{COVID-2019}}},
  author = {W{\"o}lfel, Roman and Corman, Victor M. and Guggemos, Wolfgang and Seilmaier, Michael and Zange, Sabine and M{\"u}ller, Marcel A. and Niemeyer, Daniela and Jones, Terry C. and Vollmar, Patrick and Rothe, Camilla and Hoelscher, Michael and Bleicker, Tobias and Br{\"u}nink, Sebastian and Schneider, Julia and Ehmann, Rosina and Zwirglmaier, Katrin and Drosten, Christian and Wendtner, Clemens},
  year = {2020},
  month = may,
  journal = {Nature},
  volume = {581},
  number = {7809},
  pages = {465--469},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-020-2196-x},
  abstract = {Coronavirus disease~2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8\% of cases with severe courses, and 6.1\% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity\textemdash but also aided in the control\textemdash of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6\textendash 8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11~\texttimes ~108~RNA copies per throat swab on day~4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples\textemdash in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7~days in 50\% of patients (and by day~14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XM2N77MZ\\Wlfel et al. - 2020 - Virological assessment of hospitalized patients wi.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\7W4VAXNM\\s41586-020-2196-x.html}
}

@article{wolfLateralFlowDevice,
  title = {Lateral Flow Device Specificity in Phase 4 (Post Marketing) Surveillance},
  author = {Wolf, Achim and Hulmes, Jack and Hopkins, Susan},
  pages = {12},
  abstract = {Public Health England (PHE) and Oxford University evaluated the performance of the Innova LFD device against PCR. In phase 2 and 3a, where the same sample was used for both PCR and LFD specificity analyses, no false positives were detected. We conducted a Phase 4, post marketing surveillance study in 7,546 individuals with a negative PCR result and compared those results with the LFD results from a separate sample. This study identified 21 (0.28\%) discordant test pairs and therefore concluded that the specificity of the LFD device was 99.72\%. However, this analysis assumed a sensitivity for the PCR of 100\% (i.e. that on all 21 discordant samples the PCR, and not the LFD, gave the correct result). Analysis of the Phase 4 data can also be interpreted with lower PCR sensitivity levels and is consistent with a PCR sensitivity ranging from 94.2\% to 100\% and an associated LFD specificity ranging from 100\% to 99.72\%.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8Y2UA79Y\\Wolf et al. - Lateral flow device specificity in phase 4 (post m.pdf}
}

@article{woloshinFalseNegativeTests2020,
  title = {False {{Negative Tests}} for {{SARS-CoV-2 Infection}} \textemdash{} {{Challenges}} and {{Implications}}},
  author = {Woloshin, Steven and Patel, Neeraj and Kesselheim, Aaron S.},
  year = {2020},
  month = jun,
  journal = {New England Journal of Medicine},
  publisher = {{Massachusetts Medical Society}},
  abstract = {Perspective from The New England Journal of Medicine \textemdash{} False Negative Tests for SARS-CoV-2 Infection \textemdash{} Challenges and Implications},
  copyright = {Copyright \textcopyright{} 2020 Massachusetts Medical Society. All rights reserved.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\KVURPQ32\\NEJMp2015897.html}
}

@article{wongEvidenceThatCoronavirus2020,
  title = {Evidence That Coronavirus Superspreading Is Fat-Tailed},
  author = {Wong, Felix and Collins, James J.},
  year = {2020},
  month = nov,
  journal = {Proceedings of the National Academy of Sciences},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.2018490117},
  abstract = {Superspreaders, infected individuals who result in an outsized number of secondary cases, are believed to underlie a significant fraction of total SARS-CoV-2 transmission. Here, we combine empirical observations of SARS-CoV and SARS-CoV-2 transmission and extreme value statistics to show that the distribution of secondary cases is consistent with being fat-tailed, implying that large superspreading events are extremal, yet probable, occurrences. We integrate these results with interaction-based network models of disease transmission and show that superspreading, when it is fat-tailed, leads to pronounced transmission by increasing dispersion. Our findings indicate that large superspreading events should be the targets of interventions that minimize tail exposure.},
  chapter = {Biological Sciences},
  copyright = {Copyright \textcopyright{} 2020 the Author(s). Published by PNAS.. https://creativecommons.org/licenses/by/4.0/This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).},
  isbn = {9782018490110},
  langid = {english},
  pmid = {33139561},
  keywords = {COVID-19,extreme value theory,infectious disease,SARS-CoV-2,superspreading},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5PFMETTW\\Wong and Collins - 2020 - Evidence that coronavirus superspreading is fat-ta.pdf}
}

@article{woolfExcessDeathsCOVID192020,
  title = {Excess {{Deaths From COVID-19}} and {{Other Causes}}, {{March-July}} 2020},
  author = {Woolf, Steven H. and Chapman, Derek A. and Sabo, Roy T. and Weinberger, Daniel M. and Hill, Latoya and Taylor, DaShaunda D. H.},
  year = {2020},
  month = oct,
  journal = {JAMA},
  volume = {324},
  number = {15},
  pages = {1562},
  issn = {0098-7484},
  doi = {10.1001/jama.2020.19545},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\8F5HDKTR\\Woolf et al. - 2020 - Excess Deaths From COVID-19 and Other Causes, Marc.pdf}
}

@article{woutersChallengesEnsuringGlobal2021,
  title = {Challenges in Ensuring Global Access to {{COVID-19}} Vaccines: Production, Affordability, Allocation, and Deployment},
  shorttitle = {Challenges in Ensuring Global Access to {{COVID-19}} Vaccines},
  author = {Wouters, Olivier J. and Shadlen, Kenneth C. and {Salcher-Konrad}, Maximilian and Pollard, Andrew J. and Larson, Heidi J. and Teerawattananon, Yot and Jit, Mark},
  year = {2021},
  month = feb,
  journal = {The Lancet},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(21)00306-8},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}p{$>$}The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26 758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98\%), India (91\%), China (91\%), Denmark (87\%), and South Korea (87\%), and lowest in Serbia (38\%), Croatia (41\%), France (44\%), Lebanon (44\%), and Paraguay (51\%).{$<$}/p{$>$}},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PPCBVANW\\Wouters et al. - 2021 - Challenges in ensuring global access to COVID-19 v.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\DS6M956D\\fulltext.html}
}

@article{wuCharacteristicsImportantLessons2020,
  title = {Characteristics of and {{Important Lessons From}} the {{Coronavirus Disease}} 2019 ({{COVID-19}}) {{Outbreak}} in {{China}}: {{Summary}} of a {{Report}} of 72 314 {{Cases From}} the {{Chinese Center}} for {{Disease Control}} and {{Prevention}}},
  shorttitle = {Characteristics of and {{Important Lessons From}} the {{Coronavirus Disease}} 2019 ({{COVID-19}}) {{Outbreak}} in {{China}}},
  author = {Wu, Zunyou and McGoogan, Jennifer M.},
  year = {2020},
  month = apr,
  journal = {JAMA},
  volume = {323},
  number = {13},
  pages = {1239--1242},
  publisher = {{American Medical Association}},
  issn = {0098-7484},
  doi = {10.1001/jama.2020.2648},
  abstract = {This Viewpoint summarizes key epidemiologic and clinical findings from all cases of coronavirus disease 2019 (COVID-19) reported through February 11, 2020, in mainland China, and case trends in response to government attempts to control and contain the infection.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HS5E3FZC\\Wu and McGoogan - 2020 - Characteristics of and Important Lessons From the .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\X882JG27\\2762130.html}
}

@article{xieAssociationAmbientTemperature2020,
  title = {Association between Ambient Temperature and {{COVID-19}} Infection in 122 Cities from {{China}}},
  author = {Xie, Jingui and Zhu, Yongjian},
  year = {2020},
  month = jul,
  journal = {Science of The Total Environment},
  volume = {724},
  pages = {138201},
  issn = {0048-9697},
  doi = {10.1016/j.scitotenv.2020.138201},
  abstract = {Background Coronavirus disease 2019 (COVID-19) has become a severe public health problem globally. Both epidemiological and laboratory studies have shown that ambient temperature could affect the transmission and survival of coronaviruses. This study aimed to determine whether the temperature is an essential factor in the infection caused by this novel coronavirus. Methods Daily confirmed cases and meteorological factors in 122 cities were collected between January 23, 2020, to February 29, 2020. A generalized additive model (GAM) was applied to explore the nonlinear relationship between mean temperature and COVID-19 confirmed cases. We also used a piecewise linear regression to determine the relationship in detail. Results The exposure-response curves suggested that the relationship between mean temperature and COVID-19 confirmed cases was approximately linear in the range of {$<$}3~\textdegree C and became flat above 3~\textdegree C. When mean temperature (lag0\textendash 14) was below 3~\textdegree C, each 1~\textdegree C rise was associated with a 4.861\% (95\% CI: 3.209\textendash 6.513) increase in the daily number of COVID-19 confirmed cases. These findings were robust in our sensitivity analyses. Conclusions Our results indicate that mean temperature has a positive linear relationship with the number of COVID-19 cases with a threshold of 3~\textdegree C. There is no evidence supporting that case counts of COVID-19 could decline when the weather becomes warmer, which provides useful implications for policymakers and the public.},
  langid = {english},
  keywords = {China,COVID-19,Generalized additive model,Novel coronavirus pneumonia,Temperature},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\HWFD2CDU\\Xie and Zhu - 2020 - Association between ambient temperature and COVID-.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\I73G8FBN\\S0048969720317149.html}
}

@article{xuEpidemiologicalDataCOVID192020,
  title = {Epidemiological Data from the {{COVID-19}} Outbreak, Real-Time Case Information},
  author = {Xu, Bo and Gutierrez, Bernardo and Mekaru, Sumiko and Sewalk, Kara and Goodwin, Lauren and Loskill, Alyssa and Cohn, Emily L. and Hswen, Yulin and Hill, Sarah C. and Cobo, Maria M. and Zarebski, Alexander E. and Li, Sabrina and Wu, Chieh-Hsi and Hulland, Erin and Morgan, Julia D. and Wang, Lin and O'Brien, Katelynn and Scarpino, Samuel V. and Brownstein, John S. and Pybus, Oliver G. and Pigott, David M. and Kraemer, Moritz U. G.},
  year = {2020},
  month = dec,
  journal = {Scientific Data},
  volume = {7},
  number = {1},
  pages = {106},
  issn = {2052-4463},
  doi = {10.1038/s41597-020-0448-0},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\ZS8MUHC9\\Xu et al. - 2020 - Epidemiological data from the COVID-19 outbreak, r.pdf}
}

@article{xuSeroprevalenceImmunoglobulinAntibodies2020,
  title = {Seroprevalence of Immunoglobulin {{M}} and {{G}} Antibodies against {{SARS-CoV-2}} in {{China}}},
  author = {Xu, Xin and Sun, Jian and Nie, Sheng and Li, Huiyuan and Kong, Yaozhong and Liang, Min and Hou, Jinlin and Huang, Xianzhong and Li, Dongfeng and Ma, Tean and Peng, Jiaqing and Gao, Shikui and Shao, Yong and Zhu, Hong and Lau, Johnson Yiu-Nam and Wang, Guangyu and Xie, Chunbao and Jiang, Li and Huang, Ailong and Yang, Zhenglin and Zhang, Kang and Hou, Fan Fan},
  year = {2020},
  month = jun,
  journal = {Nature Medicine},
  pages = {1--3},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-0949-6},
  abstract = {Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2\% and 3.8\% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3\% (51 of 1,542, 2.5\textendash 4.3\%, 95\% confidence interval (CI)) and 1.8\% (81 of 4,384, 1.5\textendash 2.3\%, 95\%\,CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\RKC8HWUQ\\Xu et al. - 2020 - Seroprevalence of immunoglobulin M and G antibodie.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\UZ96QQBL\\s41591-020-0949-6.html}
}

@article{yusefEarlyReleaseLarge,
  title = {Early {{Release}} - {{Large Outbreak}} of {{Coronavirus Disease}} among {{Wedding Attendees}}, {{Jordan}} - {{Volume}} 26, {{Number}} 9\textemdash{{September}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Yusef, Dawood and Hayajneh, Wail and Awad, Samah and Momany, Suleiman and Khassawneh, Basheer and Samrah, Shaher and Obeidat, Basil and Raffee, Liqaa and {Al-Faouri}, Ibrahim and Issa, Ali Bani and Zamel, Heba Al and Bataineh, Enas and Qdaisat, Reem},
  doi = {10.3201/eid2609.201469},
  abstract = {In March 2020, a wedding in Jordan led to a large outbreak of coronavirus disease (COVID-19). We collected data on 350 wedding attendees, 76 who of wh...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\XNMK8Y7E\\20-1469_article.html}
}

@article{zhangChangesContactPatterns2020,
  title = {Changes in Contact Patterns Shape the Dynamics of the {{COVID-19}} Outbreak in {{China}}},
  author = {Zhang, Juanjuan and Litvinova, Maria and Liang, Yuxia and Wang, Yan and Wang, Wei and Zhao, Shanlu and Wu, Qianhui and Merler, Stefano and Viboud, C{\'e}cile and Vespignani, Alessandro and Ajelli, Marco and Yu, Hongjie},
  year = {2020},
  month = apr,
  journal = {Science},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.abb8001},
  abstract = {Intense non-pharmaceutical interventions were put in place in China to stop transmission of the novel coronavirus disease (COVID-19). As transmission intensifies in other countries, the interplay between age, contact patterns, social distancing, susceptibility to infection, and COVID-19 dynamics remains unclear. To answer these questions, we analyze contact surveys data for Wuhan and Shanghai before and during the outbreak and contact tracing information from Hunan Province. Daily contacts were reduced 7-8-fold during the COVID-19 social distancing period, with most interactions restricted to the household. We find that children 0-14 years are less susceptible to SARS-CoV-2 infection than adults 15-64 years of age (odd ratio 0.34, 95\%CI 0.24-0.49), while in contrast, individuals over 65 years are more susceptible to infection (odd ratio 1.47, 95\%CI: 1.12-1.92). Based on these data, we build a transmission model to study the impact of social distancing and school closure on transmission. We find that social distancing alone, as implemented in China during the outbreak, is sufficient to control COVID-19. While proactive school closures cannot interrupt transmission on their own, they can reduce peak incidence by 40-60\% and delay the epidemic.},
  chapter = {Report},
  copyright = {Copyright \textcopyright{} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.},
  langid = {english},
  pmid = {32350060},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TBNTVXWF\\Zhang et al. - 2020 - Changes in contact patterns shape the dynamics of .pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\HF2P6LWV\\science.html}
}

@article{zhangEarlyReleaseSecondary,
  title = {Early {{Release}} - {{Secondary Transmission}} of {{Coronavirus Disease}} from {{Presymptomatic Persons}}, {{China}} - {{Volume}} 26, {{Number}} 8\textemdash{{August}} 2020 - {{Emerging Infectious Diseases}} Journal - {{CDC}}},
  author = {Zhang, Weiwei and Cheng, Weibin and Luo, Lei and Ma, Yu and Xu, Conghui and Qin, Pengzhe and Zhang, Zhoubin},
  doi = {10.3201/eid2608.201142},
  abstract = {We explored the secondary attack rate in different types of contact with persons presymptomatic for coronavirus disease (COVID-19). Close contacts who...},
  langid = {american},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DEKJBMR3\\20-1142_article.html}
}

@article{zhangEvolvingEpidemiologyTransmission2020,
  title = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}: A Descriptive and Modelling Study},
  shorttitle = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}},
  author = {Zhang, Juanjuan and Litvinova, Maria and Wang, Wei and Wang, Yan and Deng, Xiaowei and Chen, Xinghui and Li, Mei and Zheng, Wen and Yi, Lan and Chen, Xinhua and Wu, Qianhui and Liang, Yuxia and Wang, Xiling and Yang, Juan and Sun, Kaiyuan and Longini, Ira M and Halloran, M Elizabeth and Wu, Peng and Cowling, Benjamin J and Merler, Stefano and Viboud, Cecile and Vespignani, Alessandro and Ajelli, Marco and Yu, Hongjie},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  pages = {S1473309920302309},
  issn = {14733099},
  doi = {10.1016/S1473-3099(20)30230-9},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\T3HUUK77\\Zhang et al. - 2020 - Evolving epidemiology and transmission dynamics of.pdf}
}

@article{zhangEvolvingEpidemiologyTransmission2020a,
  title = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}: A Descriptive and Modelling Study},
  shorttitle = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}},
  author = {Zhang, Juanjuan and Litvinova, Maria and Wang, Wei and Wang, Yan and Deng, Xiaowei and Chen, Xinghui and Li, Mei and Zheng, Wen and Yi, Lan and Chen, Xinhua and Wu, Qianhui and Liang, Yuxia and Wang, Xiling and Yang, Juan and Sun, Kaiyuan and Longini, Ira M. and Halloran, M. Elizabeth and Wu, Peng and Cowling, Benjamin J. and Merler, Stefano and Viboud, Cecile and Vespignani, Alessandro and Ajelli, Marco and Yu, Hongjie},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  volume = {0},
  number = {0},
  publisher = {{Elsevier}},
  issn = {1473-3099, 1474-4457},
  doi = {10.1016/S1473-3099(20)30230-9},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}The coronavirus disease 2019 (COVID-19) epidemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in Wuhan city, Hubei province, in December, 2019, and has spread throughout China. Understanding the evolving epidemiology and transmission dynamics of the outbreak beyond Hubei would provide timely information to guide intervention policy.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We collected individual information from official public sources on laboratory-confirmed cases reported outside Hubei in mainland China for the period of Jan 19 to Feb 17, 2020. We used the date of the fourth revision of the case definition (Jan 27) to divide the epidemic into two time periods (Dec 24 to Jan 27, and Jan 28 to Feb 17) as the date of symptom onset. We estimated trends in the demographic characteristics of cases and key time-to-event intervals. We used a Bayesian approach to estimate the dynamics of the net reproduction number (\emph{R}\textsubscript{t}) at the provincial level.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}We collected data on 8579 cases from 30 provinces. The median age of cases was 44 years (33\textendash 56), with an increasing proportion of cases in younger age groups and in elderly people (ie, aged {$>$}64 years) as the epidemic progressed. The mean time from symptom onset to hospital admission decreased from 4{$\cdot$}4 days (95\% CI 0{$\cdot$}0\textendash 14{$\cdot$}0) for the period of Dec 24 to Jan 27, to 2{$\cdot$}6 days (0{$\cdot$}0\textendash 9{$\cdot$}0) for the period of Jan 28 to Feb 17. The mean incubation period for the entire period was estimated at 5{$\cdot$}2 days (1{$\cdot$}8\textendash 12{$\cdot$}4) and the mean serial interval at 5{$\cdot$}1 days (1{$\cdot$}3\textendash 11{$\cdot$}6). The epidemic dynamics in provinces outside Hubei were highly variable but consistently included a mixture of case importations and local transmission. We estimated that the epidemic was self-sustained for less than 3 weeks, with mean \emph{Rt} reaching peaks between 1{$\cdot$}08 (95\% CI 0{$\cdot$}74\textendash 1{$\cdot$}54) in Shenzhen city of Guangdong province and 1{$\cdot$}71 (1{$\cdot$}32\textendash 2{$\cdot$}17) in Shandong province. In all the locations for which we had sufficient data coverage of \emph{Rt, Rt} was estimated to be below the epidemic threshold (ie, {$<$}1) after Jan 30.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}Our estimates of the incubation period and serial interval were similar, suggesting an early peak of infectiousness, with possible transmission before the onset of symptoms. Our results also indicate that, as the epidemic progressed, infectious individuals were isolated more quickly, thus shortening the window of transmission in the community. Overall, our findings indicate that strict containment measures, movement restrictions, and increased awareness of the population might have contributed to interrupt local transmission of SARS-CoV-2 outside Hubei province.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Science Fund for Distinguished Young Scholars, National Institute of General Medical Sciences, and European Commission Horizon 2020.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32247326},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\47T529UV\\fulltext.html}
}

@article{zhangEvolvingEpidemiologyTransmission2020b,
  title = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}: A Descriptive and Modelling Study. {{Supplementary Appendix}}},
  shorttitle = {Evolving Epidemiology and Transmission Dynamics of Coronavirus Disease 2019 Outside {{Hubei}} Province, {{China}}},
  author = {Zhang, Juanjuan and Litvinova, Maria and Wang, Wei and Wang, Yan and Deng, Xiaowei and Chen, Xinghui and Li, Mei and Zheng, Wen and Yi, Lan and Chen, Xinhua and Wu, Qianhui and Liang, Yuxia and Wang, Xiling and Yang, Juan and Sun, Kaiyuan and Longini, Ira M and Halloran, M Elizabeth and Wu, Peng and Cowling, Benjamin J and Merler, Stefano and Viboud, Cecile and Vespignani, Alessandro and Ajelli, Marco and Yu, Hongjie},
  year = {2020},
  month = apr,
  journal = {The Lancet Infectious Diseases},
  pages = {S1473309920302309},
  issn = {14733099},
  doi = {10.1016/S1473-3099(20)30230-9},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LCU8DE8A\\Zhang et al. - 2020 - Evolving epidemiology and transmission dynamics of.pdf}
}

@article{zhangTransmissionDynamicsOutbreak2021,
  title = {Transmission {{Dynamics}} of an {{Outbreak}} of the {{COVID-19 Delta Variant B}}.1.617.2 \textemdash{} {{Guangdong Province}}, {{China}}, {{May}}\textendash{{June}} 2021},
  author = {Zhang, Meng and Xiao, Jianpeng and Deng, Aiping and Zhang, Yingtao and Zhuang, Yali and Hu, Ting and Li, Jiansen and Tu, Hongwei and Li, Bosheng and Zhou, Yan and Yuan, Jun and Luo, Lei and Liang, Zimian and Huang, Youzhi and Ye, Guoqiang and Cai, Mingwei and Li, Gongli and Yang, Bo and Xu, Bin and Huang, Ximing and Cui, Yazun and Ren, Dongsheng and Zhang, Yanping and Kang, Min and Li, Yan},
  year = {2021},
  month = jul,
  journal = {China CDC Weekly},
  volume = {3},
  number = {27},
  pages = {584--586},
  publisher = {{China CDC Weekly}},
  issn = {2096-7071},
  doi = {10.46234/ccdcw2021.148},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\7L9E8X54\\Zhang et al. - 2021 - Transmission Dynamics of an Outbreak of the COVID-.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IXT6WGU5\\ccdcw2021.html}
}

@article{zhaoRoleInterpersonalTraits2015,
  title = {The {{Role}} of {{Interpersonal Traits}} in {{Social Decision Making Exploring Sources}} of {{Behavioral Heterogeneity}} in {{Economic Games}}},
  author = {Zhao, Kun and Smillie, Luke D.},
  year = {2015},
  month = aug,
  journal = {Personality and Social Psychology Review},
  volume = {19},
  number = {3},
  pages = {277--302},
  issn = {1088-8683, 1532-7957},
  doi = {10.1177/1088868314553709},
  abstract = {Economic games are well-established experimental paradigms for modeling social decision making. A large body of literature has pointed to the heterogeneity of behavior within many of these games, which might be partly explained by broad interpersonal trait dispositions. Using the Big Five and HEXACO (Honesty-Humility, Emotionality, eXtraversion, Agreeableness, Conscientiousness, Openness to Experience) personality frameworks, we review the role of personality in two main classes of economic games: social dilemmas and bargaining games. This reveals an emerging role for Big Five agreeableness in promoting cooperative, egalitarian, and altruistic behaviors across several games, consistent with its core characteristic of maintaining harmonious interpersonal relations. The role for extraversion is less clear, which may reflect the divergent effects of its underlying agentic and affiliative motivational components. In addition, HEXACO honesty-humility and agreeableness may capture distinct aspects of prosocial behavior outside the bounds of the Five-Factor Model. Important considerations and directions for future studies are discussed within the emerging personality\textendash economics interface.},
  langid = {english},
  pmid = {25552474},
  keywords = {agreeableness,bargaining games,economic games,extraversion,HEXACO,honesty-humility,social dilemmas},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\DBUVTKDT\\Zhao and Smillie - 2015 - The Role of Interpersonal Traits in Social Decisio.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\69F3ZQ53\\Zhao and Smillie - 2015 - The Role of Interpersonal Traits in Social Decisio.html}
}

@article{zhaoRoleInterpersonalTraits2015a,
  title = {The {{Role}} of {{Interpersonal Traits}} in {{Social Decision Making Exploring Sources}} of {{Behavioral Heterogeneity}} in {{Economic Games}}},
  author = {Zhao, Kun and Smillie, Luke D.},
  year = {2015},
  month = aug,
  journal = {Personality and Social Psychology Review},
  volume = {19},
  number = {3},
  pages = {277--302},
  issn = {1088-8683, 1532-7957},
  doi = {10.1177/1088868314553709},
  abstract = {Economic games are well-established experimental paradigms for modeling social decision making. A large body of literature has pointed to the heterogeneity of behavior within many of these games, which might be partly explained by broad interpersonal trait dispositions. Using the Big Five and HEXACO (Honesty-Humility, Emotionality, eXtraversion, Agreeableness, Conscientiousness, Openness to Experience) personality frameworks, we review the role of personality in two main classes of economic games: social dilemmas and bargaining games. This reveals an emerging role for Big Five agreeableness in promoting cooperative, egalitarian, and altruistic behaviors across several games, consistent with its core characteristic of maintaining harmonious interpersonal relations. The role for extraversion is less clear, which may reflect the divergent effects of its underlying agentic and affiliative motivational components. In addition, HEXACO honesty-humility and agreeableness may capture distinct aspects of prosocial behavior outside the bounds of the Five-Factor Model. Important considerations and directions for future studies are discussed within the emerging personality\textendash economics interface.},
  langid = {english},
  pmid = {25552474},
  keywords = {agreeableness,bargaining games,economic games,extraversion,HEXACO,honesty-humility,social dilemmas},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\5Z58CX5J\\Zhao and Smillie - 2015 - The Role of Interpersonal Traits in Social Decisio.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\XZNK5KBA\\Zhao and Smillie - 2015 - The Role of Interpersonal Traits in Social Decisio.html}
}

@techreport{zhouInvestigatingSARSCoV2Surface2020,
  type = {Preprint},
  title = {Investigating {{SARS-CoV-2}} Surface and Air Contamination in an Acute Healthcare Setting during the Peak of the {{COVID-19}} Pandemic in {{London}}},
  author = {Zhou, Jie and Otter, Jonathan and Price, James Richard and Cimpeanu, Cristina and Meno Garcia, Danel and Kinross, James and Boshier, Piers and Mason, Sam and Bolt, Frances and Holmes, Alison H and Barklay, Wendy},
  year = {2020},
  month = may,
  institution = {{Infectious Diseases (except HIV/AIDS)}},
  doi = {10.1101/2020.05.24.20110346},
  abstract = {Objectives: To evaluate SARS-CoV-2 surface and air contamination during the peak of the COVID-19 pandemic in London. Design: Prospective cross-sectional observational study. Setting: An acute NHS healthcare provider. Participants: All inpatient wards were fully occupied by patients with COVID-19 at the time of sampling.    Interventions: Air and surface samples were collected from a range of clinical areas and a public area of the hospital. An active air sampler was used to collect three or four 1.0 m             3             air samples in each area. Surface samples were collected by swabbing approximately 25 cm             2             of items in the immediate vicinity of each air sample. SARS-CoV-2 was detected by RT-qPCR and viral culture using Vero E6 and Caco2 cells; additionally the limit of detection for culturing SARS-CoV-2 dried onto surfaces was determined.  Main outcome measures: SARS-CoV-2 detected by PCR or culture.  Results: Viral RNA was detected on 114/218 (52.3\%) of surface and 14/31 (38.7\%) air samples but no virus was cultured. The proportion of surface samples contaminated with viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces and in air in public areas of the hospital but was more likely to be found in areas immediately occupied by COVID-19 patients (67/105 (63.8\%) in areas immediately occupied by COVID-19 patients vs. 29/64 (45.3\%) in other areas (odds ratio 0.5, 95\% confidence interval 0.2-0.9, p=0.025, Fishers exact test). The PCR Ct value for all surface and air samples ({$>$}30) indicated a viral load that would not be culturable.  Conclusions: Our findings of extensive viral RNA contamination of surfaces and air across a range of acute healthcare settings in the absence of cultured virus underlines the potential risk from surface and air contamination in managing COVID-19, and the need for effective use of PPE, social distancing, and hand/surface hygiene.},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\9X3I3AX2\\Zhou et al. - 2020 - Investigating SARS-CoV-2 surface and air contamina.pdf}
}

@article{zhuSafetyTolerabilityImmunogenicity2020,
  title = {Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored {{COVID-19}} Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human Trial},
  shorttitle = {Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored {{COVID-19}} Vaccine},
  author = {Zhu, Feng-Cai and Li, Yu-Hua and Guan, Xu-Hua and Hou, Li-Hua and Wang, Wen-Juan and Li, Jing-Xin and Wu, Shi-Po and Wang, Bu-Sen and Wang, Zhao and Wang, Lei and Jia, Si-Yue and Jiang, Hu-Dachuan and Wang, Ling and Jiang, Tao and Hu, Yi and Gou, Jin-Bo and Xu, Sha-Bei and Xu, Jun-Jie and Wang, Xue-Wen and Wang, Wei and Chen, Wei},
  year = {2020},
  month = jun,
  journal = {The Lancet},
  volume = {395},
  number = {10240},
  pages = {1845--1854},
  publisher = {{Elsevier}},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(20)31208-3},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}h3{$>$}Background{$<$}/h3{$><$}p{$>$}A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.{$<$}/p{$><$}h3{$>$}Methods{$<$}/h3{$><$}p{$>$}We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 \texttimes{} 10\textsuperscript{10}, 1 \texttimes{} 10\textsuperscript{11}, and 1{$\cdot$}5 \texttimes{} 10\textsuperscript{11} viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127.{$<$}/p{$><$}h3{$>$}Findings{$<$}/h3{$><$}p{$>$}Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51\% male, 49\% female; mean age 36{$\cdot$}3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83\%) participants in the low dose group, 30 (83\%) participants in the middle dose group, and 27 (75\%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54\%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46\%]), fatigue (47 [44\%]), headache (42 [39\%]), and muscle pain (18 [17\%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.{$<$}/p{$><$}h3{$>$}Interpretation{$<$}/h3{$><$}p{$>$}The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.{$<$}/p{$><$}h3{$>$}Funding{$<$}/h3{$><$}p{$>$}National Key R\&D Program of China, National Science and Technology Major Project, and CanSino Biologics.{$<$}/p{$>$}},
  langid = {english},
  pmid = {32450106},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\IZUR4NWH\\Zhu et al. - 2020 - Safety, tolerability, and immunogenicity of a reco.pdf;C\:\\Users\\Fabian Valka\\Zotero\\storage\\IUEGM5WT\\fulltext.html}
}

@misc{zotero-826,
  howpublished = {https://portalcne.isciii.es/enecovid19/},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\LDXDGHX2\\enecovid19.html}
}

@misc{ZoteroYourPersonal,
  title = {Zotero | {{Your}} Personal Research Assistant},
  howpublished = {https://www.zotero.org/}
}

@article{zouSARSCoV2ViralLoad2020,
  title = {{{SARS-CoV-2 Viral Load}} in {{Upper Respiratory Specimens}} of {{Infected Patients}}},
  author = {Zou, Lirong and Ruan, Feng and Huang, Mingxing and Liang, Lijun and Huang, Huitao and Hong, Zhongsi and Yu, Jianxiang and Kang, Min and Song, Yingchao and Xia, Jinyu and Guo, Qianfang and Song, Tie and He, Jianfeng and Yen, Hui-Ling and Peiris, Malik and Wu, Jie},
  year = {2020},
  month = mar,
  journal = {New England Journal of Medicine},
  volume = {382},
  number = {12},
  pages = {1177--1179},
  issn = {0028-4793, 1533-4406},
  doi = {10.1056/NEJMc2001737},
  langid = {english},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\PVGI4MFY\\Zou et al. - 2020 - SARS-CoV-2 Viral Load in Upper Respiratory Specime.pdf}
}

@article{zubaIntensivpflegeUndCOVID2021,
  title = {{Intensivpflege und COVID}},
  author = {Zuba, Martin},
  year = {2021},
  pages = {14},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\A4MFQAF7\\Zuba - 2021 - Intensivpflege und COVID.pdf}
}

@article{zurlHospitalisierungenKindernUnd,
  title = {{Hospitalisierungen von Kindern und Jugendlichen in \"Osterreich mit SARS- CoV-2 Infektion}},
  author = {Zurl, Christoph and Strenger, Volker},
  pages = {8},
  langid = {german},
  file = {C\:\\Users\\Fabian Valka\\Zotero\\storage\\TX2XGCQF\\Zurl and Strenger - Hospitalisierungen von Kindern und Jugendlichen in.pdf}
}


